

49

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number
WO 03/034903 A2

(51) International Patent Classification⁷: A61B

(21) International Application Number: PCT/US02/33944

(22) International Filing Date: 23 October 2002 (23.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/335,215 23 October 2001 (23.10.2001) US

60/362,747 7 March 2002 (07.03.2002) US

60/412,618 20 September 2002 (20.09.2002) US

(71) Applicant (for all designated States except US): PSMA DEVELOPMENT COMPANY, L.L.C. [US/US]; Progenics Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MADDON, Paul, J. [US/US]; 191 Fox Meadow Road, Scarsdale, NY 10583 (US). DONOVAN, Gerald, P. [US/US]; 430 East

63rd Street, Apartment 5L, New York, NY 10021 (US). OLSON, William, C. [US/US]; 21 Fawn Court, Ossining, NY 10562 (US). SCHÜLKE, Norbert [DE/US]; 101 Ridge Road, New City, NY 10956 (US). GARDNER, Jason [US/US]; 24 Bramble Brook Road, Ardsley, NY 10502 (US). MA, Dangshe [CN/US]; 49 Glenwood Road, Millwood, NY 10546 (US).

(74) Agent: VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: PSMA ANTIBODIES AND PROTEIN MULTIMERS



WO 03/034903 A2



(57) Abstract: The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment. The invention also includes oligomeric forms of PSMA proteins, compositions comprising the multimers, and antibodies that selectively bind to the multimers.



Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*

PSMA ANTIBODIES AND PROTEIN MULTIMERSRelated Applications

This application claims the benefit under 35 U.S.C. § 119 of United States provisional application 60/335,215, filed October 23, 2001, United States provisional application 60/362,747, filed March 7, 2002, and United States provisional application 60/_____, filed September 20, 2002, each of which is incorporated herein by reference.

Field of the Invention

This invention relates generally to the field of cancer associated polypeptides and antibodies that recognize native epitopes on the polypeptides. In particular, the invention relates in part to antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, multimeric forms of PSMA proteins, antibodies that selectively bind to the multimers, and compositions containing such antibodies or multimers.

Background of the Invention

Prostate cancer is the most prevalent type of cancer and the second leading cause of death from cancer in American men, with an estimated 179,000 cases and 37,000 deaths in 1999, (Landis, S.H. *et al. CA Cancer J. Clin.* 48:6-29 (1998)). The number of men diagnosed with prostate cancer is steadily increasing as a result of the increasing population of older men as well as a greater awareness of the disease leading to its earlier diagnosis (Parker *et al.*, 1997, *CA Cancer J. Clin.* 47:5-280). The life time risk for men developing prostate cancer is about 1 in 5 for Caucasians, 1 in 6 for African Americans. High risk groups are represented by those with a positive family history of prostate cancer or African Americans.

Over a lifetime, more than 2/3 of the men diagnosed with prostate cancer die of the disease (Wingo *et al.*, 1996, *CA Cancer J. Clin.* 46:113-25). Moreover, many patients who do not succumb to prostate cancer require continuous treatment to ameliorate symptoms such as pain, bleeding and urinary obstruction. Thus, prostate cancer also represents a major cause of suffering and increased health care expenditures.

Where prostate cancer is localized and the patient's life expectancy is 10 years or more, radical prostatectomy offers the best chance for eradication of the disease.

- 2 -

Historically, the drawback of this procedure is that most cancers had spread beyond the bounds of the operation by the time they were detected. Patients with bulky, high-grade tumors are less likely to be successfully treated by radical prostatectomy.

Radiation therapy has also been widely used as an alternative to radical

5 prostatectomy. Patients generally treated by radiation therapy are those who are older and less healthy and those with higher-grade, more clinically advanced tumors. Particularly preferred procedures are external-beam therapy which involves three dimensional, confocal radiation therapy where the field of radiation is designed to conform to the volume of tissue treated; interstitial-radiation therapy where seeds of radioactive compounds are implanted using

10 ultrasound guidance; and a combination of external-beam therapy and interstitial-radiation therapy.

For treatment of patients with locally advanced disease, hormonal therapy before or following radical prostatectomy or radiation therapy has been utilized. Hormonal therapy is the main form of treating men with disseminated prostate cancer. Orchiectomy reduces

15 serum testosterone concentrations, while estrogen treatment is similarly beneficial. Diethylstilbestrol from estrogen is another useful hormonal therapy which has a disadvantage of causing cardiovascular toxicity. When gonadotropin-releasing hormone agonists are administered testosterone concentrations are ultimately reduced. Flutamide and other nonsteroidal, anti-androgen agents block binding of testosterone to its intracellular receptors.

20 As a result, it blocks the effect of testosterone, increasing serum testosterone concentrations and allows patients to remain potent--a significant problem after radical prostatectomy and radiation treatments.

Cytotoxic chemotherapy is largely ineffective in treating prostate cancer. Its toxicity makes such therapy unsuitable for elderly patients. In addition, prostate cancer is relatively

25 resistant to cytotoxic agents.

Relapsed or more advanced disease is also treated with anti-androgen therapy. Unfortunately, almost all tumors become hormone-resistant and progress rapidly in the absence of any effective therapy.

Accordingly, there is a need for effective therapeutics for prostate cancer which are

30 not overwhelmingly toxic to normal tissues of a patient, and which are effective in selectively eliminating prostate cancer cells.

Summary of the Invention

The present invention relates to antibodies or antigen-binding fragments thereof which specifically bind the extracellular domain of prostate specific membrane antigen (PSMA), compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment.

According to one aspect of the invention, isolated antibodies or antigen-binding fragments thereof are provided. The antibodies or fragments thereof specifically bind to an extracellular domain of prostate specific membrane antigen (PSMA), and competitively inhibit the specific binding of a second antibody to its target epitope on PSMA. In a second aspect of the invention, isolated antibodies or antigen-binding fragments thereof are provided which specifically bind to an epitope on prostate specific membrane antigen (PSMA) defined by a second antibody. In each of the forgoing aspects of the invention, the second antibody is selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1, and antibodies comprising (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13.

In certain embodiments, the antibody or antigen-binding fragment thereof is selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, and Abgenix 4.152.1.

In other embodiments, the antibody or antigen-binding fragment thereof is selected from the group consisting of antibodies comprising (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13, and antigen-binding fragments thereof.

In further embodiments, the antibody or antigen-binding fragments thereof is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 90% identical to the nucleotide sequence encoding the foregoing antibodies, preferably at least about 95% identical, more preferably at least about 97% identical, still more preferably at least about 98% identical, and most preferably is at least about 99% identical.

In some embodiments of the foregoing aspects, antigen-binding fragments of the isolated antibodies are provided. The antigen-binding fragments include (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding regions or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 14, 18, 22, 26 and 30, and (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or region of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 16, 20, 24, 28 and 32. In other embodiments, the antigen-binding fragment includes (a) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of amino acid sequences set forth as: SEQ ID NOs: 15, 19, 23, 27 and 31, and (b) a light chain variable region comprising an amino acid sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 17, 21, 25, 29 and 33.

In a further embodiments of the invention, isolated antigen-binding fragments of antibodies, which include a CDR of the foregoing antigen-binding fragments are provided. Preferably the CDR is CDR3.

According another aspect of the invention, expression vectors including an isolated nucleic acid molecule encoding the foregoing isolated antibodies or antigen-binding fragments is provided. Host cells transformed or transfected by these expression vectors also are provided.

- 5 -

In certain embodiments, the antibody or antigen-binding fragment thereof is selected for its ability to bind live cells, such as a tumor cell or a prostate cell, preferably LNCaP cells. In other embodiments, the antibody or antigen-binding fragment thereof mediates cytolysis of cells expressing PSMA. Preferably cytolysis of cells expressing PSMA is mediated by 5 effector cells or is complement mediated in the presence of effector cells.

In other embodiments, the antibody or antigen-binding fragment thereof inhibits the growth of cells expressing PSMA. Preferably the antibody or antigen-binding fragment thereof does not require cell lysis to bind to the extracellular domain of PSMA.

10 In further embodiments, the antibody or antigen-binding fragment thereof is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, IgE or has immunoglobulin constant and/or variable domain of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD or IgE. In other embodiments, the antibody is a bispecific or multispecific antibody.

15 In still other embodiments, the antibody is a recombinant antibody, a polyclonal antibody, a monoclonal antibody, a humanized antibody or a chimeric antibody, or a mixture of these. In particularly preferred embodiments, the antibody is a human antibody, e.g., a monoclonal antibody, polyclonal antibody or a mixture of monoclonal and polyclonal antibodies. In still other embodiments, the antibody is a bispecific or multispecific antibody.

20 Preferred antigen-binding fragments include a Fab fragment, a F(ab')₂ fragment, and a Fv fragment CDR3.

In further embodiments, the isolated antibody or antigen-binding fragment is a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293), PSMA 10.3 (PTA-3247), 25 PSMA 1.8.3 (PTA-3906), PSMA A3.1.3 (PTA-3904), PSMA A3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428), Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557), Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359), Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362), Abgenix 4.209.3 (PTA-4365), Abgenix 30 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367), Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388), Abgenix 4.232.3 (PTA-4389), Abgenix

- 6 -

4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391), Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

In certain other embodiments, the antibody or antigen-binding fragment thereof binds to a conformational epitope and/or is internalized into a cell along with the prostate specific membrane antigen. In other embodiments, the isolated antibody or antigen-binding fragment thereof is bound to a label, preferably one selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

In still other embodiments, the isolated antibody or antigen-binding fragment thereof is bound to at least one therapeutic moiety, such as a drug, preferably a cytotoxic drug, a replication-selective virus, a toxin or a fragment thereof, or an enzyme or a fragment thereof. Preferred cytotoxic drug include: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE. In other embodiments, the therapeutic moiety is an immunostimulatory or immunomodulating agent, preferably one selected from the group consisting of: a cytokine, chemokine and adjuvant.

In some embodiments, the antibodies or antigen-binding fragments of the invention specifically bind cell-surface PSMA and/or rsPSMA with a binding affinity of about 1 X 10^{-9} M or less. Preferably, the binding affinity is about 1 X 10^{-10} M or less, more preferably the binding affinity is about 1 X 10^{-11} M or less. In other embodiments the binding affinity is less than about 5 X 10^{-10} M.

In additional embodiments, the antibodies or antigen-binding fragments of the invention mediate specific cell killing of PSMA-expressing cells with an IC₅₀s of less than about 1 X 10^{-10} M. Preferably the IC₅₀s is less than about 1 X 10^{-11} M. More preferably the IC₅₀s is less than about 1 X 10^{-12} M. In other embodiments the IC₅₀s is less than about 1.5 X 10^{-11} M.

In yet other embodiments, the isolated antibody or antigen-binding fragment thereof is bound to a radioisotope. The radioisotope can emit α radiations, β radiations, or γ radiations. Preferably the radioisotope is selected from the group consisting of ²²⁵Ac, ²¹¹At, ²¹²Bi, ²¹³Bi, ¹⁸⁶Rh, ¹⁸⁸Rh, ¹⁷⁷Lu, ⁹⁰Y, ¹³¹I, ⁶⁷Cu, ¹²⁵I, ¹²³I, ⁷⁷Br, ¹⁵³Sm, ¹⁶⁶Ho, ⁶⁴Cu, ²¹²Pb, ²²⁴Ra and ²²³Ra.

According to another aspect of the invention, hybridoma cell lines are provided that produce an antibody selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 5 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1 and Abgenix 4.152.1. In some embodiments, the hybridoma cell line is selected from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-10 3258), PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293), PSMA 10.3 (PTA-3247), PSMA 1.8.3 (PTA-3906), PSMA A3.1.3 (PTA-3904), PSMA A3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428), Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557), Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359), 15 Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362), Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367), Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388), Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391), Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

According to a further aspect of the invention, compositions are provided that include the foregoing antibodies or antigen-binding fragments thereof and a pharmaceutically acceptable carrier, excipient, or stabilizer. Other compositions include a combination of two or more of the foregoing antibodies or antigen-binding fragments thereof and a pharmaceutically acceptable carrier, excipient, or stabilizer. In some embodiments, the 20 compositions also include an antitumor agent, an immunostimulatory agent, an immunomodulator, or a combination thereof. Preferred antitumor agents include a cytotoxic agent, an agent that acts on tumor neovasculature, or a combination thereof. Preferred immunomodulators include α -interferon, γ -interferon, tumor necrosis factor- α or a combination thereof. Preferred immunostimulatory agents include interleukin-2, 25 immunostimulatory oligonucleotides, or a combination thereof.

According to another aspect of the invention, kits for detecting prostate cancer for diagnosis, prognosis or monitoring are provided. The kits include the foregoing isolated

labeled antibody or antigen-binding fragment thereof, and one or more compounds for detecting the label. Preferably the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

5 The invention in another aspect provides one or more of the foregoing isolated antibodies or antigen-binding fragments thereof packaged in lyophilized form, or packaged in an aqueous medium.

10 In another aspect of the invention, methods for detecting the presence of PSMA, or a cell expressing PSMA, in a sample are provided. The methods include contacting the sample with any of the foregoing antibodies or antigen-binding fragments thereof which specifically bind to an extracellular domain of PSMA, for a time sufficient to allow the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA, and detecting the PSMA-antibody complex or PSMA-antigen-binding fragment complex. The presence of a complex in the sample is indicative of the presence in the sample of PSMA or a cell
15 expressing PSMA.

20 In another aspect, the invention provides other methods for diagnosing a PSMA-mediated disease in a subject. The methods include administering to a subject suspected of having or previously diagnosed with PSMA-mediated disease an amount of any of the foregoing antibodies or antigen-binding fragments thereof which specifically bind to an extracellular domain of prostate specific membrane antigen. The method also includes allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA, and detecting the formation of the PSMA-antibody complex or PSMA-antigen-binding fragment antibody complex to the target epitope. The presence of a complex in the subject suspected of having or previously diagnosed with prostate cancer is indicative
25 of the presence of a PSMA-mediated disease.

30 In certain embodiments of the methods, the PSMA-mediated disease is prostate cancer. In other embodiments, the PSMA-mediated disease is a non-prostate cancer, such as those selected from the group consisting of bladder cancer including transitional cell carcinoma; pancreatic cancer including pancreatic duct carcinoma; lung cancer including non-small cell lung carcinoma; kidney cancer including conventional renal cell carcinoma; sarcoma including soft tissue sarcoma; breast cancer including breast carcinoma; brain cancer including glioblastoma multiforme; neuroendocrine carcinoma; colon cancer including

colonic carcinoma; testicular cancer including testicular embryonal carcinoma; and melanoma including malignant melanoma.

In preferred embodiments of the foregoing methods, the antibody or antigen-binding fragment thereof is labeled. In other embodiments of the foregoing methods, a second antibody is administered to detect the first antibody or antigen-binding fragment thereof.

In a further aspect of the invention, methods for assessing the prognosis of a subject with a PSMA-mediated disease are provided. The methods include administering to a subject suspected of having or previously diagnosed with PSMA-mediated disease an effective amount of an antibody or antigen-binding fragment thereof according to claim A1 or B1, allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA, and detecting the formation of the complex to the target epitope. The amount of the complex in the subject suspected of having or previously diagnosed with PSMA-mediated disease is indicative of the prognosis.

In another aspect of the invention, methods for assessing the effectiveness of a treatment of a subject with a PSMA-mediated disease are provided. The methods include administering to a subject suspected treated for a PSMA-mediated disease an effective amount of the foregoing antibodies or antigen-binding fragments thereof, allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA, and detecting the formation of the complex to the target epitope. The amount of the complex in the subject suspected of having or previously diagnosed with PSMA-mediated disease is indicative of the effectiveness of the treatment.

In certain embodiments of these two aspects of the invention, the PSMA-mediated disease is prostate cancer. In other embodiments, the PSMA-mediated disease is a non-prostate cancer. In those embodiments, the non-prostate cancer preferably is selected from the group consisting of bladder cancer including transitional cell carcinoma; pancreatic cancer including pancreatic duct carcinoma; lung cancer including non-small cell lung carcinoma; kidney cancer including conventional renal cell carcinoma; sarcoma including soft tissue sarcoma; breast cancer including breast carcinoma; brain cancer including glioblastoma multiforme; neuroendocrine carcinoma; colon cancer including colonic carcinoma; testicular cancer including testicular embryonal carcinoma; and melanoma including malignant melanoma. In still other embodiments, the antibody or antigen-binding

- 10 -

fragment thereof is labeled. In further embodiments, a second antibody is administered to detect the first antibody or antigen-binding fragment thereof.

According to yet another aspect of the invention, methods for inhibiting the growth of a cell expressing PSMA are provided. The methods include contacting a cell expressing PSMA with an amount of at least one of the foregoing antibodies or antigen-binding fragments thereof which specifically binds to an extracellular domain of PSMA effective to inhibit the growth of the cell expressing PSMA.

According to another aspect of the invention, methods for inducing cytolysis of a cell expressing PSMA are provided. The methods include contacting a cell expressing PSMA with an amount of at least one of the foregoing antibodies or antigen-binding fragments thereof which specifically binds to an extracellular domain of PSMA effective to induce cytolysis of the cell expressing PSMA. In certain embodiments, the cytolysis occurs in the presence of an effector cell. In other embodiments, the cytolysis is complement mediated.

According to still another aspect of the invention, methods for treating or preventing a PSMA-mediated disease are provided. The methods include administering to a subject having a PSMA-mediated disease an effective amount of at least one of the forgoing antibodies or antigen-binding fragments thereof to treat or prevent the PSMA-mediated disease. In some embodiments, the PSMA-mediated disease is a cancer, such as prostate cancer or a non-prostate cancer (including the nonprostate cancers described elsewhere herein).

In yet a further aspect of the invention, methods for treating or preventing a PSMA-mediated disease are provided. The methods include administering to a subject having a PSMA-mediated disease or at risk of having a PSMA-mediated disease an amount of at least one of the foregoing antibodies or antigen-binding fragments thereof effective to treat or prevent the PSMA-mediated disease.

In some embodiments, the PSMA-mediated disease is a cancer, such as prostate cancer or a non-prostate cancer (including the nonprostate cancers described elsewhere herein).

In other embodiments, the method also includes administering another therapeutic agent to treat or prevent the PSMA-mediated disease at any time before, during or after the administration of the antibody or antigen-binding fragment thereof. In some of these

- 11 -

embodiments, the therapeutic agent is a vaccine, and preferably the vaccine immunizes the subject against PSMA.

In still other embodiments, the antibody or antigen-binding fragment thereof is bound to at least one therapeutic moiety, preferably a cytotoxic drug, a drug which acts on the tumor neovasculature and combinations thereof. Preferred cytotoxic drugs are selected from the group consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

In other embodiments, the antibody or antigen-binding fragment thereof is bound to a radioisotope and the radiations emitted by the radioisotope is selected from the group consisting of α , β and γ radiations. Preferably, the radioisotope is selected from the group consisting of ^{225}Ac , ^{211}At , ^{212}Bi , ^{213}Bi , ^{186}Rh , ^{188}Rh , ^{177}Lu , ^{90}Y , ^{131}I , ^{67}Cu , ^{125}I , ^{123}I , ^{77}Br , ^{153}Sm , ^{166}Ho , ^{64}Cu , ^{212}Pb , ^{224}Ra and ^{223}Ra .

The present invention provides methods for modulating at least one enzymatic activity of PSMA. As used in preferred embodiments of the methods, "modulating" an enzymatic activity of PSMA means enhancing or inhibiting the enzymatic activity. Thus in certain aspects of the invention, methods for inhibiting an enzymatic activity of PSMA are provided, and in other aspects of the invention, methods for enhancing an enzymatic activity of PSMA are provided. The terms "enhancing" and "inhibiting" in this context indicate that the enzymatic activity of PSMA is enhanced or inhibited in the presence of an antibody that specifically binds PSMA, or antigen-binding fragment thereof, relative to the level of activity in the absence of such an antibody or antigen-binding fragment thereof. Enzymatic activities of PSMA include folate hydrolase activity, N-acetylated α -linked acidic dipeptidase (NAALADase) activity, dipeptidyl dipeptidase IV activity and γ -glutamyl hydrolase activity.

Thus the invention in another aspect provides methods for modulating folate hydrolase activity. In certain embodiments of these methods, the activity is inhibited and in other embodiments, the activity is enhanced. The methods include contacting a folate hydrolase polypeptide with an amount of the foregoing isolated antibody or antigen-binding fragment thereof, under conditions wherein the isolated antibody or antigen-binding fragment thereof modulates the folate hydrolase activity. The folate hydrolase polypeptide can be isolated, contained in a sample such as a cell, a cell homogenate, a tissue, or a tissue

homogenate, or contained in an organism. The organism preferably is an animal, particularly preferably a mammal.

In another aspect of the invention, methods for modulating N-acetylated α -linked acidic dipeptidase (NAALADase) activity are provided. In certain embodiments of these 5 methods, the activity is inhibited and in other embodiments, the activity is enhanced. The methods include contacting a NAALADase polypeptide with an amount of the foregoing isolated antibody or antigen-binding fragment thereof under conditions wherein the isolated antibody or antigen-binding fragment thereof modulates NAALADase activity. The NAALADase polypeptide can be isolated, contained in a sample such as a cell, a cell 10 homogenate, a tissue, or a tissue homogenate, or contained in an organism. The organism preferably is an animal, particularly preferably a mammal.

In yet another aspect of the invention, methods for modulating dipeptidyl dipeptidase IV activity are provided. In certain embodiments of these methods, the activity is inhibited and in other embodiments, the activity is enhanced. The methods include contacting a 15 dipeptidyl dipeptidase IV polypeptide with an amount of the foregoing isolated antibody or antigen-binding fragment thereof under conditions wherein the isolated antibody or antigen-binding fragment thereof modulates dipeptidyl dipeptidase IV activity. The dipeptidyl dipeptidase IV polypeptide can be isolated, contained in a sample such as a cell, a cell homogenate, a tissue, or a tissue homogenate, or contained in an organism. The organism 20 preferably is an animal, particularly preferably a mammal.

In yet another aspect of the invention, methods for modulating γ -glutamyl hydrolase activity are provided. In certain embodiments of these methods, the activity is inhibited and in other embodiments, the activity is enhanced. The methods include contacting a γ -glutamyl hydrolase polypeptide with an amount of the foregoing isolated antibody or antigen-binding 25 fragment thereof under conditions wherein the isolated antibody or antigen-binding fragment thereof modulates γ -glutamyl hydrolase activity. The γ -glutamyl hydrolase polypeptide can be isolated, contained in a sample such as a cell, a cell homogenate, a tissue, or a tissue homogenate, or contained in an organism. The organism preferably is an animal, particularly preferably a mammal.

30 Methods of specific delivery of at least one therapeutic agent to PSMA-expressing cells are provided according to another aspect of the invention. The methods include administering an effective amount of at least one of the foregoing antibodies or antigen-

binding fragments thereof conjugated to the at least one therapeutic agent. In some embodiments, the therapeutic agent is a nucleic acid molecule, an antitumor drug, a toxin or a fragment thereof, an enzyme or a fragment thereof, a replication-selective virus, or an immunostimulatory or immunomodulating agent. Preferred antitumor drugs include 5 cytotoxic drugs, drugs which act on the tumor neovasculature and combinations thereof. Preferred cytotoxic drugs include calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE. Preferred immunostimulatory or 10 immunomodulating agent included cytokines, chemokines and adjuvants.

In still another aspect of the invention, isolated antibodies that selectively bind a PSMA protein multimer are provided. In preferred embodiments, the PSMA protein multimer is a dimer, and preferably at least one of the PSMA proteins forming the multimer is a recombinant, soluble PSMA (rsPSMA) polypeptide. Preferably the rsPSMA polypeptide 15 consists essentially of amino acids 44-750 of SEQ ID NO:1.

In a further aspect of the invention, isolated antibodies are provided that selectively bind a PSMA protein multimer and modulate one or more enzymatic activities of the PSMA protein multimer. As used in preferred embodiments of this aspect of the invention, “modulating” an enzymatic activity of a PSMA multimer means enhancing or inhibiting the 20 enzymatic activity. Thus in certain aspects of the invention, antibodies that inhibit an enzymatic activity of PSMA multimers are provided, and in other aspects of the invention, antibodies that inhibit an enzymatic activity of PSMA multimers are provided. The terms “enhancing” and “inhibiting” in this context indicate that the enzymatic activity of a PSMA multimer is enhanced or inhibited in the presence of an antibody that specifically binds the 25 PSMA multimers, or antigen-binding fragment thereof, relative to the level of activity in the absence of such an antibody or antigen-binding fragment thereof. In some embodiments, the enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity and γ -glutamyl hydrolase activity. In other embodiments, the enzymatic activity is in the extracellular domain of the PSMA 30 molecule. In still other embodiments, the antibody or antigen-binding fragment thereof specifically binds to an extracellular domain of PSMA.

5 In a further aspect, an isolated antibody or antigen-binding fragment thereof is provided that selectively binds a PSMA protein multimer. In this aspect, the isolated antibody is raised by immunizing an animal with a preparation comprising a PSMA protein multimer. Preferred preparations used in raising the antibody include those having at least about 10%, 20%, 30%, 40%, 50%, 75%, 90%, or 95% PSMA protein multimer. Preferably the PSMA protein multimer is a dimer.

10 In yet another aspect of the invention, compositions are provided that include one or more of the foregoing isolated antibodies, and an immunostimulatory molecule, such as an adjuvant and/or and a cytokine. Preferably the immunostimulatory molecule is IL-2 or an immunostimulatory oligonucleotide. In certain embodiments, the foregoing compositions 15 also include a pharmaceutically-acceptable carrier.

The invention also includes methods for inducing an immune response, including administering to a subject in need of such treatment an effective amount of the foregoing isolated antibodies or compositions.

15 The invention provides, in another aspect, isolated antibodies or antigen-binding fragments thereof that selectively bind a PSMA protein multimer and modulate at least one enzymatic activity of PSMA. As used in preferred embodiments of this aspect of the invention, "modulating" an enzymatic activity of a PSMA means enhancing or inhibiting the enzymatic activity. Thus in certain aspects of the invention, antibodies that inhibit an 20 enzymatic activity of PSMA are provided, and in other aspects of the invention, antibodies that inhibit an enzymatic activity of PSMA are provided. The terms "enhancing" and "inhibiting" in this context indicate that the enzymatic activity of PSMA is enhanced or inhibited in the presence of an antibody that specifically binds PSMA, or antigen-binding fragment thereof, relative to the level of activity in the absence of such an antibody or 25 antigen-binding fragment thereof. The enzyme, in certain embodiments, is selected from the group consisting of hydrolases and peptidases. Preferred hydrolases include folate hydrolase and γ -glutamyl hydrolase. In a particularly preferred embodiment of PSMA inhibition, the hydrolase is folate hydrolase and the antibody is mAb 5.4 or mAb 3.9. Preferred peptidases include NAALADase and dipeptidyl dipeptidase IV. In some embodiments, the enzyme is 30 active in cancer cells and has lesser activity in normal cells than in cancer cells or, preferably, no activity in normal cells. In preferred embodiments, the cancer cells in which the enzyme is active are prostate cancer cells. Compositions including the foregoing isolated antibodies

- 15 -

or antigen-binding fragments thereof, and a pharmaceutically acceptable carrier, also are provided by the invention.

In another aspect of the invention, compositions are provided that include an isolated PSMA protein multimer. Preferably the PSMA protein multimer is a dimer. In certain 5 embodiments, the compositions include at least about 10%, 20%, 30%, 40%, 50%, 75%, 90%, or 95% PSMA protein multimer. In other embodiments, the PSMA protein multimer comprises noncovalently associated PSMA proteins. The PSMA proteins preferably are noncovalently associated under nondenaturing conditions.

In certain embodiments of the foregoing compositions, at least one of the PSMA 10 proteins forming the multimer is a recombinant, soluble PSMA (rsPSMA) polypeptide. In other embodiments, the PSMA protein multimer is reactive with a conformation-specific antibody that specifically recognizes PSMA. Preferably, the PSMA protein multimer comprises PSMA proteins in a native conformation and/or the PSMA multimer is enzymatically active. In preferred embodiments, the enzymatic activity is folate hydrolase 15 activity, NAALADase activity, dipeptidyl dipeptidase IV activity and/or γ -glutamyl hydrolase activity.

In still other embodiments, the foregoing compositions also include an adjuvant and/or a cytokine or other immunostimulatory molecule. Preferred cytokines include IL-2, 20 IL-12, IL-18 and GM-CSF. In further embodiments, the foregoing compositions also include a pharmaceutically acceptable carrier.

According to yet another aspect of the invention, methods for inducing an immune response are provided. The methods include administering to a subject in need of such treatment an effective amount of one or more of the foregoing compositions.

In a further aspect, the invention includes isolated recombinant soluble PSMA 25 (rsPSMA) protein multimers, and isolated rsPSMA protein dimers. In some embodiments, the dimer includes noncovalently associated rsPSMA proteins, and preferably the rsPSMA proteins are noncovalently associated under nondenaturing conditions. In other embodiments, the isolated rsPSMA dimer is reactive with a conformation-specific antibody that specifically recognizes PSMA.

30 In a certain preferred embodiment, the isolated rsPSMA dimer is enzymatically active, with the enzymatic activity selected from the group consisting of folate hydrolase

- 16 -

activity, NAALADase activity, dipeptidyl dipeptidase IV activity and γ -glutamyl hydrolase activity.

In still another aspect of the invention, methods of screening for a candidate agent that modulates at least one enzymatic activity of a PSMA enzyme are provided. As used in 5 preferred embodiments of the methods, "modulating" an enzymatic activity of PSMA means enhancing or inhibiting the enzymatic activity. Thus in certain aspects of the invention, methods for screening for a candidate agent that inhibits an enzymatic activity of PSMA are provided, and in other aspects of the invention, methods for screening for a candidate agent that enhances an enzymatic activity of PSMA are provided. The terms "enhancing" and 10 "inhibiting" in this context indicate that the enzymatic activity of PSMA is enhanced or inhibited in the presence of a candidate agent relative to the level of activity in the absence of such an agent. The methods include mixing the candidate agent with an isolated PSMA protein multimer to form a reaction mixture, followed by adding a substrate for the PSMA enzyme to the reaction mixture, and determining the amount of a product formed from the 15 substrate by the PSMA enzyme. A change in the amount of product formed in comparison to a control is indicative of an agent capable of modulating at least one enzymatic activity of the PSMA enzyme. A decrease in the amount of product formed in comparison to a control is indicative of an agent capable of inhibiting at least one enzymatic activity of the PSMA enzyme. An increase in the amount of product formed in comparison to a control is 20 indicative of an agent capable of enhancing at least one enzymatic activity of the PSMA enzyme. In some embodiments the PSMA enzyme is selected from the group consisting of NAALADase, folate hydrolase, dipeptidyl dipeptidase IV and γ -glutamyl hydrolase. In other embodiments the PSMA multimer comprises recombinant, soluble PSMA. In yet other embodiments the candidate agent is selected from the group consisting of an antibody, a 25 small organic compound, or a peptide.

In another aspect of the invention, candidate agents that modulate at least one enzymatic activity of PSMA are provided. The candidate agents are identified according to the foregoing methods. Thus in certain aspects of the invention, candidate agents that inhibit an enzymatic activity of PSMA are provided, and in other aspects of the invention, candidate 30 agents that enhance an enzymatic activity of PSMA are provided. In certain embodiments, the agent is selected from a combinatorial antibody library, a combinatorial protein library, or a small organic molecule library.

The invention also provides methods for identifying compounds that promote dissociation of PSMA dimers. The methods include contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound, measuring the amount of PSMA monomer and/or dimer; and

5 comparing the amount of PSMA monomer and/or dimer measured in the presence of the compound with that observed in the absence of the compound. An increase in the amount of PSMA monomer measured in the presence of the compound indicates that the compound is capable of promoting dissociation of the PSMA dimer. A decrease in the amount of PSMA dimer measured in the presence of the compound indicates that the compound is capable of

10 promoting dissociation of the PSMA dimer. When the amounts of PSMA monomer and PSMA dimer are measured, the methods can include calculating a ratio of PSMA monomer to PSMA dimer and comparing the ratio obtained in the presence of the compound with that obtained in the absence of the compound. In such methods, an increase in the ratio measured in the presence of the compound indicates that the compound is capable of promoting

15 dissociation of the PSMA dimer.

The use of the foregoing compositions, molecules and agents in the preparation of medicaments also is provided. In preferred embodiments, the medicaments are useful in the treatment of conditions related to hyperproliferative diseases including cancer, and diseases of inappropriate NAALADase activity, folate hydrolase activity, dipeptidyl dipeptidase IV activity and/or γ -glutamyl hydrolase activity.

20 These and other aspects of the invention will be described in further detail in connection with the detailed description of the invention.

Brief Description of the Drawings

25 Figure 1 depicts PSMA reactivity of mAbs as determined by flow cytometry. Anti-PSMA mAbs (3.7, 3.9, 3.11, 3.12, 5.4, and 10.3) incubated with either parental 3T3 cells (denoted by black lines) or 3T3 cells engineered to express cell-surface PSMA (3T3-PSMA; gray lines).

Figure 2 shows a digitized image of immunoprecipitation of PSMA by mAbs.

30 Lysates from 3T3-PSMA cells or parental 3T3 cells were incubated with each mAb and then precipitated using Protein A/G agarose beads. After washing, proteins were resolved on a

- 18 -

polyacrylamide gel, blotted onto nitrocellulose membranes and visualized using the MAB544 anti-PSMA mAb.

Figure 3 shows the recognition of non-denatured PSMA by several PSMA antibodies that recognize PSMA conformation.

5 Figure 4 is a digitized image of a Western blot that shows the recognition of denatured PSMA by two PSMA antibodies and shows that antibodies that recognize PSMA conformation do not recognize denatured PSMA.

10 Figure 5 is a digitized image of a polyacrylamide gel that shows an analysis of purified recombinant, soluble PSMA (rsPSMA) and of full-length PSMA from 3T3 cells (3T3 PSMA) or LNCaP cells (LNCaP PSMA) by reduced and non-reduced SDS-PAGE.

Figure 6 is a digitized image of a polyacrylamide gel that depicts a Blue Native PAGE analysis of purified recombinant, soluble PSMA (Purified rsPSMA) and of full-length PSMA extracted from 3T3 cells (3T3 PSMA) or LNCaP cells (LNCaP PSMA).

15 Figure 7 shows the effect of four antibodies (mAb 3.9, mAb 5.4, mAb 7.3 and mAb J591) on the enzymatic activity of folate hydrolase through measuring the rate of cleavage of glutamate from methotrexate di-gamma glutamate by folate hydrolase present in 0.0002 μ g rsPSMA #7.

20 Figure 8 shows the effect of four antibodies (mAb 3.9, mAb 5.4, mAb 7.3 and mAb J591) on the enzymatic activity of folate hydrolase through measuring the rate of cleavage of glutamate from methotrexate di-gamma glutamate by folate hydrolase present in 0.0002 μ g rsPSMA #8.

25 Figure 9 shows the effect of four antibodies (mAb 3.9, mAb 5.4, mAb 7.3 and mAb J591) on the enzymatic activity of folate hydrolase through measuring the rate of cleavage of glutamate from methotrexate di-gamma glutamate by folate hydrolase present in lysates of C4-2 cells.

Figure 10 depicts the cloning protocol for IgG1 antibody cloning into pcDNA.

Figure 11 provides the plasmid map of a nucleic acid molecule encoding the heavy chain of antibody AB-PG1-XG1-006.

30 Figure 12 provides the plasmid map of a nucleic acid molecule encoding the heavy chain of antibody AB-PG1-XG1-026.

Figure 13 provides the plasmid map of a nucleic acid molecule encoding the heavy chain of antibody AB-PG1-XG1-051.

- 19 -

Figure 14 provides the plasmid map of a nucleic acid molecule encoding the heavy chain of antibody AB-PG1-XG1-069.

Figure 15 provides the plasmid map of a nucleic acid molecule encoding the heavy chain of antibody AB-PG1-XG1-077.

5 Figure 16 provides the plasmid map of a nucleic acid molecule encoding the heavy chain of antibody PSMA 10.3.

Figure 17 provides the plasmid map of a nucleic acid molecule encoding the light chain of antibody AB-PG1-XG1-006.

10 Figure 18 provides the plasmid map of a nucleic acid molecule encoding the light chain of antibody AB-PG1-XG1-026.

Figure 19 provides the plasmid map of a nucleic acid molecule encoding the light chain of antibody AB-PG1-XG1-051.

Figure 20 provides the plasmid map of a nucleic acid molecule encoding the light chain of antibody AB-PG1-XG1-069.

15 Figure 21 provides the plasmid map of a nucleic acid molecule encoding the light chain of antibody AB-PG1-XG1-077.

Figure 22 provides the plasmid map of a nucleic acid molecule encoding the light chain of antibody PSMA 10.3.

Figure 23 depicts the cytotoxicity of ^{225}Ac -3.9 on LNCaP target cells.

20 Figure 24 illustrates the reactivity of anti-PSMA monoclonal antibodies XG-006, XG-051, 4.40.1, 4.49.1, 4.292.1 and 4.304.1 incubated with either parent 3T3 cells (black histogram) or 3T3 cells engineered to express cell-surface human PSMA (grey histogram) and analyzed by flow cytometry.

Figure 25 illustrates the binding of the anti-PSMA Abs. Figure 25A shows that anti-25 PSMA mAbs bind to 3T3-PSMA cells and not 3T3 cells. One representative experiment from at least ten determinations is shown. Figure 25B illustrates that binding to cell-surface PSMA using serial dilutions of anti-PSMA mAb-containing culture supernatants occurred. One representative experiment from five is shown. Figure 25C shows binding to cell-surface PSMA using serial dilutions of purified anti-PSMA mAbs, XG-006 and 10.3 One 30 representative experiment is shown.

Figure 26 illustrates the immunotoxin cytotoxicity of murine anti-PSMA antibodies on C4-2 prostate cancer cells. SJ25C-1 as a control antibody is a murine anti-CD19 IgG.

- 20 -

The LD 50s (M) for 5.4, 3.9, and mJ591 antibodies were 2.27×10^{-11} , 2.29×10^{-11} and 8.82×10^{-11} , respectively.

Figure 27 illustrates the immunotoxin cytotoxicity of murine anti-PSMA antibodies on PSMA-3T3 cells. SJ25C-1 as a control antibody is a murine anti-CD19 IgG. The LD 50s (M) for 5.4, 3.9, and mJ591 antibodies were 1.64×10^{-11} , 1.96×10^{-11} and 8.90×10^{-11} , respectively.

Figure 28 provides the cytotoxicity of direct conjugated human 4.304 anti-PSMA antibodies with saporin on PSMA-3T3. The LD50 was 1.48×10^{-11} M for direct conjugated 4.304 anti-PSMA antibodies with saporin.

Figure 29 illustrates the results of the competition assay of unmodified 4.304, 4.40, mJ591 anti-PSMA antibodies used to compete with In-111 radiolabeled 4.40 and 4.304 anti-PSMA antibodies.

Figure 30 illustrates the results of the competition assay of unmodified 4.304, mJ591 anti-PSMA antibodies used to compete with In-111 radiolabeled mJ591 anti-PSMA antibodies.

Figure 31 shows an analysis of antibody PRGX1-XG-006 in association phase and dissociation phase at different concentrations of rsPSMA from 100 nM to 6.25 nM.

Figure 32 shows the results of the comparison of the fully human anti-PSMA antibodies 4.40.1, 4.49.1, 051 and 006 and the murine anti-PSMA antibody 3.9 performed using Biacore analysis.

Figure 33 provides results from the Scatchard analysis using In-111 labeled anti-PSMA antibody 3.9 of the PSMA-3T3, LNCaP and C4-2 cell lines.

Figure 34 shows *in vitro* cytotoxicity of Ac-225 labeled human anti-PSMA antibody 4.40 on prostate cancer cells.

Figure 35 shows the results of *in vivo* radioimmunotherapy with Lu-177 labeled human anti-PSMA antibodies.

Figure 36 is a series of graphs that show flow cytometry data for the binding of anti-PSMA antisera to PSMA-3T3 cells. Antisera from mice immunized with a rsPSMA dimer preparation (ABIM151, ABIM152, ABIM153, ABIM154 and ABIM155) exhibited strong binding to PSMA-expressing cells. Antisera from mice immunized with a rsPSMA monomer preparation (ABIM156, ABIM157, ABIM158, ABIM159 and ABIM160) exhibited little or no binding to PSMA-expressing cells.

Detailed Description of the Invention

The present invention provides antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, 5 compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment.

Prostate specific membrane antigen (PSMA) is a 100 kD Type II membrane glycoprotein expressed in prostate tissues and was originally identified by reactivity with a 10 monoclonal antibody designated 7E11-C5 (Horoszewicz et al., 1987, *Anticancer Res.* 7:927-935; U.S. Pat. No. 5,162,504). PSMA was obtained in purified form (Wright et al., 1990, *Antibody Immunoconjugates and Radio Pharmaceuticals* 3:Abstract 193) and characterized 15 as a type II transmembrane protein having sequence identity with the transferrin receptor (Israeli et al., 1994, *Cancer Res.* 54:1807-1811) and with NAALADase activity (Carter et al., 1996, *Proc. Natl. Acad. Sci. U.S.A.* 93:749-753). More importantly, PSMA is expressed in increased amounts in prostate cancer, and elevated levels of PSMA are also detectable in the sera of these patients (Horoszewicz et al., 1987; Rochon et al., 1994, *Prostate* 25:219-223; Murphy et al., 1995, *Prostate* 26:164-168; and Murphy et al., 1995, *Anticancer Res.* 15:1473-1479). PSMA expression increases with disease progression, becoming highest in metastatic, 20 hormone-refractory disease for which there is no present therapy. Provocative recent data indicates that PSMA is also abundantly expressed on the neovasculature of a variety of other important tumors, including bladder, pancreas, sarcoma, melanoma, lung, and kidney tumor cells, but not on normal vasculature.

One aspect of the invention provides an isolated antibody or an antigen-binding 25 fragment thereof which specifically binds to an extracellular domain of PSMA wherein the antibody or the antigen-binding fragment thereof competitively inhibits the specific binding of a second antibody to its target epitope on PSMA, and wherein the second antibody is selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, 4.248.2, 30 4.360.3, 4.7.1, 4.4.1, 4.177.3, 4.16.1, 4.22.3, 4.28.3, 4.40.2, 4.48.3, 4.49.1, 4.209.3, 4.219.3, 4.288.1, 4.333.1, 4.54.1, 4.153.1, 4.232.3, 4.292.3, 4.304.1, 4.78.1, and 4.152.1.

Another aspect of the invention provides an isolated antibody or an antigen-binding fragment thereof that specifically binds to an epitope on PSMA defined by an antibody selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, 4.248.2, 5 4.360.3, 4.7.1, 4.4.1, 4.177.3, 4.16.1, 4.22.3, 4.28.3, 4.40.2, 4.48.3, 4.49.1, 4.209.3, 4.219.3, 4.288.1, 4.333.1, 4.54.1, 4.153.1, 4.232.3, 4.292.3, 4.304.1, 4.78.1, and 4.152.1.

In particular embodiments, these antibodies are produced by hybridomas referred to herein as PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, 10 Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, and Abgenix 4.152.1, respectively.

These hybridomas were deposited with ATCC as an International Depository Authority and 15 given the following Patent Deposit Designations (Table 1):

Table 1.

Antibody	Hybridoma/Plasmid	Patent Deposit Designation	Date of Deposit
PSMA 3.7	PSMA 3.7	PTA-3257	April 5, 2001
PSMA 3.9	PSMA 3.9	PTA-3258	April 5, 2001
PSMA 3.11	PSMA 3.11	PTA-3269	April 10, 2001
PSMA 5.4	PSMA 5.4	PTA-3268	April 10, 2001
PSMA 7.1	PSMA 7.1	PTA-3292	April 18, 2001
PSMA 7.3	PSMA 7.3	PTA-3293	April 18, 2001
PSMA 10.3	PSMA 10.3	PTA-3347	May 1, 2001
	PSMA 10.3 HC in pcDNA (SEQ ID NO: 7)	PTA-4413	May 29, 2002
	PSMA 10.3 Kappa in pcDNA (SEQ ID NO: 13)	PTA-4414	May 29, 2002
PSMA 1.8.3	PSMA 1.8.3	PTA-3906	Dec. 5, 2001
PSMA A3.1.3	PSMA A3.1.3	PTA-3904	Dec. 5, 2001

- 23 -

PSMA A3.3.1	PSMA A3.3.1	PTA-3905	Dec. 5, 2001
Abgenix 4.248.2	Abgenix 4.248.2	PTA-4427	June 4, 2002
Abgenix 4.360.3	Abgenix 4.360.3	PTA-4428	June 4, 2002
Abgenix 4.7.1	Abgenix 4.7.1	PTA-4429	June 4, 2002
Abgenix 4.4.1	Abgenix 4.4.1	PTA-4556	July 18, 2002
Abgenix 4.177.3	Abgenix 4.177.3	PTA-4557	July 18, 2002
Abgenix 4.16.1	Abgenix 4.16.1	PTA-4357	May 16, 2002
Abgenix 4.22.3	Abgenix 4.22.3	PTA-4358	May 16, 2002
Abgenix 4.28.3	Abgenix 4.28.3	PTA-4359	May 16, 2002
Abgenix 4.40.2	Abgenix 4.40.2	PTA-4360	May 16, 2002
Abgenix 4.48.3	Abgenix 4.48.3	PTA-4361	May 16, 2002
Abgenix 4.49.1	Abgenix 4.49.1	PTA-4362	May 16, 2002
Abgenix 4.209.3	Abgenix 4.209.3	PTA-4365	May 16, 2002
Abgenix 4.219.3	Abgenix 4.219.3	PTA-4366	May 16, 2002
Abgenix 4.288.1	Abgenix 4.288.1	PTA-4367	May 16, 2002
Abgenix 4.333.1	Abgenix 4.333.1	PTA-4368	May 16, 2002
Abgenix 4.54.1	Abgenix 4.54.1	PTA-4363	May 16, 2002
Abgenix 4.153.1	Abgenix 4.153.1	PTA-4388	May 23, 2002
Abgenix 4.232.3	Abgenix 4.232.3	PTA-4389	May 23, 2002
Abgenix 4.292.3	Abgenix 4.292.3	PTA-4390	May 23, 2002
Abgenix 4.304.1	Abgenix 4.304.1	PTA-4391	May 23, 2002
AB-PG1-XG1-006	AB-PG1-XG1-006 Heavy Chain (SEQ ID NO: 2)	PTA-4403	May 29, 2002
	AB-PG1-XG1-006 Light Chain (SEQ ID NO: 8)	PTA-4404	
AB-PG1-XG1-026	AB-PG1-XG1-026 Heavy Chain (SEQ ID NO: 3)	PTA-4405	May 29, 2002
	AB-PG1-XG1-026 Light Chain (SEQ ID NO: 9)	PTA-4406	
AB-PG1-XG1-051	AB-PG1-XG1-051 Heavy Chain (SEQ ID NO: 4)	PTA-4407	May 29, 2002
	AB-PG1-XG1-051 Light	PTA-4408	

	Chain (SEQ ID NO: 10)		
AB-PG1-XG1-069	AB-PG1-XG1-069 Heavy Chain (SEQ ID NO: 5) AB-PG1-XG1-069 Light Chain (SEQ ID NO: 11)	PTA-4409 PTA-4410	May 29, 2002
AB-PG1-XG1-077	AB-PG1-XG1-077 Heavy Chain (SEQ ID NO: 6) AB-PG1-XG1-077 Light Chain (SEQ ID NO: 12)	PTA-4411 PTA-4412	May 29, 2002

In another aspect of the invention, antibodies having particular sequences are provided. Specifically, the antibodies are selected from the group consisting of antibodies comprising: a heavy chain encoded by a nucleic acid molecule comprising the heavy chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and a light chain encoded by a nucleic acid molecule comprising the light chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13. Also provided are antigen-binding fragments of the foregoing antibodies.

The plasmids encoding the heavy and light chains of antibodies PSMA 10.3, AB-PG1-XG1-006, AB-PG1-XG1-026, AB-PG1-XG1-051, AB-PG1-XG1-069, AB-PG1-XG1-077 were also deposited with ATCC and are shown in Table 1 above. As used herein, the names of the deposited hybridomas or plasmids may be used interchangeably with the names of the antibodies. It would be clear to one of skill in the art when the name is intended to refer to the antibody or when it refers to the plasmids or hybridomas that encode or produce the antibodies, respectively. Additionally, the antibody names may be an abbreviated form of the name shown in Table 1. For instance antibody AB-PG1-XG1-006 may be referred to as AB-PG1-XG1-006, PG1-XG1-006, XG1-006, 006, etc. In another example, the antibody name PSMA 4.232.3 may be referred to as PSMA 4.232.1, 4.232.3, 4.232.1, 4.232, etc. It is intended that all of the variations in the name of the antibody refer to the same antibody and not a different one.

Antibodies are also provided that are encoded by particular sets of heavy and light chain sequences. In one embodiment an antibody (AB-PG1-XG1-006) encoded by a nucleic

acid molecule which comprises the coding region or regions of the nucleic acid sequences set forth as :SEQ ID NOs: 2 and 8 is provided. In another embodiment the antibody (AB-PG1-XG1-026) is encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 3 and 9. In still another embodiment the antibody (AB-PG1-XG1-051) is encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 4 and 10. In yet another embodiment the antibody (AB-PG1-XG1-069) is encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 5 and 11. In another embodiment the antibody (AB-PG1-XG1-077) is encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 6 and 12. In yet another embodiment the antibody (PSMA 10.3) is encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 7 and 13.

In particularly preferred embodiments, the antibodies include a heavy chain variable region encoded by a nucleic acid molecule comprising the coding regions or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 14, 18, 22, 26 and 30, and a light chain variable region encoded by a nucleic acid molecule comprising the coding region or region of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 16, 20, 24, 28 and 32. As used herein, a “coding region” refers to a region of a nucleotide sequence that encodes a polypeptide sequence; the coding region can include a region coding for a portion of a protein that is later cleaved off, such as a signal peptide.

Those of skill in the art will appreciate that the invention includes nucleic acids and polypeptides that include nucleotide and amino acid sequences presented herein. In some instances, the nucleotide and amino acid sequences may include sequences that encode or that are signal peptides. The invention embraces each of these sequences with, or without, the portion of the sequence that encodes or is a signal peptide.

Antibodies also are provided that include particular sets of heavy and light chain variable sequences. In one embodiment an antibody (AB-PG1-XG1-006) includes an immunoglobulin variable sequence encoded by nucleic acid molecules which included the coding region or regions of the nucleic acid sequences set forth as :SEQ ID NOs: 14 and 16 is provided. Likewise the antibody may include an immunoglobulin variable sequence which

- 26 -

comprises the amino acid sequences set forth as SEQ ID NOs: 15 and 17. In another embodiment the antibody (AB-PG1-XG1-026) includes an immunoglobulin variable sequence encoded by nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 18 and 20 or includes an immunoglobulin variable sequence which comprises the amino acid sequences set forth as SEQ ID NOs: 19 and 21. In still another embodiment the antibody (AB-PG1-XG1-051) includes an immunoglobulin variable sequence encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 22 and 24 or includes an immunoglobulin variable sequence which comprises the amino acid sequences set forth as SEQ ID NOs: 23 and 25. In yet another embodiment the antibody (AB-PG1-XG1-069) includes an immunoglobulin variable sequence encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 26 and 28 or includes an immunoglobulin variable sequence which comprises the amino acid sequences set forth as SEQ ID NOs: 27 and 29. In another embodiment the antibody (AB-PG1-XG1-077) includes an immunoglobulin variable sequence encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 30 and 32 or includes an immunoglobulin variable sequence which comprises the amino acid sequences set forth as SEQ ID NOs: 31 and 33.

In certain embodiments, the antibody is encoded by a nucleic acid molecule that is highly homologous to the foregoing nucleic acid molecules. Preferably the homologous nucleic acid molecule comprises a nucleotide sequence that is at least about 90% identical to the nucleotide sequence provided herein. More preferably, the nucleotide sequence is at least about 95% identical, at least about 97% identical, at least about 98% identical, or at least about 99% identical to the nucleotide sequence provided herein. The homology can be calculated using various, publicly available software tools well known to one of ordinary skill in the art. Exemplary tools include the BLAST system available from the website of the National Center for Biotechnology Information (NCBI) at the National Institutes of Health.

One method of identifying highly homologous nucleotide sequences is via nucleic acid hybridization. Thus the invention also includes antibodies having the PSMA-binding properties and other functional properties described herein, which are encoded by nucleic acid molecules that hybridize under high stringency conditions to the foregoing nucleic acid molecules. Identification of related sequences can also be achieved using polymerase chain

reaction (PCR) and other amplification techniques suitable for cloning related nucleic acid sequences. Preferably, PCR primers are selected to amplify portions of a nucleic acid sequence of interest, such as a CDR.

The term "high stringency conditions" as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references that compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. One example of high-stringency conditions is hybridization at 65°C in hybridization buffer (3.5X SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH₂PO₄(pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.015M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetraacetic acid. After hybridization, a membrane upon which the nucleic acid is transferred is washed, for example, in 2X SSC at room temperature and then at 0.1 - 0.5X SSC/0.1X SDS at temperatures up to 68°C.

In other preferred embodiments, the antibodies include a heavy chain variable region comprising an amino acid sequence selected from the group consisting of amino acid sequences set forth as: SEQ ID NOS: 15, 19, 23, 27 and 31, and a light chain variable region comprising an amino acid sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOS: 17, 21, 25, 29 and 33. Antigen-binding fragments of the foregoing also are provided, as described elsewhere herein.

As used herein, the term "antibody" refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or V_H) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, C_H1, C_H2 and C_H3. Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or V_L) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The V_H and V_L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each V_H and V_L is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The

variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.

5 The term "antigen-binding fragment" of an antibody as used herein, refers to one or more portions of an antibody that retain the ability to specifically bind to an antigen (e.g., PSMA). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term "antigen-binding fragment" of an antibody include (i) a Fab fragment, a monovalent 10 fragment consisting of the V_L, V_H, C_L and C_{H1} domains; (ii) a F(ab')₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the V_H and CH1 domains; (iv) a Fv fragment consisting of the V_L and V_H domains of a single arm of an antibody, (v) a dAb fragment (Ward *et al.*, (1989) 15 *Nature* 341:544-546) which consists of a V_H domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, V_L and V_H, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V_L and 20 V_H regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird *et al.* (1988) *Science* 242:423-426; and Huston *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5879-5883). Such single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody. These antibody fragments are obtained using conventional procedures, such as proteolytic fragmentation procedures, as described in J. 25 Goding, *Monoclonal Antibodies: Principles and Practice*, pp 98-118 (N.Y. Academic Press 1983), which is hereby incorporated by reference as well as by other techniques known to those with skill in the art. The fragments are screened for utility in the same manner as are intact antibodies.

30 An "isolated antibody", as used herein, is intended to refer to an antibody which is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds to PSMA is substantially free of antibodies that specifically bind antigens other than PSMA). An isolated antibody that specifically binds to an epitope, isoform or variant of PSMA may, however, have cross-reactivity to other related antigens, e.g., from other species (e.g., PSMA species homologs). Moreover, an isolated antibody may

be substantially free of other cellular material and/or chemicals. As used herein, "specific binding" refers to antibody binding to a predetermined antigen. Typically, the antibody binds with an affinity that is at least two-fold greater than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely-related antigen.

5 The isolated antibodies of the invention encompass various antibody isotypes, such as IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, IgE. As used herein, "isotype" refers to the antibody class (e.g. IgM or IgG1) that is encoded by heavy chain constant region genes. The antibodies can be full length or can include only an antigen-binding fragment such as the antibody constant and/or variable domain of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, 10 IgA2, IgAsec, IgD or IgE or could consist of a Fab fragment, a F(ab')₂ fragment, and a Fv fragment.

The antibodies of the present invention can be polyclonal, monoclonal, or a mixture of polyclonal and monoclonal antibodies. The antibodies can be produced by a variety of techniques well known in the art. Procedures for raising polyclonal antibodies are well 15 known. For example anti-PSMA polyclonal antibodies are raised by administering PSMA protein subcutaneously to New Zealand white rabbits which have first been bled to obtain pre-immune serum. The PSMA can be injected at a total volume of 100 μ l per site at six different sites, typically with one or more adjustments. The rabbits are then bled two weeks after the first injection and periodically boosted with the same antigen three times every six 20 weeks. A sample of serum is collected 10 days after each boost. Polyclonal antibodies are recovered from the serum, preferably by affinity chromatography using PSMA to capture the antibody. This and other procedures for raising polyclonal antibodies are disclosed in E. Harlow, et. al., editors, *Antibodies: A Laboratory Manual* (1988), which is hereby incorporated by reference.

25 Monoclonal antibody production may be effected by techniques which are also well known in the art. The term "monoclonal antibody," as used herein, refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody displays a single binding specificity and affinity for a particular epitope. The process of monoclonal antibody production involves obtaining immune somatic cells with the potential for 30 producing antibody, in particular B lymphocytes, which have been previously immunized with the antigen of interest either *in vivo* or *in vitro* and that are suitable for fusion with a B-cell myeloma line.

- 30 -

Mammalian lymphocytes typically are immunized by *in vivo* immunization of the animal (e.g., a mouse) with the desired protein or polypeptide, e.g., with PSMA in the present invention. Such immunizations are repeated as necessary at intervals of up to several weeks to obtain a sufficient titer of antibodies. Once immunized, animals can be used as a source of antibody-producing lymphocytes. Following the last antigen boost, the animals are sacrificed and spleen cells removed. Mouse lymphocytes give a higher percentage of stable fusions with the mouse myeloma lines described herein. Of these, the BALB/c mouse is preferred. However, other mouse strains, rabbit, hamster, sheep and frog may also be used as hosts for preparing antibody-producing cells. See; Goding (in *Monoclonal Antibodies: Principles and Practice*, 2d ed., pp. 60-61, Orlando, Fla., Academic Press, 1986). In particular, mouse strains that have human immunoglobulin genes inserted in the genome (and which cannot produce mouse immunoglobulins) are preferred. Examples include the HuMAb mouse strains produced by Medarex/GenPharm International, and the XenoMouse strains produced by Abgenix. Such mice produce fully human immunoglobulin molecules in response to immunization.

Those antibody-producing cells that are in the dividing plasmablast stage fuse preferentially. Somatic cells may be obtained from the lymph nodes, spleens and peripheral blood of antigen-primed animals, and the lymphatic cells of choice depend to a large extent on their empirical usefulness in the particular fusion system. The antibody-secreting lymphocytes are then fused with (mouse) B cell myeloma cells or transformed cells, which are capable of replicating indefinitely in cell culture, thereby producing an immortal, immunoglobulin-secreting cell line. The resulting fused cells, or hybridomas, are cultured, and the resulting colonies screened for the production of the desired monoclonal antibodies. Colonies producing such antibodies are cloned, and grown either *in vivo* or *in vitro* to produce large quantities of antibody. A description of the theoretical basis and practical methodology of fusing such cells is set forth in Kohler and Milstein, *Nature* 256:495 (1975), which is hereby incorporated by reference.

Alternatively, human somatic cells capable of producing antibody, specifically B lymphocytes, are suitable for fusion with myeloma cell lines. While B lymphocytes from biopsied spleens, tonsils or lymph nodes of an individual may be used, the more easily accessible peripheral blood B lymphocytes are preferred. The lymphocytes may be derived from patients with diagnosed prostate carcinomas or another PSMA-expressing cancer. In

addition, human B cells may be directly immortalized by the Epstein-Barr virus (Cole et al., 1995, *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). Although somatic cell hybridization procedures are preferred, in principle, other techniques for producing monoclonal antibodies can be employed such as viral or oncogenic transformation of B lymphocytes.

5 Myeloma cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and enzyme deficiencies that render them incapable of growing in certain selective media which support the growth of the desired hybridomas. Examples of such myeloma cell lines that may be used for the 10 production of fused cell lines include P3-X63/Ag8, X63-Ag8.653, NS1/1.Ag 4.1, Sp2/0-Ag14, FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7, S194/5XX0 Bul, all derived from mice; R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210 derived from rats and U-266, GM1500-GRG2, LICR-LON-HMy2, UC729-6, all derived from humans (Goding, in *Monoclonal Antibodies: Principles and Practice*, 2d ed., pp. 65-66, Orlando, Fla., Academic Press, 1986; Campbell, in 15 *Monoclonal Antibody Technology, Laboratory Techniques in Biochemistry and Molecular Biology* Vol. 13, Burden and Von Knippenberg, eds. pp. 75-83, Amsterdam, Elseview, 1984).

20 Fusion with mammalian myeloma cells or other fusion partners capable of replicating indefinitely in cell culture is effected by standard and well-known techniques, for example, by using polyethylene glycol ("PEG") or other fusing agents (See Milstein and Kohler, *Eur. J. Immunol.* 6:511 (1976), which is hereby incorporated by reference).

25 In other embodiments, the antibodies can be recombinant antibodies. The term "recombinant antibody", as used herein, is intended to include antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from an animal (e.g., a mouse) that is transgenic for another species' immunoglobulin genes, antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant, combinatorial antibody library, or antibodies prepared, expressed, created or isolated by any other means that involves splicing of immunoglobulin gene sequences to other DNA sequences.

30 In yet other embodiments, the antibodies can be chimeric or humanized antibodies. As used herein, the term "chimeric antibody" refers to an antibody, that combines the murine variable or hypervariable regions with the human constant region or constant and variable

framework regions. As used herein, the term "humanized antibody" refers to an antibody that retains only the antigen-binding CDRs from the parent antibody in association with human framework regions (see, Waldmann, 1991, *Science* 252:1657). Such chimeric or humanized antibodies retaining binding specificity of the murine antibody are expected to have reduced 5 immunogenicity when administered *in vivo* for diagnostic, prophylactic or therapeutic applications according to the invention.

According to an alternative embodiment, the monoclonal antibodies of the present invention can be modified to be in the form of a bispecific antibody, or a multispecific antibody. The term "bispecific antibody" is intended to include any agent, e.g., a protein, 10 peptide, or protein or peptide complex, which has two different binding specificities which bind to, or interact with (a) a cell surface antigen and (b) an Fc receptor on the surface of an effector cell. The term "multispecific antibody" is intended to include any agent, e.g., a protein, peptide, or protein or peptide complex, which has more than two different binding specificities which bind to, or interact with (a) a cell surface antigen, (b) an Fc receptor on the 15 surface of an effector cell, and (c) at least one other component. Accordingly, the invention includes, but is not limited to, bispecific, trispecific, tetraspecific, and other multispecific antibodies which are directed to cell surface antigens, such as PSMA, and to Fc receptors on effector cells. The term "bispecific antibodies" further includes diabodies. Diabodies are bivalent, bispecific antibodies in which the V_H and V_L domains are expressed on a single 20 polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen-binding sites (see e.g., Holliger, P., *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:6444-6448; Poijak, R.J., *et al.* (1994) *Structure* 2:1121-1123).

A bispecific antibody can be formed of an antigen-binding region specific for the 25 extracellular domain of PSMA and an antigen-binding region specific for an effector cell which has tumoricidal or tumor inhibitory activity. The two antigen-binding regions of the bispecific antibody are either chemically linked or can be expressed by a cell genetically engineered to produce the bispecific antibody. (See generally, Fanger *et al.*, 1995 *Drug News & Perspec.* 8(3):133-137). Suitable effector cells having tumoricidal activity include but are 30 not limited to cytotoxic T-cells (primarily $CD8^+$ cells), natural killer cells, etc. An effective amount of a bispecific antibody according to the invention is administered to a prostrate

cancer patient and the bispecific antibody kills and/or inhibits proliferation of the malignant cells after localization at sites of primary or metastatic tumors bearing PSMA.

In certain embodiments, the antibodies are human antibodies. The term "human antibody", as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis *in vitro* or by somatic mutation *in vivo*). However, the term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse have been grafted onto human framework sequences (referred to herein as "humanized antibodies"). Human antibodies directed against PSMA are generated using transgenic mice carrying parts of the human immune system rather than the mouse system.

Fully human monoclonal antibodies also can be prepared by immunizing mice transgenic for large portions of human immunoglobulin heavy and light chain loci. See, e.g., U.S. patents 5,591,669, 5,598,369, 5,545,806, 5,545,807, 6,150,584, and references cited therein, the contents of which are incorporated herein by reference. These animals have been genetically modified such that there is a functional deletion in the production of endogenous (e.g., murine) antibodies. The animals are further modified to contain all or a portion of the human germ-line immunoglobulin gene locus such that immunization of these animals results in the production of fully human antibodies to the antigen of interest. Following immunization of these mice (e.g., XenoMouse (Abgenix), HuMAb mice (Medarex/GenPharm)), monoclonal antibodies are prepared according to standard hybridoma technology. These monoclonal antibodies have human immunoglobulin amino acid sequences and therefore will not provoke human anti-mouse antibody (HAMA) responses when administered to humans.

Preferably, the mice are 6-16 weeks of age upon the first immunization. For example, a purified or enriched preparation of PSMA antigen (e.g., recombinant PSMA or PSMA-expressing cells) is used to immunize the mice intraperitoneally (IP), although other routes of immunization known to one of ordinary skill in the art are also possible. PSMA antigen is injected in combination with an adjuvant, such as complete Freund's adjuvant, and preferably the initial injection is followed by booster immunizations with antigen in an adjuvant, such as

incomplete Freund's adjuvant. The immune response is monitored over the course of the immunization protocol with plasma samples obtained by, for example, retroorbital bleeds. The plasma is screened by ELISA (as described below), and mice with sufficient titers of anti-PSMA human immunoglobulin are used for fusions. Mice are boosted intravenously 5 with antigen 3 days before sacrifice and removal of the spleen.

In particular embodiments, the antibodies are produced by hybridomas referred to herein as PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293), PSMA 10.3 (PTA-3247), PSMA 1.8.3 (PTA-3906), PSMA A3.1.3 (PTA-3904), PSMA A3.3.1 (PTA-10 3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428), Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557), Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359), Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362), Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367), Abgenix 4.333.1 (PTA-15 4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388), Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391), Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1 (PTA-4653). These hybridomas were deposited pursuant to, and in satisfaction of, the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure with the American Type 20 Culture Collection ("ATCC") as an International Depository Authority and given the Patent Deposit Designations shown above and in Table 1.

The present invention further provides nucleic acid molecules encoding anti-PSMA antibodies and vectors comprising the nucleic acid molecules as described herein. The vectors provided can be used to transform or transfect host cells for producing anti-PSMA 25 antibodies with the specificity of antibodies described herein. In a preferred embodiment the antibodies produced will have the specificity of the antibodies AB-PG1-XG1-006, AB-PG1-XG1-026, AB-PG1-XG1-051, AB-PG1, XG1-069, AB-PG1-XG1-077 and PSMA 10.3. In one embodiment the vectors can comprise an isolated nucleic acid molecule encoding the heavy chain of the antibodies listed above encoded by a nucleic acid molecules comprising 30 the coding region or regions of the nucleic acid sequences set forth as SEQ ID NO: 2-7. In another embodiment, the vectors can comprise the nucleic acid sequences encoding the light chain of the antibodies set forth as SEQ ID NOs: 8-13. In a further embodiment the vectors

of the invention may comprise a heavy chain and a light chain sequence. In a further embodiment, plasmids are given which produce the antibodies or antigen binding fragments described herein. Plasmids of the invention include plasmids selected from the group consisting of: AB-PG1-XG1-006 Heavy Chain (SEQ ID NO: 2), AB-PG1-XG1-006 Light Chain (SEQ ID NO: 8), AB-PG1-XG1-026 Heavy Chain (SEQ ID NO: 3), AB-PG1-XG1-026 Light Chain (SEQ ID NO: 9), AB-PG1-XG1-051 Heavy Chain (SEQ ID NO: 4), AB-PG1-XG1-051 Light Chain (SEQ ID NO: 10), AB-PG1-XG1-069 Heavy Chain (SEQ ID NO: 5), AB-PG1-XG1-069 Light Chain (SEQ ID NO: 11), AB-PG1-XG1-077 Heavy Chain (SEQ ID NO: 6), AB-PG1-XG1-077 Light Chain (SEQ ID NO: 12), PSMA 10.3 Heavy Chain (SEQ ID NO: 7), and PSMA 10.3 Kappa (SEQ ID NO: 13).

The isolated antibody or antigen-binding fragment thereof preferably is selected for its ability to bind live cells expressing PSMA. In order to demonstrate binding of monoclonal antibodies to live cells expressing the PSMA, flow cytometry can be used. For example, cell lines expressing PSMA (grown under standard growth conditions) or prostate cancer cells that express PSMA are mixed with various concentrations of monoclonal antibodies in PBS containing 0.1% Tween 80 and 20% mouse serum, and incubated at 37°C for 1 hour. After washing, the cells are reacted with fluorescein-labeled anti-human IgG secondary antibody (if human anti-PSMA antibodies were used) under the same conditions as the primary antibody staining. The samples can be analyzed by a fluorescence activated cell sorter (FACS) instrument using light and side scatter properties to gate on single cells. An alternative assay using fluorescence microscopy may be used (in addition to or instead of) the flow cytometry assay. Cells can be stained exactly as described above and examined by fluorescence microscopy. This method allows visualization of individual cells, but may have diminished sensitivity depending on the density of the antigen.

Binding of the antibody or antigen-binding fragment thereof to live cells expressing PSMA can inhibit the growth of the cells or mediate cytolysis of the cells. Cytolysis can be complement mediated or can be mediated by effector cells. In a preferred embodiment, the cytolysis is carried out in a living organism, preferably a mammal, and the live cell is a tumor cell. Examples of tumors which can be targeted by the antibodies of the invention include, any tumor that expresses PSMA, such as, prostate, bladder, pancreas, lung, colon, kidney, melanomas and sarcomas. In a preferred embodiment the tumor cell is a prostate cancer cell.

The testing of antibody cytolytic activity *in vitro* by chromium release assay can provide an initial screening prior to testing *in vivo* models. This testing can be carried out using standard chromium release assays. Briefly, polymorphonuclear cells (PMN), or other effector cells, from healthy donors can be purified by Ficoll Hypaque density centrifugation, 5 followed by lysis of contaminating erythrocytes. Washed PMNs can be suspended in RPMI supplemented with 10% heat-inactivated fetal calf serum and mixed with ^{51}Cr labeled cells expressing PSMA, at various ratios of effector cells to tumor cells (effector cells:tumor cells). Purified anti-PSMA IgGs can then be added at various concentrations. Irrelevant IgG can be used as negative control. Assays can be carried out for 0-120 minutes at 37°C. Samples can 10 be assayed for cytolysis by measuring ^{51}Cr release into the culture supernatant. Anti-PSMA monoclonal antibodies can also be tested in combinations with each other to determine whether cytolysis is enhanced with multiple monoclonal antibodies.

Antibodies which bind to PSMA also can be tested in an *in vivo* model (e.g., in mice) to determine their efficacy in mediating cytolysis and killing of cells expressing PSMA, e.g., 15 tumor cells. These antibodies can be selected, for example, based on the following criteria, which are not intended to be exclusive:

- 1) binding to live cells expressing PSMA;
- 2) high affinity of binding to PSMA;
- 3) binding to a unique epitope on PSMA (to eliminate the possibility that 20 antibodies with complimentary activities when used in combination would compete for binding to the same epitope);
- 4) opsonization of cells expressing PSMA;
- 5) mediation of growth inhibition, phagocytosis and/or killing of cells expressing PSMA in the presence of effector cells;
- 6) modulation (inhibition or enhancement) of NAALADase, folate 25 hydrolase, dipeptidyl peptidase IV and/or γ -glutamyl hydrolase activities;
- 7) growth inhibition, cell cycle arrest and/or cytotoxicity in the absence of effector cells;
- 8) internalization of PSMA;
- 9) binding to a conformational epitope on PSMA;

- 10) minimal cross-reactivity with cells or tissues that do not express PSMA; and
- 11) preferential binding to dimeric forms of PSMA rather than monomeric forms of PSMA.

5 Preferred antibodies of the invention meet one or more, and preferably all, of these criteria. In a particular embodiment, the antibodies are used in combination, e.g., as a pharmaceutical composition comprising two or more different anti-PSMA antibodies or binding fragments thereof. For example, anti-PSMA antibodies having different, but complementary activities can be combined in a single therapy to achieve a desired therapeutic 10 or diagnostic effect. An illustration of this would be a composition containing an anti-PSMA antibody that mediates highly effective killing of target cells in the presence of effector cells, combined with another anti-PSMA antibody that inhibits the growth of cells expressing PSMA.

15 In a preferred aspect of the invention, the antibody or antigen-binding fragment thereof binds to a conformational epitope within the extracellular domain of the PSMA molecule. To determine if the selected human anti-PSMA antibodies bind to conformational epitopes, each antibody can be tested in assays using native protein (e.g., non-denaturing immunoprecipitation, flow cytometric analysis of cell surface binding) and denatured protein 20 (e.g., Western blot, immunoprecipitation of denatured proteins). A comparison of the results will indicate whether the antibodies bind conformational epitopes. Antibodies that bind to native protein but not denatured protein are those antibodies that bind conformational epitopes, and are preferred antibodies.

25 To determine if the selected human anti-PSMA antibodies bind preferentially (i.e., selectively and/or specifically) to a PSMA dimer, each antibody can be tested in assays (e.g., immunoprecipitation followed by Western blotting) using native dimeric PSMA protein and dissociated monomeric PSMA protein. A comparison of the results will indicate whether the antibodies bind preferentially to the dimer or to the monomer. Antibodies that bind to the PSMA dimer but not to the monomeric PSMA protein are preferred antibodies.

30 Preferred antibodies include antibodies that competitively inhibit the specific binding of a second antibody to its target epitope on PSMA. To determine competitive inhibition, a variety of assays known to one of ordinary skill in the art can be employed. For example, the cross-competition assays set forth in Examples 4 and 21 can be used to determine if an

antibody competitively inhibits binding to PSMA by another antibody. These examples provide cell-based methods employing flow cytometry or solid phase binding analysis. Other assays that evaluate the ability of antibodies to cross-compete for PSMA molecules that are not expressed on the surface of cells, in solid phase or in solution phase, also can be used.

5 These assays preferably use the PSMA multimers described herein.

Certain preferred antibodies competitively inhibit the specific binding of a second antibody to its target epitope on PSMA by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99%. Inhibition can be assessed at various molar ratios or mass ratios; for example competitive binding experiments can be conducted with a 2-fold, 3-fold, 10 4-fold, 5-fold, 7-fold, 10-fold or more molar excess of the first antibody over the second antibody.

Other preferred antibodies include antibodies that specifically (i.e., selectively) bind to an epitope on PSMA defined by a second antibody. To determine the epitope, one can use standard epitope mapping methods known in the art. For example, fragments (peptides) of 15 PSMA antigen (preferably synthetic peptides) that bind the second antibody can be used to determine whether a candidate antibody binds the same epitope. For linear epitopes, overlapping peptides of a defined length (e.g., 8 or more amino acids) are synthesized. The peptides preferably are offset by 1 amino acid, such that a series of peptides covering every 8 amino acid fragment of the PSMA protein sequence are prepared. Fewer peptides can be 20 prepared by using larger offsets, e.g., 2 or 3 amino acids. In addition, longer peptides (e.g., 9-, 10- or 11-mers) can be synthesized. Binding of peptides to antibodies can be determined using standard methodologies including surface plasmon resonance (BIACORE; see Example 22) and ELISA assays. For examination of conformational epitopes, larger PSMA fragments can be used. Other methods that use mass spectrometry to define conformational epitopes 25 have been described and can be used (see, e.g., Baerga-Ortiz et al., *Protein Science* 11:1300-1308, 2002 and references cited therein). Still other methods for epitope determination are provided in standard laboratory reference works, such as Unit 6.8 ("Phage Display Selection and Analysis of B-cell Epitopes") and Unit 9.8 ("Identification of Antigenic Determinants Using Synthetic Peptide Combinatorial Libraries") of *Current Protocols in Immunology*, 30 Coligan et al., eds., John Wiley & Sons. Epitopes can be confirmed by introducing point mutations or deletions into a known epitope, and then testing binding with one or more antibodies to determine which mutations reduce binding of the antibodies.

In one embodiment of the invention the antibody or antigen-binding fragment thereof binds to and is internalized with PSMA expressed on cells. The mechanism by which the antibody or antigen-binding fragment thereof is internalized with the prostate specific membrane antigen is not critical to the practice of the present invention. For example, the 5 antibody or antigen-binding fragment thereof can induce internalization of PSMA. Alternatively, internalization of the antibody or antigen-binding fragment thereof can be the result of routine internalization of PSMA. The antibody or antigen-binding fragment thereof can be used in an unmodified form, alone or in combination with other compositions. Alternatively, the antibody or antigen-binding fragment thereof can be bound to a substance 10 effective to kill the cells upon binding of the antibody or antigen-binding fragment thereof to prostate specific membrane antigen and upon internalization of the biological agent with the prostate specific membrane antigen.

The human PSMA antibodies of the present invention specifically bind cell-surface PSMA and/or rsPSMA with sub-nanomolar affinity. The human PSMA antibodies of the 15 present invention have binding affinities of about 1×10^{-9} M or less, preferably about 1×10^{-10} M or less, more preferably 1×10^{-11} M or less. In a particular embodiment the binding affinity is less than about 5×10^{-10} M.

An antibody can be linked to a detectable marker, an antitumor agent or an 20 immunomodulator. Antitumor agents can include cytotoxic agents and agents that act on tumor neovasculature. Detectable markers include, for example, radioactive or fluorescent markers. Cytotoxic agents include cytotoxic radionuclides, chemical toxins and protein toxins.

The cytotoxic radionuclide or radiotherapeutic isotope preferably is an alpha-emitting isotope such as ^{225}Ac , ^{211}At , ^{212}Bi , ^{213}Bi , ^{212}Pb , ^{224}Ra or ^{223}Ra . Alternatively, the cytotoxic 25 radionuclide may a beta-emitting isotope such as ^{186}Rh , ^{188}Rh , ^{177}Lu , ^{90}Y , ^{131}I , ^{67}Cu , ^{64}Cu , ^{153}Sm or ^{166}Ho . Further, the cytotoxic radionuclide may emit Auger and low energy electrons and include the isotopes ^{125}I , ^{123}I or ^{77}Br .

Suitable chemical toxins or chemotherapeutic agents include members of the enediyne family of molecules, such as calicheamicin and esperamicin. Chemical toxins can also be 30 taken from the group consisting of methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin and 5-fluorouracil. Other antineoplastic agents that may be conjugated to the anti-PSMA antibodies of the

present invention include dolastatins (U.S. Patent Nos. 6,034,065 and 6,239,104) and derivatives thereof. Of particular interest is dolastatin 10 (dolavaline-valine-dolaisoleuine-dolaproline-dolaphenine) and the derivatives auristatin PHE (dolavaline-valine-dolaisoleuine-dolaproline-phenylalanine-methyl ester) (Pettit, G.R. et al., *Anticancer Drug Des.* 13(4):243-277, 1998; Woyke, T. et al., *Antimicrob. Agents Chemother.* 45(12):3580-3584, 2001), and aurastatin E and the like. Toxins that are less preferred in the compositions and methods of the invention include poisonous lectins, plant toxins such as ricin, abrin, modeccin, botulina and diphtheria toxins. Of course, combinations of the various toxins could also be coupled to one antibody molecule thereby accommodating variable cytotoxicity. Other 10 chemotherapeutic agents are known to those skilled in the art.

Toxin-conjugated forms of the PSMA antibodies of the present invention mediate specific cell killing of PSMA-expressing cells at picomolar concentrations. The toxin-conjugated PSMA antibodies of the present invention exhibit IC₅₀s at concentrations of less than about 1 X 10⁻¹⁰M, preferably less than about 1 X 10⁻¹¹M, more preferably less than about 15 1 X 10⁻¹²M. In a particular embodiment an IC₅₀ is achieved at a concentration of less than about 1.5 X 10⁻¹¹M.

Agents that act on the tumor vasculature can include tubulin-binding agents such as combrestatin A4 (Griggs et al., *Lancet Oncol.* 2:82, 2001), angiostatin and endostatin (reviewed in Rosen, *Oncologist* 5:20, 2000, incorporated by reference herein) and interferon 20 inducible protein 10 (U.S. Patent No. 5,994,292). A number of antiangiogenic agents currently in clinical trials are also contemplated. Agents currently in clinical trials include: 2ME2, Angiostatin, Angiozyme, Anti-VEGF RhuMAb, Apra (CT-2584), Avicine, Benefin, BMS275291, Carboxyamidotriazole, CC4047, CC5013, CC7085, CDC801, CGP-41251 (PKC 412), CM101, Combretastatin A-4 Prodrug, EMD 121974, Endostatin, Flavopiridol, 25 Genistein (GCP), Green Tea Extract, IM-862, ImmTher, Interferon alpha, Interleukin-12, Iressa (ZD1839), Marimastat, Metastat (Col-3), Neovastat, Octreotide, Paclitaxel, Penicillamine, Photofrin, Photopoint, PI-88, Prinomastat (AG-3340), PTK787 (ZK22584), RO317453, Solimastat, Squalamine, SU 101, SU 5416, SU-6668, Suradista (FCE 26644), Suramin (Metaret), Tetrathiomolybdate, Thalidomide, TNP-470 and Vitaxin. additional 30 antiangiogenic agents are described by Kerbel, J. *Clin. Oncol.* 19(18s):45s-51s, 2001, which is incorporated by reference herein. Immunomodulators suitable for conjugation to anti-PSMA antibodies include α -interferon, γ -interferon, and tumor necrosis factor alpha (TNF α).

5 The coupling of one or more toxin molecules to the anti-PSMA antibody is envisioned to include many chemical mechanisms, for instance covalent binding, affinity binding, intercalation, coordinate binding, and complexation. The toxic compounds used to prepare the anti-PSMA immunotoxins are attached to the antibodies or PSMA-binding fragments thereof by standard protocols known in the art.

10 The covalent binding can be achieved either by direct condensation of existing side chains or by the incorporation of external bridging molecules. Many bivalent or polyvalent agents are useful in coupling protein molecules to other proteins, peptides or amine functions, etc. For example, the literature is replete with coupling agents such as carbodiimides, diisocyanates, glutaraldehyde, diazobenzenes, and hexamethylene diamines. This list is not intended to be exhaustive of the various coupling agents known in the art but, rather, is exemplary of the more common coupling agents.

15 In preferred embodiments, it is contemplated that one may wish to first derivatize the antibody, and then attach the toxin component to the derivatized product. Suitable cross-linking agents for use in this manner include, for example, SPDP (N-succinimidyl-3-(2-pyridyldithio)propionate), and SMPT, 4-succinimidyl-oxycarbonyl-methyl-(2-pyridyldithio)toluene.

20 In addition, protein toxins can be fused to the anti-PSMA antibody or PSMA binding fragment by genetic methods to form a hybrid immunotoxin fusion protein. To make a fusion immunotoxin protein in accordance with the invention, a nucleic acid molecule is generated that encodes an anti-PSMA antibody, a fragment of an anti-PSMA antibody, a single chain anti-PSMA antibody, or a subunit of an anti-PSMA antibody linked to a protein toxin. Such fusion proteins contain at least a targeting agent (e.g., anti-PSMA antibody subunit) and a toxin of the invention, operatively attached. The fusion proteins may also include additional 25 peptide sequences, such as peptide spacers which operatively attach the targeting agent and toxin compound, as long as such additional sequences do not appreciably affect the targeting or toxin activities of the fusion protein. The two proteins can be attached by a peptide linker or spacer, such as a glycine-serine spacer peptide, or a peptide hinge, as is well known in the art. Thus, for example, the C-terminus of an anti-PSMA antibody or fragment thereof can be fused to the N-terminus of the protein toxin molecule to form an immunotoxin that retains the 30 binding properties of the anti-PSMA antibody. Other fusion arrangements will be known to one of ordinary skill in the art.

To express the fusion immunotoxin, the nucleic acid encoding the fusion protein is inserted into an expression vector in accordance with standard methods, for stable expression of the fusion protein, preferably in mammalian cells, such as CHO cells. The fusion protein can be isolated and purified from the cells or culture supernatant using standard methodology, 5 such as a PSMA affinity column.

Radionuclides typically are coupled to an antibody by chelation. For example, in the case of metallic radionuclides, a bifunctional chelator is commonly used to link the isotope to the antibody or other protein of interest. Typically, the chelator is first attached to the antibody, and the chelator-antibody conjugate is contacted with the metallic radioisotope. A 10 number of bifunctional chelators have been developed for this purpose, including the diethylenetriamine pentaacetic acid (DTPA) series of amino acids described in U.S. patents 5,124,471, 5,286,850 and 5,434,287, which are incorporated herein by reference. As another example, hydroxamic acid-based bifunctional chelating agents are described in U.S. patent 5,756,825, the contents of which are incorporated herein. Another example is the chelating 15 agent termed *p*-SCN-Bz-HEHA (1,4,7,10,13,16-hexaazacyclo-octadecane-N,N',N'',N''',N''''-hexaacetic acid) (Deal et al., *J. Med. Chem.* 42:2988, 1999), which is an effective chelator of radiometals such as ²²⁵Ac. Yet another example is DOTA (1,4,7,10-tetraazacyclododecane N,N',N'',N''''-tetraacetic acid), which is a bifunctional chelating agent 20 (see McDevitt et al., *Science* 294:1537-1540, 2001) that can be used in a two-step method for labeling followed by conjugation.

In another aspect, the invention provides compositions comprising an isolated antibody, an antibody derivatized or linked to other functional moieties, or an antigen-binding fragment thereof or a combination of one or more of the aforementioned antibodies or antigen-binding fragments thereof. The compositions include a physiologically or 25 pharmaceutically acceptable carrier, excipient, or stabilizer mixed with the isolated antibody or antigen-binding fragment thereof. In a preferred embodiment, the compositions include a combination of multiple (e.g., two or more) isolated antibodies or antigen-binding portions thereof of the invention. Preferably, each of the antibodies or antigen-binding portions thereof of the composition binds to a distinct conformational epitope of PSMA. In one 30 embodiment, anti-PSMA antibodies having complementary activities are used in combination, e.g., as a pharmaceutical composition, comprising two or more anti-PSMA antibodies. For example, an antibody that mediates highly effective cytolysis of target cells

in the presence of effector cells can be combined with another antibody that inhibits the growth of cells expressing PSMA. As used herein, "target cell" shall mean any undesirable cell in a subject (e.g., a human or animal) that can be targeted by a composition of the invention. In preferred embodiments, the target cell is a cell expressing or overexpressing 5 PSMA. Cells expressing PSMA typically include tumor cells, such as prostate, bladder, pancreas, lung, kidney, colon tumor cells, melanomas, and sarcomas.

Pharmaceutical compositions of the invention also can be administered in combination therapy, i.e., combined with other agents. For example, the combination therapy can include a composition of the present invention with at least one anti-tumor agent, 10 immunomodulator, immunostimulatory agent, or other conventional therapy. The agent may be bound or conjugated to or formed as a recombinant fusion molecule with the PSMA antibodies of the present invention for directed targeting of the agent to PSMA-expressing cells.

The PSMA antibodies of the present invention may be used as a targeting moiety for 15 delivery of replication-selective virus to PSMA-expressing cells for tumor therapy. Replication-competent virus such as the p53 pathway targeting adenovirus mutant dl1520, ONYX-015, kill tumor cells selectively (Biederer, C. et al., J. Mol. Med. 80(3):163-175, 2002).

As used herein, "pharmaceutically acceptable carrier" or "physiologically acceptable 20 carrier" includes any and all salts, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Preferably, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). Depending on the route of administration, the active compound, i.e., antibody may be coated 25 in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound.

When administered, the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable compositions. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with 30 the effectiveness of the biological activity of the active ingredients. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents, such as supplementary immune potentiating agents including

adjuvants, chemokines and cytokines. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention.

5 A salt retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects (see e.g., Berge, S.M., et al. (1977) *J. Pharm. Sci.* 66: 1-19). Examples of such salts include acid addition salts and base addition salts. Acid addition salts include those derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, phosphorous and the like, as well as 10 from nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl substituted alkanoic acids, hydroxy alkanoic acids, aromatic acids, aliphatic and aromatic sulfonic acids and the like. Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium and the like, as well as from nontoxic organic amines, such as N,N'-dibenzylethylenediamine, N-methylglucamine, 15 chioroprocaine, choline, diethanolamine, ethylenediamine, procaine and the like.

An anti-PSMA antibody composition may be combined, if desired, with a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an 20 organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.

25 The pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.

The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.

30 The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly

and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

Compositions suitable for parenteral administration conveniently comprise a sterile aqueous or non-aqueous preparation of anti-PSMA antibodies, which is preferably isotonic

5 with the blood of the recipient. This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol.

10 Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulations suitable for oral, subcutaneous, intravenous, intramuscular, etc. administration can be found in

15 *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA.

The active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, 20 collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g., *Sustained and Controlled Release Drug Delivery Systems*, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.

25 The therapeutics of the invention can be administered by any conventional route, including injection or by gradual infusion over time. The administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, intratumor, or transdermal. When antibodies are used therapeutically, preferred routes of administration include intravenous and by pulmonary aerosol. Techniques for preparing aerosol delivery systems containing antibodies are well known to those of skill in the art. Generally, such systems 30 should utilize components which will not significantly impair the biological properties of the antibodies, such as the paratope binding capacity (see, for example, Sciarra and Cutie, "Aerosols," in *Remington's Pharmaceutical Sciences*, 18th edition, 1990, pp. 1694-1712;

incorporated by reference). Those of skill in the art can readily determine the various parameters and conditions for producing antibody aerosols without resorting to undue experimentation.

The compositions of the invention are administered in effective amounts. An 5 “effective amount” is that amount of an anti-PSMA antibody composition that alone, or together with further doses, produces the desired response, e.g. treats a malignancy in a subject. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently. This can be monitored by routine methods. The desired response to treatment of the disease or condition 10 also can be delaying the onset or even preventing the onset of the disease or condition.

Such amounts will depend, of course, on the particular condition being treated, the 15 severity of the condition, the individual patient parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can 20 be addressed with no more than routine experimentation. It is generally preferred that a maximum dose of the individual components or combinations thereof be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.

The pharmaceutical compositions used in the foregoing methods preferably are sterile and contain an effective amount of anti-PSMA antibodies for producing the desired response in a unit of weight or volume suitable for administration to a patient. The response can, for example, be measured by determining the physiological effects of the anti-PSMA antibody 25 composition, such as regression of a tumor or decrease of disease symptoms. Other assays will be known to one of ordinary skill in the art and can be employed for measuring the level of the response.

The doses of anti-PSMA antibodies administered to a subject can be chosen in accordance with different parameters, in particular in accordance with the mode of 30 administration used and the state of the subject. Other factors include the desired period of treatment. In the event that a response in a subject is insufficient at the initial doses applied,

higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits.

In general, doses can range from about 10 $\mu\text{g}/\text{kg}$ to about 100,000 $\mu\text{g}/\text{kg}$. Based upon the composition, the dose can be delivered continuously, such as by continuous pump, or at periodic intervals. Desired time intervals of multiple doses of a particular composition can be determined without undue experimentation by one skilled in the art. Other protocols for the administration of anti-PSMA antibody compositions will be known to one of ordinary skill in the art, in which the dose amount, schedule of administration, sites of administration, mode of administration and the like vary from the foregoing.

In general, doses of radionuclide delivered by the anti-PSMA antibodies of the invention can range from about 0.01 mCi/Kg to about 10 mCi/kg. Preferably the dose of radionuclide ranges from about 0.1 mCi/Kg to about 1.0 mCi/kg. The optimal dose of a given isotope can be determined empirically by simple routine titration experiments well known to one of ordinary skill in the art.

Administration of anti-PSMA antibody compositions to mammals other than humans, e.g. for testing purposes or veterinary therapeutic purposes, is carried out under substantially the same conditions as described above.

The compositions (antibodies to PSMA and derivatives/conjugates thereof) of the present invention have *in vitro* and *in vivo* diagnostic and therapeutic utilities. For example, these molecules can be administered to cells in culture, e.g. *in vitro* or *ex vivo*, or in a subject, e.g., *in vivo*, to treat, prevent or diagnose a variety of disorders. As used herein, the term "subject" is intended to include humans and non-human animals. Preferred subjects include a human patient having a disorder characterized by expression, typically aberrant expression (e.g., overexpression) of PSMA.

One aspect of the present invention relates to a method of detecting cancerous cells or portions thereof in a biological sample (e.g., histological or cytological specimens, biopsies and the like), and, in particular, to distinguish malignant tumors from normal tissues and non-malignant tumors. This method involves providing an antibody or an antigen-binding binding fragment thereof, probe, or ligand, which binds to an extracellular domain of PSMA of such cells, e.g., an anti-PSMA antibody. The anti-PSMA antibody is bound to a label that permits the detection of the cells or portions thereof (e.g., PSMA or fragments thereof liberated from such cancerous cells) upon binding of the anti-PSMA antibody to the cells or

portions thereof. The biological sample is contacted with the labeled anti-PSMA antibody under conditions effective to permit binding of the anti-PSMA antibody to the extracellular domain of PSMA of any of the cells or portions thereof in the biological sample. The presence of any cells or portions thereof in the biological sample is detected by detection of 5 the label. In one preferred form, the contact between the anti-PSMA antibody and the biological sample is carried out in a living mammal and involves administering the anti-PSMA antibody to the mammal under conditions that permit binding of the anti-PSMA antibody to PSMA of any of the cells or portions thereof in the biological sample. Again, such administration can be carried out by any suitable method known to one of ordinary skill 10 in the art.

In addition, the anti-PSMA antibodies of the present invention can be used in immunofluorescence techniques to examine human tissue, cell and bodily fluid specimens. In a typical protocol, slides containing cryostat sections of frozen, unfixed tissue biopsy samples or cytological smears are air dried, formalin or acetone fixed, and incubated with the 15 monoclonal antibody preparation in a humidified chamber at room temperature. The slides are then washed and further incubated with a preparation of a secondary antibody directed against the monoclonal antibody, usually some type of anti-mouse immunoglobulin if the monoclonal antibodies used are derived from the fusion of a mouse spleen lymphocyte and a mouse myeloma cell line. This secondary antibody is tagged with a compound, for instance 20 rhodamine or fluorescein isothiocyanate, that fluoresces at a particular wavelength. The staining pattern and intensities within the sample are then determined by fluorescent light microscopy and optionally photographically recorded.

As yet another alternative, computer enhanced fluorescence image analysis or flow cytometry can be used to examine tissue specimens or exfoliated cells, i.e., single cell 25 preparations from aspiration biopsies of tumors using the anti-PSMA antibodies of this invention. The anti-PSMA antibodies of the invention are particularly useful in quantitation of live tumor cells, i.e., single cell preparations from aspiration biopsies of prostate tumors by computer enhanced fluorescence image analyzer or with a flow cytometer. The antibodies of the invention are particularly useful in such assays to differentiate benign from malignant 30 prostate tumors since the PSMA protein to which the anti-PSMA antibodies bind is expressed in increased amounts by malignant tumors as compared to benign prostate tumors. The percent PSMA positive cell population, alone or in conjunction with determination of other

attributes of the cells (e.g., DNA ploidy of these cells), may, additionally, provide very useful prognostic information by providing an early indicator of disease progression.

In yet another alternative embodiment, the antibodies of the present invention can be used in combination with other known antibodies to provide additional information regarding the malignant phenotype of a cancer.

The method of the present invention can be used to screen patients for diseases associated with the presence of cancerous cells or portions thereof. Alternatively, it can be used to identify the recurrence of such diseases, particularly when the disease is localized in a particular biological material of the patient. For example, recurrence of prostatic disease in the prostatic fossa may be encountered following radical prostatectomy. Using the method of the present invention, this recurrence can be detected by administering a short range radiolabeled antibody to the mammal and then detecting the label rectally, such as with a transrectal detector probe.

Alternatively, the contacting step can be carried out in a sample of serum or urine or other body fluids, including but not limited to seminal fluid, prostatic fluid, ejaculate, and the like, such as to detect the presence of PSMA in the body fluid. When the contacting is carried out in a serum or urine sample, it is preferred that the biological agent recognize substantially no antigens circulating in the blood other than PSMA. Since intact cells do not excrete or secrete PSMA into the extracellular environment, detecting PSMA in serum, urine, or other body fluids generally indicates that cells are being lysed or shed. Thus, the biological agents and methods of the present invention can be used to determine the effectiveness of a cancer treatment protocol by monitoring the level of PSMA in serum, urine or other body fluids.

In a particularly preferred embodiment of the method of detecting cancerous cells in accordance with the present invention, the anti-PSMA antibodies or an antigen-binding fragment thereof, binds to and is internalized with the prostate specific membrane antigen of such cells. Again, the biological agent is bound to a label effective to permit detection of the cells or portions thereof upon binding of the biological agent to and internalization of the biological agent with the prostate specific membrane antigen.

Biological agents suitable for detecting cancerous cells include anti-PSMA antibodies, such as monoclonal or polyclonal antibodies. In addition, antibody fragments, half-antibodies, hybrid derivatives, probes, and other molecular constructs may be utilized. These

biological agents, such as antibodies, antigen-binding fragments thereof, probes, or ligands, bind to extracellular domains of prostate specific membrane antigens or portions thereof in cancerous cells. As a result, the biological agents bind not only to cells which are fixed or cells whose intracellular antigenic domains are otherwise exposed to the extracellular 5 environment. Consequently, binding of the biological agents is concentrated in areas where there are prostate cells, irrespective of whether these cells are fixed or unfixed, viable or necrotic. Additionally or alternatively, these biological agents bind to and are internalized with prostate specific membrane antigens or portions thereof in normal, benign hyperplastic, and to a greater degree in cancerous cells.

10 The antibodies or antigen-binding fragments thereof can also be utilized in *in vivo* therapy of cancer. The antibodies can be used alone or covalently attached, either directly or via linker, to a compound which kills and/or inhibits proliferation of the malignant cells or tissues following administration and localization of the conjugates. When the antibody is used by itself, it may mediate tumor destruction by complement fixation or antibody-dependent cellular cytotoxicity. Alternatively, the antibody may be administered in 15 combination with a chemotherapeutic drug to result in synergistic therapeutic effects (Baslya and Mendelsohn, 1994 *Breast Cancer Res. and Treatment* 29:127-138). A variety of different types of substances can be directly conjugated to the antibody for therapeutic uses, including radioactive metal and non-metal isotopes, chemotherapeutic drugs, toxins, etc. as 20 described above and known in the art (see, e.g., Vitetta and Uhr, 1985, *Annu. Rev. Immunol.* 3:197).

25 The antibodies or antigen-binding fragments thereof of the invention can also be administered together with complement. Accordingly, within the scope of the invention are compositions comprising antibodies or antigen-binding fragments thereof and serum or complement. These compositions are advantageous in that the complement is located in close proximity to the human antibodies or antigen-binding fragments thereof. Alternatively, the antibodies or antigen-binding fragments thereof of the invention and the complement or serum can be administered separately.

30 The antibodies can be administered with one or more immunostimulatory agents to induce or enhance an immune response, such as IL-2 and immunostimulatory oligonucleotides (e.g., those containing CpG motifs). Preferred immunostimulatory agents

stimulate specific arms of the immune system, such as natural killer (NK) cells that mediate antibody-dependent cell cytotoxicity (ADCC).

Antigens, such as the PSMA dimers described herein, can be administered with one or more adjuvants to induce or enhance an immune response. An adjuvant is a substance which 5 potentiates the immune response. Adjuvants of many kinds are well known in the art.

Specific examples of adjuvants include monophosphoryl lipid A (MPL, SmithKline Beecham); saponins including QS21 (SmithKline Beecham); immunostimulatory oligonucleotides (e.g., CpG oligonucleotides described by Kreig et al., *Nature* 374:546-9, 1995); incomplete Freund's adjuvant; complete Freund's adjuvant; montanide; vitamin E and 10 various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol, Quil A, Ribi Detox, CRL-1005, L-121, and combinations thereof.

Other agents which stimulate the immune response of the subject to PSMA multimer antigens can also be administered to the subject. For example, cytokines are also useful in vaccination protocols as a result of their lymphocyte regulatory properties. Many cytokines 15 useful for such purposes will be known to one of ordinary skill in the art, including interleukin-2 (IL-2); IL-4; IL-5; IL-12, which has been shown to enhance the protective effects of vaccines (see, e.g., *Science* 268: 1432-1434, 1995); GM-CSF; IL-15; IL-18; combinations thereof, and the like. Thus cytokines can be administered in conjunction with antibodies, antigens, chemokines and/or adjuvants to increase an immune response.

20 Chemokines useful in increasing immune responses include but are not limited to SLC, ELC, MIP3 α , MIP3 β , IP-10, MIG, and combinations thereof.

The antibodies or antigen-binding fragments thereof of the present invention can be used in conjunction with other therapeutic treatment modalities. Such other treatments include surgery, radiation, cryosurgery, thermotherapy, hormone treatment, chemotherapy, 25 vaccines, and other immunotherapies.

Also encompassed by the present invention is a method which involves using the antibodies or antigen-binding fragments thereof for prophylaxis. For example, these materials can be used to prevent or delay development or progression of cancer.

Use of the cancer therapy of the present invention has a number of benefits. Since the 30 anti-PSMA antibodies or antigen-binding fragments thereof according to the present invention preferentially target prostate cancer cells, other tissue is spared. As a result, treatment with such biological agents is safer, particularly for elderly patients. Treatment

according to the present invention is expected to be particularly effective, because it directs high levels of anti-PSMA antibodies or antigen-binding fragments thereof to the bone marrow and lymph nodes where prostate cancer metastases predominate. Moreover, tumor sites for prostate cancer tend to be small in size and, therefore, easily destroyed by cytotoxic agents. Treatment in accordance with the present invention can be effectively monitored with clinical parameters such as serum prostate specific antigen and/or pathological features of a patient's cancer, including stage, Gleason score, extracapsular, seminal, vesicle or perineural invasion, positive margins, involved lymph nodes, etc. Alternatively, these parameters can be used to indicate when such treatment should be employed.

Because the antibodies or antigen-binding fragments thereof of the present invention bind to living cells, therapeutic methods using these biological agents are much more effective than those which target lysed cells. For the same reasons, diagnostic and imaging methods which determine the location of living normal, benign hyperplastic, or cancerous cells are much improved by employing the antibodies or antigen-binding fragments thereof of the present invention. In addition, the ability to differentiate between living and dead cells can be advantageous, especially to monitor the effectiveness of a particular treatment regimen.

Also within the scope of the invention are kits comprising the compositions of the invention and instructions for use. The kits can further contain at least one additional reagent, such as complement, or one or more additional antibodies of the invention (e.g., an antibody having a complementary activity which binds to an epitope in PSMA antigen distinct from the first antibody). Other kits can include the PSMA multimers described hereinbelow.

Kits containing the antibodies or antigen-binding fragments thereof of the invention can be prepared for *in vitro* diagnosis, prognosis and/or monitoring cancer by the immunohistological, immunocytological and immunoserological methods described above. The components of the kits can be packaged either in aqueous medium or in lyophilized form. When the antibodies or antigen-binding fragments thereof are used in the kits in the form of conjugates in which a label moiety is attached, such as an enzyme or a radioactive metal ion, the components of such conjugates can be supplied either in fully conjugated form, in the form of intermediates or as separate moieties to be conjugated by the user or the kit.

5 A kit may comprise a carrier being compartmentalized to receive in close confinement therein one or more container means or series of container means such as test tubes, vials, flasks, bottles, syringes, or the like. A first of said container means or series of container means may contain one or more anti-PSMA antibodies or antigen-binding fragments thereof or PSMA. A second container means or series of container means may contain a label or linker-label intermediate capable of binding to the primary anti-PSMA antibodies (or fragment thereof).

10 Kits for use in *in vivo* tumor localization and therapy method containing the anti-PSMA antibodies or antigen-binding fragments thereof conjugated to other compounds or substances can be prepared. The components of the kits can be packaged either in aqueous medium or in lyophilized form. When the antibodies or antigen-binding fragments thereof are used in the kits in the form of conjugates in which a label or a therapeutic moiety is attached, such as a radioactive metal ion or a therapeutic drug moiety, the components of such conjugates can be supplied either in fully conjugated form, in the form of intermediates 15 or as separate moieties to be conjugated by the user of the kit.

20 In one aspect of the invention, a method for modulating at least one enzymatic activity of PSMA, the activity selected from the group consisting of N-acetylated α -linked acidic dipeptidase (NAALADase), folate hydrolase, dipeptidyl dipeptidase IV and γ -glutamyl hydrolase activity or combination thereof *in vitro* or *in vivo*. The modulation may be enhancement or inhibition of at least one enzymatic activity of PSMA.

25 In a preferred embodiment, the invention provides methods for inhibiting at least one enzymatic activity of PSMA, the activity selected from the group consisting of N-acetylated α -linked acidic dipeptidase (NAALADase), folate hydrolase, dipeptidyl dipeptidase IV and γ -glutamyl hydrolase activity or combination thereof *in vitro* or *in vivo*. The method comprises contacting a NAALADase, a folate hydrolase, a dipeptidyl dipeptidase IV and/or a γ -glutamyl hydrolase with an amount of an isolated antibody or antigen-binding fragment thereof of the invention under conditions wherein the isolated monoclonal antibody or antigen-binding fragment thereof inhibits NAALADase, folate hydrolase, dipeptidyl dipeptidase IV or γ -glutamyl hydrolase activity.

30 Tissue levels of NAALADase can be determined by detergent solubilizing homogenizing tissues, pelleting the insoluble material by centrifugation and measuring the NAALADase activity in the remaining supernatant. Likewise, the NAALADase activity in

bodily fluids can also be measured by first pelleting the cellular material by centrifugation and performing a typical enzyme assay for NAALADase activity on the supernatant.

NAALADase enzyme assays have been described by Frieden, 1959, *J. Biol. Chem.*, 234:2891. In this assay, the reaction product of the NAALADase enzyme is glutamic acid.

5 This is derived from the enzyme catalyzed cleavage of N-acetylaspartylglutamate to yield N-acetylaspartic acid and glutamic acid. Glutamic acid, in a NAD(P)⁺ requiring step, yields 2-oxoglutarate plus NAD(P)H in a reaction catalyzed by glutamate dehydrogenase. Progress of the reaction can easily and conveniently be measured by the change in absorbance at 340 nm due to the conversion of NAD(P)⁺ to NAD(P)H.

10 Folate hydrolase activity of PSMA can be measured by performing enzyme assays as described by Heston and others (e.g., *Clin. Cancer Res.* 2(9):1445-51, 1996; *Urology* 49(3A Suppl):104-12, 1997). Folate hydrolases such as PSMA remove the gamma-linked glutamates from polyglutamated folates. Folate hydrolase activity can be measured using substrates such as methotrexate tri-gamma glutamate (MTXGlu3), methotrexate di-gamma glutamate (MTXGlu2) and pteroylpentaglutamate (PteGlu5), for example using capillary electrophoresis (see *Clin. Cancer Res.* 2(9):1445-51, 1996). Timed incubations of PSMA with polyglutamated substrates is followed by separation and detection of hydrolysis products.

20 The invention also includes isolated antibodies and binding fragments thereof that selectively bind PSMA multimers. As used herein, particularly with respect to the binding of PSMA multimers by the anti-PSMA antibodies and binding fragments, "selectively binds" means that an antibody preferentially binds to a PSMA protein multimer (e.g., with greater avidity, greater binding affinity) rather than to a PSMA protein monomer. In preferred embodiments, the antibodies of the invention bind to a PSMA protein multimer with an avidity and/or binding affinity that is 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 7-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 70-fold, 100-fold, 200-fold, 300-fold, 500-fold, 1000-fold or more than that exhibited by the antibody for a PSMA protein monomer. Preferably, the antibody selectively binds a PSMA protein multimer, and not a PSMA protein monomer, i.e., substantially exclusively binds to a PSMA protein multimer. Most preferably, the antibody selectively binds a PSMA protein dimer.

- 55 -

The isolated antibody or binding fragment that selectively binds a PSMA protein multimer can, in some embodiments, modulate enzymatic activity of the PSMA protein multimer. In one such embodiment, the antibody inhibits at least one enzymatic activity such as NAALADase activity, folate hydrolase activity, dipeptidyl dipeptidase IV activity, 5 γ -glutamyl hydrolase activity, or combinations thereof. In another embodiment, the antibody enhances at least one enzymatic activity such as NAALADase activity, folate hydrolase activity, dipeptidyl dipeptidase IV activity, γ -glutamyl hydrolase activity, or combinations thereof.

A PSMA protein multimer, as used herein, is a protein complex of at least two PSMA 10 proteins or fragments thereof. The PSMA protein multimers can be composed of various combinations of full-length PSMA proteins (e.g., SEQ ID NO:1), recombinant soluble PSMA (rsPSMA, e.g., amino acids 44-750 of SEQ ID NO:1) and fragments of the foregoing that form multimers (i.e., that retain the protein domain required for forming dimers and/or higher order multimers of PSMA). In preferred embodiments, at least one of the PSMA proteins 15 forming the multimer is a recombinant, soluble PSMA (rsPSMA) polypeptide. Preferred PSMA protein multimers are dimers, particularly those formed from recombinant soluble PSMA protein. A particularly preferred embodiment is a rsPSMA homodimer.

The PSMA protein multimers referred to herein are believed to assume a native conformation and preferably have such a conformation. The PSMA proteins in certain 20 embodiments are noncovalently bound together to form the PSMA protein multimer. For example, it has been discovered that PSMA protein noncovalently associates to form dimers under non-denaturing conditions, as described in the Examples below.

The PSMA protein multimers can, and preferably do, retain the activities of PSMA. The PSMA activity may be an enzymatic activity, such as folate hydrolase activity, 25 NAALADase activity, dipeptidyl peptidase IV activity and γ -glutamyl hydrolase activity. Methods for testing the PSMA activity of multimers are well known in the art (reviewed by O'Keefe et al. in: Prostate Cancer: Biology, Genetics, and the New Therapeutics, L.W.K. Chung, W.B. Isaacs and J.W. Simons (eds.) Humana Press, Totowa, NJ, 2000, pp. 307-326), some of which are described in the Examples herein below.

30 In certain aspects, the invention also includes compositions including one or more of the isolated PSMA protein multimers described herein, such as the PSMA protein dimer. In preferred embodiments, a PSMA protein multimer composition contains at least about 10%

PSMA protein multimer. In other embodiments, the PSMA protein multimer composition contains at least about 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% PSMA protein multimer. In a preferred embodiment, the PSMA protein multimer composition contains substantially pure PSMA protein multimer, with substantially no PSMA protein monomer. It is understood that the list of specific percentages includes by inference all of the unnamed percentages between the recited percentages.

As used herein with respect to polypeptides, proteins or fragments thereof, "isolated" means separated from its native environment and present in sufficient quantity to permit its identification or use. Isolated, when referring to a protein or polypeptide, means, for example: (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may be, but need not be, substantially pure. The term "substantially pure" means that the proteins or polypeptides are essentially free of other substances with which they may be found in nature or *in vivo* systems to an extent practical and appropriate for their intended use. Substantially pure polypeptides may be produced by techniques well known in the art. Because an isolated protein may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the protein may comprise only a small percentage by weight of the preparation. The protein is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e. isolated from other proteins.

Fragments of a PSMA protein preferably are those fragments which retain a distinct functional capability of the PSMA protein. Functional capabilities which can be retained in a fragment include binding of other PSMA molecules to form dimers and higher order multimers, interaction with antibodies, interaction with other polypeptides or fragments thereof, and enzymatic activity. Other PSMA protein fragments, e.g., other recombinant soluble fragments of SEQ ID NO:1, can be selected according to their functional properties. For example, one of ordinary skill in the art can prepare PSMA fragments recombinantly and test those fragments according to the methods exemplified below.

Modifications to a PSMA polypeptide are typically made to the nucleic acid which encodes the PSMA polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids or non-amino acid moieties.

Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a

fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the PSMA amino acid sequence.

In general, modified PSMA polypeptides include polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its physiological activity. For example, 5 cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a PSMA polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Modifications conveniently are prepared by altering a nucleic acid molecule that 10 encodes the PSMA polypeptide. Mutations of a nucleic acid which encode a PSMA polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such a hairpins or loops, which can be deleterious to expression of the modified polypeptide.

15 Modifications can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the PSMA polypeptide. Modified PSMA polypeptides then can be expressed and tested for one or more activities (e.g., antibody binding, enzymatic activity, multimeric stability) to determine which mutation provides a modified polypeptide with the desired properties. Further mutations can be made 20 to modified PSMA polypeptides (or to non-modified PSMA polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a PSMA coding sequence or cDNA clone to enhance 25 expression of the polypeptide. The activity of modified PSMA polypeptides can be tested by cloning the gene encoding the modified PSMA polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the modified PSMA polypeptide, and testing for a functional capability of the PSMA polypeptides as disclosed herein. The foregoing procedures are well known to one of 30 ordinary skill in the art.

The skilled artisan will also realize that conservative amino acid substitutions may be made in PSMA polypeptides to provide functionally equivalent PSMA polypeptides, i.e.,

modified PSMA polypeptides that retain the functional capabilities of PSMA polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Modified PSMA polypeptides can be prepared according to 5 methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary functionally 10 equivalent PSMA polypeptides include conservative amino acid substitutions of SEQ ID NO:1, or fragments thereof, such as the recombinant soluble PSMA polypeptide (amino acids 44-750 of SEQ ID NO:1). Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

15 Conservative amino-acid substitutions in PSMA polypeptides typically are made by alteration of a nucleic acid encoding a PSMA polypeptide. Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis, or by chemical synthesis of a gene encoding a PSMA polypeptide. Where amino acid substitutions 20 are made to a small fragment of a PSMA polypeptide, the substitutions can be made by directly synthesizing the peptide. The activity of functionally equivalent fragments of PSMA polypeptides can be tested by cloning the gene encoding the altered PSMA polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered PSMA polypeptide, and testing for a functional capability of the 25 PSMA polypeptides as disclosed herein.

The PSMA protein multimers as described herein have a number of uses, some of 30 which are described elsewhere herein. The multimers are useful for testing of compounds that modulate PSMA enzymatic activity or PSMA multimerization. The multimers can be used to isolate antibodies that selectively bind PSMA, including those selective for conformational epitopes, those selective for binding PSMA multimers and not PSMA monomers, and those that selectively modulate an enzymatic activity of PSMA. The

multimers, particularly dimeric PSMA, also can be used to induce or increase immune responses to PSMA, as vaccine compositions.

Agents that selectively modulate an enzymatic activity of PSMA include agents that inhibit or enhance at least one enzymatic activity of PSMA, such as NAALADase activity, 5 folate hydrolase activity, dipeptidyl dipeptidase IV activity, γ -glutamyl hydrolase activity, or combinations thereof.

Thus methods of screening for candidate agents that modulate at least one enzymatic activity of a PSMA enzyme are provided in accordance with the invention. The methods can include mixing the candidate agent with an isolated PSMA protein multimer to form a 10 reaction mixture, thereby contacting the PSMA enzyme with the candidate agent. The methods also include adding a substrate for the PSMA enzyme to the reaction mixture, and determining the amount of a product formed from the substrate by the PSMA enzyme. Such methods are adaptable to automated, high-throughput screening of compounds. A decrease in the amount of product formed in comparison to a control is indicative of an agent capable of 15 inhibiting at least one enzymatic activity of the PSMA enzyme. An increase in the amount of product formed in comparison to a control is indicative of an agent capable of enhancing at least one enzymatic activity of the PSMA enzyme. The PSMA enzyme can be NAALADase, folate hydrolase, dipeptidyl dipeptidase IV and/or γ -glutamyl hydrolase. The PSMA enzyme preferably is a PSMA multimer that includes recombinant soluble PSMA, most preferably a 20 noncovalently associated dimer of PSMA in a native conformation.

The reaction mixture comprises a candidate agent. The candidate agent is preferably an antibody, a small organic compound, or a peptide, and accordingly can be selected from combinatorial antibody libraries, combinatorial protein libraries, or small organic molecule libraries. Typically, a plurality of reaction mixtures are run in parallel with different agent 25 concentrations to obtain a different response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration of agent or at a concentration of agent below the limits of assay detection.

Candidate agents encompass numerous chemical classes, although typically they are 30 organic compounds, proteins or antibodies (and fragments thereof that bind antigen). In some preferred embodiments, the candidate agents are small organic compounds, i.e., those having a molecular weight of more than 50 yet less than about 2500, preferably less than about 1000 and, more preferably, less than about 500. Candidate agents comprise functional

- 60 -

chemical groups necessary for structural interactions with polypeptides and/or nucleic acids, and typically include at least an amine, carbonyl, hydroxyl, or carboxyl group, preferably at least two of the functional chemical groups and more preferably at least three of the functional chemical groups. The candidate agents can comprise cyclic carbon or heterocyclic structure and/or aromatic or polyaromatic structures substituted with one or more of the above-identified functional groups. Candidate agents also can be biomolecules such as peptides, saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the like.

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides, synthetic organic combinatorial libraries, phage display libraries of random or non-random peptides, combinatorial libraries of proteins or antibodies, and the like. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are available or readily produced. Additionally, natural and synthetically produced libraries and compounds can be readily be modified through conventional chemical, physical, and biochemical means. Further, known agents may be subjected to directed or random chemical modifications such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs of the agents.

A variety of other reagents also can be included in the mixture. These include reagents such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to facilitate optimal protein-protein and/or protein-agent binding. Such a reagent may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease inhibitors, nuclease inhibitors, antimicrobial agents, and the like may also be used.

The mixture of the foregoing reaction materials is incubated under conditions whereby, the candidate agent interacts with the PSMA enzyme. The order of addition of components, incubation temperature, time of incubation, and other parameters of the assay may be readily determined. Such experimentation merely involves optimization of the assay parameters, not the fundamental composition of the assay. Incubation temperatures typically are between 4°C and 40°C. Incubation times preferably are minimized to facilitate rapid, high throughput screening, and typically are between 0.1 and 10 hours.

After incubation, the presence or absence of PSMA enzyme activity is detected by any convenient method available to the user. For example, the reaction mixture can contain a substrate for the PSMA enzyme. Preferably the substrate and/or the product formed by the action of the PSMA enzyme are detectable. The substrate usually comprises, or is coupled to, 5 a detectable label. A wide variety of labels can be used, such as those that provide direct detection (e.g., radioactivity, luminescence, optical, or electron density, etc) or indirect detection (e.g., epitope tag such as the FLAG epitope, enzyme tag such as horseradish peroxidase, etc.). The label may be bound to the substrate, or incorporated into the structure of the substrate.

10 A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the substrate or subsequent to separation from the substrate. Labels may be directly detected through optical or electron density, radioactive emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, streptavidin-biotin conjugates, etc. Methods 15 for detecting a variety of labels are well known in the art.

Examples

Materials and Methods

20 *DNA constructs.* All secreted PSMA constructs were derived from the original human PSMA clone p55A provided by Dr. W.D.W. Heston (Israeli et al., *Cancer Res.* 53: 227-230, 1993). The constructs were subcloned into expression vector PPI4 (Trkola et al., *Nature* 384: 184-187, 1996) for high-level expression and secretion in mammalian cells. Recombinant soluble PSMA (rsPSMA) corresponds to the entire extracellular domain of PSMA (amino acids 44-750 of SEQ ID NO:1 (GenBank Protein Accession number AAA60209)).

25 *pcDNA Plasmid Constructs:* Nucleic acid molecules encoding the anti-PSMA antibodies 10.3, 006, 026, 051, 069 and 077 were cloned into plasmid pcDNA. The cloning protocol is given in Figure 10. Primers (SEQ ID NOs: 33-36, sense and anti-sense) used for the variable 30 region amplifications are also shown. The plasmids constructed for anti-PSMA antibodies 006, 026, 051, 069, 077 and 10.3 contain nucleotide sequences encoding the heavy chain of the antibodies (SEQ ID NOs: 2-7; PTA-4403, PTA-4405, PTA-4407, PTA-4409, PTA-4411,

PTA-4413, respectively) or contain nucleotide sequences encoding light chain of the antibodies (SEQ ID NOs: 8-13; PTA-4404, PTA-4406, PTA-4408, PTA-4410, PTA-4412 and PTA-4414, respectively). Plasmid maps are given in Figures 11-22.

5 *Western blots.* Cells were lysed in PBS containing 1mM EDTA, 1% NP-40, 1% Triton X-100, and 5mg/ml aprotinin and cell debris was removed by centrifugation at 3000g for 30 min at 4°C. Lysates were separated on a 5-20% gradient gel before transfer to nitrocellulose membranes. The resulting blots were blocked in PBS containing 5% milk, 0.02% SDS and 0.1% Triton X-100 before incubation with MAB544 primary antibody (Maine Biotechnologies) at a concentration of 2mg/ml. After three washes, blots were incubated with a goat anti-mouse HRP-conjugated secondary antibody at a concentration of 0.2mg/ml. Blots are visualized using the Renaissance chemiluminescence system (Perkin-Elmer Life Sciences, Boston, MA).

10 *ELISA.* Cells were lysed in PBS containing 1mM EDTA, 1% NP-40, 1% Triton X-100, and 5mg/ml aprotinin. The resulting cell membranes were plated onto 96-well plates and dried in a sterile hood overnight. The plates were then blocked with PBS containing casein and Tween-20 before addition of mouse sera or hybridoma supernatants, using purified MAB544 (Maine Biotechnologies) or 7E11 (Cytogen) as a standard. After washing in PBS, an alkaline 20 phosphatase conjugated secondary antibody (subclass specific) was incubated and subsequently washed in PBS. The pNPP substrate was then added for colorimetric detection at a wavelength of 405 nm.

25 *Flow cytometry.* Wild-type 3T3 or PSMA-expressing 3T3 cells (10^6 cells per condition) were washed in PBS containing 0.1% NaN₃. Antibodies or sera were then added (1:100 dilution in PBS) and incubated on ice for 30 minutes. After washing in PBS+0.1% NaN₃, the cells were incubated with anti-mouse IgG+IgM (Calbiotech) for 30 minutes on ice. Cells were washed again in PBS+0.1% NaN₃ and analyzed by flow cytometry.

30 Example 1: Generation of a panel of monoclonal antibodies (mAbs) to conformational epitopes on PSMA

A panel of anti-PSMA mAbs that represent promising candidates for therapy was created. Briefly, the mAbs were generated as follows: BALB/c mice were immunized subcutaneously with recombinant PSMA at approximately three-week intervals. After a total of 4 injections, mice were sacrificed and their splenocytes fused with a myeloma cell line using standard techniques in order to create hybridomas. Individual hybridoma supernatants were screened by ELISA for reactivity with PSMA derived from either LNCaP human prostate tumor cells or from 3T3 cells engineered to express full-length human PSMA (3T3-PSMA cells). Positive clones were secondarily screened by flow cytometry for specific reactivity with intact 3T3-PSMA and LNCaP cells so as to select antibodies that recognize native, cell-surface PSMA and thus have the greatest therapeutic potential.

Mice having the ability to produce human antibodies (XenoMouse, Abgenix; Mendez et al., *Nature Genetics* 15:146, 1997) were immunized subcutaneously once or twice weekly with 5×10^6 LNCaP cells adjuvanted with alum or Titermax Gold (Sigma Chemical Co., St. Louis, MO). Animals were boosted twice with 10 μ g of recombinant PSMA protein immunoaffinity captured onto protein G magnetic microbeads (Miltenyi Biotec, Auburn, CA). PSMA mAb 3.11 was used for capture. Splenocytes were fused with NSO myeloma cells and the hybridomas that resulted were screened as above by flow cytometry to detect clones producing antibodies reactive with the extracellular portion of PSMA. One clone, 10.3 (PTA-3347), produced such antibodies.

These methods have yielded a high proportion of mAbs that react exclusively with conformation-specific epitopes on cell-surface PSMA. As shown in Fig. 1, several (mAbs 3.7, 3.9, 3.11, 5.4, and 10.3) but not all (mAb 3.12) mAbs specifically bind viable PSMA-expressing cells. Using recombinant soluble PSMA proteins expressed in Chinese hamster ovary (CHO) cell lines, it further was demonstrated that the mAbs bind epitopes in the extracellular region of PSMA. The mAbs were also tested for their ability to immunoprecipitate native PSMA from 3T3-PSMA cell lysates. The mAbs positive in flow cytometry (Fig. 1) were also effective in immunoprecipitation (Fig. 2), whereas mAb 3.12 was unreactive. Fig. 3 shows the recognition of non-denatured full-length PSMA and recombinant soluble PSMA by several PSMA antibodies that recognize PSMA conformation. This further confirms that these methods yield a preponderance of mAbs that efficiently recognize native PSMA.

The mAbs were tested for reactivity with denatured PSMA by Western blot analysis (Fig. 4). Lysates from the indicated cells and samples (controls: 3T3 cells, PSMA-negative human prostate cell lines PC-3 and DU145, mock supernatant; PSMA-positive samples: PSMA-expressing 3T3 cells, PSMA-positive human prostate cell line LNCaP, rsPSMA-positive supernatant) were resolved by SDS-PAGE, electroblotted, and probed with anti-PSMA mAbs 3.1 and 3.12 (ATCC Patent Deposit Designations PTA-3639 and PTA-3640, respectively). Four mAbs tested in parallel (3.7, 3.8, 3.9, 3.11) showed no reactivity to either full-length or secreted rsPSMA proteins. 7E11 mAb immunoprecipitated full-length but not secreted rsPSMA.

The mAbs reactive in flow cytometry and immunoprecipitation (mAbs 3.7, 3.9, 3.11, 5.4, and 10.3) were all unreactive in Western blot analysis, indicating that the mAbs do not recognize linear epitopes. Taken together, the data strongly suggest that these 5 mAbs recognize conformation-specific epitopes located in the extracellular domain of PSMA. Since mAbs to conformational epitopes typically possess the greatest affinity and specificity for antigen, they represent preferred candidates for therapy.

The reactivities of certain anti-PSMA antibodies are described in Table 2:

Table 2: anti-PSMA antibody properties

mAb	Reactivity				Epitope
	ELISA	Flow Cytometry	IP	Western	
3.1	+	+	+	+	Linear, Extracellular, exposed on native PSMA
3.7	+	+	+	-	Conformational, extracellular
3.8	+	+	+	-	Conformational, extracellular
3.9	+	+	+	-	Conformational, extracellular
3.11	+	+	+	-	Conformational, extracellular
3.12	+	-	-	+	Linear, Extracellular, not exposed on native PSMA
5.4	+	+	+	-	Conformational, extracellular
7.1	+	-	-	+	Linear, Extracellular, not exposed on

					native PSMA
7.3	+	+	+	-	Conformational, extracellular
10.3	+	+	+	-	Conformational, extracellular
1.8.3	+	+		-	Extracellular
A3.1.3	+	+		-	Extracellular
A3.3.1	+	+		-	Extracellular

The mAbs were determined by ELISA to be primarily of the mouse IgG2a, mouse IgG2b and human IgG1 isotypes, which mediate potent effector functions. Although a number of anti-PSMA mAbs have been described over the years and evaluated for therapeutic potential (see, e.g., Liu, H. *et al. Cancer Res.* 57: 3629-3634, 1997; Chang, S.S. *et al. Cancer Res.* 59: 3192-3198, 1999; Murphy, G.P. *et al. J Urology* 160: 2396-2401, 1998), none inhibit the enzymatic activity of PSMA and few recognize conformational determinants on PSMA.

10 **Example 2: Production of anti-PSMA mAbs**

To accurately and quantitatively assess the therapeutic potential of these mAbs, the mAbs are produced in a quantity and quality suitable for extensive *in vitro* and *in vivo* characterization. Briefly, the mAb-secreting hybridomas are cultured in roller bottles in DMEM/F12 medium supplemented with 10% FBS that has been depleted of bovine IgG (Life Technologies). During the production phase of the culture, cells are maintained at $\sim 5 \times 10^6$ cells/mL via twice-weekly exchanges of media. Collected media are clarified by filtration through a 0.22 micron filter and stored at -95°C prior to purification. Given an average antibody expression levels of $\sim 25 \text{ mg/L}$, approximately 3L of roller bottle supernatants are required for each antibody to allow for losses in purification.

20 Culture supernatants from a given hybridoma are pooled and loaded onto a Protein A Sepharose affinity column. Mouse IgG2a, mouse IgG2b and human IgG1 antibodies are loaded directly, but supernatants containing mouse IgG1 antibodies are adjusted to pH 8.5 and 1M NaCl prior to loading in order to promote binding. After washing the column, the mAb is eluted with low pH buffer into fractions using 1M Tris, pH 8.0. Elution peak fractions are pooled, dialyzed against PBS buffer, concentrated to 5 mg/mL and stored in sterile aliquots at -95°C . All purification procedures are carried out using endotoxin-free

buffers and sanitized chromatography columns. Purified mAbs are tested for purity by reducing and nonreducing SDS-PAGE, for PSMA binding affinity by ELISA, and for endotoxin levels by the *limulus* amebocyte lysate assay. These procedures routinely yield “animal-grade” antibody at >95% purity and <0.5 endotoxin units per milligram of protein.

5

Example 3: Evaluation of the therapeutic potential of the unlabeled mAbs *in vitro*

Purified mAbs are tested in a battery of assays for therapeutically relevant properties, including affinity, specificity, enzyme inhibitory activity and effector functions. The ideal product candidate binds and inhibits PSMA activity at subnanomolar concentrations and mediates potent cell-killing through Fc-related effector functions.

First, the mAbs’ affinity for cell-surface and secreted forms of PSMA is measured by flow cytometry and ELISA, respectively. In the flow cytometry assay, varying amounts of mAbs are incubated with 5×10^5 3T3-PSMA cells in FACS buffer (PBS containing 1% FBS and 0.1% NaN_3) for 2 hr to allow for saturation binding. Cells are washed and incubated with a phycoerythrin-coupled goat antibody to mouse IgG (ICN/Cappel) for detection of bound mAb by flow cytometry. Specific binding is calculated by subtracting the fluorescence intensity observed with parental 3T3 cells.

For ELISA, CHO cell-derived recombinant soluble PSMA protein (rsPSMA, Progenics, Tarrytown, NY) is diluted to 1 $\mu\text{g}/\text{ml}$ in 50 mM carbonate buffer, pH 9.4, and coated overnight at 4 °C onto 96-well Immulon II microtiter plates at 100 $\mu\text{l}/\text{well}$. The plates are then blocked for 2 hr with PBS buffer containing 5% BSA. mAbs are added in a range of concentrations in ELISA buffer (PBS buffer containing 2% BSA, 1% FBS and 0.5% Tween 20) for 2 hours at room temperature. The plates are washed, and horseradish peroxidase conjugated goat antibody to mouse IgG is added for 1 hr at room temperature. The plates are washed again and 3,3',5,5'-tetramethylbenzidine dihydrochloride (TMB) substrate (Pierce, Rockford, IL) is added for colorimetric readout at 450 nm using an ELISA plate reader (Molecular Devices, Sunnyvale, CA).

Example 4: mAb cross-competition binding assay

To identify whether a given group of mAbs recognize distinct or overlapping epitopes on PSMA, cross-competition binding assays are performed (Liu, H. *et al. Cancer Res* 57: 3629-3634, 1997). In this flow cytometry assay, a biotinylated test mAb is incubated with

3T3-PSMA cells in the presence or absence of varying concentrations of unlabeled competitor mAbs as described above. Following washing, phycoerythrin-conjugated streptavidin is added to determine the amount of bound biotinylated mAb. The percent inhibition is defined relative to that observed in the presence of an isotype-matched mAb of irrelevant specificity (0% inhibition) and to that observed using excess unlabeled test mAb (100% inhibition).

Example 5: Effects of mAbs on PSMA enzymatic activity

PSMA has been shown to possess both folate hydrolase and N-acetylated α -linked acidic dipeptidase (NAALADase) enzymatic activities, which may influence the proliferation and malignancies of the tumor cell (Heston, W.D.W. *Prostate: Basic and Clinical Aspects* (R.K. Naz, ed.). CRC Press, New York: 219-243, 1997). Several of the mAbs described above (mAb 3.9, mAb 5.4 and mAb 7.3) and mAb J591 (ATCC #HB-12126) were tested for folate hydrolase modulating activity using previously described assays for measuring PSMA enzymatic activity (Pinto, J.T. *et al. Clinical Cancer Res* 2: 1445-1451, 1996).

Briefly, folate hydrolase activity was measured as follows. Fifty μ M methotrexate di-gamma glutamate and 10 μ g/ml rsPSMA (premixed with anti-PSMA or irrelevant mAb) was incubated in pH 4.5 acetate buffer in a volume of 100 μ l for 2 hr at 37°C. Reactions were terminated by boiling for 5 minutes prior to separation of free, mono- and di-gamma glutamate forms of methotrexate by capillary electrophoresis on a Spectra Phoresis 1000 (Thermo Separation, San Jose, CA). The various methotrexate derivatives were quantified based on their retention times and absorbance at 300 nm.

The data show that mAb 5.4 potently blocks the enzymatic activity of purified rsPSMA protein and in lysates of C4-2 cells. C4-2 is an androgen independent derivative of the LNaCP cell line (human prostate cancer line) which expresses endogenous PSMA. More details regarding the C4-2 cell line may be found in O'Keefe D.S. *et al. Prostate* 45: 149-157, 2000). Figures 7 and 8 provide the results for two production lots of rsPSMA (rsPSMA #7 and rsPSMA #8). The results for the C4-2 cell lysates are shown in Figure 9. The figures illustrate the effect of four antibodies (mAb 3.9, mAb 5.4, mAb 7.3 and mAb J591) on the enzymatic activity of folate hydrolase by way of the rate of cleavage of glutamate from methotrexate di-gamma glutamate (MTXGlu2) by folate hydrolase present in the two

production lots of rsPSMA and in the C4-2 cell lysates. In addition to the inhibitory effects of mAb 5.4, mAb 3.9 was also found to inhibit folate hydrolase activity.

For NAALADase activity assays, rsPSMA protein is incubated with varying amounts of anti-PSMA or control mAbs in 50mM Tris pH 7.4, 1mM CoCl₂ for 10 minutes at 37°C before adding 50μl of 0.6μM N-acetylaspartyl-[³H]glutamate. After 15 minutes, the reaction is stopped by adding 1 ml of 100mM NaPO₄. Cleaved glutamate is separated from the substrate by ion exchange chromatography and detected by scintillation counting. Each measurement is performed in triplicate.

10 Example 6: Reactivity with normal and malignant human tissues by immunohistochemistry

Anti-PSMA mAbs are tested by immunohistochemistry for reactivity with both normal and malignant human tissues using an avidin-biotin peroxidase method (Silver, D.A. *et al. Clin Cancer Res* 3: 81-85, 1997). Frozen or paraffin-embedded tissues can be used. Paraffin-embedded tissue sections are deparaffinized and endogenous peroxidase activity is blocked by incubation with 1% H₂O₂ for 15 minutes. Sections are blocked in a 1:10 dilution of horse serum in 2% PBS-BSA (Sigma Chemical, St Louis, MO) for 30 minutes before overnight incubation with 2μg/ml anti-PSMA mAb in 2% PBS-BSA. After washing, sections are incubated with biotinylated secondary antibody, washed, and incubated with avidin:biotin peroxidase complexes (Vector Laboratories, Burlingame, CA) diluted 1:25 in PBS for 30 minutes. After washing, sections are visualized by immersion in PBS containing 0.05% diaminobenzidine tetrachloride, 0.01% H₂O₂, and 0.5% Triton X-100. Negative control sections are incubated with isotype-matched mAbs of irrelevant specificity. As a positive control, 7E11 (Cytogen, Princeton, NJ), a well-characterized anti-PSMA mAb, is used.

25

Example 7: Antibody-dependent cellular cytotoxicity (ADCC)

In the ADCC assay, mAbs are serially diluted and combined with ⁵¹Cr-labeled 3T3-PSMA cells or human prostate PC-3 cells that have been engineered to express human PSMA (PC-3-PSMA cells). NK effector cells are purified from lymph nodes or spleens using anti-NK microbeads (Miltenyi Biotec). Sera, NK effector cells, and ⁵¹Cr-loaded target cells are co-incubated at effector:target cell ratios of 10:1, 20:1, and 40:1, with each condition performed in triplicate. Cells are incubated 4-5 hours at 37°C before supernatants are

collected for measurement of ^{51}Cr release by gamma counting. The percent specific lysis is determined relative to that observed in the presence of isotype-matched non-specific mAb (0% lysis) to that obtained using 10% sodium dodecyl sulfate (100% lysis).

5 Example 8: Complement-mediated lysis (CML)

For CML, ^{51}Cr -loaded 3T3-PSMA or PC-3-PSMA cells serve as target cells. Serial dilutions of mAbs are co-incubated with rabbit complement and target cells for 4-5 hours at 37°C, with each condition being performed in triplicate. Supernatants are then collected and counted with a gamma counter. Specific lysis is computed as previously done with the
10 ADCC assay data.

Example 9: Anti-proliferative effects

To test anti-proliferative effects of these antibodies, anti-PSMA mAbs are serially diluted and incubated with LNCaP, PC-3-PSMA and parental PC-3 cells in log-phase growth.
15 At 4 hr, 24 hr, and 72 hr intervals, cells are removed and analyzed for density and viability by trypan blue staining and WST-1 assay (Roche Biochemicals).

Example 10: Optimization of chelation and radiolabeling procedures

The most promising mAbs identified using the procedures described in the foregoing
20 examples will be optimized for biochemical and biological stability and activity after labeling prior to evaluation in animals. Success in *in vitro* experiments is defined as identification of a radiolabeled mAb that specifically kills PSMA-expressing tumor cells at >10-fold lower concentrations than unlabeled or similarly labeled isotype control mAb.

Because the preferred α - and β -emitting isotopes are all radiometals, each of the
25 mAbs is first conjugated with an appropriate metal chelating agent. Based on the favorable *in vivo* stability data and its proven use in human clinical trials, the bifunctional chelating agent C-functionalized trans cyclohexyldiethylenetriaminepentaacetic acid (*p*-SCN-CHX-A"-DTPA) is the preferred agent for attaching either ^{90}Y or ^{213}Bi to the antibody (Brechbiel, M.W. *et al. J. Chem. Soc. Chem. Commun.* 1169-1170, 1991). A form of this chelate has previously been tested in more than 70 doses in humans in ongoing trials at Memorial-Sloan
30 Kettering Cancer Center (McDevitt, M.R. *et al. J. Nucl. Med.* 40:1722-1727, 1999). For ^{225}Ac , our initial studies will examine a novel bifunctional chelating agent termed *p*-SCN-Bz-

- 70 -

HEHA (1,4,7,10,13,16-hexaazacyclooctadecane-N,N',N'',N''',N'''',N''''-hexaacetic acid) (Deal, K.A. *et al. J. Med. Chem.* 42:2988-2992, 1999). The objective is to optimize the antibody conjugation and chelation ratios to maximize labeling yield and activity while maintaining suitable stability for *in vivo* utilization. Additional chelating agents also are used
5 as they become available from the N.I.H. and other sources.

Initially, the antibody is rendered metal-free by incubation with a large molar excess of EDTA at pH=5. The EDTA and any metals scavenged from the antibody preparation are removed via continuous buffer exchange/dialysis so as to replace the pH=5 buffer with the conjugation buffer (Nikula, T.K. *et al. Nucl. Med. Biol.* 22:387-390, 1995). Conditions that
10 yield optimal chelator to antibody ratio but still remain immunoreactive are identified by systematically varying the chelator:antibody ratio, reaction time, temperature, and/or buffer systems about initial conditions that employ a 40-fold molar excess of chelator to antibody in HEPES buffer, pH 8.5. The number of chelates bound per antibody is determined using an
15 established spectrophotometric method (Pippin, C.G. *et al. Bioconjugate Chemistry* 3: 342-345, 1992).

For ⁹⁰Y and ²²⁵Ac constructs, labeling efficiency is measured directly. For ²¹³Bi, initial antibody constructs are tested for chelation efficiency using ¹¹¹In, which has similar chelation chemistry as ²¹³Bi but possesses the advantages of a longer half life ($t_{1/2}=3$ days), ready availability, and traceable γ -emission. Once optimized using ¹¹¹In, labeling efficiency
20 is determined for ²¹³Bi.

Radiolabeled mAb is purified over a BioRad 10DG desalting column using 1% HSA as the mobile phase and evaluated by instant thin layer liquid chromatography (ITLC) and/or high performance liquid chromatography (HPLC) to determine the percent incorporation of radionuclide (Zamora, P.O. *et al. Biotechniques* 16: 306-311, 1994). ITLC and HPLC
25 provide a means of establishing purity and identifying the percent of low molecular weight radiochemical impurities (*i.e.*, metal chelates, colloids, and free metal). Duplicate ITLC strips for each mobile phase are developed, dried, and cut at the R_f of 0.5 mark and counted in a gamma counter. The HPLC system is equipped with both an online UV absorption detector and radioactivity detector. The HPLC elution profile directly correlates radioactivity
30 with protein and low molecular weight species as a function of the elution time. A TSK SW3000_{XL} column (TosoHaas, Montgomeryville, PA) is used and calibrated using a range of protein molecular weight standards.

Example 11: Affinity and immunoreactivity of radiolabeled mAbs

Once radiolabeled constructs are obtained, purified, and assessed for biochemical and radiochemical purity, biological activity is determined. Binding activity of the radioconstruct 5 is performed by Scatchard analysis of binding data obtained using whole LNCaP and 3T3-PSMA cells and/or membrane fractions as previously described (Scheinberg, D.A. *et al.* *Leukemia* 3: 440-445 (1991)).

The immunoreactivity of the synthetic constructs is evaluated in order to correlate the chelate:antibody molar ratio with the biological activity. Briefly, 2 ng of labeled mAb is 10 incubated with a ~25-fold excess of PSMA as expressed on 3T3-PSMA cells. After a 30 min incubation at 0°C, the cells are collected by centrifugation and the supernatant containing unbound mAb is added to fresh 3T3-PSMA cells for an additional 30 min at 0°C. Both sets of cells are centrifuged and washed twice with cold PBS. The cell pellets, supernatant and wash fractions are counted for radioactivity. Immunoreactivity is defined as the amount of 15 radioactivity in the cell pellets divided by the total radioactivity in the cell pellets, supernatant and wash fractions.

Example 12: mAb internalization

The activity of radiolabeled mAbs can be significantly modulated by their 20 internalization rates. Internalization of the cell surface antibody-antigen complex is measured using ¹¹¹In radiolabeled antibody constructs (Caron, P.C. *et al.* *Cancer Res* 52: 6761-6767, 1992). Briefly, 5x10⁵ 3T3-PSMA cells are incubated at 37°C with ¹¹¹In radiolabeled antibody for varying time periods. Cells are washed with PBS and cell-surface bound radiolabeled constructs are stripped with 1ml of 50mM glycine/150mM NaCl, pH=2.8. Total 25 cell-associated radioactivity and acid-resistant (internalized) radioactivity are determined by γ-counting to ascertain the rate of internalization. Parental 3T3 cells that do not express PSMA are used as a control to determine non-specific binding. Based upon previous results by other groups (Smith-Jones P.M. *et al.* *Cancer Res* 60: 5237-5243, 2000), significant internalization of PSMA after binding with one or more of the mAb constructs is expected.

Example 13: *In vitro* cytotoxicity studies

Assessment of *in vitro* cytotoxicity of α -labeled mAbs was undertaken once the immunoreactivity of the radioimmunoconjugate was established. Approximately 50,000 target cells (either LNCaP or 3T3-PSMA cells) were treated in 96 well plates and analyzed 24-96 hours later. Quantification of cell death due to ^{225}Ac -labeled constructs (or ^{213}Bi) was 5 accomplished by determining the uptake of ^3H -thymidine by surviving cells (Nikula, T.K. *et al.* *J. Nucl. Med.* 40: 166-176, 1999). Specificity was determined by use of control cells (PSMA-negative human prostate cell lines PC-3 and DU-145, as well as control 3T3 cells), blocking with excess unlabeled antibody, and control radioconjugates.

10 The cytotoxic effects of antibody conjugate concentration, specific activity, and time of exposure were then assessed. Cytotoxicity was expressed relative to that seen with 1M HCl (100% cell death) and media (background cell death). LD₅₀ values were calculated by plotting cell viability as a function of the number of ^{225}Ac atoms bound on the cells (McDevitt, M.R. *et al.* (1998) *Eur. J. Nucl. Med.* 25: 1341-1351 (1998)).

15 Multicellular spheroids of LNCaP-FGC cells had been established and were used to investigate the potential of radioimmunotherapy (RIT) to eradicate minimal disease *in vitro*. These three-dimensional spheroids mimic tissue structures more accurately than monolayer cultures and thus provide a more relevant model of solid tumors (O'Connor, K.C. *Pharm. Res.* 16: 486-493, 1999). LNCaP-FGC is a fast growing clone of the original LNCaP cell line, and the cells were grown using a liquid overlay technique to a size of 200-600 μm 20 (Ballangrud, A.M. *et al.* *Clin. Cancer Res.* 5: 3171s-3176s, 1999). In larger spheroids, the inner mass of cells becomes necrotic, while the outer rim consists of proliferating tumor cells. Antibody penetration was measured by confocal microscopy, and prior results suggested that an anti-PSMA antibody should penetrate to a depth of 40-50 μm (Ballangrud, A.M. *et al.* 7th 25 Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, Princeton NJ, 1998). The *in vitro* cytotoxicity of ^{225}Ac -3.9 on LNCaP target cells is shown in Figure 23. The percentage of viable PSMA⁺ LNCaP cells was plotted as a function of activity of the radioconjugate. Addition of a 100-fold excess of unlabeled antibody was used as a control for specificity.

30 Example 14: Evaluation of the *in vivo* efficacy of unlabeled and radiolabeled mAbs in mouse xenograft models of human prostate cancer

Antibodies that are successful in the foregoing assays demonstrate significant specificity and functional properties that suggest they will be useful for therapeutic use. The most promising of these radiolabeled and "naked" mAb constructs are evaluated in the best available mouse models of prostate cancer. The studies employ an established xenograft model in which the LNCaP human prostate tumor cell line is injected into immunocompromised nude mice and allowed to form solid tumors (Ellis, W.J. *et al. Clin Cancer Res* 2: 1039-1048 (1996), which then are treated with both radiolabeled and unlabeled anti-PSMA mAb constructs. Follow-on studies also utilize a mouse xenograft model, CWR22, which reproduces many of the key biological features of human prostate cancer.

10

LNCaP tumor cell xenograft model

A construct showing high affinity and high specificity is taken into the LNCaP tumor cell xenograft *in vivo* model for biodistribution and pharmacokinetic analysis. ¹¹¹In-labeled anti-PSMA antibody is used for these studies due to its favorable chelation chemistry, radioactive half-life and traceable gamma emission. Timepoints are evaluated as appropriate for the half-lives of ²¹³Bi, ²²⁵Ac, ¹⁷⁷Lu and ⁹⁰Y, which are the nuclides of therapeutic interest. Labeled radioconstructs (1-5 μ g) are injected i.v. into nude mice (normal and tumor bearing) and the mice are sacrificed at 5 min, 15 min, 30 min, 60 min, 2 hrs, 4 hrs, 18hrs, and 24hrs post-injection. Blood and major organs are taken from animals, weighed, and the percent radioactivity injected per gram of tissue is determined (Nikula, T.K. *et al. J. Nucl. Med.* 40: 166-176, 1999). Specificity is addressed by pre-injection with excess unlabeled construct. Macroscopic tumor volume and animal survival rates is recorded throughout the experiments.

A dose-ranging study is also conducted to determine the toxicity of the constructs when administered via i.v. or i.p. injection to normal and tumor-bearing mice. These animals are routinely examined for toxic side effects during the course of the studies by blood chemistry and physical examination. Animals are sacrificed during and at the conclusion of the study in order to collect blood and body tissues for further evaluation. Previous data has demonstrated an approximate maximum tolerated dose of 250 μ Ci/mouse, so total doses are kept below that level.

30

Once i.v. biodistribution and toxicity is documented, radiotherapy of tumors is assessed. Groups of five mice are injected with <1 μ g radiolabeled anti-PSMA mAb construct both pre- and post-tumor challenge to assess anti-tumor activity. Antigen negative

(RAJI or RAMOS) xenografted tumors are also used as a control. Other controls include (1) treatment with unlabeled anti-PSMA mAb only and (2) excess unlabeled anti-PSMA mAb pretreatment before ²¹³Bi, ²²⁵Ac, ¹⁷⁷Lu and/or ⁹⁰Y-labeled anti-PSMA to block specific targeting.

5 Groups of tumor bearing mice are injected with unlabeled anti-PSMA mAbs (at equimolar concentrations) and several dose levels of radiolabeled anti-PSMA or a similarly labeled isotype control antibody. The effect on tumor growth is assessed over time. Statistical differences between therapy groups is determined using an analysis of variance (ANOVA) method and animal survival is illustrated using Kaplan-Meier plots. The efficacy 10 of ²¹³Bi, ²²⁵Ac, ¹⁷⁷Lu and/or ⁹⁰Y-labeled anti-PSMA constructs is correlated to the data obtained *in vitro*. Success in these experiments is defined as the ability to significantly (p <0.05) increase life-span and/or decrease tumor volume as compared to a radiolabeled isotype control mAb.

Furthermore, the tumor models are used to test whether predosing with unlabeled 15 antibody prior to injection of radiolabeled antibody improves delivery of the radiolabeled antibody to the tumor. The tumor-bearing mice are injected with <1 μ g radiolabeled anti-PSMA antibody with or without a prior single injection of 5-100 μ g of unlabeled antibody. After several days, animals are sacrificed for evaluation of the distribution of radioactivity in 20 the tumor, normal tissue, and blood. If predosing with unlabeled antibody improves delivery and targeting of radiolabeled antibody to the tumors, this approach is applied and optimized in toxicity and therapeutic studies.

In addition to overall survival, the role of timing of the injection after tumor transplantation (Day 1 vs 3 vs 7), the role of dosage (dose-response curves using 3-4 dose 25 levels), the role of schedule (single vs multiple divided daily injections) and the specificity of the treatment (pre-treatment with unlabeled anti-PSMA to block targeting) is examined.

These *in vivo* studies are designed to address the maximum tolerated dose of radiolabeled antibody, the activity of the antibody, the optimal dosing schedule (single or multiple injections), and the effect on tumor size. Successful completion of this work enables 30 determination of the feasibility of PSMA-targeted alpha particle radioimmunotherapy (RIT) of prostate cancer and identifies the optimal ²¹³Bi and/or ²²⁵Ac-labeled constructs to enter into clinical development.

CWR22 mouse xenograft model

The most promising anti-PSMA mAbs in unlabeled, toxin-labeled and/or radiolabeled form are tested in the CWR22 human prostate cancer xenograft mouse model, (Wainstein, M.A. *et al. Cancer Res* 54:6049-6052 (1994); Nagabushan, M. *et al. Cancer Res* 56:3042-5 3046 (1996); Pretlow, T.G. *et al. J Natl Cancer Inst* 85:394-398 (1993)). This model has many features of the human condition including a dependence on androgens, a correlation between measured levels of PSA in serum and tumor size, and high-level expression of PSMA. Following androgen withdrawal, PSA levels decrease to nearly undetectable levels and tumor volume decreases. Later, the tumor regrows as an androgen-independent 10 neoplasm, manifest initially by a rise in PSA and later, measurable tumor growth. After androgen withdrawal, tumors regrow at variable time periods.

Four to six week old nude athymic BALB/c male mice are obtained from the National Cancer Institute-Frederick Cancer Center and maintained in pressurized ventilated caging. While immunodeficient in many respects, these mice mediate wild-type levels of ADCC and 15 CML. The CWR22 tumor line is propagated in the animals by the injection of minced tumor tissue from an established tumor into the subcutaneous tissue of the flanks of athymic nude mice together with reconstituted basement membrane (Matrigel, Collaborative Research, Bedford, MA). To maintain serum androgen levels, the mice are administered 12.5-mg sustained-release testosterone pellets (Innovative Research of America, Sarasota, FL) 20 subcutaneously before receiving tumors. Three to four weeks after inoculation, tumors of approximately 1.5 x 1.0 x 1.0 cm are measured. Androgens are withdrawn by surgical castration under pentobarbital anesthesia and removal of the sustained-release testosterone pellets. Tumor size is determined by caliper measurements of height, width and depth. PSA values are performed on the serum of the mice after tail bleeding using a Tandem-R PSA 25 immuno-radiometric assay (Hybritech, San Diego, CA).

Groups of five mice are injected with anti-PSMA mAb or a similar isotype control mAb at dosages from 5-100 μ g to assess anti-tumor activity. The effect of scheduling single doses vs. multiple divided daily injections is also examined. Macroscopic tumor volume and animal survival rates are recorded throughout the experiments. Statistical differences 30 between therapy groups are determined using an analysis of variance (ANOVA) method and animal survival are illustrated using Kaplan-Meier plots, with success defined as a difference

of $p < 0.05$. Similarly, the efficacy of "naked" mAbs is compared to that seen with ^{90}Y , ^{177}Lu , ^{213}Bi and/or ^{225}Ac -labeled anti-PSMA constructs.

These *in vivo* studies are designed to address the maximum tolerated dose of mAb, the activity of the antibody, the optimal dosage and dosing schedule (single or multiple divided injections), and the effect of treatment on tumor size. Successful completion of this work will enable determination of the feasibility of PSMA-targeted immunotherapy of prostate cancer and identification of the optimal constructs to enter into clinical development.

Example 15: Investigation Of Native PSMA Protein Conformation

10

Extraction of PSMA from the cell surface of LNCaP and 3T3 cells

LNCaP or 3T3 cells were grown to confluence in a T150 cell culture flask, detached using cell dissociation solution (Mediatech, Herndon, VA) and transferred to a 15ml conical tube. The cells were washed twice with PBS and resuspended with 2ml of M-PerTM Mammalian Protein Extraction Reagent (Pierce, Rockford, IL). Following incubation for 10 min at 4°C, cell debris and insoluble aggregates were removed by centrifugation at 15,000 rpm for 30 min at 4°C. The supernatant was transferred to a cryogenic vial and stored at -80°C until further use.

20

Production and Purification of Recombinant, Soluble PSMA (rsPSMA)

The extracellular domain of PSMA (amino acids 44-750 of the full-length protein, SEQ ID NO:1) was obtained as a secreted protein from a DXB11 Chinese hamster ovary (CHO) cell line, stably transfected with an rsPSMA expression vector. The cells were grown in a Celligen Plus 2.2L Packed Bed Bioreactor (New Brunswick Scientific, Edison, NJ) in protein-free media. The Bioreactor was operated in perfusion mode, and supernatant was collected aseptically into collection bags maintained at 4°C. The protease inhibitor aprotinin was added to the harvest supernatant, which was concentrated 25-fold prior to storage at -90°C. For purification, the concentrate was thawed and purified using subsequent steps of Concanavalin A lectin affinity chromatography and Butyl-Sepharose hydrophobic interaction chromatography. The purified protein was dialyzed against 10mM potassium phosphate, pH 7.0. The purified rsPSMA protein is dimeric, and possesses folate hydrolase enzymatic activity when tested according to published procedures (Pinto et al., *Clinical Cancer*

Research 2:1445, 1996) and reacts with each of a panel of conformation-specific monoclonal antibodies, indicating that rsPSMA adopts a native conformation.

Polyacrylamide Gel Electrophoresis (PAGE) and Western Blotting of the different PSMA

5 *proteins*

For each individual PAGE analysis, 15 μ l of each cell lysate and 5 μ l of the purified rsPSMA were used.

SDS-PAGE was performed using standard procedures. Samples were prepared by boiling for 5 minutes in the presence of Laemmli sample buffer (with or without the reducing 10 agent dithiothreitol [DTT]). Samples were then applied on a 4-15% Tris-Glycine gel (BioRad, Hercules, CA). After electrophoresis for 1h at 200V, the proteins were transferred onto nitrocellulose (BioRad) and analyzed by Western blotting.

The oligomeric nature of the different PSMA proteins was analyzed using Blue Native PAGE (BN-PAGE). Each sample was diluted with an equal volume of 2x BN-PAGE 15 sample buffer (0.1M MOPS / 0.1M Tris / 40% glycerol / 0.1% Coomassie G-250) prior to loading onto the gel. BN-PAGE was performed using 4-12% BisTris gels (Invitrogen, Carlsbad, CA) and 50mM MOPS / 50mM Tris, pH 7.7 as running buffer. Coomassie Blue was omitted from the cathode buffer to avoid interference with protein binding during the transfer of the proteins onto nitrocellulose. Following electrophoresis for 2.5hrs at 125V, the 20 proteins were transferred onto a nitrocellulose membrane (BioRad) and analyzed by Western blotting.

Western blotting was performed as follows: Subsequent to transfer, the nitrocellulose membrane was blocked with 5% milk in PBS / 0.1% Triton X-100 / 0.02% SDS, which was also used for the subsequent wash and antibody incubation steps. PSMA proteins were 25 detected using the anti-PSMA mAbs 3.1 or 3.9 (Progenics Pharmaceuticals) as primary antibody and HRP-labeled anti-mouse IgG as secondary antibody and 1h incubation at room temperature. The membranes were colorimetrically developed using chemiluminescence (NEN Plus, Perkin Elmer Life Sciences, Boston, MA).

30 *Results*

Both full-length PSMA and recombinant, soluble PSMA (rsPSMA) migrate on reducing and non-reducing SDS-PAGE with a molecular weight of ~100 kDa (Fig. 5). The

result for full-length PSMA is in accordance with prior observations (Israeli et al., U.S. Patent 5,538,866; Murphy et al., U.S. Patent 6,158,508; Israeli, et al., *Cancer Research* 54:1807, 1994; Troyer et al. *Int. J. Cancer* 62:552, 1995; Troyer et al., *The Prostate* 30:233, 1997; Grauer et al., *Cancer Research* 58:4787, 1998). In each of these reports, full-length PSMA 5 migrated as a major band of 100-120 kDa, with a minor (typically <5% of the total PSMA protein) 180-200 kDa band observed in a subset of reports (U.S. Patent 6,158,508; Troyer et al., 1995; Troyer et al., 1997). Troyer et al. (1995) describe the 180-200 kDa species as being a noncovalently associated PSMA dimer that can be disrupted with increasing concentrations of SDS detergent.

10 rsPSMA contains 94% (707 of 750) of the amino acids present in full-length PSMA, and the two proteins are not clearly resolved in this analysis, as expected.

SDS-PAGE allows the analysis of denatured proteins only. In order to examine native proteins in their native state, other techniques have to be employed, such as Blue Native PAGE (BN-PAGE). BN-PAGE is used to determine the native molecular weight of 15 proteins and their noncovalent complexes (Schägger & v. Jagow, *Anal. Biochem.* 199:223-231, 1991; Schägger et al., *Anal. Biochem.* 217:220-230, 1994). The dye Coomassie Blue G-250 binds to the hydrophobic domains on the surface of most proteins, enhances solubility, and introduces a charge shift on the native proteins resulting in migration towards the anode at pH 7.5 irrespective of the isoelectric point of the protein. Although the migration velocity 20 of proteins in BN-PAGE varies somewhat, the molecular mass of proteins can be determined by their respective end points of migration due to the decreasing pore size of the acrylamide gradient present in the gels.

When analyzed by BN-PAGE, full-length PSMA (extracted from LNCaP or 3T3 cells) as well as purified rsPSMA migrate with a molecular weight of ~190kDa (Fig. 6). This 25 surprising observation for full-length PSMA indicates that the predominant form of cell-surface PSMA is a noncovalently associated dimer. This unexpected result can be contrasted with that of previous reports (U.S. Patent 6,158,508; Troyer et al. 1995; Troyer et al., 1997), where the PSMA dimer represents a minor species in SDS-PAGE analyses. Presumably, the noncovalent PSMA dimer is largely dissociated by boiling in the presence of the denaturing 30 detergent SDS.

Moreover, the result for the purified rsPSMA protein indicates that the dimer is stabilized via interactions between extracellular amino acids in addition to or exclusive of

amino acids in the transmembrane or intracellular segments, which are not present in rsPSMA.

Example 16: Dissociation of PSMA Multimers

5 PSMA is a putative zinc metalloprotease, and site-directed mutagenesis of amino acids implicated in zinc binding results in a profound loss of enzymatic activity (Speno et al., *Molecular Pharmacology*, 55:179, 1999). These amino acids include His-377, Asp-387, Glu-425, Asp-453 and His-553. Ethylenediaminetetraacetic acid (EDTA) is a strong chelating agent for Zn^{2+} and other divalent cations, and thus has the potential to remove Zn^{2+}
10 or other coordinate divalent cations from PSMA. We have determined that EDTA treatment causes the PSMA homodimer to dissociate into monomeric subunits. Similar results can be expected for other agents that possess similar chelating properties, such as ethyleneglycol-bis(beta-aminoethyl ether) (EGTA).

15 The purified rsPSMA protein was incubated with or without 10mM EDTA for 16 hr at 4°C and then analyzed by BN-PAGE. Under these conditions, the EDTA-treated protein was monomeric, whereas rsPSMA remained dimeric in the absence of EDTA. Although the dissociation of the PSMA dimer into monomer was essentially complete, any residual dimeric protein can be removed if desired by gel filtration, ultracentrifugation or other size-based separation methods that are well-known to those skilled in the art.

20

Example 17: Methods for identifying promoters of PSMA dissociation

Compounds are screened for the ability to promote dissociation of PSMA dimers using a method that includes:

- (a) contacting a PSMA dimer with a compound under conditions that do not 25 promote dissociation of the PSMA dimer in the absence of the compound;
- (b) measuring the amount of PSMA monomer; and
- (c) comparing the amount of PSMA monomer measured in the presence of the compound with that observed in the absence of the compound.

An increase in the amount of PSMA monomer measured in the presence of the 30 compound indicates that the compound is capable of promoting dissociation of the PSMA dimer.

- 80 -

In a further embodiment, compounds are screened for the ability to promote dissociation of PSMA dimers using a method that includes:

- (a) contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound;
- 5 (b) measuring the amount of PSMA dimer; and
- (c) comparing the amount of PSMA dimer measured in the presence of the compound with that observed in the absence of the compound.

A decrease in the amount of PSMA dimer measured in the presence of the compound indicates that the compound is capable of promoting dissociation of the PSMA dimer.

10

In a further embodiment, compounds are screened for the ability to promote dissociation of PSMA dimers using a method that includes:

- (a) contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound;
- 15 (b) measuring the amounts of PSMA monomer and PSMA dimer;
- (c) calculating a ratio of PSMA monomer to PSMA dimer; and
- (d) comparing the ratio obtained in (c) with that obtained in the absence of the compound.

An increase in the ratio measured in the presence of the compound indicates that the compound is capable of promoting dissociation of the PSMA dimer.

Example 18: Cell surface PSMA binding studies

Flow cytometry

25 Parent 3T3 cells or PSMA-expressing 3T3 cells (2×10^5 cells per condition) were washed in PBS and incubated with PBS containing goat serum (10% v/v) for 20 minutes on ice to block non-specific binding sites. Anti-PSMA monoclonal antibodies (unpurified form in supernatants or purified mAbs) were added in serial dilutions to cells in 100 μ l PBS and incubated on ice for 30 minutes. Control anti-human IgG (Caltag, Burlingame, CA) was used to establish background binding. After two washes in PBS, the cells were incubated with anti-human IgG (BD Pharmingen, San Diego, CA) for 30 minutes on ice. Cells were washed twice in PBS, resuspended in 250 μ l PBS and analyzed by flow cytometry using a FACScan machine (Becton Dickinson, Franklin Lakes, NJ) and CellQuest software. Viable cells were

gated by forward scatter and side scatter parameters, and binding was quantified using histogram plots of mean fluorescence intensity (MFI) levels.

5 Anti-PSMA mAbs XG-006 (PTA-4403 and PTA-4404, heavy and light chain plasmids), XG-051 (PTA-4407 and PTA-4408), 4.40.1 (PTA-4360; 4.40, 4.40.1 and 4.40.2 are the same antibody that represent different stages of subcloning the hybridoma), 4.49.1, 4.292.1 (PTA-4390) and 4.304.1 were found to avidly bind to cell surface PSMA (Figure 24).

Maximal Binding

10 Flow cytometry data (mean fluorescence intensity v. antibody concentration) were transposed and plotted using Excel software (Microsoft, Redmond, WA). Results from representative experiments of at least three determinations are depicted in Figures 25A-25C. Binding was compared by calculation of 50% effective concentration (EC50) using the Forecast function in Excel. The EC50 value represents the concentration of antibody 15 required for half-maximal binding.

Anti-PSMA mAbs 10.3 (PSMA 10.3) and XG-006 were found to bind to 3T3-PSMA cells and not 3T3 cells (Figure 25A). Antibody (26nM) was added to cells, which were analyzed by flow cytometry. Binding to cell-surface PSMA using serial dilutions of anti-PSMA mAb-containing culture supernatants of XG-006, 4.304.1, XG-026 (PTA-4405 and 20 PTA-4406) and 4.49.1 also was demonstrated (Figure 25B). Binding to cell-surface PSMA using serial dilutions of purified anti-PSMA mAbs XG-006 and 10.3 is represented by Figure 25C.

Example 19: Cytotoxicity of toxin-labeled antibody

25 PSMA-3T3, LNCaP, and/or C4-2 cells (and control cell lines 3T3 and PC3 that do not express PSMA) were plated at 2,500 cells/100 μ L/well in 96-well microplates (Falcon) and were incubated overnight at 37 °C in the presence of 5% CO₂. The media used for PSMA-3T3 (and 3T3) and LNCaP (and C4-2 and PC3) was DMEM or RMPI 1640, respectively, containing 2 mM L-glutamine, 10% FBS, and 1% penicillin-streptomycin. 50 ng (in 50 μ L) 30 of Mab-Zap or Hum-ZAP (Advanced Targeting Systems, San Diego, CA) in medium was added in each well. Mab-Zap and Hum-Zap are goat anti-mouse IgG antibody or goat anti-human IgG antibody covalently linked to saporin, the most potent of the plant ribosome-

inactivating proteins (RIP) from the seeds of the plant *Saponaria officinalis*. Saporin induces cell death by apoptosis (Bergamaschi, G., Perfetti, V., Tonon, L., Novella, A., Lucotti, C., Danova, M., Glennie, M.J., Merlini, G., Cazzola, M. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. *Br J Haematol* 93, 789-94. 5 (1996)). The Mab-Zap did not bind to or internalize in cells in the absence of an appropriate primary antibody.

Murine 3.9, 5.4, mJ591 (ATCC# HB-12126) and human 006, 4.40, 4.304 anti-PSMA antibodies (and control IgG antibodies) were added into plates at different concentrations to bring the total volume to 200 μ L in triplicate. The plates were kept cold on ice for at least 30 10 min to maximize Map-Zap or Hum-Zap binding to PSMA antibodies before internalization. The plates were incubated for 2 days and then the medium was changed and incubated for another 2 days. After 4 days incubation, the medium was withdrawn and fresh medium containing 10 % Alamar Blue (20 μ L, Bioscience, Camarillo, CA) was added into each well and incubated for 2 hrs. A CytoFlour plate reader was used to measure fluorescence in 96- 15 well plates at wavelengths of 530 nm excitation and 590 nm emission. Internalization of toxin was mediated by anti-PSMA antibodies. The cell kill is illustrated in Figure 26 on C4-2 cells and in Figure 27 on PSMA-3T3 cells.

Human 4.304 anti-PSMA antibody was directly conjugated with saporin (Wrenn et al., *Brain Res.* 740:175-184, 1996), and its cytotoxicity was demonstrated using a similar 20 protocol as described above (see Figure 28).

Example 20: Immunoreactivity

PSMA-3T3, LNCaP and C4-2 were used as PSMA expressing cell lines and 3T3 was used as a control cell line not expressing PSMA. The cells were blocked with 10% goat 25 serum on ice to reduce non-specific binding in this assay.

A small amount (1-5 ng) of labeled mAb was added into a cell pellet of 10 million cells and incubated at 0°C (on ice) with gentle mixing. After a 1 hour incubation, the cells were collected by centrifugation and the supernatant containing unbound mAb was transferred to a fresh cell pellet for an additional 1 hour incubation at 0°C. Both sets of cells 30 were centrifuged and washed twice with cold PBS. The cell pellets, supernatant and wash fractions were counted for radioactivity. Immunoreactivity is defined as the amount of

radioactivity in the cell pellets divided by the total radioactivity in the cell pellets, supernatant and wash fractions. These data are shown below in Table 3.

Table 3. Immunoreactivity of In-111 radiolabeled antibody on PSMA expressing cells

Radiolabeled mAb	Immunoreactivity (%)	Cell line
In-111 4.304	92.6 (1.4)	PSMA-3T3 (3T3)
	92.6	PSMA-3T3
	91.4 (1.7)	PSMA-3T3 (3T3)
	89.1	LNCaP
	92.4	C4-2
	Average= 91.6 ± 1.5	
In-111 4.40	87.7 (0.5)	PSMA-3T3 (3T3)
	86.8	PSMA-3T3
	89.4 (1.5)	PSMA-3T3 (3T3)
	Average= 88.0 ± 1.3	
In-111 mJ591	58.5	PSMA-3T3
	54.9 (1.1)	PSMA-3T3 (3T3)
	Average= 56.7 ± 2.5	
In-111 3.9	88	LNCaP
	87	C4-2
	89 (2)	PSMA-3T3 (3T3)
	95.3 (0.5)	PSMA-3T3 (3T3)
	88.6	PSMA-3T3
	84.8	C4-2
	89.3	PSMA-3T3
	Average= 88.6 ± 3.2	

Antibodies 4.40, 4.304 and mJ591 were conjugated to the bifunctional chelate CHX-A"-DTPA and antibody 3.9 was conjugated to C-DOTA.

Example 21: Competitive binding assay to identify binding epitopes

To identify whether a given group of mAbs recognize distinct or overlapping epitopes on PSMA, competition binding assays were performed with In-111 radiolabeled antibodies.

2×10^5 cells (100 μ L) of PSMA-3T3 were plated into 96-well microplates, and antibodies

5 4.40, 4.304 and mJ591 (100 μ L) at different concentrations (series dilution) were added. The cells were incubated at 0°C for 30 min. 20 μ L of In-111 radiolabeled CHX-A⁺-DTPA antibody constructs were added into each well. After a 2 hour incubation on ice for competition binding, the cells were washed 5 times using cold PBS. The cells containing bound In-111 antibodies were recovered from microplates into test tubes and counted in a

10 gamma counter.

Results detailed in Figures 29 show that mJ591 blocked In-111 4.40 binding to PSMA-3T3 cells and did not block In-111 4.304. In addition, 4.40 and 4.304 did not block each other. Unmodified antibodies 4.304 and mJ591 were also used to compete with In-111 radiolabeled mJ591. Human 4.304 did not compete with In-111 mJ591 for binding to

15 PSMA-3T3 (Figure 30).

Example 22: Binding affinity using Biacore 3000

To determine the kinetics and affinity of the antibodies, the antibodies in crude supernatants, in purified form and in bifunctional chelate modified forms were analyzed

20 using a Biacore 3000 instrument (Biacore Inc., Piscataway, NJ). Biacore 3000 is a fully automated surface plasmon resonance (SPR)-based biosensor system that is designed to provide real-time kinetic data from assay formats that require no tags or labeling of compounds for biomolecular interactions. It is ideal for screening crude supernatants.

The streptavidin-coated sensor chips (SA chips, Biacore) were used to capture 25 biotinylated anti-human IgG antibody (Sigma, St. Louis, MO). The entire sensor chip surface was conditioned with five injections of conditioning solution (1 M NaCl, 50 mM NaOH) and equilibrated with PBS buffer containing 0.005% polysorbate 20. Two to three thousand resonance units (RU) of biotinylated anti-human IgG antibody (Sigma) were immobilized onto the SA chip followed by an injection of regeneration buffer (glycine-HCl, pH 2.2).

30 Antibodies in supernatants were diluted to 2 μ g/mL in PBS buffer and captured onto one anti-human IgG flow cell, while isotype-matched control human antibody (Sigma) was similarly captured on a second flow cell. rsPSMA at different concentrations in PBS buffer was

flowed over the cells at 30 μ L/min for 3 min in an “association phase” followed by a “dissociation phase” for 10 min. SPR was monitored and displayed as a function of time. For each antibody at one concentration, the chip was regenerated and equilibrated. An example of the analysis of antibody PRGX1-XG-006 in association phase and dissociation phase at different concentrations of rsPSMA from 100 nM to 6.25 nM is shown in Figure 31. Thermodynamic and kinetic rate constants of binding were calculated using the Biacore Evaluation software. For example, the affinity of XG-006 antibodies in a supernatant to rsPSMA was determined to be 4.92×10^{-10} M with a K_a of 1.3×10^5 M⁻¹ s⁻¹ and a K_d of 6.4×10^{-5} s⁻¹. Selective data for several human PSMA antibodies in crude supernatant, purified form, and modified with bifunctional chelate is listed in Table 4 for comparison.

Binding activity of In-111 radiolabeled antibodies was determined by Scatchard analysis of binding data obtained using PSMA-expressing cells (LNCaP, C4.2, PSMA-3T3 and parental 3T3 as a control). The experimental procedures and methods of data analysis have been described previously (Scheinberg, D.A. *et al. Leukemia* 3: 440-445 (1991)).

15

Table 4: Kinetic rate constants of antibodies in crude supernatant, purified, bifunctional chelate modified forms along with KD determined using In-111 radiolabeled Scatchard analysis.

Antibodies	Ka (M ⁻¹ ,s ⁻¹)	Kd (s ⁻¹)	KD (M ⁻¹)	Avg KD
006 Supernatant	1.30E+05	6.40E-05	4.92E-10	4.92E-10
Purified 006-1	2.94E+05	1.37E-04	4.66E-10	
Purified 006-2	2.26E+05	1.27E-04	5.62E-10	5.14E-10
4.40 Supernatant	2.10E+05	1.25E-04	5.95E-10	5.95E-10
Purified 4.40-1	2.54E+05	1.52E-04	5.98E-10	
Purified 4.40-2	2.43E+05	2.37E-04	9.75E-10	7.87E-10
CHX-4.40-1	2.57E+05	1.60E-04	6.23E-10	
CHX-4.40-2	2.47E+05	1.55E-04	6.28E-10	6.25E-10
IN-111CHX-4.40-1			4.44E-09	
IN-111CHX-4.40-2			4.95E-09	4.70E-09
4.304 Supernatant	1.40E+05	1.25E-04	8.93E-10	8.93E-10
Purified 4.304-1	8.31E+04	1.20E-04	1.44E-09	
Purified 4.304-2	1.06E+05	6.33E-05	5.97E-10	1.02E-09
CHX-4.304-1	6.19E+04	1.21E-04	1.95E-09	
CHX-4.304-2	6.79E+04	1.49E-04	2.19E-09	2.07E-09
IN-111CHX-4.304-1			9.63E-09	
IN-111CHX-4.304-2			5.97E-09	7.80E-09
10.3 Supernatant	1.90E+05	3.63E-04	1.91E-09	1.91E-09
Purified 10.3-1	3.28E+05	6.32E-05	1.93E-10	
Purified 10.3-2	2.96E+05	6.43E-05	2.17E-10	2.05E-10

A comparison of the fully human antibodies 4.40.1, 4.49.1, 051 and 006 and the murine antibody 3.9 was performed by Biacore. For each antibody for comparison, response was normalized to 100 RU. The graph of time vs. response difference for these antibodies is 5 given in Figure 32. The binding affinities for these antibodies were determined to be 6.1 , 6.7, 5.8, 4.8 and 13.7×10^{-10} M, respectively.

Example 23: Characterization of cell lines for *in vitro* and *in vivo* studies

Results from a Scatchard analysis using In-111 labeled anti-PSMA antibody 3.9 are 10 represented in Figure 33. Transfected murine 3T3 cells express >1 million copies of PSMA per cell, LNCAP cells (androgen dependent human prostate cancer cell line) express 0.64 million copies, while C4-2 cells (androgen independent) express 0.25 million copies per cell. The affinity of 3.9 for cell surface PSMA is 6.4 nM for PSMA-3T3, 4.0 nM for LNCAP and 3.3 nM for C4-2 (4.6 nM is the average of these data).

15

A summary of the analyses of crude supernatants for the human anti-PSMA antibodies is given in Table 5 below.

Table 5: Characterization of anti-PSMA monoclonal antibodies

	Ab Conc (μ g/mL)		Binding to 3T3- PSMA (FACS)			C4.2 FACS	Anti-PSMA Western	Biacore studies		
	PGNX	Lysate EIA	PGNX FACS	AVG Max binding	AVG EC50			KD, M-1 ($\times 10^{10}$)	Ka, M-1s-1 ($\times 10^5$)	Kd, s-1 ($\times 10^5$)
Supernatant										
PRGX1-XG1-026	4.7	ND ¹	ND	148	2.4	ND	Conf. ²	2.0	1.5	2.9
4.4.1	4.7	0.08	7	8	ND	5.2	Conf.	4.2	2.3	9.7
PRGX1-XG1-006	1.8	0.39	114	183	3.4	9.5	Conf.	4.8	1.3	6.4
PRGX1-XG1-051	3.5	0.48	83	202	2.0	9.9	Conf.	5.8	1.4	8.2
4.40.1	4.3	0.33	53	163	2.3	10.8	Conf.	6.1	2.1	12.5
4.49.1	2.6	0.36	362	162	0.9	16.2	Conf.	6.7	3.1	20.7
4.292.1	2.7	0.18	75	195	6.0	9.2	Conf.	6.8	1.2	8.5
4.304.1	4.1	0.39	92	184	9.1	8.4	Conf.	8.7	1.4	12.5
4.232.1	2.4	0.49	97	138	2.7	6.0	Linear ³	9.4	1.5	13.8
4.153.1	5.9	0.29	279	182	5.3	14.8	Conf.	9.5	1.2	11.8
4.333.1	2.9	0.18	82	168	3.1	6.6	Conf.	11	0.7	8.5
PRGX1-XG1-077	3.9	0.45	392	227	6.0	12.4	Conf.	16	0.6	10.4
10.3	8.5	1.06	ND	ND	ND	ND	ND	19	1.9	36.4
pure 10.3		0.44	130	181	7.5	ND	Conf.	ND		
					4.7					
4.22.1	2.8	0.08	7	ND	ND	4.7	ND	20	1.7	33
4.248.1	3.5	0.37	7	ND	ND	4.1	Conf.	27	1.0	28
4.54.1	10	0.14	267	162	3.9	13.6	ND	30	1.9	56
4.7.1	5	0.23	156	141	1.6	10.2	Conf.	32	1.7	56
4.78.1	5.3	0.00	205	118	1.0	7.9	Conf.	53	2.4	125
4.48.1	4.9	0.06	14	ND	ND	7.7	ND	62	0.9	59
4.209.1	3.5	0.22	60	ND	ND	6.7	ND	142	0.9	125
4.177.1	1.1	0.15	236	174	2.4	10.6	ND	155	0.6	93
4.152.1	3.4	0.38	81	85	4.0	7.5	ND	163	0.8	126
4.28.1	4.2	0.04	112	155	4.2	11.3	ND	167	1.2	192
4.16.1	5.3	0.00	8	ND	ND	7.8	ND	177	1.8	313
4.360.1	1.5	0.02	112	130	2.2	7.9	ND	197	1.0	201
4.288.1	15.4	0.02	67	141	4.1	6.5	ND	198	1.3	257
4.219.2	0.5	0.34	69	ND	ND	5.9	ND	ND		
PRGX1-XG1-069	6.5	ND	ND	71	7.9	ND	ND	No Binding		
Murine 3.9								13.7	0.7	9.7
Control								6.34	2.24	14.2

¹ ND=not determined² conf.=conformational epitope³ linear=linear epitope

Example 24: Cytotoxicity of radiolabeled antibody

The *in vitro* cytotoxicity of Ac-225 labeled anti-PSMA antibody was determined using methodology similar to that used in Example 19. Prostate cancer cells (100 μ L of C4-2, LNCaP, and PC3 cells at a concentration of 2×10^4 cells/mL) were placed into separate 5 well of a 96 well microplate. After overnight incubation, the cells were treated with Ac-225 labeled human anti-PSMA 4.40 antibody at different concentrations for over 4 days. Cell cytotoxicity was quantified using Alamar Blue (Biosource International, Camarillo, CA).

Figure 34 shows a plot of cell survival vs. Ac-225 activity concentration. The EC50 for PSMA expressing cells (C4-2 and LNCaP) was < 2 nCi/mL. However, the EC50 was 420 10 nCi/mL for PC3 cells, which do not express PSMA on the cell surface. Therefore, the Ac- 225 labeled human anti-PSMA 4.40 antibody shows > 200-fold selectivity in killing PSMA expressing prostate cancer cells (C4-2 and LNCaP) vs. control cells (PC3).

Example 25: *In Vivo* Radioimmunotherapy with Lu-177 Labeled Antibodies

15 Athymic nude mice from the National Cancer Institute were implanted subcutaneously with 2×10^6 PSMA-3T3 cells. After measurable tumors appeared at day 7 post implantation, the mice were treated by injection with either a single 250 μ Ci dose human anti-PSMA antibody 4.40 or 4.304 labeled with Lu-177 (University of Missouri Research Reactor), or were injected with buffer only as control. The tumor size of individual animals 20 was measured using an electronic caliper. Figure 35 shows a plot of the median tumor size in each group over time. Tumor growths were substantially reduced in Lu-177 antibody treated groups compared to the control group.

Example 26: Immunization with rsPSMA dimer preparations

25

Immunization

BALB/c mice were immunized by subcutaneous injection at days 0, 7, 14, and 42 with either 5 μ g clinical rsPSMA lot # 4019-C001 (75 % dimer/25 % monomer) or 5 μ g 30 rsPSMA batch # TD045-003 run 1/peak 2 (100 % monomer) and adjuvanted with 50 μ g alhydrogel per dose. Serum was drawn 10 days after the fourth immunization and analyzed by enzyme-linked immunoassay (EIA) and flow cytometry.

EIA

rsPSMA lot # 4019-C001 or rsPSMA batch # TD045-003 run 1/peak 2 was passively adsorbed to 96-well microtiter plates. Remaining binding sites on the plate were blocked with a PBS/Casein/Tween 20 buffer. Serially diluted mouse serum or controls were added 5 and bound antibody was detected using a goat anti-mouse IgG antibody conjugated to alkaline phosphatase. The EIA was developed with the substrate pNPP which produces a color change that is directly proportional to the amount of anti-PSMA antibody bound. Absorbance was read at 405 nm with a correction of 620 nm. Antibody titer was defined as the highest dilution of mouse serum yielding a blank corrected absorbance of 0.1. Immune 10 mouse serum with a known anti-PSMA titer or normal mouse serum with no anti-PSMA reactivity was used as controls.

Flow Cytometry Analysis

PSMA-3T3 cells were incubated with 200 μ L of immune serum at a dilution of 1/50 15 in PBS with 0.1 % sodium azide on ice for 30 minutes. Immune mouse serum with known anti-PSMA titer or normal mouse serum with no anti-PSMA reactivity was used as controls. The cells were washed twice with PBS with 0.1 % sodium azide and incubated for 30 minutes on ice with FITC-conjugated goat anti-mouse IgG. Cells were washed once, 20 resuspended in PBS with 0.1 % sodium azide and subjected to flow cytometric analysis on FACScaliber (Becton Dickinson).

Results

5/5 mice immunized with rsPSMA lot # 4019-C001 showed an anti-PSMA antibody response by EIA. Antibody titer was similar for assay plates coated with rsPSMA lot # 4019- 25 C001 (75 % dimer/25 % monomer) and assay plates coated with rsPSMA batch # TD045-003 run 1/peak 2 (100 % monomer). Median response for the group was 1/6400.

4/5 mice immunized with rsPSMA batch # TD045-003 run 1/peak 2 showed an anti-PSMA antibody response by EIA. One mouse was negative. Antibody titer was similar for assay plates coated with rsPSMA lot # 4019-C001 (75 % dimer/25 % monomer) and assay 30 plates coated with rsPSMA batch # TD045-003 run 1/peak 2 (100 % monomer). Median response for the group was 1/6400.

The results of the EIA analysis are provided in Table 6.

- 90 -

Table 6: Specificity of the anti-PSMA antibody response in mice vaccinated 4 times with rsPSMA 5 µg/dose and 50 µg/dose Alhydrogel

Mouse ID #	Immunogen	EIA Titer vs. Lot 4019-C001	EIA Titer vs. Batch TD045-003 run1/peak 2	Median RFI vs. PSMA-3T3 cells
ABIM151	4019-C001 Dimer	1/3200	1/3200	84
ABIM152	4019-C001 Dimer	1/3200	1/3200	41
ABIM153	4019-C001 Dimer	1/25600	1/25600	76
ABIM154	4019-C001 Dimer	1/12800	1/12800	63
ABIM155	4019-C001 Dimer	1/6400	1/6400	74
ABIM156	Monomer	1/1600	1/1600	5
ABIM157	Monomer	1/6400	1/12800	8
ABIM158	Monomer	0	0	6
ABIM159	Monomer	1/6400	1/6400	6
ABIM160	Monomer	1/6400	1/6400	12

5

As shown in Fig. 36, anti-PSMA antibody in the serum of mice immunized with a dimer preparation of rsPSMA (lot # 4019-C001) showed strong binding to PSMA-3T3 cells. Anti-PSMA antibody in the serum of mice immunized with a 100% monomer preparation of rsPSMA (batch # TD045-003 run 1/peak 2) showed no binding to PSMA-3T3 cells.

10

Although the invention has been described in detail for the purpose of illustration, it is understood that such detail is solely for that purpose and variations can be made by those skilled in the art without departing from the spirit and scope of the invention which is defined 15 by the following claims.

The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference.

Claims

1. An isolated antibody or an antigen-binding fragment thereof which specifically binds to an epitope on prostate specific membrane antigen (PSMA), wherein the antibody or the antigen-binding fragment thereof competitively inhibits the specific binding of a second antibody to its target epitope on PSMA, wherein the second antibody is selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1, and antibodies comprising:
 - (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and
 - (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13.
- 20 2. The isolated antibody or antigen-binding fragment of claim 1, wherein the second antibody comprises:
 - (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 2, and
 - (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 8.
- 25 3. The isolated antibody or antigen-binding fragment of claim 1, wherein the second antibody comprises:
 - (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 3, and
 - (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 9.

4. The isolated antibody or antigen-binding fragment of claim 1, wherein the second antibody comprises:

5 (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 4, and

regions of a nucleotide sequence set forth as SEQ ID NO: 10.

5. The isolated antibody or antigen-binding fragment of claim 1, wherein the second antibody comprises:

10 (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 5, and

regions of a nucleotide sequence set forth as SEQ ID NO: 11.

15

6. The isolated antibody or antigen-binding fragment of claim 1, wherein the second antibody comprises:

15 (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 6, and

20

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 12.

7. The isolated antibody or antigen-binding fragment of claim 1, wherein the second antibody comprises:

25

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 7, and

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 13.

30

8. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA

- 93 -

7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 5 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1 and antigen-binding fragments thereof.

9. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody or antigen-binding fragment thereof is selected from the group 10 consisting of antibodies comprising:

(a) a heavy chain encoded by a nucleic acid molecule comprising the heavy chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and

(b) a light chain encoded by a nucleic acid molecule comprising the light chain coding 15 region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13, and antigen-binding fragments thereof.

10. The isolated antibody or antigen-binding fragment of claim 9, wherein the second 20 antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 2, and

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 8.

25

11. The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 3, and

30 (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 9.

- 94 -

12. The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 4, and

5 (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 10.

12. The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

10 (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 5, and

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 11.

15 13. The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 6, and

20 (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 12.

14. The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

25 (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 7, and

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 13.

30 15. An isolated antibody which specifically binds to an extracellular domain of prostate specific membrane antigen, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 90% identical to the nucleotide sequence encoding the antibody of claim 9.

16. The isolated antibody of claim 15, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 95% identical.

5 17. The isolated antibody of claim 15, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 97% identical.

18. The isolated antibody of claim 15, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 98% identical.

10 19. The isolated antibody of claim 15, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 99% identical.

20. An antigen-binding fragment of the isolated antibody of claim 9, comprising:

15 (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding regions or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 14, 18, 22, 26 and 30, and

20 (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or region of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 16, 20, 24, 28 and 32.

21. An antigen-binding fragment of the isolated antibody of claim 20, comprising:

25 (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 14, and

(b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 16.

22. An antigen-binding fragment of the isolated antibody of claim 20, comprising:

30 (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 18, and

(b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 20.

23. An antigen-binding fragment of the isolated antibody of claim 20, comprising:
 - (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 22, and
 - 5 (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 24.
24. An antigen-binding fragment of the isolated antibody of claim 20, comprising:
 - (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the
 - 10 coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 26, and
 - (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 28.
25. An antigen-binding fragment of the isolated antibody of claim 20, comprising:
 - (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 30, and
 - (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 32.
- 20 26. The antigen-binding fragment of the isolated antibody of claim 9, comprising:
 - (a) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of amino acid sequences set forth as: SEQ ID NOs: 15, 19, 23, 27 and 31, and
 - 25 (b) a light chain variable region comprising an amino acid sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 17, 21, 25, 29 and 33.
27. An antigen-binding fragment of the isolated antibody of claim 26, comprising:
 - (a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 15, and
 - 30 (b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 17.

- 97 -

28. An antigen-binding fragment of the isolated antibody of claim 26, comprising:
 - (a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 19, and
 - (b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 21.
29. An antigen-binding fragment of the isolated antibody of claim 26, comprising:
 - (a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 23, and
 - (b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 25.
30. An antigen-binding fragment of the isolated antibody of claim 26, comprising:
 - (a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 27, and
 - (b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 29.
31. An antigen-binding fragment of the isolated antibody of claim 26, comprising:
 - (a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 31, and
 - (b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 33.
32. An isolated antigen-binding fragment which comprises a CDR of the antigen-binding fragment according to claim 20 or claim 26.
33. The isolated antigen-binding fragment of claim 32, wherein the CDR is CDR3.
34. An expression vector comprising an isolated nucleic acid molecule encoding the isolated antibody or antigen-binding fragment of any one of claims 1-33.

- 98 -

35. An expression vector comprising an isolated nucleic acid molecule encoding the heavy chain of AB-PG1-XG1-006 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 2.

5 36. An expression vector comprising an isolated nucleic acid molecule encoding the light chain of AB-PG1-XG1-006 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 8.

10 37. An expression vector comprising an isolated nucleic acid molecule encoding the heavy and light chains of AB-PG1-XG1-006 encoded by the nucleic acid molecules comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 2 and 8.

15 38. An expression vector comprising an isolated nucleic acid molecule encoding the heavy chain of AB-PG1-XG1-026 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 3.

20 39. An expression vector comprising an isolated nucleic acid molecule encoding the light chain of AB-PG1-XG1-026 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 9.

25 40. An expression vector comprising an isolated nucleic acid molecule encoding the heavy and light chains of AB-PG1-XG1-026 encoded by the nucleic acid molecules comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 3 and 9.

30 41. An expression vector comprising an isolated nucleic acid molecule encoding the heavy chain of AB-PG1-XG1-051 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 4.

- 99 -

42. An expression vector comprising an isolated nucleic acid molecule encoding the light chain of AB-PG1-XG1-051 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 10.

5 43. An expression vector comprising an isolated nucleic acid molecule encoding the heavy and light chains of AB-PG1-XG1-051 encoded by the nucleic acid molecules comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 4 and 10.

10 44. An expression vector comprising an isolated nucleic acid molecule encoding the heavy chain of AB-PG1-XG1-069 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 5.

15 45. An expression vector comprising an isolated nucleic acid molecule encoding the light chain of AB-PG1-XG1-069 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 11.

20 46. An expression vector comprising an isolated nucleic acid molecule encoding the heavy and light chains of AB-PG1-XG1-069 encoded by the nucleic acid molecules comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 5 and 11.

25 47. An expression vector comprising an isolated nucleic acid molecule encoding the heavy chain of AB-PG1-XG1-077 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 6.

48. An expression vector comprising an isolated nucleic acid molecule encoding the light chain of AB-PG1-XG1-077 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 12.

30

49. An expression vector comprising an isolated nucleic acid molecule encoding the heavy and light chains of AB-PG1-XG1-077 encoded by the nucleic acid molecules

- 100 -

comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 6 and 12.

50. An expression vector comprising an isolated nucleic acid molecule encoding the heavy chain of AB-PG1-XG1-006 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 7.
51. An expression vector comprising an isolated nucleic acid molecule encoding the light chain of AB-PG1-XG1-006 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 13.
52. An expression vector comprising an isolated nucleic acid molecule encoding the heavy and light chains of AB-PG1-XG1-006 encoded by the nucleic acid molecules comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 7 and 13.
53. A host cell transformed or transfected by the expression vector of claim 34.
54. A plasmid which produces the antibody or antigen binding fragments of any one of claims 1-33
55. The plasmid of claim 54, wherein the plasmid is selected from the group consisting of: AB-PG1-XG1-006 Heavy Chain (SEQ ID NO: 2), AB-PG1-XG1-006 Light Chain (SEQ ID NO: 8), AB-PG1-XG1-026 Heavy Chain (SEQ ID NO: 3), AB-PG1-XG1-026 Light Chain (SEQ ID NO: 9), AB-PG1-XG1-051 Heavy Chain (SEQ ID NO: 4), AB-PG1-XG1-051 Light Chain (SEQ ID NO: 10), AB-PG1-XG1-069 Heavy Chain (SEQ ID NO: 5), AB-PG1-XG1-069 Light Chain (SEQ ID NO: 11), AB-PG1-XG1-077 Heavy Chain (SEQ ID NO: 6), AB-PG1-XG1-077 Light Chain (SEQ ID NO: 12), PSMA 10.3 Heavy Chain (SEQ ID NO: 7), and PSMA 10.3 Kappa (SEQ ID NO: 13).

- 101 -

56. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody or antigen-binding fragment thereof is selected for its ability to bind live cells.

5 57. The isolated antibody or antigen-binding fragment thereof of claim 56, wherein the cell is a tumor cell.

58. The isolated antibody or antigen-binding fragment thereof of claim 57, wherein the tumor cell is a prostate tumor cell.

10 59. The isolated antibody or antigen-binding fragment thereof of claim 58, wherein the tumor cell is a LNCaP cell.

60. The isolated antibody or antigen-binding fragment thereof according to claim 1, 15 wherein said antibody or antigen-binding fragment thereof mediates cytolysis of cells expressing PSMA.

61. The isolated antibody or antigen-binding fragment thereof of claim 60 wherein cytolysis of cells expressing PSMA is mediated by effector cells.

20 62. The isolated antibody or antigen-binding fragment thereof of claim 60 wherein cytolysis of cells expressing PSMA is complement mediated in the presence of effector cells.

63. The isolated antibody or antigen-binding fragment thereof according to claim 1, 25 wherein said antibody or antigen-binding fragment thereof inhibits the growth of cells expressing PSMA.

64. The isolated antibody or antigen-binding fragment thereof according to claim 1, 30 wherein said antibody or antigen-binding fragment thereof does not require cell lysis to bind to the epitope on PSMA.

- 102 -

65. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, IgE or has immunoglobulin constant and/or variable domain of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, 5 IgA2, IgAsec, IgD or IgE.

66. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a recombinant antibody.

10 67. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a polyclonal antibody.

68. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a monoclonal antibody.

15 69. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a humanized antibody.

70. The isolated antibody or antigen-binding fragment thereof according to claim 69, 20 wherein said antibody is a monoclonal antibody.

71. The isolated antibody or antigen-binding fragment thereof according to claim 69, wherein said antibody is a polyclonal antibody.

25 72. The isolated antibody or antigen-binding fragment thereof according to claim 69, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

73. The isolated antibody or antigen-binding fragment thereof according to claim 1, 30 wherein said antibody is a chimeric antibody.

74. The isolated antibody or antigen-binding fragment thereof according to claim 73, wherein said antibody is a monoclonal antibody.

75. The isolated antibody or antigen-binding fragment thereof according to claim 73, wherein said antibody is a polyclonal antibody.

5 76. The isolated antibody or antigen-binding fragment thereof according to claim 73, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

77. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a human antibody.

10 78. The isolated antibody or antigen-binding fragment thereof according to claim 77, wherein said antibody is a monoclonal antibody.

15 79. The isolated antibody or antigen-binding fragment thereof according to claim 77, wherein said antibody is a polyclonal antibody.

80. The isolated antibody or antigen-binding fragment thereof according to claim 77, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

20 81. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a bispecific or multispecific antibody.

82. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein the isolated antigen-binding fragment is selected from the group consisting of a Fab fragment, a F(ab')₂ fragment, and a Fv fragment CDR3.

25 83. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody is a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293), PSMA 10.3 (PTA-3247), PSMA 1.8.3 (PTA-3906), PSMA A3.1.3 (PTA-3904), PSMA A3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428),

- 104 -

Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557),
Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359),
Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362),
Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367),
5 Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388),
Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391),
Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

84. The isolated antibody or antigen-binding fragment thereof according to claim 1,
10 wherein the antibody or antigen-binding fragment thereof binds to a conformational epitope.

85. The isolated monoclonal antibody or antigen-binding fragment thereof according to
claim 1, wherein the antibody or antigen-binding fragment thereof is internalized into a cell
with the prostate specific membrane antigen.

15 86. A hybridoma cell line that produces an antibody selected from the group consisting of
PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA
10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3,
Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix
20 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3,
Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3,
Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1 and Abgenix 4.152.1.

25 87. The hybridoma cell line of claim 86, wherein the hybridoma cell line is selected from
the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA
3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293),
PSMA 10.3 (PTA-3247) , PSMA 1.8.3 (PTA-3906), PSMA A3.1.3 (PTA-3904), PSMA
A3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428), Abgenix
4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557), Abgenix 4.16.1
30 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359), Abgenix 4.40.2
(PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362), Abgenix 4.209.3
(PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367), Abgenix 4.333.1

- 105 -

(PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388), Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391), Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

5 88. A composition comprising:
an antibody or antigen-binding fragment thereof according to any one of claims 1-33
and a pharmaceutically acceptable carrier, excipient, or stabilizer.

10 89. The composition of claim 88, further comprising an antitumor agent, an
immunostimulatory agent, an immunomodulator, or a combination thereof.

90. The composition of claim 89, wherein the antitumor agent is a cytotoxic agent, an
agent that acts on tumor neovasculature, or a combination thereof.

15 91. The composition of claim 89, wherein the immunomodulator is α -interferon,
 γ -interferon, tumor necrosis factor- α or a combination thereof.

92. The composition of claim 89, wherein the immunostimulatory agent is interleukin-2,
immunostimulatory oligonucleotides, or a combination thereof.

20 93. A composition comprising:
a combination of two or more antibodies or antigen-binding fragments thereof
according to any one of claims 1-33 and a pharmaceutically acceptable carrier, excipient, or
stabilizer.

25 94. The composition of claim 93, further comprising an antitumor agent, an
immunostimulatory agent, an immunomodulator, or a combination thereof.

95. The composition of claim 94, wherein the antitumor agent is a cytotoxic agent, an
agent that acts on tumor neovasculature, or a combination thereof.

96. The composition of claim 94, wherein the immunomodulator is α -interferon, γ -interferon, tumor necrosis factor- α or a combination thereof.

97. The composition of claim 94, wherein the immunostimulatory agent is interleukin-2, immunostimulatory oligonucleotides, or a combination thereof.

98. The isolated antibody or antigen-binding fragment thereof of claim 1, bound to a label.

99. The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 98, wherein the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

100. A composition comprising:
an antibody or antigen-binding fragment thereof according to claim 98 and
a pharmaceutically acceptable carrier, excipient, or stabilizer.

101. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof specifically binds cell-surface PSMA and/or rsPSMA with a binding affinity of about $1 \times 10^{-9} M$ or less.

102. The isolated antibody or antigen-binding fragment thereof of claim 101, wherein the binding affinity is about $1 \times 10^{-10} M$ or less.

103. The isolated antibody or antigen-binding fragment thereof of claim 102, wherein the binding affinity is about $1 \times 10^{-11} M$ or less.

104. The isolated antibody or antigen-binding fragment thereof of claim 101, wherein the binding affinity is less than about $5 \times 10^{-10} M$.

105. The isolated antibody or antigen-binding fragment thereof of claim 1, bound to at least one therapeutic moiety.

5 106. The isolated antibody or antigen-binding fragment thereof of claim 105, wherein the antibody or antigen-binding fragment thereof mediates specific cell killing of PSMA-expressing cells with an IC₅₀s of less than about 1 X 10⁻¹⁰M.

107. The isolated antibody or antigen-binding fragment thereof of claim 106, wherein the IC₅₀s is less than about 1 X 10⁻¹¹M.

108. The isolated antibody or antigen-binding fragment thereof of claim 107, wherein the IC₅₀s is less than about 1 X 10⁻¹²M.

15 109. The isolated antibody or antigen-binding fragment thereof of claim 106, wherein the IC₅₀s is less than about 1.5 X 10⁻¹¹M.

110. The isolated antibody or antigen-binding fragment thereof of claim 105, wherein the therapeutic moiety is a drug.

20 111. The isolated antibody or antigen-binding fragment thereof of claim 105, wherein the therapeutic moiety is a replication selective virus.

112. The isolated antibody or antigen-binding fragment thereof of claim 110, wherein the drug is a cytotoxic drug.

25 113. The isolated antibody or antigen-binding fragment thereof of claim 112, wherein the cytotoxic drug is selected from the group consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, 30 doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

- 108 -

114. The isolated antibody or antigen-binding fragment thereof of claim 105, wherein the therapeutic moiety is a toxin or a fragment thereof.

115. The isolated antibody or antigen-binding fragment thereof of claim 105, wherein the 5 therapeutic moiety is an enzyme or a fragment thereof.

116. The isolated antibody or antigen-binding fragment thereof of claim 105, wherein the therapeutic moiety is an immunostimulatory or immunomodulating agent.

10 117. The isolated antibody or antigen-binding fragment thereof of claim 116, wherein the immunostimulatory or immunomodulating agent is selected from the group consisting of: a cytokine, chemokine and adjuvant.

15 118. A composition comprising:
the antibody or antigen-binding fragment of claim 105 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

119. The isolated antibody or antigen-binding fragment thereof of 1, bound to a radioisotope.

20 120. The isolated antibody or antigen-binding fragment thereof according to claim 119, wherein the radioisotope emits α radiations.

121. The isolated antibody or antigen-binding fragment thereof according to claim 119, 25 wherein the radioisotope emits β radiations.

122. The isolated antibody or antigen-binding fragment thereof according to claim 119, wherein the radioisotope emits γ radiations.

30 123. The isolated antibody or antigen-binding fragment thereof according to claim 119, wherein the radioisotope is selected from the group consisting of ^{225}Ac , ^{211}At , ^{212}Bi , ^{213}Bi , ^{186}Rh , ^{188}Rh , ^{177}Lu , ^{90}Y , ^{131}I , ^{67}Cu , ^{125}I , ^{123}I , ^{77}Br , ^{153}Sm , ^{166}Ho , ^{64}Cu , ^{212}Pb , ^{224}Ra and ^{223}Ra .

124. A composition comprising the isolated antibody or antigen-binding fragment thereof of claim 119 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

5 125. A kit for detecting prostate cancer for diagnosis, prognosis or monitoring comprising: the isolated labeled antibody or antigen-binding fragment thereof of claim 98, and one or more compounds for detecting the label.

10 126. A kit according to claim 125, wherein the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

127. The isolated antibody or antigen-binding fragment thereof of any of claims 1, 98, 105 or 119 packaged in lyophilized form.

15 128. The isolated antibody or antigen-binding fragment thereof of any of claims 1, 98, 105 or 119 packaged in an aqueous medium.

20 129. An isolated antibody or an antigen-binding fragment thereof which specifically binds to an epitope on prostate specific membrane antigen (PSMA) defined by an antibody selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA B3.1.3, PSMA B3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 25 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1, and antibodies comprising:

30 (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and

- 110 -

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13.

5 130. The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA B3.1.3, PSMA B3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3,

10 Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1 and antigen-binding fragments thereof.

15 131. The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of antibodies comprising:

(a) a heavy chain encoded by a nucleic acid molecule comprising the heavy chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and

20 (b) a light chain encoded by a nucleic acid molecule comprising the light chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13,

and antigen-binding fragments thereof.

25 132. An isolated antibody which specifically binds to an epitope on prostate specific membrane antigen, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 90% identical to the nucleotide sequence encoding the antibody of claim 131.

30 133. The isolated antibody of claim 132, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 95% identical.

134. The isolated antibody of claim 132, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 97% identical.

5 135. The isolated antibody of claim 132, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 98% identical.

136. The isolated antibody of claim 132, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 99% identical.

10

137. An antigen-binding fragment of the isolated antibody of claim 131, comprising:

(a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding regions or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 14, 18, 22, 26 and 30, and

15

(b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or region of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 16, 20, 24, 28 and 32.

138. The antigen-binding fragment of the isolated antibody of claim 131, comprising:

20

(a) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of amino acid sequences set forth as: SEQ ID NOs: 15, 19, 23, 27 and 31, and

(b) a light chain variable region comprising an amino acid sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 17, 21, 25, 29 and 33.

25

139. An isolated antigen-binding fragment which comprises a CDR of the antigen-binding fragment according to claim 137 or claim 138.

140. The isolated antigen-binding fragment of claim 139, wherein the CDR is CDR3.

30

141. An expression vector comprising an isolated nucleic acid molecule encoding the isolated antibody or antigen-binding fragment of any one of claims 129-137.

142. A host cell transformed or transfected by the expression vector of claim 141.

143. The isolated antibody or antigen-binding fragment thereof according to claim 129,
5 wherein said antibody or antigen-binding fragment thereof is selected for its ability to bind
live cells.

144. The isolated antibody or antigen-binding fragment thereof of claim 143, wherein the
cell is a tumor cell.

10

145. The isolated antibody or antigen-binding fragment thereof of claim 144, wherein the
tumor cell is a prostate tumor cell.

146. The isolated antibody or antigen-binding fragment thereof of claim 145, wherein the
15 tumor cell is a LNCaP cell.

147. The isolated antibody or antigen-binding fragment thereof according to claim 129,
wherein said antibody or antigen-binding fragment thereof mediates cytolysis of cells
expressing PSMA.

20

148. The isolated antibody or antigen-binding fragment thereof of claim 147 wherein
cytolysis of cells expressing PSMA is mediated by effector cells.

149. The isolated antibody or antigen-binding fragment thereof of claim 147 wherein
25 cytolysis of cells expressing PSMA is complement mediated in the presence of effector cells.

150. The isolated antibody or antigen-binding fragment thereof according to claim 129,
wherein said antibody or antigen-binding fragment thereof inhibits the growth of cells
expressing PSMA.

151. The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody or antigen-binding fragment thereof does not require cell lysis to bind to the epitope on PSMA.

5 152. The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, IgE or has immunoglobulin constant and/or variable domain of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgA or IgE.

10 153. The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody is a recombinant antibody.

15 154. The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody is a polyclonal antibody.

155. The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody is a monoclonal antibody.

20 156. The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody is a humanized antibody.

157. The isolated antibody or antigen-binding fragment thereof according to claim 156, wherein said antibody is a monoclonal antibody.

25 158. The isolated antibody or antigen-binding fragment thereof according to claim 156, wherein said antibody is a polyclonal antibody.

159. The isolated antibody or antigen-binding fragment thereof according to claim 156, 30 wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

- 114 -

160. The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody is a chimeric antibody.

161. The isolated antibody or antigen-binding fragment thereof according to claim 160, 5 wherein said antibody is a monoclonal antibody.

162. The isolated antibody or antigen-binding fragment thereof according to claim 160, wherein said antibody is a polyclonal antibody.

10 163. The isolated antibody or antigen-binding fragment thereof according to claim 160, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

164. The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody is a human antibody.

15 165. The isolated antibody or antigen-binding fragment thereof according to claim 164, wherein said antibody is a monoclonal antibody.

166. The isolated antibody or antigen-binding fragment thereof according to claim 164, 20 wherein said antibody is a polyclonal antibody.

167. The isolated antibody or antigen-binding fragment thereof according to claim 164, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

25 168. The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody is a bispecific or multispecific antibody.

169. The isolated antibody or antigen-binding fragment thereof according to claim 129, 30 wherein the isolated antigen-binding fragment is selected from the group consisting of a Fab fragment, a F(ab')2 fragment, and a Fv fragment CDR3.

170. The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein the antibody is a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293), PSMA 10.3 (PTA-3247), PSMA 1.8.3 (PTA-3906), PSMA B3.1.3 (PTA-3904), PSMA B3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428), Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557), Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359), Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362), 10 Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367), Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388), Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391), Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

15 171. The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein the antibody or antigen-binding fragment thereof binds to a conformational epitope.

172. The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 129, wherein the antibody or antigen-binding fragment thereof is internalized into a cell 20 with the prostate specific membrane antigen.

173. A hybridoma cell line that produces an antibody selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA B3.1.3, PSMA B3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, 25 Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1 and Abgenix 4.152.1.

30 174. The hybridoma cell line of claim 173, wherein the hybridoma cell line is selected from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-

3293), PSMA 10.3 (PTA-3247), PSMA 1.8.3 (PTA-3906), PSMA B3.1.3 (PTA-3904),
PSMA B3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428),
Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557),
Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359),
5 Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362),
Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367),
Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388),
Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391),
Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

10

175. A composition comprising:

an antibody or antigen-binding fragment thereof according to any one of claims 129-140 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

15

176. The composition of claim 175, further comprising an antitumor agent, an immunostimulatory agent, an immunomodulator, or a combination thereof.

177. The composition of claim 176, wherein the antitumor agent is a cytotoxic agent, an agent that acts on tumor neovasculature, or a combination thereof.

20

178. The composition of claim 176, wherein the immunomodulator is α -interferon, γ -interferon, tumor necrosis factor- α or a combination thereof.

25

179. The composition of claim 176, wherein the immunostimulatory agent is interleukin-2, immunostimulatory oligonucleotides, or a combination thereof.

180. A composition comprising:

a combination of two or more antibodies or antigen-binding fragments thereof according to any one of claims 129-140 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

30

181. The composition of claim 180, further comprising an antitumor agent, an immunostimulatory agent, an immunomodulator, or a combination thereof.

182. The composition of claim 181, wherein the antitumor agent is a cytotoxic agent, an agent that acts on tumor neovasculature, or a combination thereof.

183. The composition of claim 181, wherein the immunomodulator is α -interferon, γ -interferon, tumor necrosis factor- α or a combination thereof.

184. The composition of claim 181, wherein the immunostimulatory agent is interleukin-2, immunostimulatory oligonucleotides, or a combination thereof.

185. The isolated antibody or antigen-binding fragment thereof of claim 129, bound to a label.

186. The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 185, wherein the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

187. A composition comprising:
an antibody or antigen-binding fragment thereof according to claim 185 and
a pharmaceutically acceptable carrier, excipient, or stabilizer.

188. The isolated antibody or antigen-binding fragment thereof of claim 129, wherein the antibody or antigen-binding fragment thereof specifically binds cell-surface PSMA and/or rsPSMA with a binding affinity of about $1 \times 10^{-9} M$ or less.

189. The isolated antibody or antigen-binding fragment thereof of claim 188, wherein the binding affinity is about $1 \times 10^{-10} M$ or less.

- 118 -

190. The isolated antibody or antigen-binding fragment thereof of claim 189, wherein the binding affinity is about $1 \times 10^{-11} M$ or less.

191. The isolated antibody or antigen-binding fragment thereof of claim 188, wherein the binding affinity is less than about $5 \times 10^{-10} M$.

192. The isolated antibody or antigen-binding fragment thereof of claim 129, bound to at least one therapeutic moiety.

193. The isolated antibody or antigen-binding fragment thereof of claim 192, wherein the antibody or antigen-binding fragment thereof mediates specific cell killing of PSMA-expressing cells with an IC_{50s} of less than about $1 \times 10^{-10} M$.

194. The isolated antibody or antigen-binding fragment thereof of claim 193, wherein the IC_{50s} is less than about $1 \times 10^{-11} M$.

195. The isolated antibody or antigen-binding fragment thereof of claim 194, wherein the IC_{50s} is less than about $1 \times 10^{-12} M$.

196. The isolated antibody or antigen-binding fragment thereof of claim 193, wherein the IC_{50s} is less than about $1.5 \times 10^{-11} M$.

197. The isolated antibody or antigen-binding fragment thereof of claim 192, wherein the therapeutic moiety is a drug.

198. The isolated antibody or antigen-binding fragment thereof of claim 192, wherein the therapeutic moiety is a replication-selective virus.

199. The isolated antibody or antigen-binding fragment thereof of claim 197, wherein the drug is a cytotoxic drug.

200. The isolated antibody or antigen-binding fragment thereof of claim 199, wherein the cytotoxic drug is selected from the group consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, 5 doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

201. The isolated antibody or antigen-binding fragment thereof of claim 192, wherein the therapeutic moiety is a toxin or a fragment thereof.

10 202. The isolated antibody or antigen-binding fragment thereof of claim 192, wherein the therapeutic moiety is an enzyme or a fragment thereof.

203. The isolated antibody or antigen-binding fragment thereof of claim 192, wherein the therapeutic moiety is an immunostimulatory or immunomodulating agent.

15 204. The isolated antibody or antigen-binding fragment thereof of claim 203, wherein the immunostimulatory or immunomodulating agent is selected from the group consisting of: a cytokine, chemokine and adjuvant.

20 205. A composition comprising:
the antibody or antigen-binding fragment of claim 192 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

206. The isolated antibody or antigen-binding fragment thereof of 129, bound to a 25 radioisotope.

207. The isolated antibody or antigen-binding fragment thereof according to claim 206, wherein the radioisotope emits α radiations.

30 208. The isolated antibody or antigen-binding fragment thereof according to claim 206, wherein the radioisotope emits β radiations.

209. The isolated antibody or antigen-binding fragment thereof according to claim 206, wherein the radioisotope emits γ radiations.

210. The isolated antibody or antigen-binding fragment thereof according to claim 206, 5 wherein the radioisotope is selected from the group consisting of ^{225}Ac , ^{211}At , ^{212}Bi , ^{213}Bi , ^{186}Rh , ^{188}Rh , ^{177}Lu , ^{90}Y , ^{131}I , ^{67}Cu , ^{125}I , ^{123}I , ^{77}Br , ^{153}Sm , ^{166}Ho , ^{64}Cu , ^{212}Pb , ^{224}Ra and ^{223}Ra .

211. A composition comprising the isolated antibody or antigen-binding fragment thereof of claim 206 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

10

212. A kit for detecting prostate cancer for diagnosis, prognosis or monitoring comprising: the isolated labeled antibody or antigen-binding fragment thereof of claim 185, and one or more compounds for detecting the label.

15

213. A kit according to claim 212, wherein the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

20

214. The isolated antibody or antigen-binding fragment thereof of any of claims 129, 185, 192 or 206 packaged in lyophilized form.

215. The isolated antibody or antigen-binding fragment thereof of any of claims 129, 185, 192 or 206 packaged in an aqueous medium.

25

216. A method for detecting the presence of PSMA, or a cell expressing PSMA, in a sample comprising:
contacting the sample with an antibody or antigen-binding fragment thereof according to claim 1 or 129 for a time sufficient to allow the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA, and
30 detecting the PSMA-antibody complex or PSMA-antigen-binding fragment complex, wherein the presence of a complex in the sample is indicative of the presence in the sample of PSMA or a cell expressing PSMA.

217. A method for diagnosing a PSMA-mediated disease in a subject comprising:
administering to a subject suspected of having or previously diagnosed with PSMA-
mediated disease an isolated amount of an antibody or antigen-binding fragment thereof
5 according to claim 1 or 129,
allowing the formation of a complex between the antibody or antigen-binding
fragment thereof and PSMA,
detecting the formation of the PSMA-antibody complex or PSMA-antigen-binding
fragment complex to the target epitope,
10 wherein the presence of a complex in the subject suspected of having or previously
diagnosed with PSMA-mediated disease is indicative of the presence of a PSMA-mediated
disease.

218. The method of claim 217 wherein the PSMA-mediated disease is prostate cancer.
15

219. The method of claim 217 wherein the PSMA-mediated disease is a non-prostate
cancer.

220. The method of claim 219 wherein the non-prostate cancer is selected from the group
20 consisting of bladder cancer including transitional cell carcinoma; pancreatic cancer
including pancreatic duct carcinoma; lung cancer including non-small cell lung carcinoma;
kidney cancer including conventional renal cell carcinoma; sarcoma including soft tissue
sarcoma; breast cancer including breast carcinoma; brain cancer including glioblastoma
multiforme; neuroendocrine carcinoma; colon cancer including colonic carcinoma; testicular
25 cancer including testicular embryonal carcinoma; and melanoma including malignant
melanoma.

221. The method of claim 216 or claim 217 wherein the antibody or antigen-binding
fragment thereof is labeled.

30 222. The method of claim 216 or claim 217 wherein a second antibody is administered to
detect the first antibody or antigen-binding fragment thereof.

223. A method for assessing the prognosis of a subject with a PSMA-mediated disease: administering to a subject suspected of having or previously diagnosed with PSMA-mediated disease an effective amount of an antibody or antigen-binding fragment thereof according to claim 1 or 129,

5 allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA,

detecting the formation of the complex to the target epitope,

wherein the amount of the complex in the subject suspected of having or previously

10 diagnosed with PSMA-mediated disease is indicative of the prognosis.

224. A method for assessing the effectiveness of a treatment of a subject with a PSMA-mediated disease: administering to a subject suspected treated for a PSMA-mediated disease an effective

15 amount of an antibody or antigen-binding fragment thereof according to claim 1 or 129,

allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA,

detecting the formation of the complex to the target epitope,

wherein the amount of the complex in the subject suspected of having or previously

20 diagnosed with PSMA-mediated disease is indicative of the effectiveness of the treatment.

225. The method of claim 223 or 224 wherein the PSMA-mediated disease is prostate cancer.

25 226. The method of claim 223 or 224 wherein the PSMA-mediated disease is a non-prostate cancer.

227. The method of claim E4 wherein the non-prostate cancer is selected from the group consisting of bladder cancer including transitional cell carcinoma; pancreatic cancer

30 including pancreatic duct carcinoma; lung cancer including non-small cell lung carcinoma; kidney cancer including conventional renal cell carcinoma; sarcoma including soft tissue sarcoma; breast cancer including breast carcinoma; brain cancer including glioblastoma

- 123 -

multiforme; neuroendocrine carcinoma; colon cancer including colonic carcinoma; testicular cancer including testicular embryonal carcinoma; and melanoma including malignant melanoma.

5 228. The method of claim 223 or claim 224 wherein the antibody or antigen-binding fragment thereof is labeled.

229. The method of claim 223 or claim 224 wherein a second antibody is administered to detect the first antibody or antigen-binding fragment thereof.

10

230. A method for inhibiting the growth of a cell expressing PSMA comprising: contacting a cell expressing PSMA with an amount of an antibody or antigen-binding fragment thereof according to claim 1 or 129 which specifically binds to an extracellular domain of PSMA effective to inhibit the growth of the cell expressing PSMA.

15

231. A method for inducing cytolysis of a cell expressing PSMA comprising: contacting a cell expressing PSMA with an amount of an antibody or antigen-binding fragment thereof according to claim 1 or 129 which specifically binds to an extracellular domain of PSMA effective to induce cytolysis of the cell expressing PSMA.

20

232. The method of claim 231 wherein the cytolysis occurs in the presence of an effector cell.

233. The method of claim 231 wherein the cytolysis is complement mediated.

25

234. A method for treating or preventing a PSMA-mediated disease comprising: administering to a subject having a PSMA-mediated disease or at risk of having a PSMA-mediated disease an effective amount of an antibody or antigen-binding fragment thereof according to claim 1 or 129 to treat or prevent the PSMA-mediated disease.

30

235. The method of claim 234 wherein the PSMA-mediated disease is a cancer.

- 124 -

236. The method for claim 235 wherein the cancer is a prostate cancer.

237. The method for claim 235 wherein the cancer is a non-prostate cancer.

5 238. A method for treating or preventing a PSMA-mediated disease comprising:
administering to a subject having a PSMA-mediated disease or at risk of having a
PSMA-mediated disease an amount of an antibody or antigen-binding fragment thereof
according to claim 1 or 129 effective to treat or prevent the PSMA-mediated disease.

10 239. The method of claim 238, wherein the PSMA-mediated disease is a cancer.

240. The method of claim 239, wherein the cancer is prostate cancer.

241. The method of claim 239 wherein the cancer is a non-prostate cancer.

15 242. The method of claim 241, wherein the non-prostate cancer is selected from the group
consisting of: bladder cancer including transitional cell carcinoma; pancreatic cancer
including pancreatic duct carcinoma; lung cancer including non-small cell lung carcinoma;
kidney cancer including conventional renal cell carcinoma; sarcoma including soft tissue
20 sarcoma; breast cancer including breast carcinoma; brain cancer including glioblastoma
multiforme; neuroendocrine carcinoma; colon cancer including colonic carcinoma; testicular
cancer including testicular embryonal carcinoma; and melanoma including malignant
melanoma.

25 243. The method of claim 238, further comprising administering another therapeutic agent
to treat or prevent the PSMA-mediated disease at any time before, during or after the
administration of the antibody or antigen-binding fragment thereof.

244. The method of claim 243, wherein the therapeutic agent is a vaccine.

30 245. The method of claim 244, wherein the vaccine immunizes the subject against PSMA.

246. The method of claim 243, wherein the antibody or antigen-binding fragment thereof is bound to at least one therapeutic moiety.

247. The method of claim 246, wherein the therapeutic moiety is a cytotoxic drug, a drug 5 which acts on the tumor neovasculature and combinations thereof.

248. The method of claim 247, wherein the cytotoxic drug is selected from the group consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5- 10 fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

249. The method of claim 246, wherein the antibody or antigen-binding fragment thereof is bound to a radioisotope, wherein the radiations emitted by the radioisotope is selected from 15 the group consisting of α , β and γ radiations.

250. The method of claim 249, wherein the radioisotope is selected from the group consisting of ^{225}Ac , ^{211}At , ^{212}Bi , ^{213}Bi , ^{186}Rh , ^{188}Rh , ^{177}Lu , ^{90}Y , ^{131}I , ^{67}Cu , ^{125}I , ^{123}I , ^{77}Br , ^{153}Sm , ^{166}Ho , ^{64}Cu , ^{212}Pb , ^{224}Ra and ^{223}Ra .

20
251. A method for inhibiting folate hydrolase activity comprising:
contacting a folate hydrolase polypeptide with an amount of isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 129 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits the folate hydrolase 25 activity.

252. The method of claim 251 wherein the folate hydrolase polypeptide is isolated.

253. The method of claim 251 wherein the folate hydrolase polypeptide is contained in a 30 sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

254. The method of claim 251 wherein the folate hydrolase polypeptide is contained in an organism.

255. The method of claim 254 wherein the organism is an animal.

5

256. The method of claim 255 wherein the animal is a mammal.

257. A method for enhancing folate hydrolase activity comprising:

10 contacting a folate hydrolase polypeptide with an amount of isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 129 under conditions wherein the isolated antibody or antigen-binding fragment thereof enhances the folate hydrolase activity.

258. The method of claim 257 wherein the folate hydrolase polypeptide is isolated.

15

259. The method of claim 257 wherein the folate hydrolase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

20 260. The method of claim 257 wherein the folate hydrolase polypeptide is contained in an organism.

261. The method of claim 260 wherein the organism is an animal.

25 262. The method of claim 261 wherein the animal is a mammal.

263. A method for inhibiting N-acetylated α -linked acidic dipeptidase (NAALADase) activity comprising:

30 contacting a NAALADase polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 129 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits NAALADase activity.

- 127 -

264. The method for claim 263 wherein the NAALADase polypeptide is isolated.

265. The method for claim 263 wherein the NAALADase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

266. The method for claim 263 wherein the NAALADase polypeptide is contained in an organism.

10 267. The method for claim 266 wherein the organism is an animal.

268. The method for claim 267 wherein the animal is a mammal.

269. A method for enhancing N-acetylated α -linked acidic dipeptidase (NAALADase) activity comprising:
15 contacting a NAALADase polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 129 under conditions wherein the isolated antibody or antigen-binding fragment thereof enhances NAALADase activity.

20 270. The method for claim 269 wherein the NAALADase polypeptide is isolated.

271. The method for claim 269 wherein the NAALADase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

25

272. The method for claim 269 wherein the NAALADase polypeptide is contained in an organism.

273. The method for claim 272 wherein the organism is an animal.

30

274. The method for claim 273 wherein the animal is a mammal.

- 128 -

275. A method for inhibiting dipeptidyl dipeptidase IV activity comprising:
contacting a dipeptidyl dipeptidase IV polypeptide with an amount of an isolated
antibody or antigen-binding fragment thereof according to claim 1 or claim 129 under
conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits
5 dipeptidyl dipeptidase IV activity.

276. The method for claim 275 wherein the dipeptidyl dipeptidase IV polypeptide is
isolated.

10 277. The method for claim 275 wherein the dipeptidyl dipeptidase IV polypeptide is
contained in a sample selected from the group consisting of a cell, a cell homogenate, a
tissue, or a tissue homogenate.

15 278. The method for claim 275 wherein the dipeptidyl dipeptidase IV polypeptide is
contained in an organism.

279. The method for claim 278 wherein the organism is an animal.

280. The method for claim 279 wherein the animal is a mammal.

20 281. A method for inhibiting dipeptidyl dipeptidase IV activity comprising:
contacting a dipeptidyl dipeptidase IV polypeptide with an amount of an isolated
antibody or antigen-binding fragment thereof according to claim 1 or claim 129 under
conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits
25 dipeptidyl dipeptidase IV activity.

282. The method for claim 281 wherein the dipeptidyl dipeptidase IV polypeptide is
isolated.

30 283. The method for claim 281 wherein the dipeptidyl dipeptidase IV polypeptide is
contained in a sample selected from the group consisting of a cell, a cell homogenate, a
tissue, or a tissue homogenate.

284. The method for claim 281 wherein the dipeptidyl dipeptidase IV polypeptide is contained in an organism.

5 285. The method for claim 284 wherein the organism is an animal.

286. The method for claim 285 wherein the animal is a mammal.

287. A method for inhibiting γ -glutamyl hydrolase activity comprising:

10 contacting a γ -glutamyl hydrolase polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 129 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits γ -glutamyl hydrolase activity.

15 288. The method for claim 287 wherein the γ -glutamyl hydrolase polypeptide is isolated.

289. The method for claim 287 wherein the γ -glutamyl hydrolase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

20 290. The method for claim 287 wherein the γ -glutamyl hydrolase polypeptide is contained in an organism.

291. The method for claim 290 wherein the organism is an animal.

25 292. The method for claim 291 wherein the animal is a mammal.

293. A method for inhibiting γ -glutamyl hydrolase activity comprising:

30 contacting a γ -glutamyl hydrolase polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 129 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits γ -glutamyl hydrolase activity.

294. The method for claim 293 wherein the γ -glutamyl hydrolase polypeptide is isolated.

295. The method for claim 293 wherein the γ -glutamyl hydrolase polypeptide is contained
5 in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

296. The method for claim 293 wherein the γ -glutamyl hydrolase polypeptide is contained
in an organism.

10 297. The method for claim 296 wherein the organism is an animal.

298. The method for claim 297 wherein the animal is a mammal.

15 299. A method of specific delivery of at least one therapeutic agent to PSMA-expressing cells, comprising:
administering an effective amount of an antibody or antigen-binding fragment thereof according to claim 1 or 129 conjugated to the at least one therapeutic agent.

20 300. The method of claim 299, wherein the therapeutic agent is a nucleic acid molecule.

301. The method of claim 299, wherein the therapeutic agent is an antitumor drug.

25 302. The method of claim 301, wherein the antitumor drug is selected from the group consisting of: a cytotoxic drug, a drug which acts on the tumor neovasculature and combinations thereof.

303. The method of claim 302, wherein the cytotoxic drug is selected from the group consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

304. The method of claim 299, wherein the therapeutic moiety is a toxin or a fragment thereof.

5 305. The method of claim 299, wherein the therapeutic moiety is an enzyme or a fragment thereof.

306. The method of claim 299, wherein the therapeutic moiety is a replication-selective virus.

10 307. The method of claim 299, wherein the therapeutic moiety is an immunostimulatory or immunomodulating agent.

15 308. The method of claim 307, wherein the immunostimulatory or immunomodulating agent is selected from the group consisting of: a cytokine, chemokine and adjuvant.

309. An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer.

20 310. The isolated antibody or antigen-binding fragment thereof of claim 309, wherein the PSMA protein multimer is a dimer.

311. The isolated antibody or antigen-binding fragment thereof of claim 310, wherein at least one of the PSMA proteins forming the multimer is a recombinant, soluble PSMA (rsPSMA) polypeptide.

25 312. The isolated antibody or antigen-binding fragment thereof of claim 311, wherein the rsPSMA polypeptide consists essentially of amino acids 44-750 of SEQ ID NO:1.

30 313. An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer, wherein the isolated antibody inhibits at least one enzymatic activity of the PSMA protein multimer.

314. The isolated antibody or antigen-binding fragment thereof of claim 313, wherein the enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity, γ -glutamyl hydrolase activity and combinations thereof.

5

315. The isolated antibody or antigen-binding fragment thereof of claim 313, wherein the enzymatic activity is in the extracellular domain of the PSMA molecule.

10 316. The isolated antibody or antigen-binding fragment thereof of claim 313, wherein the antibody or antigen-binding fragment thereof specifically binds to an extracellular domain of PSMA.

15 317. An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer, wherein the isolated antibody enhances at least one enzymatic activity of the PSMA protein multimer.

20 318. The isolated antibody or antigen-binding fragment thereof of claim 317, wherein the enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity, γ -glutamyl hydrolase activity and combinations thereof.

25 319. The isolated antibody or antigen-binding fragment thereof of claim 317, wherein the enzymatic activity is in the extracellular domain of the PSMA molecule.

320. The isolated antibody or antigen-binding fragment thereof of claim 317, wherein the antibody or antigen-binding fragment thereof specifically binds to an extracellular domain of PSMA.

30 321. A composition comprising an isolated antibody or antigen-binding fragment thereof as in any of claims 309 – 320, and an immunostimulatory oligonucleotide.

- 133 -

322. A composition comprising an isolated antibody or antigen-binding fragment thereof as in any of claims 309 – 320, and a cytokine.

5 323. The composition of claim 322, wherein the cytokine is selected from the group consisting of IL-2, IL-12, IL-18 and GM-CSF.

324. The composition of any of claims 321 – 323, further comprising a pharmaceutically-acceptable carrier.

10 325. A method for inducing an immune response comprising administering to a subject in need of such treatment an effective amount of the isolated antibody or composition of any of claims 309-324.

15 326. An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer and inhibits at least one enzymatic activity of PSMA.

327. The isolated antibody or antigen-binding fragment thereof of claim 326, wherein the enzyme is selected from the group consisting of hydrolases and peptidases.

20 328. The isolated antibody or antigen-binding fragment thereof of claim 327, wherein the hydrolase is selected from the group consisting of folate hydrolase and γ -glutamyl hydrolase.

329. The isolated antibody or antigen-binding fragment thereof of claim 328, wherein the hydrolase is folate hydrolase and the antibody is mAb 5.4 or mAb 3.9.

25 330. The isolated antibody or antigen-binding fragment thereof of claim 327, wherein the peptidase is selected from the group consisting of NAALADase and dipeptidyl dipeptidase IV.

30 331. The isolated antibody or antigen-binding fragment thereof of claim 326, wherein the enzyme is active in cancer cells and has lesser activity in normal cells than in cancer cells or no activity in normal cells.

332. The isolated antibody or antigen-binding fragment thereof of claim 331, wherein the cancer cells are prostate cancer cells.

5 333. An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer and enhances at least one enzymatic activity of PSMA.

334. The isolated antibody or antigen-binding fragment thereof of claim 333, wherein the enzyme is selected from the group consisting of hydrolases and peptidases.

10 335. The isolated antibody or antigen-binding fragment thereof of claim 334, wherein the hydrolase is selected from the group consisting of folate hydrolase and γ -glutamyl hydrolase.

336. The isolated antibody or antigen-binding fragment thereof of claim 334, wherein the peptidase is selected from the group consisting of NAALADase and dipeptidyl dipeptidase IV.

15 337. The isolated antibody or antigen-binding fragment thereof of claim 333, wherein the enzyme is active in normal cells and has lesser activity in cancer cells than in normal cells or no activity in cancer cells.

20 338. The isolated antibody or antigen-binding fragment thereof of claim 337, wherein the cancer cells are prostate cancer cells.

25 339. An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer, wherein the isolated antibody is raised by immunizing an animal with a preparation comprising a PSMA protein multimer.

340. A composition comprising the isolated antibody or antigen-binding fragment thereof of claims 326 – 339, and a pharmaceutically acceptable carrier.

30 341. A composition comprising an isolated PSMA protein multimer.

342. The composition of claim 341, wherein the PSMA protein multimer is a dimer.

343. The composition of claim 341, wherein the composition comprises at least about 10%
5 PSMA protein multimer.

344. The composition of claim 343, wherein the composition comprises at least about 20%
PSMA protein multimer.

10 345. The composition of claim 344, wherein the composition comprises at least about 30%
PSMA protein multimer.

346. The composition of claim 345, wherein the composition comprises at least about 40%
PSMA protein multimer.

15 347. The composition of claim 346, wherein the composition comprises at least about 50%
PSMA protein multimer.

348. The composition of claim 347, wherein the composition comprises at least about 75%
20 PSMA protein multimer.

349. The composition of claim 348, wherein the composition comprises at least about 90%
PSMA protein multimer.

25 350. The composition of claim 349, wherein the composition comprises at least about 95%
PSMA protein multimer.

351. The composition of claim 341, wherein the PSMA protein multimer comprises
noncovalently associated PSMA proteins.

30 352. The composition of claim 351, wherein the PSMA proteins are noncovalently
associated under nondenaturing conditions.

353. The composition of any of claims 341-352, wherein at least one of the PSMA proteins forming the multimer is a recombinant, soluble PSMA (rsPSMA) polypeptide.

5 354. The composition of claim 341, wherein the PSMA protein multimer is reactive with a conformation-specific antibody that specifically recognizes PSMA.

355. The composition of claim 341, wherein the PSMA protein multimer comprises PSMA proteins in a native conformation.

10 356. The composition of claim 341, wherein the PSMA multimer is enzymatically active.

357. The composition of claim 356, wherein the enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity, γ -glutamyl hydrolase activity and combinations thereof.

15 358. The composition of any of claims 341-357, further comprising an adjuvant.

359. The composition of any of claims 341-357, further comprising a cytokine.

20 360. The composition of claim 359, wherein the cytokine is selected from the group consisting of IL-2, IL-12, IL-18 and GM-CSF.

361. The composition of any of claims 341-360, further comprising a pharmaceutically acceptable carrier.

25 362. A method for inducing an immune response comprising administering to a subject in need of such treatment an effective amount of the composition of any of claims 341-361.

30 363. An isolated recombinant soluble PSMA (rsPSMA) protein multimer.

364. An isolated rsPSMA protein dimer.

365. The isolated rsPSMA protein dimer of claim 364, wherein the dimer comprises noncovalently associated rsPSMA proteins.

5 366. The isolated rsPSMA protein dimer of claim 365, wherein the rsPSMA proteins are noncovalently associated under nondenaturing conditions.

367. The isolated rsPSMA protein dimer of claim 364, wherein the isolated rsPSMA dimer is reactive with a conformation-specific antibody that specifically recognizes PSMA.

10 368. The isolated rsPSMA protein dimer of claim 364, wherein the isolated rsPSMA dimer is enzymatically active.

369. The isolated rsPSMA protein dimer of claim 368, wherein the enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity, γ -glutamyl hydrolase activity and combinations thereof.

15 370. A method of screening for a candidate agent that inhibits at least one enzymatic activity of a PSMA enzyme comprising

20 a) mixing the candidate agent with an isolated PSMA protein multimer to form a reaction mixture, followed by

b) adding a substrate for the PSMA enzyme to the reaction mixture, and

c) determining the amount of a product formed from the substrate by the PSMA enzyme, wherein a decrease in the amount of product formed in comparison to a control is indicative of an agent capable of inhibiting at least one enzymatic activity of the PSMA enzyme.

25 371. The method of screening of claim 370, wherein the PSMA enzyme is selected from the group consisting of NAALADase, folate hydrolase, dipeptidyl dipeptidase IV and γ -glutamyl hydrolase.

30

372. The method of screening of claim 370, wherein the PSMA multimer comprises recombinant soluble PSMA.

373. The method of screening of claim 370, wherein the candidate agent is selected from 5 the group consisting of an antibody, a small organic compound, or a peptide.

374. A candidate agent that inhibits at least one enzymatic activity of PSMA identified according to the method of claim 370.

10 375. The candidate agent according to claim 374, wherein the agent is selected from a combinatorial antibody library, a combinatorial protein library, or a small organic molecule library.

15 376. A method of screening for a candidate agent that enhances at least one enzymatic activity of a PSMA enzyme comprising

a) mixing the candidate agent with an isolated PSMA protein multimer to form a reaction mixture, followed by

b) adding a substrate for the PSMA enzyme to the reaction mixture, and

c) determining the amount of a product formed from the substrate by the PSMA

20 enzyme, wherein an increase in the amount of product formed in comparison to a control is indicative of an agent capable of enhancing at least one enzymatic activity of the PSMA enzyme.

377. The method of screening of claim 376, wherein the PSMA enzyme is selected from 25 the group consisting of NAALADase, folate hydrolase, dipeptidyl dipeptidase IV and γ -glutamyl hydrolase.

378. The method of screening of claim 376, wherein the PSMA multimer comprises recombinant soluble PSMA.

30

379. The method of screening of claim 376, wherein the candidate agent is selected from the group consisting of an antibody, a small organic compound, or a peptide.

380. A candidate agent that enhances at least one enzymatic activity of PSMA identified according to the method of claim 376.

5 381. The candidate agent according to claim 380, wherein the agent is selected from a combinatorial antibody library, a combinatorial protein library, or a small organic molecule library.

382. A method for identifying a compound that promotes dissociation of PSMA dimers, 10 comprising

contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound;
measuring the amount of PSMA monomer; and
comparing the amount of PSMA monomer measured in the presence of the compound 15 with that observed in the absence of the compound;
wherein an increase in the amount of PSMA monomer measured in the presence of the compound indicates that the compound is capable of promoting dissociation of the PSMA dimer.

20 383. A method for identifying a compound that promotes dissociation of PSMA dimers, comprising

contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound;
measuring the amount of PSMA dimer; and
comparing the amount of PSMA dimer measured in the presence of the compound 25 with that observed in the absence of the compound;
wherein a decrease in the amount of PSMA dimer measured in the presence of the compound indicates that the compound is capable of promoting dissociation of the PSMA dimer.

30 384. A method for identifying a compound that promotes dissociation of PSMA dimers, comprising

- 140 -

contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound;

measuring the amounts of PSMA monomer and PSMA dimer;

calculating a ratio of PSMA monomer to PSMA dimer; and

5 comparing the ratio obtained in the presence of the compound with that obtained in the absence of the compound;

wherein an increase in the ratio measured in the presence of the compound indicates that the compound is capable of promoting dissociation of the PSMA dimer.




Fig. 1

2/33




Fig. 2

3/33

CELL TYPE	CHO	3T3	3T3	CHO	3T3	CHO	3T3	CHO	3T3	3T3
PSMA EXP	+	+	-	+	+	-	+	+	+	-
IP mAb	3.11	3.11	3.11	3.9	3.9	3.9	7E11	7E11	7E11	7E11

Fig. 3

4/33




Fig. 4




Fig. 5

5/33





Fig. 6

6/33



7/33

EFFECT OF VARIOUS ANTIBODIES ON THE RATE OF glu CLEAVED FROM MTXglu2 BY FOLATE HYDROLASE ACTIVITY PRESENT IN 0.0002 ug rSPSMA #8




Fig. 8

8/33

EFFECT OF VARIOUS ANTIBODIES ON THE RATE OF glu CLEAVED FROM MTXglu2 BY FOLATE HYDROLASE ACTIVITY PRESENT IN C4-2 CELL MEMBRANE PREP, 8/15/01




Fig. 9

9/33

Human IgG1 cloning - into pcDNA

Construction of pcDNA-huCK and pcDNA-huIgG1

		PCR product	Vector
CK	Sense	5' XbaI HindIII BamHI NheI 3'	5' NheI NotI 3'
	Anti-sense	EcoRI NotI	(pcDNA.neo)
C γ 1	Sense	5' XbaI KpnI HindIII BamHI NheI 3'	5' NheI/PmeI 3'
	Anti-sense	EcoRI XbaI PmeI	(pcDNA Hygro)

Construction of pcDNA-Ab (V-C cassette)

		PCR product	Vector
VK	Sense	BgIII or BamHI (if necessary)*	5' BamHI NheI 3'
	Anti-sense	NheI	(pcDNA-huCK)
V γ 1	Sense	BgIII or BamHI (if necessary)*	5' BamHI NheI 3'
	Anti-sense	XbaI	(pcDNA-huIgG1)

*BamHI primer is used if the V region has an internal BgIII site

Human IgG cloning- V-C cassette from pcDNA into "production" vector

Insert from pcDNA

IgK 5' HindIII or BamHI (if alternate sense primer used)

3' EcoRI, NotI, XbaI, XbaI or PmeI

IgG1 5' KpnI, HindIII or BamHI (if alternate sense primer used)

3' EcoRI*, XbaI or PmeI

* 2nd EcoRI site present in hygromycin resistance gene

Primers used for V region amplification

VK-sense:

5' GAAGATCT~~ACG~~ ATG + 20-23 bp leader sequence 3'

BgIII Kozak

VK anti-sense(reverse/complementary):

5' AACTA GCT AGC AGT TCC AGA TTT CAA CTG CTC ATC AGA T 3'S A T G S K L Q E D S (aa. 23-13 C γ 1)

NheI

CLONING SITE OF NheI CODES FOR A S - THEREFORE NO AMINO ACID CHANGE DUE TO CLONING.

V γ -SENSE:5' GAAGATCT~~ACG~~ ATG + 17-29bp leader sequence 3'

BgIII KOZAK

V γ anti-sense(reverse/complementary):5' GC TCT AGA GGG TGC CAG GGG GAA GAC CGA T 3'(R) S P A L P F V S (aa. 14-7 C γ 1)

XbaI

Cloning into

5' CG GCT AGC
S (A)

CLONING SITE JUNCTION OF XbaI/NheI (TCT AGC) CODES FOR S S - THEREFORE NO AMINO ACID CHANGE DUE TO CLONING

Fig. 10




Fig. 11




Fig. 12




Fig. 13




Fig. 14




Fig. 15




Fig. 16

16/33




Fig. 17




Fig. 18




Fig. 19




Fig. 20




Fig. 21




Fig. 22

22/33




Fig. 23

23/33






Fig. 24

24/33



25/33




Fig. 25C

26/33




Fig. 26

27/33




Fig. 27

28/33




Fig. 28

COMPETITION




Fig. 29

29/33




Fig. 30

30/33




Fig. 31




Fig. 32

31/33




Fig. 33




Fig. 34

32/33




Fig. 35

33/33




Fig. 36

SEQUENCE LISTING

<110> PSMA DEVELOPMENT COMPANY, L.L.C.

MADDON, Paul J.

DONOVAN, Gerald P.

OLSON, William C.

SCHÜLKE, Norbert

GARDNER, Jason

MA, Dangsue

<120> PSMA ANTIBODIES AND PROTEIN MULTIMERS

<130> P00453.70005.WO

<150> US 60/335,215

<151> 2001-10-23

<150> US 60/362,747

<151> 2001-03-07

<150> US 60/____,____

<151> 2002-09-20

<160> 33

<170> PatentIn version 3.1

<210> 1

<211> 750

<212> PRT

<213> Homo sapiens

<400> 1

Met Trp Asn Leu Leu His Glu Thr Asp Ser Ala Val Ala Thr Ala Arg
1 5 10 15

Arg Pro Arg Trp Leu Cys Ala Gly Ala Leu Val Leu Ala Gly Gly Phe
20 25 30

Phe Leu Leu Gly Phe Leu Phe Gly Trp Phe Ile Lys Ser Ser Asn Glu
35 40 45

Ala Thr Asn Ile Thr Pro Lys His Asn Met Lys Ala Phe Leu Asp Glu
50 55 60

Leu Lys Ala Glu Asn Ile Lys Lys Phe Leu Tyr Asn Phe Thr Gln Ile
65 70 75 80

Pro His Leu Ala Gly Thr Glu Gln Asn Phe Gln Leu Ala Lys Gln Ile
85 90 95

Gln Ser Gln Trp Lys Glu Phe Gly Leu Asp Ser Val Glu Leu Ala His
100 105 110

Tyr Asp Val Leu Leu Ser Tyr Pro Asn Lys Thr His Pro Asn Tyr Ile
115 120 125

Ser Ile Ile Asn Glu Asp Gly Asn Glu Ile Phe Asn Thr Ser Leu Phe
130 135 140

Glu Pro Pro Pro Pro Gly Tyr Glu Asn Val Ser Asp Ile Val Pro Pro
145 150 155 160

Phe Ser Ala Phe Ser Pro Gln Gly Met Pro Glu Gly Asp Leu Val Tyr
165 170 175

Val Asn Tyr Ala Arg Thr Glu Asp Phe Phe Lys Leu Glu Arg Asp Met
180 185 190

Lys Ile Asn Cys Ser Gly Lys Ile Val Ile Ala Arg Tyr Gly Lys Val
195 200 205

Phe Arg Gly Asn Lys Val Lys Asn Ala Gln Leu Ala Gly Ala Lys Gly
210 215 220

Val Ile Leu Tyr Ser Asp Pro Ala Asp Tyr Phe Ala Pro Gly Val Lys
225 230 235 240

Ser Tyr Pro Asp Gly Trp Asn Leu Pro Gly Gly Gly Val Gln Arg Gly
245 250 255

3/63

Asn Ile Leu Asn Leu Asn Gly Ala Gly Asp Pro Leu Thr Pro Gly Tyr
260 265 270

Pro Ala Asn Glu Tyr Ala Tyr Arg Arg Gly Ile Ala Glu Ala Val Gly
275 280 285

Leu Pro Ser Ile Pro Val His Pro Ile Gly Tyr Tyr Asp Ala Gln Lys
290 295 300

Leu Leu Glu Lys Met Gly Gly Ser Ala Pro Pro Asp Ser Ser Trp Arg
305 310 315 320

Gly Ser Leu Lys Val Pro Tyr Asn Val Gly Pro Gly Phe Thr Gly Asn
325 330 335

Phe Ser Thr Gln Lys Val Lys Met His Ile His Ser Thr Asn Glu Val
340 345 350

Thr Arg Ile Tyr Asn Val Ile Gly Thr Leu Arg Gly Ala Val Glu Pro
355 360 365

Asp Arg Tyr Val Ile Leu Gly Gly His Arg Asp Ser Trp Val Phe Gly
370 375 380

Gly Ile Asp Pro Gln Ser Gly Ala Ala Val Val His Glu Ile Val Arg
385 390 395 400

Ser Phe Gly Thr Leu Lys Lys Glu Gly Trp Arg Pro Arg Arg Thr Ile
405 410 415

Leu Phe Ala Ser Trp Asp Ala Glu Glu Phe Gly Leu Leu Gly Ser Thr
420 425 430

Glu Trp Ala Glu Glu Asn Ser Arg Leu Leu Gln Glu Arg Gly Val Ala
435 440 445

Tyr Ile Asn Ala Asp Ser Ser Ile Glu Gly Asn Tyr Thr Leu Arg Val
450 455 460

Asp Cys Thr Pro Leu Met Tyr Ser Leu Val His Asn Leu Thr Lys Glu
465 470 475 480

Leu Lys Ser Pro Asp Glu Gly Phe Glu Gly Lys Ser Leu Tyr Glu Ser
485 490 495

Trp Thr Lys Lys Ser Pro Ser Pro Glu Phe Ser Gly Met Pro Arg Ile
500 505 510

Ser Lys Leu Gly Ser Gly Asn Asp Phe Glu Val Phe Phe Gln Arg Leu
515 520 525

Gly Ile Ala Ser Gly Arg Ala Arg Tyr Thr Lys Asn Trp Glu Thr Asn
530 535 540

Lys Phe Ser Gly Tyr Pro Leu Tyr His Ser Val Tyr Glu Thr Tyr Glu
545 550 555 560

Leu Val Glu Lys Phe Tyr Asp Pro Met Phe Lys Tyr His Leu Thr Val
565 570 575

Ala Gln Val Arg Gly Gly Met Val Phe Glu Leu Ala Asn Ser Ile Val
580 585 590

Leu Pro Phe Asp Cys Arg Asp Tyr Ala Val Val Leu Arg Lys Tyr Ala
595 600 605

Asp Lys Ile Tyr Ser Ile Ser Met Lys His Pro Gln Glu Met Lys Thr
610 615 620

Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr
625 630 635 640

Glu Ile Ala Ser Lys Phe Ser Glu Arg Leu Gln Asp Phe Asp Lys Ser
645 650 655

Asn Pro Ile Val Leu Arg Met Met Asn Asp Gln Leu Met Phe Leu Glu
660 665 670

Arg Ala Phe Ile Asp Pro Leu Gly Leu Pro Asp Arg Pro Phe Tyr Arg
675 680 685

His Val Ile Tyr Ala Pro Ser Ser His Asn Lys Tyr Ala Gly Glu Ser
690 695 700

Phe Pro Gly Ile Tyr Asp Ala Leu Phe Asp Ile Glu Ser Lys Val Asp
705 710 715 720

Pro Ser Lys Ala Trp Gly Glu Val Lys Arg Gln Ile Tyr Val Ala Ala
725 730 735

Phe Thr Val Gln Ala Ala Ala Glu Thr Leu Ser Glu Val Ala
740 745 750

<210> 2

<211> 7570

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 2

gacggatcgg gagatctccc gatcccstat ggtcgactct cagtacaatc tgctctgatg	60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg	120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc	180
ttagggtag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt	240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agccatata	300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaaacgacc	360
cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc	420
attgacgtca atgggtggac tatttacggt aaactgcccc cttggcagta catcaagtgt	480
atcatatgcc aagtacgccc octattgacg tcaatgacgg taaatggccc gcctggcatt	540
atgcccagta catgaccta tgggactttc ctacttggca gtacatctac gtattagtca	600
tcgctattac catggtgatg cgggtttggc agtacatcaa tgggcgtgga tagcggtttg	660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc	720
aaaatcaacg ggactttcca aatgtcgta acaactccgc cccattgacg caaatggcg	780
gtaggcgtgt acgggtggag gtctatataa gcagagctct ctggctaact agagaaccca	840
ctgcttactg gcttatcgaa attaatacga ctcaactatag ggagacccaa gctggctaga	900
ggtaccaagc ttggatctca ccatggagtt gggactgcgc tggggcttcc tcgttgctct	960
tttaagaggt gtccagtgtc aggtgcaatt ggtggagtct gggggaggcg tggtccagcc	1020
tgggagggtcc ctgagactct cctgtgcagc gtctggattc gccttcagta gataatggcat	1080
gcactgggtc cgccaggctc caggcaaggg gctggagtgg gtggcagtt tatggtatga	1140
tggaaagtaat aaataactatg cagactccgt gaagggccga ttcaccatct ccagagacaa	1200
ttccaagaac acgcagtatc tgcaaatgaa cagcctgaga gccgaggaca cggctgtgt	1260
ttactgtgcg agaggcggtg acttcctcta ctactactat tacggatgg acgtctgggg	1320
ccaagggacc acggtcacccg tctcctcagc ctccaccaag gggccatcg tcttccccct	1380
ggcacccctct agcaagagca cctctggggg cacagcggcc ctgggctgcc tggtaagga	1440
ctacttcccc gaaccgggtga cggtgtcggt gaactcaggc gcccctgacca gccccgtgca	1500

caccttcccg gctgtcctac agtcctcagg actctactcc ctcagcagcg tggtgaccgt	1560
gcccctccagc agcttggca cccagaccta catctgcaac gtgaatcaca agcccagcaa	1620
caccaagggtg gacaagagag ttggtgagag gccagcacag ggagggaggg tgtctgctgg	1680
aagccaggct cagcgctcct gcctggacgc atcccgcta tgcagtccta gtccagggca	1740
gcaaggcagg ccccgtctgc ctcttacccc ggaggcctct gcccgccta ctcatgctca	1800
gggagagggt ctcttggtt tttccccagg ctctggcag gcacaggcta ggtgcggcta	1860
acccaggccc tgccacacaaa ggggcaggtg ctgggctcag acctgccaag agccatatcc	1920
gggaggaccc tgcccttgac ctaagcccac cccaaaggcc aaactctcca ctccctcagc	1980
tcggacacct tcttcctcc cagattccag taactccaa tcttctctct gcagagccca	2040
aatcttgta caaaaactcac acatgcccac cgtgcccagg taagccagcc caggcctcgc	2100
cctccagctc aaggcgggac aggtccctta gagtagcctg catccaggga caggccccag	2160
ccgggtgctg acacgtccac ctccatctct tcctcagcac ctgaactcct ggggggaccg	2220
tcagtcttcc tcttccccc aaaacccaag gacaccctca tgcactcccg gaccctgag	2280
gtcacatgcg tgggtggta cgtgagccac gaagaccctg aggtcaagtt caactggtag	2340
gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacaacagc	2400
acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag	2460
tacaagtgcg aggtctccaa caaagccctc ccagccccc tcgagaaaac catctccaa	2520
gccaaagggtg ggaccctgtgg ggtgcgaggg ccacatggac agaggccggc tggcccacc	2580
ctctgcctcg agagtgaccg ctgtaccaac ctctgtccct acagggcagc cccgagaacc	2640
acaggtgtac accctgcccc catccggga ggagatgacc aagaaccagg tcagcctgac	2700
ctgcctggtc aaaggcttct atcccgacg catcgccgtg gagtggaga gcaatggca	2760
gccggagaac aactacaaga ccacgcctcc cgtgctggac tccgacggct ctttcttcc	2820
ctatacgcaag ctcaccgtgg acaagagcag gtggcagcag gggAACGTCT tctcatgctc	2880
cgtgatgcat gaggctctgc acaaccacta cacgcagaag agcctctccc tgtctccggg	2940
taaatgagaa ttccctcgagt ctagagggcc cgtttaaacc cgctgatcag cctcgactgt	3000
gccttctagt tgccagccat ctgttggttt cccctccccc gtgccttcct tgaccctgga	3060
agggtgcact cccactgtcc tttccataata aatgaggaa attgcacgc attgtctgag	3120
taggtgtcat tctattctgg ggggtgggt gggcaggac agcaaggggg aggattggga	3180
agacaatagc aggcacgtcg gggatgcggc gggctctatg gcttctgagg cgaaagaac	3240
cagctggggc tctagggggt atccccacgc gccctgtac ggcgcattaa ggcggcggg	3300
tgtggtggtt acgcgcagcg tgacccgtac acttgccagc gcccctagcgc ccgcctt	3360

cgctttcttc ctttcctttc tcgcccacgtt cgccggcttt ccccgtcaag ctctaaatcg 3420
 gggcatccct ttagggttcc gatttagtgc tttacggcac ctcgacccca aaaaacttga 3480
 ttagggtgat gggtcacgta gtggggccatc gccctgatag acgggttttc gcccttgac 3540
 gttggagtcc acgttcttta atagtggact cttgttccaa actggaacaa cactcaaccc 3600
 tatctcggtc tattcttttgc atttataagg gattttgggg atttcggcct attggttaaa 3660
 aaatgagctg atttaacaaa aatttaacgc gaattaattc tgtggaatgt gtgtcagtt 3720
 gggtgtggaa agtccccagg ctccccaggc aggcaagaatc atgcaaagca tgcatactcaa 3780
 ttagtcagca accaggtgtg gaaagtcccc aggctccccca gcaggcagaa gtatgcaaag 3840
 catgcatactc aatttagtcag caaccatagt cccgccccata actccgccccca tcccgccccct 3900
 aactccgcccc agttccgcccc attctccgccc ccatggctga ctaattttttt ttatattatgc 3960
 agaggccgag gccgcctctg cctctgagct attccagaag tagtgaggag gctttttgg 4020
 aggcctaggc ttttgcacaaa agctccggg agcttgtata tccattttcg gatctgatca 4080
 gcacgtgatg aaaaagcctg aactcaccgc gacgtctgtc gagaagtttc tgatcgaaaa 4140
 gttcgacagc gtctccgacc tgatgcagct ctcggaggc gaagaatctc gtgtttcag 4200
 cttcgatgtta ggagggcgtg gatatgtcct ggggtaaat agctgcgcgg atggtttcta 4260
 caaagatcgatgtatc ggcactttgc atcggccgcg ctcccgattc cgaaagtgc 4320
 tgacattggg gaattcagcg agagcctgac ctattgcattc tcccgccgtg cacagggtgt 4380
 cacgttgcaa gacctgcctg aaaccgaact gcccgcgtt ctgcagccgg tcgcccggc 4440
 catggatgcg atcgcgtgcgg ccgatcttag ccagacgagc gggttcggcc cattcggacc 4500
 gcaaggaatc ggtcaataaca ctacatggcg tgatttcata tgcgcgatttgc ctgatcccc 4560
 tgtgtatcac tggcaaaactg tgatggacga caccgtcagt gcgtccgtcg cgcaaggctct 4620
 cgatgagctg atgctttggg ccgaggactg ccccgaaatgc cggcacccctcg tgcacgcgg 4680
 tttcggctcc aacaatgtcc tgacggacaa tggccgcata acagcggtca ttgactggag 4740
 cgaggcgatg ttcggggatt cccaatacga ggtcgccaaac atcttcttct ggaggccgtg 4800
 gttggcttgcgatg atggagcagc agacgcgtca cttcgagcgg aggcatccgg agcttgcagg 4860
 atcgcgcgg ctccggcgatg atatgcgtccg cattggcttt gaccaactct atcagagctt 4920
 ggttgacggc aatttcgatg atgcagcttgc ggccgcagggt cgatgcgcacg caatcgccg 4980
 atccggagcc gggactgtcg ggccgtacaca aatcgccccgc agaagcgcgg ccgtctggac 5040
 cgatggctgt gtatggatgtac tgcgcgtatag tggaaaccga cgcccccagca ctcgtccgag 5100
 ggcaaaaggaa tagcgcgtgc tacgagattt cgattccacc gccgccttct atgaaaagggtt 5160
 gggcttcgga atcgccccccggg acgttccggc ctggatgtac ctccagcgcg gggatctcat 5220

gctggagttc ttcgcccacc ccaacttgtt tattgcagct tataatggtt acaaataaag	5280
caatagcatc acaaatttca caaataaagc attttttca ctgcattcta gttgtggttt	5340
gtccaaactc atcaatgtat cttatcatgt ctgtataccg tcgaccccta gctagagctt	5400
ggcgtaatca tggtcatacg tggccctgt gtgaaattgt tatccgctca caattccaca	5460
caacatacga gccggaagca taaagtgtaa agccctgggt gcctaattgag tgagctaact	5520
cacattaatt gcgttgcgct cactgcccgc tttccagtcg ggaaacctgt cgtgccagct	5580
gcattaatga atcggccaac gcgcggggag aggccgtttg cgtattggc gctctccgc	5640
ttcctcgctc actgactcgc tgcgctcggt cgttcggctg cggcgagcgg tatcagctca	5700
ctcaaaggcg gtaatacggt tatccacaga atcagggat aacgcaggaa agaacatgtg	5760
agcaaaaaggc cagcaaaaagg ccaggaaccg taaaaaggcc gcgttgctgg cgaaaaa	5820
taggctccgc cccccctgacg agcatcacaa aaatcgacgc tcaagtcaga ggtggcggaa	5880
cccgacagga ctataaagat accaggcggt tccccctgga agctccctcg tgcgctctcc	5940
tgttccgacc ctgcccgtta ccggataacct gtccgccttt ctccctcgg gaagcgtggc	6000
gttttctcaa tgctcacgct gtaggtatct cagttcggtg taggtcggtc gctccaagct	6060
gggctgtgtg cacgaacccc ccgttcagcc cgaccgctgc gccttatccg gtaactatcg	6120
tcttgagtcc aaccccgtaa gacacgactt atcgccactg gcagcagcca ctggtaacag	6180
gattagcaga gcgaggtatg taggcggtgc tacagagttc ttgaagtggt ggcttaacta	6240
cggtacact agaaggacag tatttggat ctgcgctctg ctgaagccag ttacctcgg	6300
aaaaagagtt ggtagctttt gatccggcaa acaaaccacc gctggtagcg gtggtttttt	6360
tgtttcaag cagcagatta cgccgagaaa aaaaggatct caagaagatc ctttgatctt	6420
ttctacgggg tctgacgctc agtggAACGA aaactcacgt taaggattt tggtcatgag	6480
attatcaaaa agatcttca cctagatcct tttaaattaa aaatgaagtt ttaaatcaat	6540
ctaaagtata tatgagtaaa cttggctga cagttaccaa tgcttaatca gtgaggcacc	6600
tatctcagcg atctgtctat ttgcgttcatc catagttgcc tgactccccg tcgtgttagat	6660
aactacgata cgggaggggct taccatctgg ccccaagtgc gcaatgatac cgccgacacc	6720
acgctcaccg gctccagatt tatcagcaat aaaccagcca gccggaaaggc ccgagcgcag	6780
aagtggctt gcaactttat ccgcctccat ccagtctatt aattgttgcc gggaaagctag	6840
agtaagttagt tcgcccagtta atagttgcg caacgttggtt gccattgcta caggcatcg	6900
ggtgtcacgc tcgtcggtt gtagggcttc attcagctcc ggttcccaac gatcaaggcg	6960
agttacatga tccccatgt tggcaaaaaa agcggttagc tccctcggc tcggatcg	7020
tgtcagaagt aagttggccg cagtgattatc actcatggtt atggcagcac tgcataattc	7080

tcttactgtc atgccatccg taagatgctt ttctgtgact ggtgagtaact caaccaagtc	7140
attctgagaa tagtgtatgc ggcgaccgag ttgctcttgc cccgcgtcaa tacggataa	7200
taccgcgcca catagcagaa cttaaaagt gctcatcatt ggaaaacggtt ctccgggccc	7260
aaaactctca aggatcttac cgctgttgag atccagttcg atgtaaccca ctcgtgcacc	7320
caactgatct tcagcatctt ttactttcac cagcgtttct gggtgagcaa aaacaggaag	7380
gcaaaatgcc gcaaaaaagg gaataagggc gacacggaaa tggtgaatac tcatactctt	7440
ccttttcaa tattattgaa gcatttatca gggttattgt ctcatgagcg gatacatatt	7500
tgaatgtatt tagaaaaata aacaaatagg ggttccgcgc acattttcccc gaaaagtgcc	7560
acctgacgtc	7570

<210> 3

<211> 7597

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 3

gacggatcgagatctccc gatcccstat ggtcgactct cagtaatac tgctctgatg	60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg	120
cgagaaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatt aagaatctgc	180
ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt	240
gattattgac tagttattaa tagtaatcaa ttacgggttc attagttcat agccatata	300
tggagttccg cgttacataa cttacgtaa atggcccgcc tggctgaccg cccaaacgacc	360
cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc	420
attgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt	480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt	540
atgcccagta catgaccta tggacttgc ctacttggca gtacatctac gtattagtca	600
tcgctattac catggtgatg cgggtttggc agtacatcaa tggcggttgg tagcggtttg	660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tggagtttg tttggcacc	720
aaaatcaacg ggactttcca aatgtcgta acaactccgc cccattgacg caaatggcg	780
gtaggcgtgt acgggtggag gtctatataa gcagagctct ctggctaact agagaaccca	840
ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga	900

ggtaccaagc ttggatctca ccatgggtc aaccgccatc ctcaccatgg agttggggct	960
gcgcgtggtt ctccctcggtt ctcttttaag aggtgtccag tgtcaggtgc agctggtgaa	1020
gtctggggga ggcgtggtcc agcctggag gtccctgaga ctctcctgtg cagcgtctgg	1080
attcaccttc agtaactatg tcatgcactg ggtccgccag gctccaggca aggggctggaa	1140
gtgggtggca attatatggt atgatggaag taataaatac tatgcagact ccgtgaaggg	1200
ccgattcacc atctccagag acaattccaa gaacacgctg tatctgaaa tgaacagcct	1260
gagagccgag gacacggctg tgtattactg tgcgggtgga tataactgga actacgagta	1320
ccactactac ggtatggacg tctggggcca agggaccacg gtcaccgtct cctcagcctc	1380
caccaagggc ccatcggtct tccccctggc accctctagc aagagcacct ctgggggcac	1440
agcggccctg ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg tgtcgtggaa	1500
ctcaggcgcc ctgaccagcg gcgtgcacac cttcccgct gtcctacagt cctcaggact	1560
ctactccctc agcagcgtgg tgaccgtgcc ctccagcagc ttgggcaccc agacctacat	1620
ctgcaacgtg aatcacaagc ccagcaacac caaggtggac aagagagttg gtgagaggcc	1680
agcacagggc gggagggtgt ctgctgaaag ccaggctcag cgctcctgcc tggacgcac	1740
ccggctatgc agtcccagtc cagggcagca aggccaggccc cgtctgcctc ttcacccggaa	1800
ggcctctgcc cgccccactc atgctcaggc agagggtctt ctggctttt ccccaggctc	1860
tggcaggca caggctaggt gcccctaacc caggccctgc acacaaaggc gcaggtgctg	1920
ggctcagacc tgccaagagc catatccggg aggaccctgc ccctgaccta agcccacccc	1980
aaaggccaaa ctctccactc cctcagctcg gacaccttct ctcctccacag attccagtaa	2040
ctcccaatct tctctctgca gagcccaaattt cttgtgacaa aactcacaca tgcccaccgt	2100
gcccaggtaa gccagccag gctcgccct ccagctcaag gcgggacagg tgccctagag	2160
tagcctgcat ccagggacag gccccagccg ggtgctgaca cgtccacctc catctttcc	2220
tcagcacctg aactcctggg gggaccgtca gtcttcctct tccccccaaa acccaaggac	2280
accctcatga tctccggac ccctgaggac acatgcgtgg tggtgacgt gagccacgaa	2340
gaccctgagg tcaagttcaa ctggtaacgtg gacggcgtgg aggtgcataa tgccaagaca	2400
aagccgcggg aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg	2460
caccaggact ggctgaatgg caaggagtac aagtgcagg tctccaacaa agccctccca	2520
gcccccatcg agaaaaccat ctccaaagcc aaaggtggaa cccgtgggggt gcgagggcca	2580
catggacaga ggccggctcg gcccacccctc tgccctgaga gtgaccgctg taccacac	2640
tgtccctaca gggcagcccc gagaaccaca ggtgtacacc ctgccccat cccgggagga	2700
gatgaccaag aaccaggtca gcctgacctg cctggtaaaa ggcttctatc ccagcgcacat	2760

cgccgtggag tgggagagca atggcagcc ggagaacaac tacaagacca cgcctccgt	2820
gctggactcc gacggctcct tcttcctcta tagcaagctc accgtggaca agagcaggtg	2880
gcagcagggg aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac	2940
gcagaagagc ctctccctgt ctccggtaa atgagaattc ctcgagtcta gagggccgt	3000
ttaaacccgc tgatcagcct cgactgtgcc ttctagttgc cagccatctg ttgtttgcc	3060
ctccccctg cttcccttga ccctggaagg tgccactccc actgtcctt cctaataaaa	3120
tgagggaaatt gcatcgatt gtctgagtag gtgtcattct attctgggg gtgggggtggg	3180
gcaggacagc aagggggagg attgggaaga caatagcagg catgctggg atgcgggtggg	3240
ctctatggct tctgaggcgg aaagaaccag ctggggctct aggggtatc cccacgcgcc	3300
ctgttagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga ccgctacact	3360
tgccagcggcc cttagcggcc ctccttcgc ttcttcctt tccttcgc ccacgttcgc	3420
cggcttcctt cgtcaagctc taaatcgaaa catccctta gggttccgat ttagtgctt	3480
acggcacctc gaccccaaaa aacttgatta gggtgatggt tcacgtagtg ggccatcgcc	3540
ctgatagacg gtttttcgcc ctttgacgtt ggagtccacg ttcttaata gtggactctt	3600
gttccaaact ggaacaacac tcaaccctat ctcggtctat tctttgatt tataagggat	3660
tttgggatt tcggcctatt ggtaaaaaaa tgagctgatt taacaaaaat ttaacgcgaa	3720
ttaattctgt ggaatgtgtg tcagtttaggg tggaaaagt ccccaggttc cccaggcagg	3780
cagaagtatg caaagcatgc atctcaatta gtcagcaacc aggtgtggaa agtccccagg	3840
ctccccagca ggcagaagta tgcaaaagcat gcatctcaat tagtcagcaa ccatagtccc	3900
cccccttaact ccgccttac ccgccttaac tccgccttgc tccgccttgc ctccgccttgc	3960
tggctgacta atttttttta ttatgcaga ggccgaggcc gcctctgcct ctgagctatt	4020
ccagaagtag tgaggaggct ttttggagg cctaggctt tgcaaaaagc tcccgaggagc	4080
ttgtatatcc attttcggat ctgatcagca cgtgatgaaa aagcctgaac tcaccgcgac	4140
gtctgtcgag aagtttctga tcgaaaagtt cgacagcgtc tccgacctga tgcagctctc	4200
ggagggcgaa gaatctcggt ctttcagctt cgatgttagga gggcgtggat atgtcctgcg	4260
ggtaaatagc tgccgcgtat gtttctacaa agatcgat gtttctgc accttcgcac	4320
ggccgcgttc ccgattccgg aagtgcgttga cattggggaa ttcaagcggaa gcctgaccta	4380
ttgcatctcc cggcggtcac agggtgcac gttgcaagac ctgcctgaaa ccgaactgccc	4440
cgctgttctg cagccggcgtc cggaggccat ggatgcgtc gctgcggccg atcttagccaa	4500
gacgagcggg ttccggccat tcggaccgca aggaatcggt caatacacta catggcgtga	4560
tttcatatgc gcgattgctg atccccatgt gtatcactgg caaaactgtga tggacgcacac	4620

cgtcagtgcg tccgtcgcg aggctctcg a tagctgatg ctttggccg aggactgccc 4680
cgaagtccgg cacctcggtgc acgcggattt cggtccaa aatgtccctga cggacaatgg 4740
ccgcataaca gcggtcattt actggagcga ggcgttcc ggggattccc aatacgaggt 4800
cgccaacatc ttcttcttggaa ggccgtggtt ggcttgtatg gaggcagcaga cgcgtactt 4860
cgagcggagg catccggagc ttgcaggatc gcccggctc cggcgatata tgctccgcat 4920
tggtcttgcac caactctatc agagcttggt tgacggcaat ttgcgtatg cagcttggc 4980
gcaggggtcga tgcgacgcaa tcgtccgatc cggagccggg actgtccggc gtacacaaat 5040
cgcccgccaga agcgcggccg tctggaccga tggctgtgtaa gaagtactcg ccgatagtgg 5100
aaaccgacgc cccagcactc gtccgagggc aaaggaatag cacgtgtac gagatttcga 5160
ttccaccggcc gccttctatg aaaggttggg ctgcggatc gtttccggg acgccggctg 5220
gatgatccctc cagcgcgggg atctcatgct ggagttcttc gcccacccca acttgtttat 5280
tgcagttat aatggttaca aataaagcaa tagcatcaca aatttcacaa ataaagcatt 5340
tttttcaactg cattcttagtt gtggttgtc caaactctatc aatgtatctt atcatgtctg 5400
tataccgtcg acctctagct agagcttggc gtaatcatgg tcatacgatgt ttccgtgtg 5460
aaattgttat ccgctcacaat ttccacacaa catacgagcc ggaagcataa agttaaagc 5520
ctggggtgcc taatgagtga gctaactcac attaattgcg ttgcgtcac tgcccgctt 5580
ccagtcggga aacctgtcgt gcccagctgca ttaatgaatc ggccaaacgcg cggggagagg 5640
cggtttgcgt attgggcgtt ctccgccttc ctgcgtact gactcgctgc gtcgggtcgt 5700
tcggctgcgg cgagcggat cagctactc aaaggcggta atacggttat ccacagaatc 5760
aggggataac gcaggaaaga acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa 5820
aaaggccgcg ttgctggcgt tttccatag gctccggccc cctgacgagc atcacaaaaaa 5880
tcgacgctca agtcagaggt ggcgaaaccc gacaggacta taaagatacc aggcgtttcc 5940
ccctggaaac tccctcggtc gctctctgt tccgaccctg ccgttaccg gataacctgtc 6000
cgcccttctc cttcgggaa gcgtggcgct ttctcaatgc tcacgctgtt ggtatctcag 6060
ttcgggtgttag gtcgttcgtt ccaagctggg ctgtgtgcac gaaccccccgtt ttcagccgaa 6120
ccgctgcgc ttatccggta actatcgatc tgagtccaa cccgtaaagac acgacttatac 6180
gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgttag gccgtgtac 6240
agagttcttgcgtt aagtgggtggc ctaactacgg ctacactaga aggacagtat ttggatctg 6300
cgctctgctg aagccagttt cttcggaaa aagagttggt agctcttgcgtt ccggcaaaaca 6360
aaccaccgct ggtagcgggtg gttttttgtt ttgcgtatcag cagattacgc gcagaaaaaaa 6420
aggatctcaa gaagatcctt tgcgttttc tacgggtgtt gacgctcagt ggaacgaaaa 6480

ctcacgttaa gggattttgg tcatgagatt atcaaaaagg atcttcacct agatccttt	6540
aaattaaaaa tgaagttta aatcaatcta aagtatatat gagtaaactt ggtctgacag	6600
ttaccaatgc ttaatcagtg aggcacctat ctcagcgatc tgtctatttc gttcatccat	6660
agttgcctga ctccccgtcg tgtagataac tacgataacgg gagggcttac catctggccc	6720
cagtgctgca atgataccgc gagacccacg ctcaccggct ccagatttat cagcaataaa	6780
ccagccagcc ggaagggccg agcgcagaag tggtcctgca actttatccg cctccatcca	6840
gtcttattaat tgttgcccggg aagctagagt aagtagttcg ccagttataa gtttgcgcaa	6900
cgttgggcc attgctacag gcacgtggt gtcacgctcg tcgtttggta tggcttcatt	6960
cagctccggc tcccaacgat caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc	7020
ggtagctcc ttggcgtcctc cgatcggtgt cagaagtaag ttggccgcag tgttatcact	7080
catggttatg gcagcaactgc ataattctct tactgtcatg ccacatccgtaa gatgctttc	7140
tgtgactggc gagtactcaa ccaagtcatt ctgagaatag tgtatgcggc gaccgagttg	7200
ctcttgcggc gcgtaatac gggataatac cgccgcacat agcagaactt taaaagtgt	7260
catcatttggaa aaacgttctt cggggcgaaaa actctcaagg atcttaccgc tgttgagatc	7320
cagttcgatg taacccactc gtgcacccaa ctgatcttca gcatcttta ctttaccag	7380
cgtttctggg tgagcaaaaa caggaaggca aatgccgca aaaaaggaa taagggcgac	7440
acggaaatgt tgaataactca tactcttcct tttcaatat tattgaagca tttatcaggg	7500
ttattgtctc atgagcggat acatatttga atgtatattag aaaaataaaac aaataggggt	7560
tcggcgacaca tttccccgaa aagtgcacc tgacgtc	7597

<210> 4

<211> 7579

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 4

ccgcatagtt aagccagtt ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatt aagaatctgc 180
ttagggttag gcgttttgcg ctgcttcgct atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 300

tggagttccg	cgttacataa	cttacggtaa	atggcccgcc	tggctgaccg	cccaacgacc	360
cccgcccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420
attgacgtca	atgggtggac	tatttacggt	aaactgccc	cttggcagta	catcaagtgt	480
atcatatgcc	aagtacgccc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	540
atgcccagta	catgaccta	tgggactttc	ctacttggca	gtacatctac	gtattagtca	600
tcgttattac	catggtgatg	cggtttggc	agtacatcaa	tgggcgtgga	tagcggttg	660
actcacgggg	atttccaagt	ctccacccca	ttgacgtcaa	tgggagtttgc	ttttggcacc	720
aaaatcaacg	ggactttcca	aaatgtcgta	acaactccgc	cccattgacg	caaatggcgc	780
gtaggcgtgt	acgggtggag	gtctatataa	gcagagctct	ctggcttaact	agagaaccca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcactatag	ggagacccaa	gctggctaga	900
gttaccaagc	ttggatctca	ccatggagtt	gggacttagc	tgggtttcc	tcgttgctct	960
tttaagaggt	gtccagtgtc	aggccagct	ggtggagtct	gggggaggcg	tggccagcc	1020
tgggaggtcc	ctgagactct	cctgtcagc	gtctggattc	accttcagta	gctatggcat	1080
gcactgggtc	cgccaggctc	caggcaaggg	gctggactgg	gtggcaatta	tttggcatga	1140
tggaagtaat	aaatactatg	cagactccgt	gaagggccga	ttcaccatct	ccagagacaa	1200
ttccaagaag	acgctgtacc	tgcaaatgaa	cagttgaga	gccgaggaca	cggctgtgta	1260
ttactgtcg	agagcttggg	cctatgacta	cggtgactat	gaatactact	tcggtatgga	1320
cgtctgggc	caagggacca	cggtcaccgt	ctcctcagcc	tccaccaagg	gcccatcggt	1380
cttccccctg	gcaccctcta	gcaagagcac	ctctggggc	acagcggccc	tggctgcct	1440
ggtaaggac	tacttccccg	aaccggtgac	ggtgtcgtgg	aactcaggcg	ccctgaccag	1500
cggcgtgcac	accttcccgg	ctgtcctaca	gtcctcagga	ctctactccc	tcagcagcgt	1560
ggtgaccgtg	ccctccagca	gcttggcac	ccagacctac	atctgcaacg	tgaatcacaa	1620
gcccagcaac	accaaggtgg	acaagagagt	tggtgagagg	ccagcacagg	gagggagggt	1680
gtctgctgga	agccaggctc	agcgctcctg	cctggacgca	tcccggctat	gcagtcccag	1740
tccagggcag	caaggcaggc	cccgtctgcc	tcttcacccg	gaggcctctg	cccgccccac	1800
tcatgctcag	ggagagggtc	ttctggctt	ttccccaggc	tctggcagg	cacaggctag	1860
gtgcccctaa	cccaggccct	gcacacaaag	ggcaggtgc	tgggctcaga	cctgccaaga	1920
gccatatccg	ggaggaccct	gcccctgacc	taagcccacc	ccaaaggcca	aactctccac	1980
tccctcagct	cggacacccctt	ctctcctccc	agattccagt	aactccaaat	cttctctctg	2040
cagagccaa	atcttgtgac	aaaactcaca	catgcccacc	gtgcccaggt	aagccagccc	2100
aggcctcgcc	ctccagctca	aggcgggaca	ggtgcccctag	agtagcctgc	atccagggac	2160

aggccccagc	cgggtgctga	cacgtccacc	tccatctctt	cctcagcacc	tgaactcctg	2220
gggggaccgt	cagtcttcct	cttcccccca	aaacccaagg	acaccctcat	gatctcccg	2280
acccctgagg	tcacatgcgt	ggtggtggac	gtgagccacg	aagaccctga	ggtcaagttc	2340
aactggta	cggtacg	ggaggtgc	aatgccaaga	caaagccg	ggaggagcag	2400
tacaacagca	cgtaccgtgt	ggtcagcgtc	ctcaccgtcc	tgcaccagga	ctggctgaat	2460
ggcaaggagt	acaagtgcaa	ggtctccaac	aaagccctcc	cagccccat	cgagaaaacc	2520
atctccaaag	ccaaaggtgg	gaccgtggg	gtgcgaggc	cacatggaca	gaggccggct	2580
cggcccaccc	tctgccctga	gagtgaccgc	tgtaccaacc	tctgtcccta	cagggcagcc	2640
ccgagaacca	caggtgtaca	ccctgcccc	atcccggag	gagatgacca	agaaccaggt	2700
cagcctgacc	tgcctggtca	aaggcttcta	tcccagcgcac	atgcgcgtgg	agtggagag	2760
caatgggcag	ccggagaaca	actacaagac	cacgcctccc	gtgctggact	ccgacggctc	2820
cttcttcctc	tatagcaagc	tcaccgtgga	caagagcagg	tggcagcagg	ggaacgtctt	2880
ctcatgctcc	gtgatgcatt	aggctctgca	caaccactac	acgcagaaga	gcctctccct	2940
gtctccgggt	aaatgagaat	tcctcgagtc	tagagggccc	gtttaaacc	gctgatcagc	3000
ctcgactgtg	ccttctagtt	gccagccatc	tgttgtttgc	ccctccccg	tgccttcctt	3060
gaccctggaa	ggtgccactc	ccactgtcct	ttcctaataa	aatgaggaaa	ttgcatacgca	3120
ttgtctgagt	aggtgtcatt	ctattctggg	gggtgggggt	ggcaggacca	gcaaggggga	3180
ggattggaa	gacaatagca	ggcatgctgg	ggatgcgggt	ggctctatgg	cttctgaggc	3240
ggaaagaacc	agctggggct	ctaggggta	tccccacgcg	ccctgttagcg	gcgcattaag	3300
cgcggcgggt	gtgggtggta	cgcgcagcgt	gaccgctaca	cttgcagcgc	ccctagcgcc	3360
cgctccttc	gtttcttc	cttccttct	cgcacgttc	gcccgtttc	cccgtaagc	3420
tctaaatcg	ggcatccctt	tagggtccg	attagtgtc	ttacggcacc	tgcaccccaa	3480
aaaacttgc	tagggtgatg	gttcacgtag	tggccatcg	ccctgataga	cggttttcg	3540
ccctttgacg	ttggagtc	cgttctttaa	tagtgactc	ttgttccaaa	ctggaacaac	3600
actcaaccct	atctcggtct	attctttga	tttataaggg	attttgggg	tttcggccta	3660
ttggttaaaa	aatgagctga	tttaacaaaa	atttaacgcg	aattaattct	gtggaatgtg	3720
tgtcagttag	ggtgtggaaa	gtccccaggc	tccccaggca	ggcagaagta	tgcaaagcat	3780
gcatctcaat	tagtcagcaa	ccaggtgtgg	aaagtcccc	ggctccccag	caggcagaag	3840
tatgcaaagc	atgcatctca	attagtgc	aaccatagtc	ccgccccaa	ctccgccccat	3900
cccgccccata	actccgcccc	gttccgcccc	ttctccgccc	catggctgac	taatttttt	3960
tatttatgca	gaggccgagg	cgcctctgc	ctctgagct	ttccagaagt	agtgaggagg	4020

cttttttggaa ggcctaggct tttgcaaaaa gctcccgaaa gcttgtatata ccattttcgg	4080
atctgatcag cacgtgatga aaaagcctga actcaccgcg acgtctgtcg agaagttct	4140
gatcgaaaaag ttcgacagcg tctccgaccc gatgcagctc tcggaggcg aagaatctcg	4200
tgctttcagc ttcgatgtag gagggcgtgg atatgtcctg cgggtaaata gctgcgcccga	4260
tggtttctac aaagatcggt atgtttatcg gcactttgca tcggccgcgc tcccgattcc	4320
ggaagtgcct gacattgggg aattcagcga gagcctgacc tattgcattt cccgcgcgtgc	4380
acagggtgtc acgttgcaag acctgcctga aaccgaaactg cccgctgttc tgcagccgggt	4440
cgccggaggcc atggatgcga tcgctgcggc cgatcttagc cagacgagcg ggttcggccc	4500
attcggaccg caaggaatcg gtcaatacac tacatggcgt gatttcatat ggcgcattgc	4560
tgatccccat gtgtatcact ggcaaactgt gatggacgac accgtcagtg cgtccgtcgc	4620
gcaggctctc gatgagctga tgctttggc cgaggactgc cccgaagtcc ggacacctcg	4680
gcacgcggat ttccggctcca acaatgtcct gacggacaat ggccgcataa cagcggctcat	4740
tgactggagc gagggcgatgt tcggggattc ccaatacggag gtcgccaaca tcttcttctg	4800
gaggccgtgg ttggcttgcg tggagcagca gacgcgctac ttccgagcgga ggcatccgga	4860
gcttgcagga tcgcccggc tccggcgta tatgctccgc attggcttgc accaactcta	4920
tcagagcttgc ttgacggca atttcgatga tgcagcttgc ggcgcagggtc gatgcgacgc	4980
aatcgcccgaa tccggagccg ggactgtcgg gcttacacaa atcgcccgca gaagcgcggc	5040
cgtctggacc gatggctgtg tagaagtact cgccgatagt ggaaaccgac gccccagcac	5100
tcgtccgagg gcaaaggaat agcacgtgct acgagatttcc gattccaccc cccgcattcta	5160
tgaaagggttgc ggcttcggaa tcgtttccg ggacgcggc tggatgatcc tccagcgcgg	5220
ggatctcatg ctggagttct tcgcccaccc caacttgcattt attgcagctt ataatggtta	5280
caaataaagc aatagcatca caaatttcac aaataaagca ttttttcac tgcattctag	5340
ttgtggtttgc tccaaactca tcaatgtatc ttatcatgtc tgcataccgt cgacctctag	5400
ctagagcttgc gctaatcat ggtcatacgct gttcctgtc tgaaattgtt atccgctcac	5460
aattccacac aacatacggag ccggaagcat aaagtgtaaa gcttgggtg cctaatgagt	5520
gagctaactc acattaatttgc gttgcgcgc actgcccgc ttccagtcgg gaaacctgtc	5580
gtgccagctg cattaatgaa tcggccaaacg cgccggggaga ggccgtttgc gtattggcg	5640
ctcttcggct tcctcgctca ctgactcgct ggcgcggcgt gttcggctgc ggcgagcggt	5700
atcagctcac tcaaaggcgta taatacggtt atccacagaa tcagggata acgcaggaaa	5760
gaacatgtga gcaaaaaggcc agcaaaaaggc caggaaccgt aaaaaggccg cgttgcgtgc	5820
gtttttccat aggctccgccc cccctgacga gcatcacaaa aatcgacgct caagtcagag	5880

gtggcggaaaac ccgacaggac tataaagata ccagggcgaaa cccccctggaa gtcgcctcggt	5940
gcgctctccct gttccgacccc tgccgcttac cggataacctg tccgccttcc tcccttcggg	6000
aagcgtggcg ctttctcaat gctcacgctg taggtatctc agttcggtgt aggtcggtcg	6060
ctccaaagctg ggctgtgtgc acgaacccccc cgttcagcccc gaccgctgctg ccttataccgg	6120
taactatcgt cttgagtcca accccggtaag acacgactta tcgcccactgg cagcagccac	6180
tggtaaacagg attagcagag cgaggtatgt aggcgggtgct acagagttct tgaagtggtg	6240
gcctaactac ggctacacta gaaggacagt atttgggtatc tgccgtctgc tgaagccagt	6300
taccttcggaa aaaagagttg gtagctcttgc atccggcaaa caaaccacccg ctggtagcgg	6360
tggttttttt gtttgcagaagc agcagattac ggcgcagaaaa aaaggatctc aagaagatcc	6420
tttgatcttt tctacgggggt ctgacgctca gtggAACGAA aactcacgtt aagggatttt	6480
ggtcatgaga ttatcaaaaaa ggatcttcac ctagatcctt taaaattaaa aatgaagttt	6540
taaatcaatc taaagtatata atgagtaaac ttggctcgac agttaccaat gcttaatcag	6600
tgaggcacct atctcagcga tctgtctatt tcggtcatcc atagttgcct gactccccgt	6660
cgtgtagata actacgatac gggagggctt accatctggc cccagtgcgtg caatgataacc	6720
gcgagaccca cgctcaccgg ctccagattt atcagcaata aaccagccag ccggaaaggc	6780
cgagcgcaga agtggtcctg caactttatc cgcctccatc cagttatattt attgttgcgg	6840
ggaagctaga gtaagtagtt cgccagttaa tagttgcgc aacgttgtg ccattgtac	6900
aggcatcgtg gtgtcagct cgtcggtttgg tatggcttca ttcaagctccg gttcccaacg	6960
atcaaggcga gttacatgat ccccccattttt gtgcaaaaaaa gcggtagtct cttcggtcc	7020
tccgatcggtt gtcagaagta agttggccgc agtgttatca ctcattggta tggcagcact	7080
gcataattctt cttactgtca tgccatccgt aagatgcttt tctgtgactg gtgagttactc	7140
aaccaagtca ttctgagaat agtgttatgcg gcgaccgagt tgctcttgc cggcgtaat	7200
acgggataat acccgccac atagcagaac tttaaaaatgt ctcattttttt gaaaacgttc	7260
tccggggcga aaactctcaa ggatcttacc gctgttgaga tccagttcgaa tgtaacccac	7320
tcgtgcacccc aactgatctt cagcatctt tactttcacc agcggttctg ggtgagcaaa	7380
aacaggaagg caaaaatgcgg caaaaaagg aataaggcg acacggaaat gttgaataact	7440
catactcttc ctttttcaat attattgaag catttatcag gtttattgtc tcatgagcgg	7500
atacatatttt gaatgtatTTT agaaaaataa acaaataagg gttccgcgcacatTTTTCCG	7560
aaaaagtgcgcacatTTTTCCG	7579

<211> 7558

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 5

cttgggcacc cagacctaca tctgcaacgt gaatcacaag cccagcaaca ccaagggtgga	1620
caagagagtt ggtgagaggc cagcacaggg agggagggtg tctgctggaa gccaggctca	1680
gcgcctcctgc ctggacgcat cccggctatg cagtcccagt ccagggcagc aaggcaggcc	1740
ccgtctgcct cttcacccgg aggcctctgc ccccccact catgctcagg gagagggtct	1800
tctggctttt tccccaggct ctgggcaggc acaggctagg tgccccataac ccaggccctg	1860
cacacaaagg ggcaggtgct gggctcagac ctgccaagag ccataccgg gaggaccctg	1920
cccctgacct aagcccaccc caaaggccaa actctccact ccctcagctc ggacacccctc	1980
tctccctcca gattccagta actcccaatc ttctctctgc agagccaaa tcttgtgaca	2040
aaactcacac atgcccaccc tgcccaggta agccagccca ggcctcgccc tccagctcaa	2100
ggcgggacag gtgccttaga gtgcctgca tccagggaca ggccccagcc gggtgctgac	2160
acgtccaccc ccatctcttc ctcagcacct gaactcctgg ggggaccgtc agtcttcctc	2220
ttccccccaa aacccaagga caccctcatg atctcccgga cccctgaggt cacatgcgtg	2280
gtggtggacg tgagccacga agaccctgag gtcaagttca actggtaacgt ggacggcgtg	2340
gaggtgcata atgccaagac aaagccgcgg gaggagcagt acaacagcac gtaccgtgt	2400
gtcagcgtcc tcaccgtctc gcaccaggac tggctgaatg gcaaggagta caagtgcag	2460
gtctccaaca aagccctccc agccccatc gagaaaacca tctccaaagc caaagggtgg	2520
accctgtgggg tgcgagggcc acatggacag aggcggctc ggcccacccct ctgcccctgag	2580
agtgaccgct gtaccaaccc ctgtccctac agggcagccc cgagaaccac aggtgtacac	2640
cctgccccca tcccgggagg agatgaccaa gaaccaggc agcctgaccc gcctggtaaa	2700
aggcttctat cccagcgaca tcgcccgtga gtgggagagc aatgggcagc cggagaacaa	2760
ctacaagacc acgcctcccg tgctggactc cgacggctcc ttcttcctct atagcaagct	2820
caccgtggac aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg tgatgcata	2880
ggctctgcac aaccactaca cgcagaagag cctctccctg tctccggta aatgagaatt	2940
cctcgagtct agagggcccg tttaaaccccg ctgatcagcc tcgactgtgc cttctagttg	3000
ccagccatct gttgtttgcc cctccccgt gccttccttg accctggaaag gtgccactcc	3060
cactgtccctt tcctaataaa atgagggaaat tgcacgtcat tgtctgagta ggtgtcattc	3120
tattctgggg ggtgggggtgg ggcaggacag caagggggag gattggaaag acaatagcag	3180
gcatgctggg gatgcgggtgg gctctatggc ttctgaggcg gaaagaacca gctggggctc	3240
taggggtat ccccacgcgc cctgtagcgg cgcattaagc gcggcgggtg tggtggttac	3300
gcgcagcgtg accgctacac ttgccagcgc cctagcgcccc gtcctttcg ctttcttccc	3360
ttcctttctc gcaacgttcg ccggcttcc cctgtcaagct cttaatccgg gcacccctt	3420

agggttccga ttttagtgctt tacggcacct cgacccaaa aaacttgatt agggtgatgg	3480
ttcacgtagt gggccatcg cctgatagac ggaaaaatcg cctttgacgt tggagtccac	3540
gttcttaat agtggactct ttttccaaac tggaaacaaca ctcaacccta tctcggtcta	3600
ttctttgtat ttataaggga ttttgggat ttcggcctat tggtaaaaaa atgagctgat	3660
ttaacaaaaa ttaacgcga attaattctg tggaaatgtgt gtcagttagg gtgtggaaag	3720
tccccaggct ccccaggcag gcagaagtat gcaaagcatg catctcaatt agtcagcaac	3780
cagggtgtga aagtccccag gtcggcggc aggcagaagt atgcaaagca tgcatactaa	3840
ttagtcagca accatagtcc cgccccaaac tccgccccatc ccggccctaa ctccggccag	3900
ttccggccat tctccggccc atggctgact aattttttt atttatgcag aggccgaggc	3960
cgcctctgcc tctgagctat tccagaagta gtgaggaggc tttttggag gcctaggctt	4020
ttgcaaaaag ctccccggag cttgtatatac cattttcgga tctgatcagc acgtgatgaa	4080
aaagcctgaa ctcaccgcga cgtctgtcga gaagtttctg atcgaaaagt tcgacagcgt	4140
ctccgacctg atgcagctct cggaggcga agaatctcgt gctttcagct tcgatgtagg	4200
agggcgtgga tatgtcctgc gggtaaatag ctgcggcgat ggtttctaca aagatcgta	4260
tgtttatcgg cactttgcat cggccgcgt cccgattccg gaagtgcctt acattgggga	4320
attcagcgag agcctgaccc attgcatactc ccgcgtgca cagggtgtca cggtgcaaga	4380
cctgcctgaa accgaactgc ccgctgttct gcagccggc gggaggcca tggatgcgtat	4440
cgctgcggcc gatcttagcc agacgagcgg gttcggccca ttccggaccgc aaggaatcgg	4500
tcaatacact acatggcgtg atttcataatc cgccattgtct gatccccatg tttatcactg	4560
gcaaaactgtg atggacgaca ccgtcagtgc gtccgtcg caggctctcg atgagctgat	4620
gttttgggcc gaggactgcc ccgaagtcgg gcacccgtg caccggatt tcggctccaa	4680
caatgtcctg acggacaatg gcccataac agcggtcatt gactggagcg aggcgtatgtt	4740
cggggattcc caatacgggg tcgccaacat cttttctgg aggccgtgg tggcttgtat	4800
ggagcagcag acgcgtact tcgagcggag gcatccggag cttgcaggat cgccggcgt	4860
ccggggcgtat atgctccgca ttggcttgc ccaactctat cagagcttgg ttgacggcaa	4920
tttcgatgtat gcagcttggg cgcagggtcg atgcgcacgc atcgatccgtat ccggagccgg	4980
gactgtcggg cgtacacaaa tcgcccccag aagcgccggc gtctggaccg atggctgtgt	5040
agaagtactc gccgatagtg gaaaccgacg ccccgacact cgtccgaggg caaaggaata	5100
gcacgtgcta cgagatttcg attccacccgc cgccttctat gaaaggtgg gtttcggaaat	5160
cgttttccgg gacgcccggct ggatgtatcc ccagcgggg gatctcatgc tggagtttt	5220
cgccccacccc aacttggta ttgcagctta taatggttac aaataaaagca atagcatcac	5280

aaatttcaca aataaaagcat tttttcact gcattctagt tgtggttgt ccaaactcat 5340
caatgtatct tatcatgtct gtataccgtc gacctctagc tagagcttgg cgtaatcatg 5400
gtcatacgctg tttcctgtgt gaaattgtta tccgctcaca attccacaca acatacgagc 5460
cggaagcata aagtgtaaag cctgggggtgc ctaatgagtg agctaactca cattaattgc 5520
gttgcgctca ctgccccgtt tccagtcggg aaacctgtcg tgccagctgc attaatgaat 5580
cgcccaacgc gcggggagag gcgggttgcg tattgggcgc tcttccgctt cctcgctcac 5640
tgactcgctg cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt 5700
aatacggtta tccacagaat cagggataa cgcaaggaaag aacatgtgag caaaaggcca 5760
gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc 5820
ccctgacgag catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact 5880
ataaaagatac caggcgtttc cccctggaag ctccctcggt cgctctcctg ttccgaccct 5940
gccgcttacc ggataacctgt ccgcctttct cccttcggga agcgtggcgc tttctcaatg 6000
ctcacgctgt aggtatctca gttcggtgta ggtcggtcgc tccaaagctgg gctgtgtgca 6060
cgaacccccc gttcagcccg accgctgcgc cttatccggta aactatcgctc ttgagtccaa 6120
cccgtaaga cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc 6180
gaggtatgta ggcggtgcta cagagttctt gaagtggtgg ccttaactacg gctacactag 6240
aaggacagta tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg 6300
tagctcttga tccggcaaac aaaccaccgc tggtagcggt ggtttttttgg tttgcaagca 6360
gcagattacg cgcaaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc 6420
tgacgctcag tggAACgaaa actcacgtt aaggattttg gtcatgagat tatcaaaaag 6480
gatcttcacc tagatcctt taaattaaaa atgaagtttt aaatcaatct aaagtatata 6540
tgagtaaact tggctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgt 6600
ctgtctattt cgttcatcca tagttgcctg actcccccgtc gtgttagataa ctacgatacg 6660
ggagggctta ccatctggcc ccagtgcgtc aatgataccg cgagaccac gcteaccggc 6720
tccagattta tcagcaataa accagccagc cggaaggggcc gagcgcagaa gtggctctgc 6780
aactttatcc gcctccatcc agtctattaa ttgttgccgg gaagctagag taagtagttc 6840
gccagttaat agttgcgca acgttgcgtc cattgcgtaca ggcacatcggtt gtcacgctc 6900
gtcggttgggt atggcttcat tcagctccgg ttcccaacgta tcaaggcgag ttacatgatc 6960
ccccatgttg tgcaaaaaaag cggttagctc ctgcggcctt ccgcgttgc tcagaagtaa 7020
gttggccgca gtgttatcac tcattgttat ggcagcactg cataattctc ttactgtcat 7080
gccatccgta agatgctttt ctgtgactgg tgagttactca accaagtctat tctgagaata 7140

gtgtatgcgg cgaccgagtt gctctgccc ggcgtcaata cgggataata ccgcgcacaca	7200
tagcagaact ttaaaaagtgc tcatacattgg aaaacgttct tcggggcgaa aactctcaag	7260
gatcttaccc ctgtttagat ccagttcgat gtaaccact cgtgcaccca actgatcttc	7320
agcatctttt actttcacca gcgtttctgg gtgagcaaaa acaggaaggc aaaaatgccgc	7380
aaaaaaaggga ataagggcga cacggaaatg ttgaatactc atactcttcc tttttcaata	7440
ttattgaagc atttatcagg gttattgtct catgagcgga tacatatttgc aatgtatttta	7500
aaaaaaataaa caaatagggg ttccgcac atttccccga aaagtgccac ctgacgtc	7558

<210> 6

<211> 7576

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 6	
gacggatcg ggatctccc gatcccstat ggtcgactct cagtacaatc tgctctgatg	60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggagggtcgct gagtagtgcg	120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc	180
ttagggtagt gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cggtgacatt	240
gattatttgc tagttattaa tagtaatcaa ttacgggttc attagttcat agccatata	300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaaacgacc	360
cccgccccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc	420
attgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt	480
atcatatgcc aagtacgccc cctatttgcg tcaatgacgg taaatggccc gcctggcatt	540
atgcccagta catgaccta tggactttc ctacttggca gtacatctac gtattagtca	600
tcgcttattac catggtgatg cggtttggc agtacatcaa tggcgtgga tagcggtttg	660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tggagtttg ttttggcacc	720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatggcg	780
gtaggcgtgt acgggtggag gtctatataa gcagagctct ctggctaact agagaaccca	840
ctgcttactg gcttacccaa attaatacga ctcactatag ggagacccaa gctggctaga	900
ggtaccaagc ttggatctca ccatggagtt tggctgtgc tggatttcc tcgttgcct	960
tttaagaggt gtccagtgtc aggtgcagct ggtggagtct gggggaggcg tggccagcc	1020

tgggaggtcc	ctgagactct	cctgtgcagc	ctctggattc	accttcattt	gctatggcat	1080
gcactgggtc	cggcaggctc	caggcaaggg	gctggagtgg	gtggcagttt	tatcatatga	1140
tggaagtaat	aaatactatg	cagactccgt	gaagggccga	ttcaccatct	ccagagacaa	1200
ttccaagaac	acgctgtatc	tgcaaatgaa	cagcctgaga	gctgaggaca	cggctgtgt	1260
ttactgtgcg	agagtattag	tgggagcttt	atattattat	aactactacg	ggatggacgt	1320
ctggggccaa	gggaccacgg	tcaccgtctc	ctcagcctcc	accaaggggcc	catcggtctt	1380
ccccctggca	ccctctagca	agagcacctc	tgggggcaca	gcggccctgg	gctgcctgg	1440
caaggactac	ttccccgaac	cggtgacggt	gtcgtggAAC	tcaggcgccc	tgaccagcgg	1500
cgtgcacacc	ttcccccgtg	tcctacagtc	ctcaggactc	tactccctca	gcagcgtgg	1560
gaccgtgccc	tccagcagct	tgggcaccca	gacctacatc	tgcaacgtga	atcacaagcc	1620
cagcaacacc	aaggtggaca	agagagttgg	tgagaggcca	gcacagggag	ggagggtgtc	1680
tgctggaagc	caggctcagc	gtccctgcct	ggacgcattcc	cggctatgca	gtccctagtcc	1740
agggcagcaa	ggcaggcccc	gtctgcctct	tcacccggag	gcctctgccc	gcccccactca	1800
tgctcaggga	gagggtcttc	tggcttttc	cccaggctct	ggcaggcac	aggctaggtg	1860
ccccctaacc	aggccctgca	cacaaagggg	caggtgctgg	gctcagaccc	gccaagagcc	1920
atatccggga	ggaccctgcc	cctgacctaa	gcccacccca	aaggccaaac	tctccactcc	1980
ctcagctcgg	acacttctc	tcctccaga	ttccagtaac	tcccaatctt	ctctctgcag	2040
agcccaaatac	ttgtgacaaa	actcacacat	gcccaccgtg	cccaggttaag	ccagcccccagg	2100
cctcgcctc	cagctcaagg	cgggacaggt	gccttagagt	agcctgcattc	cagggacagg	2160
ccccagccgg	gtgctgacac	gtccacctcc	atctttctt	cagcacctga	actcctgggg	2220
ggaccgtcag	tcttcctctt	ccccccaaaa	cccaaggaca	ccctcatgat	ctcccgacc	2280
cctgaggtca	catgcgtgg	ggtggacgtg	agccacgaag	accctgaggt	caagttcaac	2340
tgg tacgtgg	acggcgtgg	ggtgcataat	gccaagacaa	agccgcggga	ggagcagtac	2400
aacagcacgt	accgtgtgg	cagcgtctc	accgtctgc	accaggactg	gctgaatggc	2460
aaggagtaca	agtgcacagg	ctccaaacaaa	gcctccctt	ccccatcga	gaaaaccatc	2520
tccaaagcca	aaggtggac	ccgtgggggt	cgagggccac	atggacagag	gccggctcg	2580
cccaccctct	gccctgagag	tgaccgctgt	accaacctct	gtccctacag	ggcagccccc	2640
agaaccacag	gtgtacaccc	tgccccatc	ccgggaggag	atgaccaaga	accaggtcag	2700
cctgacctgc	ctggtaaaag	gtttctatcc	cagcgcacatc	gccgtggagt	gggagagcaa	2760
tgggcagccg	gagaacaact	acaagaccac	gcctccctgt	ctggactccg	acggctccct	2820
tttcctctat	agcaagctca	ccgtggacaa	gagcagggtgg	cagcaggggaa	acgtcttctc	2880

atgctccgtg atgcatgagg ctctgcacaa ccactacacg cagaagagcc tctccctgtc	2940
tccgggtaaa tgagaattcc tcgagtc tag agggcccggtt taaaccgct gatcagcctc	3000
gactgtgcct tctagttgcc agccatctgt tggttgcccc tccccgtgc cttcccttgac	3060
cctggaaaggt gccactccca ctgtcccttc ctaataaaaat gaggaaattg catcgattg	3120
tctgagtagg tgcattcta ttctgggggg tgggtgggg caggacagca agggggagga	3180
ttggaaagac aatagcaggc atgctgggg tgcgggtggc tctatggctt ctgaggcgg	3240
aagaaccagc tggggctcta ggggtatcc ccacgcgccc ttagcgccg cattaagcgc	3300
ggcgggtgtg gtggttacgc gcagcgtgac cgctacactt gccagcgc tagcgccgc	3360
tccttcgct ttctccctt ccttcgcg cacttcgccc ggctttcccc gtcaagctct	3420
aaatcggggc atcccttag ggttccgatt tagtgctta cggcacctcg accccaaaaa	3480
acttgattag ggtgatggtt cacgtagtgg gcatcgccc tgatagacgg ttttcgccc	3540
tttgacgttg gagtccacgt tcttaatag tggactcttgc ttccaaactg gaacaacact	3600
caaccctatc tcggcttatt ctttgattt ataaggatt ttggggattt cggcctattg	3660
gttaaaaaat gagctgattt aacaaaaatt taacgcgaat taattctgtg gaatgtgtgt	3720
cagttagggt gtggaaagtc cccaggctcc ccaggcaggc agaagtatgc aaagcatgca	3780
tctcaattag tcagcaacca ggtgtggaaa gtcggcaggc tccccagcag gcagaagtat	3840
gcaaaggcatg catctcaatt agtcagcaac catagtcggc cccctaactc cgcccatccc	3900
gcccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa tttttttat	3960
ttatgcagag gccgaggccg cctctgcctc tgagctattc cagaagttagt gaggaggctt	4020
ttttggaggc ctaggctttt gcaaaaagct cccggagct tggatatcca ttttcggatc	4080
tgatcagcac gtgatgaaaa agcctgaact caccgcgacg tctgtcgaga agtttctgat	4140
cggaaagtgc gacagcgtct ccgacctgat gcagctctcg gagggcgaag aatctcgat	4200
tttcagcttc gatgttaggag ggctgtgata tgcctgcgg gtaaaatagct gcccgtatgg	4260
tttctacaaa gategttatg tttatcgca cttgcattcg gccgcgtcc cgattccgga	4320
agtgcgtac attggggat tcaagcgagag cctgacctat tgcattctcc gcccgtgcaca	4380
gggtgtcagc ttgcaagacc tgcctgaaac cgaactgccc gctgttctgc agccggcgc	4440
ggaggccatg gatgcgtatcg ctgcggccga tcttagccag acgagcggt tcggccatt	4500
cggaccgcaa ggaatcggtc aatacactac atggcgtat ttcattatgcg cgattcgat	4560
tccccatgtg tatactggc aaactgtatgc ggacgacacc gtcagtgcgt cggtcgca	4620
ggctctcgat gagctgatgc tttggccga ggactgcccc gaagtccggc acctcgatgc	4680
cgcggatttc ggctccaaca atgtcctgac ggacaatggc cgatcataacag cggtcattga	4740

ctggagcgag	gcatgttcg	gggattccca	atacgaggtc	gccaacatct	tcttctggag	4800
gccgtggttg	gcttgtatgg	agcagcagac	gcgctacttc	gagcggaggc	atccggagct	4860
tgcaggatcg	ccgcggctcc	gggcgtatata	gctccgcatt	ggtcttgcacc	aactctatca	4920
gagcttggtt	gacggcaatt	tcgatgtatgc	agcttggcg	cagggtcgat	gcgacgcaat	4980
cgtcgcgcgc	ggagccggga	ctgtcggcg	tacacaaatc	gcccgcagaa	gcgcggccgt	5040
ctggaccgat	ggctgtgttag	aagtactcgc	cgatagtgga	aaccgacgcc	ccagcactcg	5100
tccgagggca	aaggaatagc	acgtgctacg	agatttcgat	tccaccgcgc	ccttctatga	5160
aaggttgggc	ttcggaatcg	ttttccggga	cgccggctgg	atgatccctcc	agcgcggggga	5220
tctcatgctg	gagttcttcg	cccacccaa	cttgcatttatt	gcagctata	atggttacaa	5280
ataaagcaat	agcatcacaa	atttcacaaa	taaagcattt	ttttcactgc	attctagttg	5340
tggtttgc	aaactcatca	atgtatctta	tcatgtctgt	ataccgtcga	cctctagcta	5400
gagcttggcg	taatcatggt	catagctgtt	tcctgtgtga	aattgttatac	cgctcacaat	5460
tccacacaaac	atacgagccg	gaagcataaa	gtgtaaagcc	tgggggtgcct	aatgagttag	5520
ctaaactcaca	ttaattgcgt	tgcgctact	gcccgccttc	cagtcgggaa	acctgtcgtg	5580
ccagctgcat	taatgaatcg	gccaacgcgc	ggggagaggc	ggtttgcgta	ttggggcgtc	5640
ttccgcctcc	tcgctcactg	actcgctgcg	ctcggtcggt	cggctgcggc	gagcggtatac	5700
agctcaactca	aaggcggtaa	tacggttatc	cacagaatca	ggggataacg	caggaaagaa	5760
catgtgagca	aaaggccagc	aaaaggccag	gaaccgtaaa	aaggccgcgt	tgctggcggtt	5820
tttccatagg	ctccgcctcc	ctgacgagca	tcacaaaaat	cgacgctcaa	gtcagaggtg	5880
gcgaaacccg	acaggactat	aaagatacca	ggcggttccc	cctggaagct	ccctcggtcg	5940
ctctccgtt	ccgaccctgc	cgcttaccgg	atacctgtcc	gcctttctcc	cttcgggaag	6000
cgtggcgctt	tctcaatgct	cacgctgttag	gtatctcagt	tcgggttagg	tcgttcgcctc	6060
caagctggc	tgtgtgcacg	aaccccccgt	tcaagccgac	cgctgcgcct	tatccggtaa	6120
ctatcgctt	gagtccaacc	cggtaagaca	cgacttatcg	ccactggcag	cagccactgg	6180
taacaggatt	agcagagcga	ggtatgttagg	cggtgctaca	gagttcttga	agtgggtggcc	6240
taactacggc	tacactagaa	ggacagtatt	ttgttatctgc	gctctgctga	agccagttac	6300
cttcggaaaa	agagttggta	gtcttgatc	cgccaaacaa	accaccgctg	gtagcgggtgg	6360
ttttttgtt	tgcaaggcgc	agattacgcg	cagaaaaaaaa	ggatctcaag	aagatccctt	6420
gatctttct	acggggctcg	acgctcagt	gaacgaaaac	tcacgttaag	ggattttggt	6480
catgagatta	tcaaaaagga	tcttcaccta	gatcctttta	aattaaaaat	gaagttttaa	6540
atcaatctaa	agtatatatg	agtaaacttg	gtctgacagt	taccaatgt	taatcgtga	6600

ggcacctatc tcagcgatct	gtctatttcg	ttcatccata	gttgcctgac	tcccccgtcgt	6660
gtagataact acgatacggg	agggcttacc	atctggccccc	agtgctgcaa	tgataccgcg	6720
agaccacgc tcacccggctc	cagatttatac	agaataaaac	cagccagccg	gaagggccga	6780
gcgcagaagt ggtcctgcaa	ctttatccgc	ctccatccag	tctattaatt	gttgcgggaa	6840
agcttagagta agtagttcgc	cagttaatag	tttgcgcaac	gttgttgc	ttgtacagg	6900
catcggtgt tcacgctcgt	cgtttggtat	ggcttcattc	agctccggtt	cccaacgatc	6960
aaggcgagtt acatgatccc	ccatgttgtg	caaaaaagcg	gttagctcct	tcggtcctcc	7020
gatcggtgtc agaagtaagt	tggccgcagt	gttatcactc	atggttatgg	cagcaactgca	7080
taatttctt actgtcatgc	catccgtaa	atgctttct	gtgactggtg	agtactcaac	7140
caagtcattc tgagaatagt	gtatgcggcg	accgagttgc	tcttgcccg	cgtcaatacg	7200
ggataatacc gcgccacata	gcagaacttt	aaaagtgtc	atcattggaa	aacgttcttc	7260
ggggcgaaaa ctctcaagga	tcttaccgct	gtttagatcc	agttcgatgt	aacccactcg	7320
tgcacccaac tgatcttcag	catctttac	tttccaccagc	gtttctgggt	gagaaaaaac	7380
aggaaggcaa aatgccgcaa	aaaaggaaat	aagggcgaca	cggaaatgtt	gaatactcat	7440
actcttcctt ttcaatatt	attgaagcat	ttateagggt	tattgtctca	tgagcggata	7500
catatttcaa tgtatattaga	aaaataaaca	aataggggtt	ccgcgcacat	ttccccgaaa	7560
agtgcaccc	gacgtc				7576

<210> 7

<211> 7561

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 7

gacggatcgg gagatctccc	gatcccctat	ggtcgactct	cagtacaatc	tgctctgatg	60	
ccgcatagtt aagccagtat	ctgctccctg	cttgcgtgtt	ggaggtcgct	gagtagtgcg	120	
cggcaaaat ttaagctaca	acaaggcaag	gcttgaccga	caattgcatg	aagaatctgc	180	
ttagggtag	gcgtttgcg	ctgcttcgcg	atgtacgggc	cagatatacg	240	
gattattgac	tagttattaa	tagtaatcaa	ttacggggtc	attagttcat	agcccatata	300
tggagttccg	cgttacataa	cttacggtaa	atggcccgcc	tggctgaccg	cccaacgacc	360
cccgccccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420

attgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt	480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt	540
atgccagta catgaccta tgggacttc ctacttggca gtacatctac gtattagtca	600
tgcctattac catggtgatg cggtttggc agtacatcaa tgggcgtgga tagcggtttg	660
actcacgggg atttccaagt ctccaccca ttgacgtcaa tgggagtttgc ttttggcacc	720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatggcg	780
gtaggcgtgt acgggtggag gtctatataa gcagagctct ctggctaact agagaaccca	840
ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga	900
ggtaccggat ctcaccatgg agttgggct gagctgggtt ttcctcggtt ctcttttaag	960
aggtgtccag tgtcaggagc agctggtgga gtctggggga ggcgtggtcc agcctggag	1020
gtccctgaga ctctcctgtg cagcgtctgg attcaccttc agtacctatg gcatgcactg	1080
ggtccgcag gctccaggca aggggctgga gtgggtggca gttacatggc atgatggaa	1140
taataaatac tatgcagact ccgtgaaggg ccgattcacc atctccagag acaactccaa	1200
gaacacgctg tatctgcaaa tgaacagcct gagagccgag gacacggctg tgtattactg	1260
tgcgagagga ggagtggag caacttacta ctactactac ggtatggacg tctggggcca	1320
agggaccacg gtcaccgtct cctcagcctc caccaagggc ccatcggctt tccccctggc	1380
accctctagc aagagcacct ctggggcac agcggccctg ggctgcctgg tcaaggacta	1440
cttccccgaa ccggtgacgg tgcgtggaa ctcaggcgcc ctgaccagcg gcgtgcacac	1500
cttccccggct gtcctacagt cctcaggact ctactccctc agcagcgtgg tgaccgtgcc	1560
ctccagcagc ttgggcaccc agacctacat ctgcaacgtg aatcacaagc ccagcaacac	1620
caaggtggac aagagagttg gtgagaggcc agcacaggga gggagggtgt ctgctggaa	1680
ccaggctcag cgctcctgcc tggacgcattc ccggctatgc agtcccagtc cagggcagca	1740
aggcaggccc cgtctgcctc ttcacccgga ggctctgcc cgccccactc atgctcagg	1800
agagggtctt ctggctttt ccccaggctc tggcaggca caggctaggt gcccctaacc	1860
caggccctgc acacaaaggg gcaggtgctg ggctcagacc tgccaagagc catatccggg	1920
aggaccctgc ccctgaccta agcccacccc aaaggccaaa ctctccactc cctcagctcg	1980
gacaccttct ctctccctcag attccagtaa ctcccaatct tctctctgca gagccaaat	2040
cttgtgacaa aactcacaca tgcccaccgt gcccaggtaa gccagccag gcctgcctt	2100
ccagctcaag gcgggacagg tgccctagag tagcctgcatt ccagggacag gccccagccg	2160
ggtgctgaca cgtccacctc catctcttcc tcagcacctg aactcctggg gggaccgtca	2220
gtcttcctct tccccccaaa acccaaggac accctcatga tctccggac ccctgaggtc	2280

acatgcgtgg tggtgtggacgt gagccacgaa gaccctgagg tcaagttcaa ctggtaacgtg 2340
 gacggcgtgg aggtgcataa tgccaagaca aagccgcggg aggagcagta caacagcacg 2400
 taccgtgtgg tcagcgtcct caccgtcctg caccaggact ggctgaatgg caaggagtagc 2460
 aagtgcagg tctccaacaa agccctccca gccccatcg agaaaaccat ctccaaagcc 2520
 aaagggtggga cccgtggggt gcgaggggcca catggacaga ggccggctcg gcccaccctc 2580
 tgccctgaga gtgaccgctg taccaacctc tgtccctaca gggcagcccc gagaaccaca 2640
 ggtgtacacc ctgccccat cccgggagga gatgaccaag aaccaggtca gcctgacctg 2700
 cctggtcaaa ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc 2760
 ggagaacaac tacaagacca cgcctccctg gctggactcc gacggctct tcttcctcta 2820
 tagcaagctc accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt 2880
 gatgcacatgag gctctgcaca accactacac gcagaagagc ctctccctgt ctccggtaa 2940
 atgactcgag tctagagggc ccgtttaaac ccgctgatca gcctcgactg tgccttctag 3000
 ttgccagcca tctgttgttt gcccctcccc cgtgccttcc ttgaccctgg aaggtgccac 3060
 tcccactgtc ctttcctaataat aaaaatgagga aattgcacatcg cattgtctga gttaggtgtca 3120
 ttctattctg ggggtgggg tggggcagga cagcaagggg gaggattggg aagacaatag 3180
 cagggcatgct ggggatgcgg tgggctctat ggcttctgag gcggaaagaa ccagctgggg 3240
 ctctaggggg tatccccacg cgccctgttag cgccgcattta agcgcggcgg gtgtgggtgt 3300
 tacgcgcagc gtgaccgctt cacttgcctag cgccttagcg cccgctcctt tcgctttctt 3360
 cccttccttt ctgcgccacgt tcgcccgtt tccccgtcaa gctctaaatc gggcatccc 3420
 ttttagggttc cgattttagtg cttaacggca cctcgacccc aaaaaacttg attagggtga 3480
 tggttcacgt agtgggcccatt cgcctgtata gacggttttt cgcctttga cgttggagtc 3540
 cacgttcttt aatagtggac tcttgttcca aactggaaaca acactcaacc ctatctcggt 3600
 ctattctttt gatttataag ggattttggg gatttcggcc tattggtaa aaaaatgagct 3660
 gatttaacaa aaatttaacg cgaattaatt ctgtggaaatg tgtgtcagtt agggtgtgga 3720
 aagtccccag gctccccagg caggcagaag tatgcaaagc atgcacatctca attagtcagc 3780
 aaccaggtgt ggaaagtccc caggctcccc agcaggcaga agtatgcaaa gcatgcacatct 3840
 caattagtca gcaaccatag tccccccctt aactccggcc atcccgcccc taactccgccc 3900
 cagttccgccc cattctccgc cccatggctg actaattttt ttatattatg cagaggccga 3960
 ggccgcctct gcctctgagc tattccagaa gtgtgagga ggctttttt gaggcctagg 4020
 cttttgcacaa aagctccccgg gagcttgcata atccattttc ggatctgatc agcacgtgat 4080
 gaaaaagcctt gaaactcaccg cgacgtctgt cgagaagttt ctgatcgaaa agttcgacag 4140

cgtctccgac ctgatgcaga tctcgaggc cgaagaatct cgtgcttca gcttcgatgt	4200
aggagggcgt ggatatgtcc tgcggtaaa tagctgcgcc gatggttct acaaagatcg	4260
ttatgtttat cggcactttg catcgccgc gctcccattt ccggaagtgc ttgacattgg	4320
ggaattcagc gagagcctga cctattgcat ctcccgcgt gcacagggtg tcacgttgca	4380
agacctgcct gaaaccgaac tgcccgtgt tctgcagccg gtcgcggagg ccatggatgc	4440
gatcgctgcg gccgatctta gccagacgag cgggttcggc ccattcgac cgcaaggaat	4500
cggtaatac actacatggc gtgatttcat atgcgcgatt gctgatcccc atgtgtatca	4560
ctggcaaact gtgatggacg acaccgtcag tgcgtccgtc ggcgcaggctc tcgatgagct	4620
gatgctttgg gccgaggact gccccgaagt ccggcacctc gtgcacgcgg atttcggctc	4680
caacaatgtc ctgacggaca atggccgcat aacagcggtc attgactgga gcgaggcgat	4740
gttcggggat tcccaatacg aggtcgccaa catcttcttc tggaggccgt ggttggcttg	4800
tatggagcag cagacgcgc acttcgagcg gaggcatccg gagcttgcag gatcgccgcg	4860
gctccggcg tatatgctcc gcattggctc tgaccaactc tatcagagct tggttgacgg	4920
caatttcgat gatgcagctt gggcgcaggg tcgatgcac gcaatcgccat gatccggagc	4980
cgggactgtc gggcgtaacaa aatcgcccg cagaagcgcg gccgtctggc ccgatggctg	5040
tgtagaagtta ctcgcccata gttggaaaccg acgccccagc actcgccga gggcaaagga	5100
atagcacgtc ctacgagatt tcgattccac cggccgccttc tatgaaaggt tggcttgg	5160
aatcggtttc cgggacgccc gctggatgat cctccagcgc gggatctca tgctggagtt	5220
cttcgcccac cccaacttgc ttattgcagc ttataatggt tacaataaaa gcaatagcat	5280
cacaaatttc acaaataaaag cattttttc actgcattct agttgtggtt tgtccaaact	5340
catcaatgtc tcttatcatg tctgtatacc gtgcacctct agctagagct tggcgtaatc	5400
atggtcatac ctgtttcctg tgtgaaattt ttatccgcac acaattccac acaacatacg	5460
agccggaaagc ataaagtgtc aagcctgggg tgccataatgc gtgagctaacc tcacattaat	5520
tgcgttgcgc tcactgccc gttccagtc gggaaacctg tcgtgccagc tgcattatgc	5580
aatcggccaa cgcgcggggg gaggcggtt gcttattggg cgctttccg cttccctcgct	5640
cactgactcg ctgcgcgtcg tcgttccggc gcccgcgcgt gtatcagctc actcaaaggc	5700
ggtaataacgg ttatccacag aatcaggggta aacgcgagga aagaacatgt gagcaaaagg	5760
ccagcaaaag gccaggaacc gtaaaaaggc cgcttgctg gcgttttcc ataggctccg	5820
ccccccctgac gagcatcaca aaaatcgacg ctcaagtcag aggtggcgaa acccgacagg	5880
actataaaaga taccaggcgt ttccccctgg aagctccctc gtgcgtctc ctgttccgac	5940
cctgcccgtt accggatacc tgcgtccgtt tctcccttcg ggaagcgtgg cgctttctca	6000

atgctcacgc tggtaggtatc tcagttcggt gtaggtcggt cgctccaagc tgggctgtgt 6060
gcacgaaccc cccgttcagc ccgaccgctg cgcccttatcc ggttaactatc gtcttgagtc 6120
caaccggta agacacgact tatcgccact ggcagcagcc actggtaaca ggatttagcag 6180
agcgaggtat gtaggcggtg ctacagagtt ctgtaaagtgg tggcctaact acggctacac 6240
tagaaggaca gtatggta tctgcgtct gctgaagcca gttacctcg gaaaaagagt 6300
tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggtttt ttgtttgcaa 6360
gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat ctttgatct tttctacggg 6420
gtctgacgct cagtggAACG aaaaactcacg ttaaggatt ttggcatga gattatcaaa 6480
aaggatctc acctagatcc tttaaatta aaaaatgaagt tttaaatcaa tctaaagtat 6540
atatgagtaa acttggtctg acagttacca atgcttaatc agtgaggcac ctatctcagc 6600
gatctgtcta tttcggtcat ccatagttgc ctgactcccc gtcgtgtaga taactacgat 6660
acgggagggc ttaccatctg gccccagtgc tgcaatgata ccgcgagacc cacgctcacc 6720
ggctccagat ttatcagcaa taaaccagcc agccggaagg gccgagcgcga gaagtggtcc 6780
tgcaacttta tccgcctcca tccagtttat taattgttgc cgggaagcta gagtaagttag 6840
ttcgcagtt aatagtttgc gcaacgttgc tgccattgtc acaggcatcg tgggtcacg 6900
ctcgtcggtt ggtatggctt cattcagctc cgggtccaa cgtcaaggc gagttacatg 6960
atccccatg ttgtcaaaaa aagcggtagt ctccttcggc cctccgatcg ttgtcagaag 7020
taagttggcc gcagtgttat cactcatggt tatggcagca ctgcataatt ctcttactgt 7080
catgccatcc gtaagatgct tttctgtgac tggtagtac tcaaccaagt cattctgaga 7140
atagtgtatg cggcgaccga gttgctttc cccggcgtca atacggata ataccgcgc 7200
acatagcaga actttaaaag tgctcatcat tggaaaacgt tcttcggggc gaaaactctc 7260
aaggatctt ccgctgttga gatccagttc gatgtaaacc actcgtgcac ccaactgatc 7320
ttcagcatct ttactttca ccagcggttc tgggtgagca aaaacaggaa ggcaaaatgc 7380
cgcaaaaaag ggaataaggg cgacacggaa atgttgaata ctcatactct tccttttca 7440
atattattga agcatttatac agggttatttgc tctcatgagc ggatacatat ttgaatgtat 7500
tttagaaaaat aaacaaatag gggcccgac cacatttccc cgaaaagtgc cacctgacgt 7560
c 7561

<210> 8

<211> 6082

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 8

gacggatcg gagatctccc gatccccat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagtt ctgtccctg ctttgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc 180
ttagggttag gcgttttgcg ctgttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacgggtc attagttcat agcccatata 300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaaacgacc 360
cccgccccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaaatggccc gcctggcatt 540
atgcccagta catgaccta tgggactttc ctacttggca gtacatctac gtattagtca 600
tcgctattac catggtgatg cggttttggc agtacatcaa tggcgtgga tagcggtttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tggagtttgc ttttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatggcgc 780
gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca 840
ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga 900
aagcttggat ctcaccatga gggccctgc tcagctcctg ggactcctgc tgctctggct 960
cccaagataacc agatgtgaca tccagatgac ccagtctcca tcctccctgt ctgcacatgt 1020
aggagacaga gtcaccatca cttgcccggc gagtcaggc attagcaatt atttagcctg 1080
gtatcagcag aaaacaggga aagttcctaa gttccgtatc tatgaagcat ccactttgca 1140
atcaggggtc ccacatcggt tcagtggcgg tggatctggg acagatttca ctctcaccat 1200
cagcagcctg cagcctgaag atgttgcac ttattactgt caaaattata acagtgcggc 1260
attcactttc ggcctggga ccaaagtggta tatcaaacga actgtggctg caccctctgt 1320
cttcatcttc cgcgcacatcg atgagcaggta gaaatctggta actgtctggctg ttgtgtgcct 1380
gctgaataac ttctatccca gagaggccaa agtacagtgg aagggtggata acgcctccca 1440
atcgggttaac tcccaggaga gtgtcacaga gcaggacagc aaggacagca cctacagcct 1500
cagcagcacc ctgacgctga gcaaagcaga ctacgagaaa cacaaggatct acgcctgcga 1560
agtacccat cagggcctga gtcggccgt cacaaagagc ttcaacaggg gagagtgtta 1620
ggaattcgcg gccgcgtcgag tctagaggc cctgtttaaac cgcgtatca gcctcgactg 1680

tgccctctag ttgccagcca tctgtgttt gcccccccc cgtgccttcc ttgaccctgg	1740
aagggtccac tcccactgtc ctttcctaataaaatgagga aattgcatacg cattgtctga	1800
gtagggtgtca ttcttattctg ggggggtgggg tggggcagga cagcaagggg gaggattggg	1860
aagacaatacg caggcatgtctggatgcgg tgggtcttatggctctgag gcgaaagaa	1920
ccagctgggg ctctaggggg tatccccacg cggccctgttag cggcgcatta agcgcggcgg	1980
gtgtgggtgt tacgcgcagc gtgaccgcta cacttgccag cggccctagcg cccgcctt	2040
tcgtttctt cccttcctt ctgcacgt tcgcggctt tccccgtcaa gctctaaatc	2100
ggggcatccc tttagggttc cgatttagtg ctttacggca cctcgacccc aaaaaacttg	2160
attagggtga tggttcacgt agtggccat cggccctgata gacggttttt cggcccttga	2220
cgttggagtc cacgttctt aatagtggac tcttgcgttca aactggaaaca acactcaacc	2280
ctatctcggt ctattcttt gatttataag ggattttggg gatttggcc tattggtaa	2340
aaaatgagct gatttaacaa aaatttaacg cgaattaatt ctgtgaaatg tgtgtcagtt	2400
agggtgtgga aagtccccag gctccccagg caggcagaag tatgcaaagc atgcatactca	2460
attagtcagc aaccagggtgt ggaaagtccc caggctcccc agcaggcaga agtatgcaaa	2520
gcatgcatct caattagtca gcaaccatag tccccccccct aactccgccc atcccgcccc	2580
taactccgccc cagttccgccc cattctccgc cccatggctg actaattttt tttatttatg	2640
cagaggccga ggcgcctct gcctctgagc tattccagaa gtagtgagga ggcttttttg	2700
gaggcctagg ctttgcaaa aagctcccgagcatttttgcgtat atccattttc ggatctgatc	2760
aagagacagg atgaggatcg tttcgcatga ttgaacaaga tggattgcac gcaggttctc	2820
cggccgcttg ggtggagagg ctattccggctatgcactggcacaacagaca atcggctgct	2880
ctgatccgc cgtgttccgg ctgtcagcgc agggcgccc ggttttttt gtcaagaccg	2940
acctgtccgg tggccctgaat gaactgcagg acgaggcagc gcggctatcg tggctggcca	3000
cgcacggcgt tccttgcgc gctgtgtcg acgttgcac tgaaggggaa agggactggc	3060
tgctattggg cgaagtgcgc gggcaggatc tcctgtcatc tcaccttgcgt cctgcccaga	3120
aagtatccat catggctgat gcaatgcggc ggctgcatac gcttgcatacg gtcacgttgc	3180
cattcgacca ccaagcgaaa catcgcatcg agcgagcagc tactcgatg gaagccggc	3240
ttgtcgatca ggatgatctg gacgaagagc atcaggggct cgcgcacggc gaaactgttcg	3300
ccaggctcaa ggcgcgcgt cccgacggcg aggatctcgatcgatccat ggcgatgcct	3360
gcttgccgaa tatcatggtg gaaaatggcc gctttctgg attcatcgac tggccggc	3420
tgggtgtggc ggaccgctat caggacatag cgttggctac cgtgatatt gctgaagagc	3480
ttggcggcga atgggctgac cgcttcctcg tgctttacgg tattcgccgt cccgattcg	3540

agcgcacatcg cttctatcg cttcttgcg agttcttctg agcgggactc tggggttcga 3600
aatgaccgac caagcgacgc ccaacctgcc atcacgagat ttcgattcca cggccgcctt 3660
ctatgaaagg ttgggcttcg gaatcgaaaa ccgggacgcc ggctggatga tcctccagcg 3720
cggggatctc atgctggagt tcttcgccc ccccaacttg tttattgcag cttataatgg 3780
ttacaaaataa agcaatagca tcacaaaattt cacaataaa gcattttttt cactgcattc 3840
tagttgtggt ttgtccaaac tcatcaatgt atcttatcat gtctgtatac cgtcgacctc 3900
tagctagagc ttggcgtaat catggcata gctgtttcct gtgtgaaatt gttatccgct 3960
cacaattcca cacaacatac gagccggaag cataaaagtgt aaagcctggg gtgcctaatg 4020
agtgagctaa ctcacattaa ttgcgttgcg ctcaactgccc gctttccagt cggaaacct 4080
gtcgtgccag ctgcatttaat gaatcgcca acgcgcgggg agaggcgggt tgcgtattgg 4140
gchgctttcc gcttcctcgc tcactgactc gctgcgctcg gtcgttcggc tgccggcagc 4200
ggtatcagct cactcaaagg cggttaatacg gttatccaca gaatcagggg ataacgcagg 4260
aaagaacatg tgagcaaaag gccagcaaaa ggccaggaac cgtaaaaagg cccgcgttgct 4320
ggcggttttc cataggctcc gccccctga cgagcatcac aaaaatcgac gctcaagtca 4380
gaggtggcga aacccgacag gactataaag ataccaggcg tttccccctg gaagctccct 4440
cgtgcgtct cctgttccga ccctgcccgt taccggatac ctgtccgcct ttctcccttc 4500
gggaagcgtg ggcgtttctc aatgctcacg ctgttaggtat ctcaagtccgg tgcgttgcgt 4560
tcgctccaag ctgggctgtg tgcacgaacc ccccggtcag cccgaccgct ggccttatac 4620
cggttaactat cgtctttagt ccaacccggta aagacacgac ttatgcac tggcagcagc 4680
caactggtaac aggattagca gagcgaggta tgtaggcggt gctacagagt tcttgaagtg 4740
gtggccctaac tacggctaca cttagaaggac agtatttggt atctgcgtct tgctgaagcc 4800
agttaccttc gaaaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag 4860
cggtggtttt tttgtttgca agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga 4920
tcctttgatc ttttctacgg ggtctgacgc tcagtggAAC gaaaactcac gttaaaggat 4980
tttggcatg agattatcaa aaaggatctt cacctagatc cttttaaatt aaaaatgaag 5040
ttttaaatca atctaaagta tatatgagta aacttggtct gacagttacc aatgcttaat 5100
caactggaggca cctatctcag cgatctgtct atttcgttca tccatagttg cctgactccc 5160
cgtcgttgcgtataactacga tacgggaggc cttaccatct ggccccagtg ctgcaatgtat 5220
accgcgagac ccacgctcac cggctccaga tttatcagca ataaaccagc cagccggaag 5280
ggccgagcgc agaagtggtc ctgcaactttt atccgcctcc atccagtcata ttaattgttg 5340
ccgggaaagct agagtaagta gttcgccagt taatagtttgcg ccaacgttgc ttgcattgc 5400

tacaggcatac	gtgggtcac	gctcgctgtt	tggtatggct	tcattcagct	ccgggtcccc	5460
acgatcaagg	cgagttacat	gatccccat	gttgtgcaaa	aaagcggtta	gctccttcgg	5520
tcctccgatc	gttgtcagaa	gtaagttggc	cgcaagtgtta	tcactcatgg	ttatggcago	5580
actgcataat	tctcttactg	tcatgccatc	cgtaaagatgc	ttttctgtga	ctggtgagta	5640
ctcaaccaag	tcattctgag	aatagtgtat	gccccgaccc	agttgtctt	gccccggcg	5700
aatacggat	aataccgcgc	cacatagcag	aactttaaaa	gtgctcatca	ttggaaaacg	5760
ttcttcgggg	cgaaaaactct	caaggatctt	accgctgtt	agatccagtt	cgatgttaacc	5820
cactcgtgca	cccaactgat	cttcagcatc	ttttactttc	accagcg	tttctgtgagc	5880
aaaaacacagga	aggcaaaaatg	ccgcaaaaaaa	gggaataagg	gacacacgga	aatgttgaat	5940
actcataactc	ttcccttttc	aatattattt	aagcatttt	cagggttatt	gtctcatgag	6000
cggatacata	tttgaatgta	tttagaaaaaa	taaacaaata	ggggttccgc	gcacatttcc	6060
ccgaaaaagtg	ccacctgacg	tc				6082

<210> 9

<211> 6082

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 9

gacggatcgg	gagatctccc	gatcccstat	ggtcgactct	cagtacaatc	tgctctgatg	60
ccgcatagtt	aagccagtat	ctgctccctg	cttgtgtgtt	ggaggtcgct	gagtagtgcg	120
cgagcaaaat	ttaagctaca	acaaggcaag	gcttgaccga	caattgcatt	aagaatctgc	180
ttagggttag	gcgttttgcg	ctgcttcgcg	atgtacgggc	cagatatacg	cgttgacatt	240
gattattgac	tagttattaa	tagtaatcaa	ttacggggtc	attagttcat	agccatata	300
tggagttccg	cgttacataa	cttacggtaa	atggcccgcc	tggctgaccc	cccaacgacc	360
cccgcccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420
attgacgtca	atgggtggac	tatttacggt	aaactgccc	cttggcagta	catcaagtgt	480
atcatatgcc	aagtacgccc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	540
atgcccagta	catgacctta	tgggacttcc	ctacttggca	gtacatctac	gtatttagtca	600
tcgcttattac	catggtgatg	cggtttggc	agtacatcaa	tgggcgtgga	tagcggtttg	660
actcacgggg	atttccaagt	ctccacccca	ttgacgtcaa	tgggagttt	ttttggcacc	720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatggcg	780
gtaggcgtgt acgggtggag gtctatataa gcagagctct ctggctaact agagaaccca	840
ctgcttactg gtttatcgaa attaatacga ctcaactatag ggagacccaa gctggctaga	900
aagcttggat ctcaccatga gggtccccgc tcagctcctg gggctcctgc tgctctgtt	960
cccagggtgcc agatgtgaca tccagatgac ccagtctcca tcctcactgt ctgcacatgt	1020
aggagacaga gtcaccatca cttgtcgggc gagtcaggc attaccaatt atttagcctg	1080
tttcagcag aaaccaggaa aagccctaa gtcccttatac tatgtcgat ccagtttgc	1140
aagtgggtc ccatcaaagt tcagcggcag tggatctggg acagattca gtctcaccat	1200
cagcagcctg cagcctgaag attttgcac ttattactgc caacagtata atagttaccc	1260
gatcaccttc ggccaaggaa cacgactgga gattaaacga actgtggctg caccatctgt	1320
tttcatcttc ccgcacatctg atgagcagtt gaaatctgga actgctagcg ttgtgtgcct	1380
gctgaataac ttctatccca gagaggccaa agtacagtgg aaggtggata acgcctcca	1440
atcgggtaac tcccaggaga gtgtcacaga gcaggacagc aaggacagca cctacagcct	1500
cagcagcacc ctgacgctga gcaaagcaga ctacgagaaa cacaaagtct acgcctgcga	1560
agtcacccat cagggcctga gctcgccgt cacaaagagc ttcaacaggg gagagtgtta	1620
ggaattcgcg gccgctcgag tctagagggc ccgtttaaac ccgctgatca gcctcgactg	1680
tgccttctag ttgccagcca tctgttgttt gcccccccc cgtgccttcc ttgaccctgg	1740
aaggtgccac tcccactgtc ctttcttaat aaaatgagga aattgcacatcg cattgtctga	1800
gtaggtgtca ttctattctg ggggggtgggg tggggcagga cagcaagggg gaggattggg	1860
aagacaatag cagggcatgct ggggatgcgg tgggtctat ggcttctgag gcggaaagaa	1920
ccagctgggg ctctaggggg tatccccacg cgcctgttag cggcgcattta agcgcggcgg	1980
gtgtgggtgt tacgcgcagc gtgaccgcta cacttgccag cgccttagcg cccgctcctt	2040
tgcctttctt cccttcctt ctgcacgt tcgcggcatt tccccgtcaa gctctaaatc	2100
ggggcatccc ttttagggttc cgattttagtg ctttacggca cctcgacccc aaaaaacttg	2160
attagggtga tggttcacgt agtggccat cgcctgtata gacggttttt cgcctttga	2220
cgttggagtc cacgttctt aatagtggac tcttgttcca aactggaaaca acactcaacc	2280
ctatctcggt ctattcttt gatttataag ggattttggg gatttcggcc tattggttaa	2340
aaaatgagct gatttaacaa aaatttaacg cgaattaatt ctgtggaatg tgtgtcagtt	2400
agggtgtgga aagtccccag gtccccccagg caggcagaag tatgcaaagc atgcacatctca	2460
attagtcagc aaccagggtgt ggaaagtccc caggctcccc agcaggcaga agtatgcaaa	2520
gcatgcacatct caatttagtca gcaaccatag tccccccccct aactccggccc atcccgcccc	2580

taactccgcc cagttccgccc cattctccgc cccatggctg actaattttt tttatTTATG	2640
cagaggccga ggccgcctct gcctctgagc tattccagaa gtagtgagga ggcttttttg	2700
gaggccctagg ctTTTgcAAA aagctcccgg gagettgtat atccattttc ggatctgatc	2760
aagagacagg atgaggatcg ttTCGcatga ttgaacaaga tggattgcac gcaggttctc	2820
cggccgcttg ggtggagagg ctattccgct atgactgggc acaacagaca atccggctgct	2880
ctgatgcccgc cgtgttccgg ctgtcagcgc agggggggccc ggTTCTTTT gtcaagaccg	2940
acctgtccgg tgccctgaat gaactgcagg acgaggcagc gcggctatcg tggctggcca	3000
cgacggggct tccttgcgca gctgtgctcg acgttgcac tgaagcggga agggactggc	3060
tgctattggg cgaagtgcgg gggcaggatc tcctgtcatc tcaccttgc tctggcaga	3120
aagtatccat catggctgat gcaatgcggc ggctgcatac gcttgcattcg gctacctgccc	3180
cattcgacca ccaagcgaaa catcgcatcg agcgagcactg tactcggatg gaagccggc	3240
ttgtcgatca ggatgatctg gacgaagagc atcaggggct cgcgcagcc gaactgttcg	3300
ccaggctcaa ggcgcgcatg cccgacggcg aggatctcg cgtgaccat ggcgatgcct	3360
gcttgcgaa tatcatggtg gaaaatggcc gcttttctgg attcatcgac tgtggccggc	3420
tgggtgtggc ggaccgctat caggacatag cgttggctac ccgtgatatt gctgaagagc	3480
ttggcggcga atgggctgac cgcttcctcg tgctttacgg tATCGCCGCT cccgattcgc	3540
agcgcatcgc ctTCTATCGC CTTCTTGACG agttttctcg agcgggactc tggggttcga	3600
aatgaccgac caagcgacgc ccaacctgcc atcacgagat ttgcattcca ccggccgcTT	3660
ctatgaaagg ttgggcttcg gaatcgTTT ccgggacgccc ggctggatga tcctccagcg	3720
cggggatctc atgctggagt tCTTCGCCA ccccaacttg ttTATTGCAg cttataatgg	3780
ttacaaaataa agcaatagca tcacaaattt cacaataaa gcatttttt cactgcattc	3840
tagttgtggt ttgtccaaac tcatcaatgt atcttatcat gtctgtatAC cgTCGACCTC	3900
tagctagac ttggcgtaat catggcata gctgtttccct gtgtgaaatt gttatccgct	3960
cacaattcca cacaacatac gagccggaag cataaaagtgt aaAGCCTGGG GTGCCTAATG	4020
agtgagctaa ctcacattaa ttgcgttgcg ctcaCTGCC GCTTCCAGT CGGGAAACCT	4080
gtcgtgccag ctgcattaaat gaatcgGCC acgcgcgggg agaggcggTT tgcttattgg	4140
gCGCTCTTCC GCTTCCTCGC tcaCTGACTC GCTGCGCTCG GTCGTTCCGC TGCGGCGAGC	4200
ggtatcagct cactcaaagg cggtataACG gttatccaca gaatcagggg ataacgcagg	4260
aaagaacatg ttagcaaaag gcccAGcaAAA ggccAGGAAC CGTAAAGGAGG CGCGTGTGCT	4320
ggcgtttttc cataggctcc gccccCTGA CGAGCATCAC AAAAATCGAC GCTCAAGTCA	4380
gaggTGGCGA AACCCGACAG GACTATAAAG ATACCAGGCG TTTCCCCCTG GAAGCTCCCT	4440

cgtgcgtctt	cctgttccga	ccctgccgct	taccggatac	ctgtccgcct	ttctcccttc	4500
gggaagcgtg	gcgccttctc	aatgctcact	ctgttaggtat	ctcagttcgg	tgttaggtcgt	4560
tcgctccaag	ctgggctgtg	tgcacgaacc	ccccgttcag	cccgaccgct	gcgccttatac	4620
cggtaactat	cgtcttgagt	ccaaacccgtt	aagacacgac	ttatcgccac	tggcagcagc	4680
cactggtaac	aggattagca	gagcgaggta	tgttaggcgtt	gctacagagt	tcttgaagtg	4740
gtggcctaac	tacggctaca	ctagaaggac	agtatttggt	atctgcgttc	tgctgaagcc	4800
agttaccccttc	ggaaaaaagag	ttggtagctc	ttgatccggc	aaacaaacca	ccgctggtag	4860
cggtggtttt	tttggtttgc	agcagcagat	tacgcgcaga	aaaaaaggat	ctcaagaaga	4920
tcctttgatc	ttttctacgg	ggtctgacgc	tcagtggAAC	aaaaactcAC	gttaagggat	4980
tttggtcatg	agattatcaa	aaaggatctt	cacctagatc	cttttaaatt	aaaaatgaag	5040
ttttaaatca	atctaaagta	tatatgagta	aacttggtct	gacagttacc	aatgcttaat	5100
cagtgaggca	cctatctcag	cgatctgtct	atttcgttca	tccatagttg	cctgactccc	5160
cgtcgtgttag	ataactacga	tacgggaggg	cttaccatct	ggccccagtg	ctgcaatgat	5220
accgcgagac	ccacgctcac	cggctccaga	tttatcagca	ataaaaccagc	cagccggaag	5280
ggccgagcgc	agaagtggtc	ctgcaacttt	atccgcctcc	atccagtcta	ttaattgttg	5340
ccgggaagct	agagtaagta	gttcgccagt	taatagtttg	cgcaacgttg	ttgccattgc	5400
tacaggcatc	gtgggtgtcac	gtcgtcggt	tggtatggct	tcattcagct	ccggttccca	5460
acgatcaagg	cgagttacat	gatccccat	gttgtgcAAA	aaagcggttA	gtcccttcgg	5520
tcctccgatc	gttgcagaa	gtaagttggc	cgcagtgtta	tcactcatgg	ttatggcagc	5580
actgcataat	tctcttactg	tcatgccatc	cgtaagatgc	ttttctgtga	ctggtgagta	5640
ctcaaccaag	tcattctgag	aatagtgtat	gcggcgaccg	agttgctctt	gcccccgcgc	5700
aatacgggat	aataccgcgc	cacatagcag	aactttaaa	gtgctcatca	ttggaaaacg	5760
ttcttcgggg	cgaaaaactct	caaggatctt	accgctgttg	agatccagtt	cgatgtaaacc	5820
cactcgtgca	cccaactgat	cttcagcatc	tttactttc	accagcgttt	ctgggtgagc	5880
aaaaacacgga	aggcaaaaatg	ccgaaaaaaa	gggaaaataagg	gcccacacgga	aatgttgaat	5940
actcataactc	ttcccttttc	aatattattt	aagcatttat	cagggttatt	gtctcatgag	6000
cggatacata	tttgaatgt	tttagaaaa	taaacaata	gggggtccgc	gcacatttcc	6060
ccgaaaaagtg	ccacctgacg	tc				6082

<210> 10

<211> 6082

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 10
gacggatcgg gagatctccc gatcccstat ggtcgactct cagtacaatc tgctctgatg 60
ccgcatagtt aagccagttat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg 120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgoatg aagaatctgc 180
ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt 240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agccatata 300
tggagttccg cggttacataa cttacggtaa atggcccgcc tggctgaccg cccaaacgacc 360
cccgccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 420
attgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt 480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 540
atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 600
tcgctattac catggtgatg cgggtttggc agtacatcaa tggcgtgga tagcggttg 660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tggagtttgc tttggcacc 720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatggcg 780
gtaggcgtgt acgggtggag gtctatataa gcagagctct ctggctaact agagaaccca 840
ctgcttactg gcttatcgaa attaatacga ctcaactatag ggagacccaa gctggctaga 900
aagcttggat ctcaccatga gggccctgc tcagctcctg gggccctgc tgctctgtt 960
cccagggtgcc agatgtgaca tccagatgac ccagtctcca tcctcaactgt ctgcacatgt 1020
aggagacaga gtcaccatca cttgtcgggc gagtcaggc attagccatt atttagcctg 1080
gtttcagcag aaaccaggaa aagccctaa gtcctgatc tatgctgcat ccagttgca 1140
aagtggggtc ccatcaaagt tcagcggcag tggatctggg acagatttca ctctcaccat 1200
cagcagccta cagcctgaag attttgcac ttattactgc caacagtata atagttccc 1260
gctcaacttc ggccggaggaa ccaagggtgga gatcaaacga actgtggctg caccatctgt 1320
cttcacatcc cccatctg atgagcagtt gaaatctggc actgctagcg ttgtgtgcct 1380
gctgaataac ttctatccca gagaggccaa agtacagtgg aagggtggata acggccctcca 1440
atcgggtaac tcccaggaga gtgtcacaga gcaggacagc aaggacagca cctacagcct 1500
cagcagcacc ctgacgctga gcaaagcaga ctacgagaaa cacaaagtct acgcctgcga 1560
agtcaaccat cagggcctga gtcgcccgt cacaaagagc ttcaacaggg gagagtgtta 1620

ggaattcgcg	gccgctcgag	tctagagggc	ccgttaaac	ccgctgatca	gcctcgactg	1680
tgccttctag	ttgccagcca	tctgttgttt	gcccccccc	cgtgccttcc	ttgaccctgg	1740
aagggtgccac	tcccactgtc	ctttcctaata	aaaatgagga	aattgcatacg	cattgtctga	1800
gtaggtgtca	ttcttattctg	gggggtgggg	tggggcagga	cagcaagggg	gaggattggg	1860
aagacaatacg	caggcatgct	ggggatgcgg	tgggctctat	ggcttctgag	gcggaaagaa	1920
ccagctgggg	ctctaggggg	tatccccacg	cgcctgttag	cggcgcatta	agcgcggcgg	1980
gtgtgggtgt	tacgcgcagc	gtgaccgcta	cacttgccag	cgcctagcg	ccgcctcctt	2040
tcgccttctt	cccttcctt	ctgcacgt	tcgcggctt	tcccgtaa	gctctaaatc	2100
ggggcatccc	tttagggttc	cgathtagtg	cttacggca	cctcgacccc	aaaaaacttg	2160
attagggtga	tggttcacgt	agtggccat	cgcctgtata	gacggttttt	cgcctttga	2220
cgttggagtc	cacgttcttt	aatagtggac	tcttgttcca	aactggaaaca	acactcaacc	2280
ctatctcggt	ctattctttt	gatttataag	ggattttggg	gatttcggcc	tattggtaa	2340
aaaatgagct	gatttaacaa	aaatttaacg	cgaattaatt	ctgtggaatg	tgtgtcagtt	2400
agggtgtgga	aagtccccag	gctccccagg	caggcagaag	tatgcaaagc	atgcatactca	2460
attagtcagc	aaccaggtgt	ggaaagtccc	caggtcccc	agcaggeaga	agtatgcaaa	2520
gcatgcacat	caattagtca	gcaaccatag	tcccgcccc	aactccgccc	atcccgcccc	2580
taactccgccc	cagttccgccc	cattctccgc	cccatggctg	actaattttt	tttattttatg	2640
cagaggccga	ggccgcctct	gcctctgagc	tattccagaa	gtagtgagga	ggctttttg	2700
gaggcctagg	cttttgcaaa	aagctcccg	gagcttgtat	atccattttc	ggatctgatc	2760
aagagacagg	atgaggatcg	tttcgcata	ttgaacaaga	tggattgcac	gcaggttctc	2820
cggccgcttgc	ggtggagagg	ctattccgct	atgactggc	acaacagaca	atccgctgct	2880
ctgatgcgc	cgtgttccgg	ctgtcagcgc	agggcgccc	ggttttttt	gtcaagacccg	2940
acctgtccgg	tgcctgtaa	gaactgcagg	acgaggcagc	gcggctatcg	tggctggcca	3000
cgacggcgt	tccttgcgc	gctgtgctcg	acgttgcac	tgaagcggga	aggactggc	3060
tgctattttgg	cgaagtgcgg	ggcaggatc	tcctgtcatc	tcaccttgc	cctgcccaga	3120
aagtatccat	catggctgat	gcaatgcggc	ggctgcatac	gcttgcatacg	gctacctgcc	3180
cattcgacca	ccaagcgaaa	catgcatacg	agcgagcaca	tactcgatg	gaagccggc	3240
ttgtcgatca	ggatgatctg	gacgaagagc	atcagggct	cgcgcagcc	gaactgttcg	3300
ccaggctcaa	ggcgccatg	cccgacggcg	aggatctcg	cgtgacccat	ggcgatgcct	3360
gcttgcgaa	tatcatggtg	gaaaatggcc	gcttttctgg	attcatcgac	tgtggccggc	3420
tgggtgtggc	ggaccgctat	caggacatag	cgtggctac	ccgtgatatt	gctgaagagc	3480

ttggcggcga atgggctgac cgcttcctcg tgctttacgg tatcgccgct cccgattcgc	3540
agcgcatcgc cttctatcgc cttcttgcacg agttcttctg agcgggactc tggggttcga	3600
aatgaccgac caagcgacgc ccaacctgcc atcacgagat ttcgattcca ccggcgctt	3660
ctatgaaagg ttgggcttcg gaatcgaaaa ccgggacgccc ggctggatga tcctccagcg	3720
cggggatctc atgctggagt tcttcgccc ccccaacttg tttattgcag cttataatgg	3780
ttacaaataa agcaatagca tcacaaattt cacaaataaa gcatttttt cactgcattc	3840
tagttgttgt ttgtccaaac tcatcaatgt atcttatcat gtctgtatac cgtcgaccc	3900
tagctagagc ttggcgtaat catggcata gctgtttcct gtgtgaaatt gttatccgct	3960
cacaattcca cacaacatac gagccgaaag cataaaagtgt aaagcctggg gtgcctaatt	4020
agttagctaa ctcacattaa ttgcgttgcg ctcaactgccc gctttccagt cggaaacct	4080
gtcgtgccag ctgcattaat gaatcgcca acgcgcgggg agaggcggtt tgcgtattgg	4140
gctgtcttcc gcttcctcgc tcaactgactc gctgcgcctcg gtcgttcggc tgccggcagc	4200
ggtatcagct cactcaaagg cggtaatacg gttatccaca gaatcagggg ataacgcagg	4260
aaagaacatg tgagcaaaag gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct	4320
ggcgttttc cataggctcc gccccctga cgagcatcac aaaaatcgac gctcaagtca	4380
gaggtggcga aacccgacag gactataaag ataccaggcg tttccccctg gaagctccct	4440
cgtgcgtctt cctgttccga ccctgcgcct taccggatac ctgtccgcct ttctcccttc	4500
gggaagcgtg ggcgtttctc aatgctcactc ctgttaggtat ctcaaggcg tgcgttcgt	4560
tcgctccaag ctgggctgtg tgcacgaacc ccccggttccag cccgaccgct ggccttatac	4620
cggtaactat cgtcttgcgtt ccaacccgggt aagacacgcac ttatgcgcac tggcagcagc	4680
cactggtaac aggattagca gagcgaggta tgcgttcgtt gctacagagt tcttgaagt	4740
gtggcctaac tacggctaca ctagaaggac agtatttgggt atctgcgcctc tgctgaagcc	4800
agttaccttc ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgcgtggtag	4860
cggtggtttt tttgtttgca agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga	4920
tcctttgatc ttttctacgg ggtctgcacgc tcagtgaaac gaaaactcactc gttaaaggat	4980
tttggtcatg agattatcaa aaaggatctt cacctagatc cttttaaatt aaaaatgaag	5040
ttttaaatca atctaaagta tatatgagta aacttggctc gacagttacc aatgcttaat	5100
cagtgaggca cctatctcag cgatctgtct atttcgttca tccatagttt cctgactccc	5160
cgtcggttag ataaactacga tacgggaggg cttaccatct ggccccagtg ctgcaatgat	5220
accgcgagac ccacgctcac cggctccaga tttatcagca ataaaccagc cagccgaaag	5280
ggccgagcgc agaagtggtc ctgcaacttt atccgcctcc atccagtctt ttaattgttg	5340

ccgggaagct agagtaagta	gttcgccagt taatagtttgc	cgcaacgttgc	ttgccattgc	5400		
tacaggcattc	gtgggtgtcac	gctcgctgtt	tgttatggct	tcattcagct	ccggttccca	5460
acgatcaagg	cgagttacat	gatccccat	gtgtgcaaa	aaagcggtt	gctccttcgg	5520
tcctccgatc	gttgcagaa	gtaagttggc	cgcagtgta	tcactcatgg	ttatggcagc	5580
actgcataat	tctcttactg	tcatgccatc	cgtaagatgc	ttttctgtga	ctggtgagta	5640
ctcaaccaag	tcattcttag	aatagtgtat	gccccgacccg	agttgcctt	gccccggcgtc	5700
aatacggat	aataccgcgc	cacatagcag	aactttaaaa	gtgctcatca	ttggaaaaacg	5760
ttcttcgggg	cgaaaaactct	caaggatctt	accgctgttgc	agatccagtt	cgatgttaacc	5820
cactcggtca	cccaactgat	cttcagcatc	ttttactttc	accagcgttt	ctgggtgagc	5880
aaaaacagga	aggcaaaaatg	ccgcaaaaaaa	gggaataagg	gcgacacgga	aatgttgaat	5940
actcataactc	ttccttttcc	aatattatttgc	aagcattttat	cagggttatt	gtctcatgag	6000
cggatacata	tttgaatgtt	tttagaaaaaa	taaacaaata	ggggttccgc	gcacatttcc	6060
ccgaaaagtg	ccacctgacg	tc				6082

<210> 11

<211> 6085

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 11	gacggatcgg	gagatctccc	gatccccat	ggtcgactct	cagtacaatc	tgctctgatg	60
	ccgcatagtt	aagccagtt	ctgctccctg	tttgtgtgtt	ggaggtcgct	gagtagtgcg	120
	cgagaaaaat	ttaagctaca	acaaggcaag	gcttgaccga	caattgcatt	aagaatctgc	180
	ttagggtag	gcgttttgcg	ctgcttcgcg	atgtacgggc	cagatatacg	cgttgacatt	240
	gattattgac	tagttattaa	tagtaatcaa	ttacggggtc	attagttcat	agcccatata	300
	tggagttccg	cgttacataa	cttacggtaa	atggcccgcc	tggctgaccg	cccaacgacc	360
	cccgccatt	gacgtcaata	atgacgtatg	ttcccatagt	aacgccaata	gggactttcc	420
	attgacgtca	atgggtggac	tatttacggt	aaactgcccc	cttggcagta	catcaagtgt	480
	atcatatgcc	aagtacgccc	cctattgacg	tcaatgacgg	taaatggccc	gcctggcatt	540
	atgcccagta	catgaccctta	tgggactttc	ctacttggca	gtacatctac	gtatttagtca	600
	tcgctattac	catggtgatg	cggtttggc	agtacatcaa	tggcggtgga	tagcggttg	660

actcacgggg	atttccaagt	ctccacccca	ttgacgtcaa	tgggagttt	ttttggcacc	720
aaaatcaacg	ggactttcca	aatgtcgta	acaactccgc	cccattgacg	caaatggcg	780
gtagggcgtgt	acggtgggag	gtctatataa	gcagagctct	ctggctaact	agagaaccca	840
ctgcttactg	gcttatcgaa	attaatacga	ctcaactatag	ggagacccaa	gctggctaga	900
aagcttggat	ctcaccatga	gggtccccgc	tcagcttctc	ttccttctgc	tactctggct	960
cccagatacc	actggaggaa	tagtgatgac	gcagtctcca	gccaccctgt	ctgtgtctcc	1020
aggggaaaga	gccaccctct	cctgcaggac	cagtcagagt	attggctgga	acttagcctg	1080
gtaccaacag	aaacctggcc	aggctccag	gctcctcatc	tatggtgcatt	cttccaggac	1140
cactggtatac	ccagccaggt	tcagtggcag	tgggtctggg	acagagttca	ctctcaccat	1200
cagcagcctg	cagtctgaag	attctgcagt	ttattactgt	cagcattatg	ataactggcc	1260
catgtgcagt	tttggccagg	ggaccgagct	ggagatcaa	cgaactgtgg	ctgcaccatc	1320
tgtcttcatc	ttcccgccat	ctgatgagca	gttgaatct	ggaactgcta	gcgttgtgt	1380
cctgctgaat	aacttctatc	ccagagaggc	caaagtacag	tggaaggtgg	ataacgcct	1440
ccaatcgggt	aactcccagg	agagtgtcac	agagcaggac	agcaaggaca	gcacctacag	1500
cctcagcagc	accctgacgc	tgagcaaagc	agactacgag	aaacacaaag	tctacgcctg	1560
cgaagtcaacc	catcagggcc	tgagctcgcc	cgtcacaaag	agttcaaca	ggggagagtg	1620
ttaggaattc	gcggccgctc	gagtctagag	ggcccgittt	aaccgcgtga	tcagcctcgat	1680
ctgtgccttc	tagttgccag	ccatctgttg	tttgcctctc	ccccgtgcct	tccttgaccc	1740
tggaaggtgc	cactcccact	gtccttcct	aataaaatga	ggaaattgca	tcgcattgtc	1800
tgagtaggtg	tcattctatt	ctgggggtg	gggtggggca	ggacagcaag	ggggaggatt	1860
gggaagacaa	tagcaggcat	gctggggatg	cggtgggctc	tatggcttct	gaggcggaaa	1920
gaaccagctg	gggctctagg	gggtatcccc	acgcgcctg	tagcggcgca	ttaagcgcgg	1980
cgggtgtgg	ggttacgcgc	agcgtgaccg	ctacacttgc	cagcgcctta	gcgcggctc	2040
ctttcgcttt	cttcccttcc	tttctcgcca	cgttcgcccgg	ctttccccgt	caagctctaa	2100
atcggggcat	ccctttaggg	ttccgattta	gtgcttacg	gcacctcgac	cccaaaaaac	2160
ttgattaggg	tgttgttca	cgtagtggc	catgcgcctg	atagacggtt	tttgcctt	2220
tgacgttgga	gtccacgttc	tttaatagtg	gactctgtt	ccaaactggaa	acaacactca	2280
accctatctc	ggtctattct	tttgatttat	aaggatttt	ggggatttcg	gcctattgg	2340
taaaaaatga	gctgatttaa	caaaaattta	acgcgaatta	attctgtgg	atgtgtgtca	2400
gttagggtgt	ggaaagtccc	caggctcccc	aggcaggcag	aagtatgcaa	agcatgcattc	2460
tcaatttagtc	agcaaccagg	tgtggaaagt	ccccaggctc	cccagcaggc	agaagtatgc	2520

aaagcatgca tctcaattag tcagcaacca tagtcccgcc cctaactccg cccatcccgc	2580
ccctaactcc gcccagttcc gcccattctc cgccccatgg ctgactaatt ttttttattt	2640
atgcagaggc cgaggccgccc tctgcctctg agctattcca gaagttagtga ggaggctttt	2700
ttggaggcct aggctttgc aaaaagctcc cgggagcttg tatatccatt ttccggatctg	2760
atcaagagac aggatgagga tcgttcgca tgattgaaca agatggattt cacgcaggtt	2820
ctccggccgc ttgggtggag aggctattcg gctatgactg ggcacaacag acaatcggt	2880
gctctgatgc cgccgtgttc cggctgtcag cgcaggggcg cccggttctt tttgtcaaga	2940
ccgacctgtc cggtgccctg aatgaactgc aggacgaggc agcgcggcta tcgtggctgg	3000
ccacgacggg cgttccttgc gcagctgtgc tcgacgttgt cactgaagcg ggaagggact	3060
ggctgctatt gggcgaagtg cgggggcagg atctcctgtc atctcacctt gctcctgccc	3120
agaaagtatac catcatggct gatgcaatgc ggcggctgca tacgcttgat cccgctaccc	3180
gcccaattcga ccaccaagcg aaacatcgca tcgagcgagc acgtactcgg atggaagccg	3240
gtcttgcga tcaggatgat ctggacgaag agcatcaggg gctcgcgcca gccgaactgt	3300
tcgcccaggct caaggcgcgc atgcccacg gcgaggatct cgtcgtgacc catggcgatg	3360
cctgccttgcgaaatcatg gtggaaaatg gccgctttt tggattcatc gactgtggcc	3420
ggctgggtgt ggcggaccgc tatcaggaca tagcgttggc tacccgtgat attgctgaag	3480
agcttggcgg cgaatgggcgt gaccgcttcc tcgtgcctta cggtatcgcc gctcccgatt	3540
cgcagcgcacat cgccttctat cgccttcttgc acgagttctt ctgagcggga ctctggggtt	3600
cgaaatgacc gaccaagcgacg cggccaaacct gccatcacga gatttcgatt ccaccggcgc	3660
cttctatgaa aggttggcgt tcggaatcgat ttccggac gccggctggat tgatcctcca	3720
gcgccggggat ctcatgctgg agttcttcgc ccacccaaac ttgtttattt cagttataaa	3780
tggttacaaa taaagcaata gcatcacaaa ttccacaaaat aaagcatttt ttctactgca	3840
ttcttagttgt ggtttgtcca aactcatcaa tgtatctt catgtctgta tacccgtcgac	3900
ctctagctag agcttggcgt aatcatggc atagctgttt cctgtgtgaa attgttatcc	3960
gctcacaatt ccacacaaaca tacgagccgg aagcataaaag tgtaaaggctt ggggtgccta	4020
atgagtgagc taactcacat taattgcgtt gcgctcactg cccgctttcc agtcgggaaa	4080
cctgtcgtgc cagctgcatt aatgaatcgg ccaacgcgcg gggagaggcg gtttgcgtat	4140
tgggcgtct tccgcttcct cgctcactga ctcgcgtgc tcggcgttcc ggctgcggcg	4200
agcggtatca gctcactcaa aggccgtaat acggttatcc acagaatcag gggataacgc	4260
aggaaaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaaa aggccgcgtt	4320
gctggcggtt ttccataggc tccgcccccc tgacgagcat cacaaaaatc gacgctcaag	4380

tcagagggtgg	cgaaacccga	caggactata	aagataccag	gcgttcccc	ctggaagctc	4440
cctcggtgcgc	tctcctgttc	cgaccctgcc	gcttaccgga	tacctgtccg	cctttctccc	4500
ttcgggaagc	gtggcgcttt	ctcaatgctc	acgctgtagg	tatctcagtt	cggtgttaggt	4560
cgttcgctcc	aagctgggct	gtgtcacga	accccccgtt	cagcccgacc	gctgcccctt	4620
atccggtAAC	tatcgctttg	agtccaaACCC	ggtaagacac	gacttatcgc	cactggcAGC	4680
agccactggT	aacaggatta	gcagagcgag	gtatgttaggc	ggtgctacag	agttcttgaa	4740
gtggtggcct	aactacggct	acactagaag	gacagtattt	ggtatctgcg	ctctgctgaa	4800
gccagttacc	ttcggaaaaaa	gagttggtag	ctcttgatcc	ggcaaacaaa	ccaccgctgg	4860
tagcgggtggT	ttttttgttt	gcaaggcagca	gattacgcgc	agaaaaaaaaag	gatctcaaga	4920
agatcctttg	atctttctta	cggggctctga	cgctcagtgg	aacgaaaact	cacgttaagg	4980
gattttggTC	atgagattat	caaaaaggat	ctt'cacctag	atcctttaa	ataaaaatg	5040
aagttttaaa	tcaatctaaa	gtatatatga	gtaaaacttgg	tctgacagtt	accaatgctt	5100
aatcagtgag	gcacctatct	cagcgatctg	tctatttcgt	tcatccatag	ttgcctgact	5160
ccccgtcgtg	tagataacta	cgatacggga	gggcttacca	tctggcccca	gtgctgcaat	5220
gataccgcga	gacccacgct	caccggctcc	agatttatca	gcaataaaacc	agccagccgg	5280
aaggcccggag	cgcagaagtg	gtcctgcaac	tttatccgcc	tccatccagt	ctattaattg	5340
ttgccccggaa	gctagagtaa	gtagttcgcc	agttaatagt	ttgcgcacg	ttgtttgccat	5400
tgctacaggc	atcggtgtgt	cacgctcgtc	gttggtatg	gcttcattca	gctccgggttc	5460
ccaaacgatca	aggcgagtt	catgatcccc	catgttgc	aaaaaaagcgg	ttagctcctt	5520
cggtcctccg	atcggtgtca	gaagtaagtt	ggccgcagtg	ttatcactca	tggttatggc	5580
agcaactgcat	aattctctta	ctgtcatgcc	atccgtaaga	tgctttctg	tgactggtga	5640
gtactcaacc	aagtcttct	gagaatagtg	tatgcggcga	ccgagttgct	cttgcggcgc	5700
gtcaataacgg	gataataacgg	cgcacatag	cagaacttta	aaagtgcctca	tcattggaaa	5760
acgttcttcg	gggcgaaaac	tctcaaggat	cttaccgctg	ttgagatcca	gttcgatgt	5820
acccactcgt	gcacccaaact	gatcttcagc	atctttact	ttcaccagcg	tttctgggtg	5880
agcaaaaaaca	ggaaggcaaa	atgccgaaa	aaagggaata	agggcgacac	ggaaatgttg	5940
aataactcata	cttttcctt	ttcaatatta	ttgaagcatt	tatcagggtt	attgtctcat	6000
gagcggatac	atatttgaat	gtatTTtagaa	aaataaaacaa	ataggggttc	cgcgcacatt	6060
tccccgaaaa	gtgccacctg	acgtc				6085

<211> 6097

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 12

gacggatcgg gagatctccc gatcccstat ggtcgactct cagtacaatc tgctctgatg	60
ccgcatagtt aagccagtt ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg	120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc	180
ttagggttag gcgccccggcg ctgcttcgct atgtacgggc cagatatacg cggtgacatt	240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata	300
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc	360
ccgcatttgcatt gacgtcaata atgacgtatg ttccatagt aacgccaata gggactttcc	420
atgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt	480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt	540
atgcccagta catgacacctt tgggactttc ctacttggca gtacatctac gtattagtca	600
tcgctattac catggtgatg cggtttggc agtacatcaa tggcgtgga tagcggtttg	660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttgc tttggcacc	720
aaaatcaacg ggactttcca aatgtcgta acaactccgc cccattgacg caaatggcgc	780
gtaggcgtgt acgggtggag gtctatataa gcagagctct ctggctact agagaaccca	840
ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga	900
aagcttggat ctcaccatga gggccctgc tcagctcctg gggctgctaa tgctctggat	960
acctggatcc agtgcagata ttgtgatgac ccagactcca ctctctctgt ccgtcacccca	1020
tggacagccg gcctccatct cctgcaagtc tagtcagagc ctctgcata gtatggaaa	1080
gaccttttg tattggtatac tgcagaagcc aggccagcct ccacagctcc tgatctatga	1140
ggtttccaaac cggttctctg gagtgccaga tagttcagt ggcagcgggt cagggacaga	1200
tttcacactg aaaatcagcc gggtgaggc tgaggatgtt gggctttatt actgcattca	1260
aagtatacag ctcccgctca ctgcggcgg agggaccaag gtggagatca aacgaactgt	1320
ggctgcacca tctgtcttca tcttcccgcc atctgatgag cagttgaaat ctgaaactgc	1380
tagcgttgcgtg tgcctgctga ataacttcta tcccaagagag gccaaagtac agtggaaagg	1440
ggataacgcc ctccaatcgg gtaactccca ggagagtgtc acagagcagg acagcaagga	1500
cagcacctac agcctcagca gcaccctgac gctgagcaaa gcagactacg agaaacacaa	1560

agtctacgcc tgcgaaagtca cccatcaggg cctgagctcg cccgtcacaa agagcttcaa 1620
caggggagag tgtaggaat tcggggccgc tcgagtctag agggcccggt taaacccgct 1680
gatcagccctc gactgtgcct tctagttgcc accatctgt tggttgcctt cccccgtgc 1740
cttccttgcac cctggaaggt gccactccca ctgtccttcc ctaataaaat gaggaaattg 1800
catcgcatgg tctgagtagg tgtcattcta ttctgggggg tgggtgggg caggacagca 1860
agggggagga ttgggaagac aatagcaggc atgctgggg a tgcgggtggc tctatggctt 1920
ctgaggcgg aagaaccagc tggggctcta ggggttatcc ccacgcgccc tgtagcggcg 1980
cattaagcgc ggcgggtgtg gtggttacgc gcagcgtgac cgctacactt gccagcgccc 2040
tagcgcccgc tccttcgct ttctccctt ccttctcgc cacgttcgccc ggcttcccc 2100
gtcaagctct aaatcgggc atcccttag ggttccgatt tagtgcttta cggcacctcg 2160
accccaaaaa acttgattag ggtgatggtt cacgtagtgg gccatcgccc tgatagacgg 2220
ttttcgccc tttgacggtt gagtccacgt tcttaatag tggactcttgc ttccaaactg 2280
gaacaacact caaccctatc tcggtctatt ctggattt ataaggatt ttggggattt 2340
cggcctattt gttaaaaat gagctgattt aacaaaaatt taacgcgaat taattctgtg 2400
gaatgtgtgt cagtttaggtt gtggaaagtc cccaggctcc ccaggcaggc agaagtatgc 2460
aaagcatgca tctcaattttt tcagcaacca ggtgtggaaa gtccccaggc tccccagcag. 2520
gcagaagtat gcaaagcatg catctcaattt agtcagcaac catagtcccg cccctaactc 2580
cgcccatccc gcccctaact ccggccagtt ccggccattc tccggccat ggctgactaa 2640
ttttttttat ttatgcagag gcccggccg cctctgcctc tgagctattt cagaagtagt 2700
gaggaggctt ttttggaggc ctaggctttt gcaaaaagct cccggagct tttatcc 2760
tttcggatc tgatcaagag acaggatgag gatcgttcg catgattgaa caagatggat 2820
tgcacgcagg ttctccggcc gcttgggtgg agaggctattt cggctatgac tgggcacaac 2880
agacaatcggtt ctgtctgtt gcccgggtgt tccggctgtc agcgcagggg cggccgggttc 2940
ttttgtcaaa gaccgacctg tccggtgccc tgaatgaact gcaggacgag gcagcgcggc 3000
tatcggtggctt ggccacgacg ggcttcctt ggcgcagctgt gctcgacgtt gtcactgaag 3060
cgggaaaggga ctggctgcta ttggcgaag tgccggggca ggatctccttgc tcatctcacc 3120
ttgctcctgc cggaaagta tccatcatgg ctgatgcaat gcccgggtgt catacgcttgc 3180
atccggctac ctggccattc gaccaccaag cgaaacatcg catcgacgca gcacgtactc 3240
ggatggaaagc cggcttgc gatcaggatg atctggacga agagcatcag gggctcgcc 3300
cagccgaact gttcgccagg ctcaaggcgc gcatgcccga cggcgaggat ctcgtcgtga 3360
ccccatggcga tgcctgcttgc cccatggcgaatatca tgggtggaaaaa tggccqctt tctqgattca 3420

tcgactgtgg ccggctgggt gtggcggacc gctatcagga catagcggtg gctacccgtg	3480
atattgctga agagcttggc ggcgaatggg ctgaccgctt cctcggtctt tacggtatcg	3540
ccgctcccgta ttgcagcgc atgccttct atgccttct tgacgagttc ttctgagcgg	3600
gactctgggg ttcgaaatga ccgaccaagc gacgcccac ctgccatcac gagatttcga	3660
ttccacccgcc gccttctatg aaagggttggg cttcggaaatc gttttccggg acgcggctg	3720
gatgatcctc cagcgcgggg atctcatgct ggagttctc gcccacccca acttgtttat	3780
tgcagcttat aatggttaca aataaagcaa tagcatcaca aatttcacaa ataaagcatt	3840
tttttcaactg cattctagtt gtggttgtc caaactcatc aatgtatctt atcatgtctg	3900
tataccgtcg acctctagct agagcttggc gtaatcatgg tcatacgctgt ttccgtgtg	3960
aaattgttat ccgctcacaa ttccacacaa catacgagcc ggaagcataa agtgtaaagc	4020
ctggggtgcc taatgagtga gctaactcac attaattgcg ttgcgtcac tgcccgcttt	4080
ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccaacgcg cggggagagg	4140
cggttgcgtt attgggcgtt ctccgttc ctgcgtcact gactcgctgc gctcggtcgt	4200
tcggctgcgg cgagcggtat cagctactc aaaggcggta atacggttat ccacagaatc	4260
aggggataaac gcaggaaaga acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa	4320
aaaggccgcg ttgctggcgt ttttccatag gctccgcccc cctgacgagc atcacaaaaaa	4380
tcgacgctca agtcagaggt ggcgaaaccc gacaggacta taaagataacc aggcgtttcc	4440
ccctggaagc tccctcggtc gctctctgt tccgaccctg ccgcttaccg gatacctgtc	4500
cgccttctc ctttcggaa gcgtggcgct ttctcaatgc tcacgctgtt ggtatctcag	4560
ttcggtgttag gtcgttcgtc ccaagctggg ctgtgtgcac gaaccccccgttca gggccgttt	4620
ccgctgcgcc ttatccggta actatcgct tgagtccaaac ccggtaagac acgacttatac	4680
gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgttag gcggtgtac	4740
agagttcttg aagtgggtggc ctaactacgg ctacactaga aggacagtat ttggtatctg	4800
cgctctgctg aagccagtta ctttcggaaa aagagttgggt agctcttgat ccggcaaaca	4860
aaccaccgct ggtagcgggtg gttttttgtt ttgcaagcag cagattacgc gcagaaaaaa	4920
aggatctcaa gaagatcctt tgatctttc tacgggtct gacgctcagt ggaacgaaaa	4980
ctcacgttaa gggatttgg tcatgagatt atcaaaaaagg atcttccacat agatcctttt	5040
aaataaaaaa tgaagttta aatcaatcta aagtatataat gagtaaactt ggtctgacag	5100
ttaccaatgc ttaatcagtg aggcacctat ctcagcgtac tgcgttatttc gttcatccat	5160
agttgcctga ctccccgtcg tgcgtataac tacgataacgg gagggcttac catctggccc	5220
cagtgcgtca atgataaccgc gagaccacg ctcacccgct ccagatttat cagcaataaa	5280

ccagccagcc ggaagggccg agcgacagaag tggcctgca actttatccg cctccatcca	5340
gtctattaat tggccggg aagctagagt aagtagttcg ccagttaata gttgcgcaa	5400
cgttgtgcc attgctacag gcatcgtggt gtcacgctcg tcgtttggta tggcttcatt	5460
cagctccggt tcccaacgat caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc	5520
ggttagctcc ttgggtcctc cgatcgttgt cagaagtaag ttggccgcag tggttatcact	5580
catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa gatgctttc	5640
tgtgactggg gagtactcaa ccaagtcatt ctgagaatag tgtatgcggc gaccgagttg	5700
ctcttgcggc gcgtcaatac gggataatac cgccgcacat agcagaactt taaaagtgt	5760
catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tggtagatc	5820
cagttcgatg taacccactc gtgcacccaa ctgatcttca gcatcttttta ctttaccag	5880
cgtttctggg tgagcaaaaa caggaaggca aaatgcgcga aaaaaggaa taagggcgac	5940
acggaaatgt tgaataactca tactcttcct ttttcaatat tattgaagca tttatcaggg	6000
ttattgtctc atgagcggat acatatttga atgtattttag aaaaataaaac aaataggggt	6060
tccgcgcaca ttccccgaa aagtgcacc tgacgtc	6097

<210> 13

<211> 6094

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 13	
gacggatcgg gagatctccc gatcccstat ggtcgactct cagtacaatc tgctctgatg	60
ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg	120
cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc	180
ttagggtagt gcttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt	240
gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agccatata	300
tggagttccg cgttacataa cttacggtaa atggccgcgc tggctgacccg cccaaacgacc	360
cccgccattt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc	420
atgacgtca atgggtggac tatttacggt aaactgccc cttggcagta catcaagtgt	480
atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt	540
atgcccagta catgaccccta tgggacttgc ctacttggca gtacatctac gtattagtca	600

tcgctattac catggtgatg cggtttggc agtacatcaa tgggcgtgga tagcggtttg	660
actcacgggg atttccaagt ctccacccca ttgacgtcaa tggaggtttg tttggcacc	720
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatggcg	780
gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca	840
ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga	900
aagcttggat ctcaccatgg tggcagac ccaggtcttc atttctctgt tactctggat	960
ctctgggcc tacgggaca tcgtatgac ccagtctcca gactccctgg ctgtgtctct	1020
ggcgagagg gccaccatca actgcaagtc caaccagagt gtcttacaca gctccaacaa	1080
taagaactat ttagcttggt accagcagaa accaggacag cctcctaaat tgctcattta	1140
ttgggcattc ctccggaaat cgggggtccc tgaccgcttc agtggcagcg ggtctgggac	1200
agatttcaact ctcaccatca gcagctgca ggctgaagat gtggcagttt attactgtca	1260
ccaatattat tctactttat atacttcgg cggagggacc aaggttagaga tcaaacgaac	1320
ygtggctgca ccatctgtct tcatcttccc gccatctgat gagcagttga aatctggAAC	1380
tgctagcgTT gtgtgcctgc tgaataactt ctatcccaga gaggccaaag tacagtggaa	1440
ggtggtataac gccctccaaat cggtaactc ccaggagagt gtcacagagc aggacagcaa	1500
ggacagcacc tacagcctca gcagcaccct gacgctgagc aaagcagact acgagaaaca	1560
caaagtctac gcctgcaag tcaccatca gggcctgagc tcgcccgtca caaagagctt	1620
caacagggga gagtgttagg cggccgctcg agtctagagg gcccgttAA acccgctgat	1680
cagcctcgac tgtgccttct agttgccagc catctgttgc ttgcccctcc cccgtgcctt	1740
ccttgaccct ggaaggtgcc actcccactg tcctttccta ataaaatgag gaaattgcatt	1800
cgcattgtct gagtaggtgt cattctattt tgggggggtgg ggtggggcag gacagcaagg	1860
gggaggattg ggaagacaat agcaggcatg ctggggatgc ggtgggtctt atggcttctg	1920
aggcggaaag aaccagctgg ggctcttaggg ggtatccccca cgcgcctgt agcggcgcatt	1980
taagcgcggc ggggtgtggt gttacgcgca gcgtgaccgc tacacttgcg agcgccttag	2040
cgcgccttcc ttctgccttc ttcccttcct ttctgcac gttcgccggc ttccccgtc	2100
aagctctaaa tcggggcatc cctttagggt tccgatttag tgctttacgg cacctcgacc	2160
ccaaaaaaact tgatttaggt gatggttcac gtagtggcc atgcgcctgt tagacggttt	2220
ttcgcccttt gacggtggag tccacgttct ttaatagtgg actcttgcctt caaactggaa	2280
caacactcaa ccctatctcg gtctattctt ttgatttata agggattttg gggatttcgg	2340
cctattggtt aaaaaatgag ctgatttaac aaaaattaa cgcgaattaa ttctgtggaa	2400
tgtgtgtcag ttaggggtgtg gaaagtcccc aggctccca ggcaggcaga agtatgcaaa	2460

gcatgcatct caattagtca gcaaccagggt gtggaaagtc cccaggctcc ccagcaggca	2520
gaagtatgca aagcatgcat ctcaattagt cagcaaccat agtcccggcc ctaactccgc	2580
ccatcccgcc cctaactccg cccagttccg cccattctcc gccccatggc tgactaattt	2640
tttttattta tgccaggagcc gaggccgcct ctgcctctga gctattccag aagtagtgag	2700
gaggctttt tggaggccta ggctttgca aaaagctccc gggagcttgt atatccattt	2760
tcggatctga tcaagagaca gnatgaggat cgtttcgcatt gattgaacaa gatggattgc	2820
acgcagggttc tccggccgct tgggtggaga ggctattcgg ctatgactgg gcacaacaga	2880
caatcggctg ctctgatgcc gccgtgttcc ggctgtcagc gcaggggcgc ccggttcttt	2940
ttgtcaagac cgacctgtcc ggtgccctga atgaactgca ggacgaggca gcgcggctat	3000
cgtggctggc cacgacgggc gttccttgcg cagctgtgct cgacgttgct actgaagcgg	3060
gaagggactg gctgctattt ggcgaagtgc cggggcagga tctcctgtca tctcaccttgc	3120
ctcctgccga gaaagtatcc atcatggctg atgcaatgca gcccgtgcatt acgcttgatc	3180
cggttacccgtt cccatttcgac caccaagcga aacatcgcat cgagcggagca cgtactcgga	3240
tggaaaggccgg tcttgcgtat caggatgatc tggacgaaga gcatcagggg ctgcgcggcag	3300
ccgaactgtt cgccaggctc aaggcgcgc a tgccgcacgg cgaggatctc gtcgtgaccc	3360
atggcgatgc ctgcttgccg aatatcatgg tggaaaatgg ccgttttct ggattcatcg	3420
actgtggccg gctgggtgtg gcggaccgct atcaggacat agcggtggct acccgtgata	3480
ttgctgaaga gcttggccgc gaatgggctg accgcttcct cgtgctttac ggtatcgccg	3540
ctcccgatttgc gcaagcgcatttgc gcttcttgc gcttcttgc ctagtttttc tgagcgggac	3600
tctgggggttc gaaatgaccg accaagcgcac gcccacccctg ccatcacgag atttcgatttgc	3660
caccggccgc ttctatgaaa ggttgggctt cggaaatcggtt ttccggacgg ccggctggat	3720
gatcctccatcg cgccgggatc tcatgctggat gttcttcgc caccggacttgc tgtttatttgc	3780
agcttataat ggttacaaat aaagcaatag catcacaaat ttcacaaata aagcattttt	3840
ttcactgcat tctagttgtg gtttgcatttactcatcaat gtatcttac atgtctgtat	3900
accgtcgacc tctagctaga gcttggcgta atcatggtca tagctgtttc ctgtgtgaaa	3960
ttgttatccg ctacacaaatcc cacacaaatcc acgagccggaa agcataaagt gtaaaaggctg	4020
gggtgcctaa tgagtgagct aactcacatt aattgcgttgc gctcactgc ccgttccca	4080
gtcggggaaac ctgtcggtcc agctgcatttgc atgaatcgcc caacgcgcgg ggagaggcgg	4140
tttgcgtatt gggcgctttt ccgttccctc gctcaactgac tggctgcgtctt ccgtcggttgc	4200
gctgcggcga gcggtatcag ctcaactcaaa ggcggtaata cggttatccca cagaatcagg	4260
ggataacgcgca ggaaagaaca tggtagccaa aggccagcaa aaggccacca accgtaaaaaa	4320

ggccgcgttg	ctggcgaaaa	tccataggct	ccggccccc	gacgagcatc	acaaaaatcg	4380
acgctcaagt	cagagggtggc	gaaacccgac	aggactataa	agataaccagg	cgtttcccc	4440
tggaagctcc	ctcggtcgct	ctccgttcc	gaccctgccc	cttaccggat	acctgtccgc	4500
ctttctccct	tcgggaagcg	tggcgcttcc	tcaatgctca	cgctgttaggt	atctcagttc	4560
ggttaggtc	gttcgctcca	agctgggctg	tgtgcacgaa	ccccccgttc	agecccgaccg	4620
ctgcgcctta	tccggtaact	atcgcttga	gtccaaacccg	gtaagacacg	acttatcgcc	4680
actggcagca	gccactggta	acaggattag	cagagcgagg	tatgttaggcg	gtgctacaga	4740
gttcttgaag	tggtggccta	actacggcta	cactagaagg	acagtatttgc	gtatctgcgc	4800
tctgctgaag	ccagttaccc	tcggaaaaaag	agttggtagc	tcttgatccg	gcaaacaac	4860
caccgcgtgt	agcggtgggt	tttttgggg	caagcagcag	attacgcgc	gaaaaaaaaagg	4920
atctcaagaa	gatcctttga	tcttttctac	ggggtctgac	gctcagtgg	acgaaaaactc	4980
acgttaagg	attttggtca	tgagattatc	aaaaaggatc	ttcacctaga	tcctttaaa	5040
ttaaaaatga	agttttaaat	caatctaaag	tatataatgag	taaacttgg	ctgacagtta	5100
ccaatgctta	atcagtgagg	cacctatctc	acgcatactgt	ctatccgtt	catccatagt	5160
tgcctgactc	cccggtcggt	agataactac	gatacgggag	ggcttaccat	ctggccccag	5220
tgctgcaatg	ataccgcgag	acccacgc	accggctcca	gatttatcag	caataaacca	5280
gccagccgga	agggccgagc	gcagaagtgg	tcctgcaact	ttatccgc	ccatccagtc	5340
tattaattgt	tgccggaaag	ctagagtaag	tagttcgcc	gttaatagtt	tgcgcaacgt	5400
tgttgccatt	gctacaggca	tcgtgggtgc	acgctcg	tttggatgg	cttcattcag	5460
ctccgggtcc	caacgatcaa	ggcgagttac	atgatcccc	atgttg	aaaaagcggt	5520
tagctccctc	ggtcctccga	tcgttgc	aagtaagtt	gcccgcgt	tatcactcat	5580
ggttatggca	gcactgcata	attctttac	tgtcatgcca	tccgtaa	gctttctgt	5640
gactggtgag	tactcaacca	agtcatctg	agaatagtgt	atgcggcgac	cgagttgc	5700
ttgccccggcg	tcaataacggg	ataataccgc	gccacatagc	agaactttaa	aagtgc	5760
cattggaaaa	cgttcttcgg	ggcgaaaact	ctcaaggatc	ttaccgc	tgagatccag	5820
ttcgatgtaa	cccaactcg	cacccaaactg	atottcagca	tctttactt	tcaccagcg	5880
ttctgggtga	gcaaaaaacag	gaaggcaaaa	tgccgc	aaggaaataa	ggcgacacg	5940
gaaatgtga	atactcatac	tcttccttt	tcaatattat	tgaagcattt	atcagggtt	6000
ttgtctcatg	agcggataca	tatttgaatg	tatttagaaa	aataaaca	taggggttcc	6060
gcgcacattt	ccccgaaaag	tgccac	ctga	cgtc		6094

<210> 14

52/63

<211> 481

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/BglII cloning junction, signal peptide, V region, portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning junction

<400> 14

ggatctcacc	atggagttgg	gactgcgctg	gggcttcctc	gttgctctt	taagaggtgt	60
ccagtgtcag	gtgcaattgg	tggagttctgg	gggaggcggt	gtccagccctg	ggaggtccct	120
gagactctcc	tgtgcagcgt	ctggattcgc	cttcagtaga	tatggcatgc	actgggtccg	180
ccaggctcca	gcgaaggggc	tggagtgggt	ggcagttata	tggatgatg	gaagtaataa	240
atactatgca	gactccgtga	agggccgatt	caccatctcc	agagacaatt	ccaagaacac	300
gcagtatctg	caaatacaca	gcctgagagc	cgaggacacg	gctgtgtatt	actgtgcgag	360
aggcggtgac	ttcctctact	actactatta	cggtatggac	gtctggggcc	aagggaccac	420
ggtcaccgtc	tcctcagcct	ccaccaaggg	ccatcggtc	ttccccctgg	caccctctag	480
c						481

<210> 15

<211> 142

<212> PRT

<213> Homo sapiens

<400> 15

Met	Glu	Leu	Gly	Leu	Arg	Trp	Gly	Phe	Leu	Val	Ala	Leu	Leu	Arg	Gly
1				5					10				15		

Val	Gln	Cys	Gln	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Val	Val	Gln
				20			25						30		

Pro	Gly	Arg	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Ala	Phe
				35			40				45				

Ser	Arg	Tyr	Gly	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu
				50			55				60				

Glu	Trp	Val	Ala	Val	Ile	Trp	Tyr	Asp	Gly	Ser	Asn	Lys	Tyr	Tyr	Ala
65				70			75				80				

Asp	Ser	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn
				85			90				95				

53/63
 Thr Gln Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
 100 105 110

Tyr Tyr Cys Ala Arg Gly Gly Asp Phe Leu Tyr Tyr Tyr Tyr Gly
 115 120 125

Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 130 135 140

<210> 16

<211> 463

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/BglII cloning junction, signal peptide, V region, portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning junction

<400> 16

ggatctcacc	atgagggtcc	ctgctcagct	cctggactc	ctgctgtct	ggctcccaga	60
taccagatgt	gacatccaga	tgacccagtc	tccatcctcc	ctgtctgcat	ctgtaggaga	120
cagagtcacc	atcacttgcc	ggcgcagtc	ggcattagc	aattattnag	cctggtatca	180
gcagaaaaca	gggaaaagttc	ctaagttcct	gatctatgaa	gcatccactt	tgcaatcagg	240
ggtcccatct	cggttcagtg	gcggtggtatc	tggacagat	ttcactctca	ccatcagcag	300
cctgcagcct	gaagatgttg	caacttatta	ctgtcaaaat	tataacagtg	ccccattcac	360
tttcggccct	gggaccaaag	tggatatcaa	acgaactgtg	gctgcaccct	ctgtcttcat	420
cttcccgcca	tctgatgagc	agttgaaatc	tggaactgct	agc		463

<210> 17

<211> 127

<212> PRT

<213> Homo sapiens

<400> 17

Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Pro
 1 5 10 15

Asp Thr Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser
 20 25 30

Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly
 35 40 45

Ile Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Thr Gly Lys Val Pro
 50 55 60

Lys Phe Leu Ile Tyr Glu Ala Ser Thr Leu Gln Ser Gly Val Pro Ser
65 70 75 80

Arg Phe Ser Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
85 90 95

Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Tyr Asn
100 105 110

Ser Ala Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
115 120 125

<210> 18

<211> 508

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/BglII cloning junction, signal peptide, V region, portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning junction

<400> 18

ggatctcacc atggggtcaa ccgccatcct caccatggag ttggggctgc gctgggtct 60

cctcggtgct ctttaagag gtgtccagtgc tcaggtgcag ctgggtggagt ctggggggagg 120

cgtggtccag cctgggaggt ccctgagact ctccctgtgca gcgtctggat tcaccttcag 180

taactatgtc atgcactggg tccgccaggc tccaggcaag gggctggagt gggtggcaat 240

tatatggat gatggaagta ataaatacta tgcaactcc gtgaagggcc gattcaccat 300

ctccagagac aattccaaga acacgctgta tctgcaaatg aacagcctga gagccgagga 360

cacggctgtg tattactgtg cgggtggata taactggaac tacgagtacc actactacgg 420

tatggacgtc tggggccaag ggaccacggc caccgtctcc tcagcctcca ccaagggccc 480

atcggtcttc cccctggcac cctctagc 508

<210> 19

<211> 143

<212> PRT

<213> Homo sapiens

<400> 19

Met Glu Leu Gly Leu Arg Trp Val Leu Leu Val Ala Leu Leu Arg Gly
1 5 10 15

Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Val Val Gln
20 25 30

Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
 35 40 45

Ser Asn Tyr Val Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
 50 55 60

Glu Trp Val Ala Ile Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala
 65 70 75 80

Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
 85 90 95

Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
 100 105 110

Tyr Tyr Cys Ala Gly Gly Tyr Asn Trp Asn Tyr Glu Tyr His Tyr Tyr
 115 120 125

Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 130 135 140

<210> 20

<211> 463

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/BglII cloning junction, signal peptide, V region, portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning junction

<400> 20

ggatctcacc atgagggtcc ccgctcagct cctggggctc ctgctgctct gttcccagg 60

tgccagatgt gacatccaga tgacccagtc tccatcctca ctgtctgcat ctgttaggaga 120

cagagtcacc atcacttgtc gggcgagtca gggcattacc aattatttag cctggttca 180

gcagaaacca gggaaagccc ctaagtccct tatctatgct gcattcagg ttcaaagtgg 240

ggtcccatca aagttcagcg gcagtggatc tggacagat ttcaagtctca ccatcagcag 300

cctgcagcct gaagattttg caacttatta ctgccaacag tataatagtt acccgatcac 360

cttcggccaa gggacacgac tggagattaa acgaactgtg gctgcaccat ctgtcttcat 420

cttcccgcca tctgtatgagc agttgaaatc tggaaactgct agc 463

<210> 21

<211> 127

<212> PRT

<213> Homo sapiens

<400> 21

Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Cys Phe Pro
 1 5 10 15

Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser
 20 25 30

Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly
 35 40 45

Ile Thr Asn Tyr Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro
 50 55 60

Lys Ser Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser
 65 70 75 80

Lys Phe Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser
 85 90 95

Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn
 100 105 110

Ser Tyr Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
 115 120 125

<210> 22

<211> 490

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/BglII cloning junction, signal peptide, V region, portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning junction

<400> 22

ggatctcacc atggagttgg gacttagctg gtttttcctc gttgctcttt taagaggtgt 60

ccagtgtcag gtccagctgg tggagctgg gggaggcgtg gtccagcctg ggaggtccct 120

gagactctcc tgtgcagcgt ctggattcac cttcagtagc tatggcatgc actgggtccg 180

ccaggctcca ggcaggggc tggactgggt ggcaattatt tggcatgatg gaagtaataa 240

atactatgca gactccgtga agggccgatt caccatctcc agagacaatt ccaagaagac 300

gctgtacctg caaatgaaca gtttgagagc cgaggacacg gctgtgtatt actgtgcgag 360

agcttgggcc tatgactacg gtgactatga atactacttc ggtatggacg tctggggcca 420

agggaccacg gtcaccgtct cctcagcctc caccaagggc ccatacggtct tccccctggc 480

accctcttagc 490

<210> 23

<211> 145

<212> PRT

<213> Homo sapiens

<400> 23

Met Glu Leu Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly
1 5 10 15

Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Val Val Gln
20 25 30

Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
35 40 45

Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
50 55 60

Asp Trp Val Ala Ile Ile Trp His Asp Gly Ser Asn Lys Tyr Tyr Ala
65 70 75 80

Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys
85 90 95

Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
100 105 110

Tyr Tyr Cys Ala Arg Ala Trp Ala Tyr Asp Tyr Gly Asp Tyr Glu Tyr
115 120 125

Tyr Phe Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser
130 135 140

Ser
145

<210> 24

<211> 463

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/BglIII cloning junction, signal peptide, V region, portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning junction

<400> 24

ggatctcacc atgagggtcc ctgctcagct cctggggctc ctgctgcctt gtttcccagg 60

tgccagatgt gacatccaga tgacccagtc tccatcctca ctgtctgcat ctgtaggaga 120

cagagtcacc atcacttgtc gggcgagtca gggcattagc cattatttag cctggttca 180

gcagaaacca gggaaagccc ctaagtccct gatctatgct gcatccagtt tgcaaagtgg 240

ggtcccatca aagttcagcg gcagtggatc tggacagat ttcactctca ccatcagcag 300

58/63						
cctacagcct	gaagattttg	caacttatta	ctgccaacag	tataatagtt	tcccgctcac	360
tttcggcgg	gggaccaagg	tggagatcaa	acgaactgtg	gctgcaccat	ctgtcttcat	420
cttcccgcca	tctgatgagc	agttgaaatc	tggaactgct	agc		463

<210> 25

<211> 127

<212> PRT

<213> Homo sapiens

<400> 25

Met	Arg	Val	Pro	Ala	Gln	Leu	Leu	Gly	Leu	Leu	Leu	Cys	Phe	Pro
1					5				10				15	

Gly	Ala	Arg	Cys	Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser
					20			25					30		

Ala	Ser	Val	Gly	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Ala	Ser	Gln	Gly
					35			40					45		

Ile	Ser	His	Tyr	Leu	Ala	Trp	Phe	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Pro
					50			55					60		

Lys	Ser	Leu	Ile	Tyr	Ala	Ala	Ser	Ser	Leu	Gln	Ser	Gly	Val	Pro	Ser
					65			70					75		80

Lys	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser
					85			90					95		

Ser	Leu	Gln	Pro	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Tyr	Asn
					100			105					110		

Ser	Phe	Pro	Leu	Thr	Phe	Gly	Gly	Thr	Lys	Val	Glu	Ile	Lys	
					115			120				125		

<210> 26

<211> 469

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/BgIII cloning junction, signal peptide, V region, portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning junction

<400> 26

ggatccacc	atgggtcaa	ccgtcatcct	cgccttcctc	ctggctgttc	tccaggagt	60
-----------	-----------	------------	------------	------------	-----------	----

ctgtgccgag	gtgcagctgg	tgcagtcgg	agcagaggtg	aaaaagcccg	gggagtctct	120
------------	------------	-----------	------------	------------	------------	-----

gaagatctcc	tgtagggtt	ctggatacag	cttaccagt	tactggatcg	gtgggtgcg	180
------------	-----------	------------	-----------	------------	-----------	-----

		59/63				
ccagatgcc	gggaaaggcc	tggagtggat	ggggatcatc	tatcctggtg	actctgatac	240
cagatacagc	ccgtccttcc	aaggccaggt	caccatctca	gccgacaagt	ccatcagcac	300
cgcctacctg	cagtggagca	gcctgaaggc	ctcgacacc	gccatgtatt	actgtgcgag	360
acggatggca	gcagctggcc	cctttgacta	ctggggccag	ggaaccctgg	tcaccgtctc	420
ctcagcetcc	accaagggcc	catcggttt	ccccctggca	ccctctagc		469

<210> 27

<211> 138

<212> PRT

<213> Homo sapiens

<400> 27

Met Gly Ser Thr Val Ile Leu Ala Leu Leu Leu Ala Val Leu Gln Gly
1 5 10 15

Val Cys Ala Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
20 25 30

Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe
35 40 45

Thr Ser Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu
50 55 60

Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser
65 70 75 80

Pro Ser Phe Gln Gln Gly Val Thr Ile Ser Ala Asp Lys Ser Ile Ser
85 90 95

Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met
100 105 110

Tyr Tyr Cys Ala Arg Arg Met Ala Ala Ala Gly Pro Phe Asp Tyr Trp
115 120 125

Gly Gln Gly Thr Leu Val Thr Val Ser Ser
130 135

<210> 28

<211> 466

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/BglII cloning junction, signal peptide, V region, portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning junction

60/63

<400> 28		
ggatctcacc atgagggtcc ccgctcagct totcttcctt ctgctactct ggctcccaga	60	
taccactgga ggaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga	120	
aagagccacc ctctcctgca ggaccagtca gagtattggc tggaacttag cctggcacca	180	
acagaaaacct ggccaggctc ccaggctcct catctatggt gcatcttcca ggaccactgg	240	
tatcccagcc aggttcagtg gcagtgggtc tggacagag ttcactctca ccatcagcag	300	
cctgcagtct gaagattctg cagtttatta ctgtcagcat tatgataact ggcccatgtg	360	
cagtttggc caggggaccg agctggagat caaacgaact gtggctgcac catctgtctt	420	
catcttcccg ccatctgatg agcagttgaa atctgaaact gctagc	466	

<210> 29

<211> 128

<212> PRT

<213> Homo sapiens

<400> 29

Met Arg Val Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro			
1	5	10	15

Asp Thr Thr Gly Gly Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser		
20	25	30

Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Gln Ser		
35	40	45

Ile Gly Trp Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro		
50	55	60

Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Thr Thr Gly Ile Pro Ala			
65	70	75	80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser		
85	90	95

Ser Leu Gln Ser Glu Asp Ser Ala Val Tyr Tyr Cys Gln His Tyr Asp		
100	105	110

Asn Trp Pro Met Cys Ser Phe Gly Gln Gly Thr Glu Leu Glu Ile Lys		
115	120	125

<210> 30

<211> 487

<212> DNA

<213> Artificial Sequence

<220>

61/63

<223> Includes BamHI/BglII cloning junction, signal peptide, V region, portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning junction

<400> 30
 ggatctcacc atggagtttg ggctgtgctg gattttcctc gttgctctt taagaggtgt 60
 ccagtgtcag gtgcagctgg tggagctgg gggaggcgtg gtccagcctg ggaggtccct 120
 gagactctcc tgtgcagccct ctggattcac cttcatttagc tatggcatgc actgggtccg 180
 ccaggctcca ggcaaggggc tggagtggtt ggcagttata tcataatgatg gaagtaataa 240
 atactatgca gactccgtga agggcccatt caccatctcc agagacaatt ccaagaacac 300
 gctgtatctg caaatgaaca gcctgagagc tgaggacacg gctgtgtatt actgtgcgag 360
 agtatttagtg ggagctttat attattataa ctactacggg atggacgtct ggggccaagg 420
 gaccacggtc accegtctcct cagcctccac caagggccca tcggtcttcc ccctggcacc 480
 ctcttagc 487

<210> 31

<211> 144

<212> PRT

<213> Homo sapiens

<400> 31

Met Glu Phe Gly Leu Cys Trp Ile Phe Leu Val Ala Leu Leu Arg Gly
 1 5 10 15

Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln
 20 25 30

Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
 35 40 45

Ile Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
 50 55 60

Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala
 65 70 75 80

Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
 85 90 95

Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
 100 105 110

Tyr Tyr Cys Ala Arg Val Leu Val Gly Ala Leu Tyr Tyr Tyr Asn Tyr
 115 120 125

Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 130 135 140

<210> 32

<211> 478

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/BglII cloning junction, signal peptide, V region, portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning junction

<400> 32

ggatctcacc	atgagggtcc	ctgctagct	cctggggctg	ctaatgtct	ggatacctgg	60
atccagtgca	gatattgtga	tgaccagac	tccactctct	ctgtccgtca	cccttggaca	120
gccggcctcc	atctcctgca	agtctagtca	gagcctcctg	catagtgatg	gaaagacctt	180
tttgtattgg	tatctgcaga	agccaggcca	gcctccacag	ctcctgatct	atgaggttcc	240
caaccggttc	tctggagtgc	cagataggtt	cagtggcagc	gggtcaggga	cagatttcac	300
actgaaaatc	agccgggtgg	aggctgagga	tgttgggctt	tattactgca	tgcaaagtat	360
acagcttccg	ctcactttcg	gcggaggggac	caaggtggag	atcaaacgaa	ctgtggctgc	420
accatctgtc	ttcatcttcc	cgccatctga	tgagcagttg	aaatctggaa	ctgctagc	478

<210> 33

<211> 132

<212> PRT

<213> Homo sapiens

<400> 33

Met	Arg	Val	Pro	Ala	Gln	Leu	Leu	Gly	Leu	Leu	Met	Leu	Trp	Ile	Pro
1					5						10			15	

Gly	Ser	Ser	Ala	Asp	Ile	Val	Met	Thr	Gln	Thr	Pro	Leu	Ser	Leu	Ser
					20			25			30				

Val	Thr	Pro	Gly	Gln	Pro	Ala	Ser	Ile	Ser	Cys	Lys	Ser	Ser	Gln	Ser
					35			40			45				

Leu	Leu	His	Ser	Asp	Gly	Lys	Thr	Phe	Leu	Tyr	Trp	Tyr	Leu	Gln	Lys
					50			55			60				

Pro	Gly	Gln	Pro	Pro	Gln	Leu	Leu	Ile	Tyr	Glu	Val	Ser	Asn	Arg	Phe
					65			70			75			80	

Ser	Gly	Val	Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe
					85			90			95				

Thr	Leu	Lys	Ile	Ser	Arg	Val	Glu	Ala	Glu	Asp	Val	Gly	Leu	Tyr	Tyr
					100			105			110				

WO 03/034903

PCT/US02/33944

Cys Met Gln Ser Ile Gln Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys
115 120 125

Val Glu Ile Lys
130

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number
WO 03/034903 A3

(51) International Patent Classification⁷: C07H 21/04, C12N 5/12, C07K 16/00, A61K 39/395, G01N 33/53

(74) Agent: VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(21) International Application Number: PCT/US02/33944

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 23 October 2002 (23.10.2002)

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/335,215	23 October 2001 (23.10.2001)	US
60/362,747	7 March 2002 (07.03.2002)	US
60/412,618	20 September 2002 (20.09.2002)	US

(71) Applicant (for all designated States except US): PSMA DEVELOPMENT COMPANY, L.L.C. [US/US]; Progenics Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

Published:

— with international search report

(88) Date of publication of the international search report:
30 October 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): MADDON, Paul, J. [US/US]; 191 Fox Meadow Road, Scarsdale, NY 10583 (US). DONOVAN, Gerald, P. [US/US]; 430 East 63rd Street, Apartment 5L, New York, NY 10021 (US). OLSON, William, C. [US/US]; 21 Fawn Court, Ossining, NY 10562 (US). SCHÜLKE, Norbert [US/US]; 101 Ridge Road, New City, NY 10956 (US). GARDNER, Jason [US/US]; 24 Bramble Brook Road, Ardsley, NY 10502 (US). MA, Dangshe [US/US]; 49 Glenwood Road, Millwood, NY 10546 (US).

WO 03/034903 A3

(54) Title: PSMA ANTIBODIES AND PROTEIN MULTIMERS

(57) Abstract: The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment. The invention also includes oligomeric forms of PSMA proteins, compositions comprising the multimers, and antibodies that selectively bind to the multimers.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/33944

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/04; C12N 5/12; C07K 16/00; A61K 39/395; G01N 33/53
 US CL : 530/387.1, 388.85, 350, 388.85, 391.7; 424/130.1, 156.1, 181.1; 536/23.53; 435/7.1/326

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/387.1, 388.85, 350, 388.85, 391.7; 424/130.1, 156.1, 181.1; 536/23.53; 435/7.1/326

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97/35616 A1 (PACIFIC NORTHWEST CANCER FOUNDATION) 02 October 1997 (02/10/97), see entire document, especially page 4-5, Figure 2, page 12, page 16, page 18-26.	1-33, 35-53, 56-87, 98-384
Y	US 6,107,090 A (BANDER) 22 August 2000 (22/08/00), see entire document, especially column 7-15.	1-33, 35-52, 56-87, 98-384
Y	US 5,804,602 A (SLUSHER et al) 08 September 1998 (08/08/98), see entire document, especially column 18, lines 25-43.	263-268

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	
"A"	document defining the general state of the art which is not considered to be of particular relevance
"B"	earlier application or patent published on or after the international filing date
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"	document referring to an oral disclosure, use, exhibition or other means
"P"	document published prior to the international filing date but later than the priority date claimed
"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"	document member of the same patent family

Date of the actual completion of the international search

13 March 2003 (13.03.2003)

Date of mailing of the international search report

07 MAY 2003

Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231
 Facsimile No. (703)305-3230

Authorized officer

Larry R. Helms

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

PCT/US02/33944

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-33, 56-85, 88-140, 143-172, 175-215, drawn to an antibody that competes for binding to a second antibody that binds to PSMA.

Group II, claim(s) 34-55, 141-142, drawn to DNA

Group III, claim(s) 86-87, 173-174, drawn to hybridomas.

Group IV, claim(s) 216, 221, 222, drawn to a method of detecting PSMA.

Group V, claim(s) 217-221, 222, drawn to a method of diagnosing PSMA.

Group VI, claim(s) 223, 225, 226, 118, 229, drawn to a method of assessing the prognosis of a subject withPSMA.

Group VII, claim(s) 224, 225, 226, 227-229, drawn to a method of assessing the effectiveness of treatment.

Group VIII, claim(s) 231-233, drawn to a method of inducing cytolysis of a cell.

Group IX, claim(s) 234-250, drawn to a method of treating a PSMA disease.

Group X, claim(s) 251-256, drawn to a method of inhibiting folate hydrolase activity.

Group XI, claim(s) 257-262, drawn to a method of enhancing folate hydrolase activity.

Group XII, claim(s) 263-268, drawn to a method of inhibiting NAALADase activity.

Group XIII, claim(s) 269-274, drawn to a method of enhancing NAADLADase activity.

Group XIV, claim(s) 275-286, drawn to a method of inhibiting dipeptidyl dipeptidase IV peptide.

Group XV, claim(s) 287-298, drawn to a method of inhibiting gamma glutamyl hydrolase activity.

Group XVI, claim(s) 299-308, drawn to a method of specific delivery of a therapeutic agent to a PSMA cell.

Group XVII, claim(s) 309-361, drawn to a an antibody that binds a multimer.

Group XVIII, claim(s) 362 drawn to a method of inducing an immune response.

Group XIX, claim(s) 363-369, drawn to a recombinant PSMA multimer.

Group XX, claim(s) 370-375, drawn to a method of screening for a candidate that inhibits enzymatic activity of PSMA.

Group XXI, claim(s) 376-381, drawn to a method of screening for a candidate that enhances enzymatic activity of PSMA.

Group XXII, claim(s) 382, drawn to a method of identifying a compound.

Group XXIII, claim(s) 383, drawn to a method of identifying a compound.

INTERNATIONAL SEARCH REPORT

PCT/US02/33944

Group XXIV, claim(s) 384, drawn to a method of identifying a compound.

The inventions listed as Groups I-XXIV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the technical feature recited in Groups I-XXIV is an antibody that competes for binding to a second antibody that binds PSMA. However, WO 97/35616 teaches antibodies to PSMA and as such they would compete for binding to a second antibody recited in Group I. Therefore the technical feature linking Groups I-XXIV does not contribute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

Continuation of B. FIELDS SEARCHED Item 3:

CAPLUS, MEDLINE, BIOSIS, WEST, USPATFULL, PIR, SWISSPROT, GENEMBL

Search terms: PSMA, antibody, prostate specific membrane antigen, SEQ ID Nos, expression vector, host cell, monoclonal, polyclonal, Fab, label, diagnosing, treatment, NAALADase, folate hydrolase, dipeptidyl dipeptidase IV, gamma glutamyl hydrolasePSMA multimer, dimer.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number
WO 2003/034903 A3

(51) International Patent Classification⁷: C07H 21/04, C12N 5/12, C07K 16/00, A61K 39/395, G01N 33/53
(74) Agent: VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(21) International Application Number:

PCT/US2002/033944

(22) International Filing Date: 23 October 2002 (23.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/335,215 23 October 2001 (23.10.2001) US
60/362,747 7 March 2002 (07.03.2002) US
60/412,618 20 September 2002 (20.09.2002) US

(71) Applicant (for all designated States except US): PSMA DEVELOPMENT COMPANY, L.L.C. [US/US]; Progenics Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MADDON, Paul, J. [US/US]; 191 Fox Meadow Road, Scarsdale, NY 10583 (US). DONOVAN, Gerald, P. [US/US]; 430 East 63rd Street, Apartment 5L, New York, NY 10021 (US). OLSON, William, C. [US/US]; 21 Fawn Court, Ossining, NY 10562 (US). SCHÜLKE, Norbert [US/US]; 101 Ridge Road, New City, NY 10596 (US). GARDNER, Jason [US/US]; 24 Bramble Brook Road, Ardsley, NY 10502 (US). MA, Dangshe [US/US]; 49 Glenwood Road, Millwood, NY 10546 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with amended claims

(88) Date of publication of the international search report: 30 October 2003

Date of publication of the amended claims: 13 May 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2003/034903 A3

(54) Title: PSMA ANTIBODIES AND PROTEIN MULTIMERS

(57) Abstract: The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment. The invention also includes oligomeric forms of PSMA proteins, compositions comprising the multimers, and antibodies that selectively bind to the multimers.

AMENDED CLAIMS

[received by the International Bureau on 23 May 2003 (23.05.03);
original claims 12-384 replaced by amended claims 13-385;
remaining claims unchanged (46 pages)]

Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1 and antigen-binding fragments thereof.

5

9. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of antibodies comprising:

10 (a) a heavy chain encoded by a nucleic acid molecule comprising the heavy chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and
(b) a light chain encoded by a nucleic acid molecule comprising the light chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13,
15 and antigen-binding fragments thereof.

10. The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

20 (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 2, and
(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 8.

25 11. The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 3, and
(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 9.

30

12. The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 4, and

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 10.

5

13. The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 5, and

10 (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 11.

14. The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

15 (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 6, and

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 12.

20 15. The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 7, and

25 (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 13.

16. An isolated antibody which specifically binds to an extracellular domain of prostate specific membrane antigen, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 90% identical to the nucleotide sequence encoding the antibody of claim 9.

30 17. The isolated antibody of claim 16, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 95% identical.

18. The isolated antibody of claim 16, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 97% identical.
- 5 19. The isolated antibody of claim 16, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 98% identical.
20. The isolated antibody of claim 16, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 99% identical.
- 10 21. An antigen-binding fragment of the isolated antibody of claim 9, comprising:
 - (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding regions or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 14, 18, 22, 26 and 30, and
 - (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or region of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 16, 20, 24, 28 and 32.
- 15 22. An antigen-binding fragment of the isolated antibody of claim 21, comprising:
 - (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 14, and
 - (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 16.
- 20 23. An antigen-binding fragment of the isolated antibody of claim 21, comprising:
 - (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 18, and
 - (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 20.
- 25 24. An antigen-binding fragment of the isolated antibody of claim 21, comprising:
 - (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 22, and

(b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 24.

25. An antigen-binding fragment of the isolated antibody of claim 21, comprising:
 - 5 (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 26, and
(b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 28.
- 10 26. An antigen-binding fragment of the isolated antibody of claim 21, comprising:
 - (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 30, and
(b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 32.
- 15 27. The antigen-binding fragment of the isolated antibody of claim 9, comprising:
 - (a) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of amino acid sequences set forth as: SEQ ID NOs: 15, 19, 23, 27 and 31, and
20 (b) a light chain variable region comprising an amino acid sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 17, 21, 25, 29 and 33.
28. An antigen-binding fragment of the isolated antibody of claim 27, comprising:
 - 25 (a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 15, and
(b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 17.
29. An antigen-binding fragment of the isolated antibody of claim 27, comprising:
 - 30 (a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 19, and
(b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 21.

30. An antigen-binding fragment of the isolated antibody of claim 27, comprising:
 - (a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 23, and
 - 5 (b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 25.
31. An antigen-binding fragment of the isolated antibody of claim 27, comprising:
 - (a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 27, and
 - 10 (b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 29.
32. An antigen-binding fragment of the isolated antibody of claim 27, comprising:
 - (a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 31, and
 - 15 (b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 33.
- 20 33. An isolated antigen-binding fragment which comprises a CDR of the antigen-binding fragment according to claim 21 or claim 27.
34. The isolated antigen-binding fragment of claim 33, wherein the CDR is CDR3.
- 25 35. An expression vector comprising an isolated nucleic acid molecule encoding the isolated antibody or antigen-binding fragment of any one of claims 1-34.
36. An expression vector comprising an isolated nucleic acid molecule encoding the heavy chain of AB-PG1-XG1-006 encoded by a nucleic acid molecules comprising the 30 coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 2.

37. An expression vector comprising an isolated nucleic acid molecule encoding the light chain of AB-PG1-XG1-006 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 8.

5 38. An expression vector comprising an isolated nucleic acid molecule encoding the heavy and light chains of AB-PG1-XG1-006 encoded by the nucleic acid molecules comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 2 and 8.

10 39. An expression vector comprising an isolated nucleic acid molecule encoding the heavy chain of AB-PG1-XG1-026 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 3.

15 40. An expression vector comprising an isolated nucleic acid molecule encoding the light chain of AB-PG1-XG1-026 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 9.

20 41. An expression vector comprising an isolated nucleic acid molecule encoding the heavy and light chains of AB-PG1-XG1-026 encoded by the nucleic acid molecules comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 3 and 9.

25 42. An expression vector comprising an isolated nucleic acid molecule encoding the heavy chain of AB-PG1-XG1-051 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 4.

30 43. An expression vector comprising an isolated nucleic acid molecule encoding the light chain of AB-PG1-XG1-051 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 10.

44. An expression vector comprising an isolated nucleic acid molecule encoding the heavy and light chains of AB-PG1-XG1-051 encoded by the nucleic acid molecules

comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 4 and 10.

45. An expression vector comprising an isolated nucleic acid molecule encoding the 5 heavy chain of AB-PG1-XG1-069 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 5.

46. An expression vector comprising an isolated nucleic acid molecule encoding the light 10 chain of AB-PG1-XG1-069 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 11.

47. An expression vector comprising an isolated nucleic acid molecule encoding the 15 heavy and light chains of AB-PG1-XG1-069 encoded by the nucleic acid molecules comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 5 and 11.

48. An expression vector comprising an isolated nucleic acid molecule encoding the 20 heavy chain of AB-PG1-XG1-077 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 6.

49. An expression vector comprising an isolated nucleic acid molecule encoding the light 25 chain of AB-PG1-XG1-077 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 12.

50. An expression vector comprising an isolated nucleic acid molecule encoding the 30 heavy and light chains of AB-PG1-XG1-077 encoded by the nucleic acid molecules comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 6 and 12.

51. An expression vector comprising an isolated nucleic acid molecule encoding the heavy chain of AB-PG1-XG1-006 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 7.

52. An expression vector comprising an isolated nucleic acid molecule encoding the light chain of AB-PG1-XG1-006 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 13.

5 53. An expression vector comprising an isolated nucleic acid molecule encoding the heavy and light chains of AB-PG1-XG1-006 encoded by the nucleic acid molecules comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 7 and 13.

10 54. A host cell transformed or transfected by the expression vector of claim 35.

55. A plasmid which produces the antibody or antigen binding fragments of any one of claims 1-34.

15 56. The plasmid of claim 55, wherein the plasmid is selected from the group consisting of: AB-PG1-XG1-006 Heavy Chain (SEQ ID NO: 2), AB-PG1-XG1-006 Light Chain (SEQ ID NO: 8), AB-PG1-XG1-026 Heavy Chain (SEQ ID NO: 3), AB-PG1-XG1-026 Light Chain (SEQ ID NO: 9), AB-PG1-XG1-051 Heavy Chain (SEQ ID NO: 4), AB-PG1-XG1-051 Light Chain (SEQ ID NO: 10), AB-PG1-XG1-069 Heavy Chain (SEQ ID NO: 5), AB-
20 PG1-XG1-069 Light Chain (SEQ ID NO: 11), AB-PG1-XG1-077 Heavy Chain (SEQ ID NO: 6), AB-PG1-XG1-077 Light Chain (SEQ ID NO: 12), PSMA 10.3 Heavy Chain (SEQ ID NO: 7), and PSMA 10.3 Kappa (SEQ ID NO: 13).

25 57. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody or antigen-binding fragment thereof is selected for its ability to bind live cells.

58. The isolated antibody or antigen-binding fragment thereof of claim 57, wherein the cell is a tumor cell.

30 59. The isolated antibody or antigen-binding fragment thereof of claim 58, wherein the tumor cell is a prostate tumor cell.

60. The isolated antibody or antigen-binding fragment thereof of claim 59, wherein the tumor cell is a LNCaP cell.

61. The isolated antibody or antigen-binding fragment thereof according to claim 1,
5 wherein said antibody or antigen-binding fragment thereof mediates cytolysis of cells
expressing PSMA.

62. The isolated antibody or antigen-binding fragment thereof of claim 61 wherein
cytolysis of cells expressing PSMA is mediated by effector cells.

10

63. The isolated antibody or antigen-binding fragment thereof of claim 61 wherein
cytolysis of cells expressing PSMA is complement mediated in the presence of effector cells.

15

64. The isolated antibody or antigen-binding fragment thereof according to claim 1,
wherein said antibody or antigen-binding fragment thereof inhibits the growth of cells
expressing PSMA.

20

65. The isolated antibody or antigen-binding fragment thereof according to claim 1,
wherein said antibody or antigen-binding fragment thereof does not require cell lysis to bind
to the epitope on PSMA.

25

66. The isolated antibody or antigen-binding fragment thereof according to claim 1,
wherein said antibody or antigen-binding fragment thereof is selected from the group
consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, IgE or has
immunoglobulin constant and/or variable domain of IgG1, IgG2, IgG3, IgG4, IgM, IgA1,
IgA2, IgAsec, IgD or IgE.

30

67. The isolated antibody or antigen-binding fragment thereof according to claim 1,
wherein said antibody is a recombinant antibody.

68. The isolated antibody or antigen-binding fragment thereof according to claim 1,
wherein said antibody is a polyclonal antibody.

69. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a monoclonal antibody.

70. The isolated antibody or antigen-binding fragment thereof according to claim 1, 5 wherein said antibody is a humanized antibody.

71. The isolated antibody or antigen-binding fragment thereof according to claim 70, wherein said antibody is a monoclonal antibody.

10 72. The isolated antibody or antigen-binding fragment thereof according to claim 70, wherein said antibody is a polyclonal antibody.

73. The isolated antibody or antigen-binding fragment thereof according to claim 70, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

15 74. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a chimeric antibody.

20 75. The isolated antibody or antigen-binding fragment thereof according to claim 74, wherein said antibody is a monoclonal antibody.

76. The isolated antibody or antigen-binding fragment thereof according to claim 74, wherein said antibody is a polyclonal antibody.

25 77. The isolated antibody or antigen-binding fragment thereof according to claim 74, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

78. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a human antibody.

30 79. The isolated antibody or antigen-binding fragment thereof according to claim 78, wherein said antibody is a monoclonal antibody.

80. The isolated antibody or antigen-binding fragment thereof according to claim 78, wherein said antibody is a polyclonal antibody.

81. The isolated antibody or antigen-binding fragment thereof according to claim 78, 5 wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

82. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a bispecific or multispecific antibody.

10 83. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein the isolated antigen-binding fragment is selected from the group consisting of a Fab fragment, a $F(ab')_2$ fragment, and a Fv fragment CDR3.

15 84. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody is a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293), PSMA 10.3 (PTA-3247), PSMA 1.8.3 (PTA-3906), PSMA A3.1.3 (PTA-3904), PSMA A3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428), 20 Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557), Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359), Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362), Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367), Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388), 25 Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391), Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

30 85. The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof binds to a conformational epitope.

86. The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof is internalized into a cell with the prostate specific membrane antigen.

87. A hybridoma cell line that produces an antibody selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, 5 Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1 and Abgenix 4.152.1.

10 88. The hybridoma cell line of claim 87, wherein the hybridoma cell line is selected from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293), PSMA 10.3 (PTA-3247), PSMA 1.8.3 (PTA-3906), PSMA A3.1.3 (PTA-3904), PSMA A3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428), Abgenix 15 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557), Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359), Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362), Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367), Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388), Abgenix 4.232.3 20 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391), Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

89. A composition comprising:
an antibody or antigen-binding fragment thereof according to any one of claims 1-34
25 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

90. The composition of claim 89, further comprising an antitumor agent, an immunostimulatory agent, an immunomodulator, or a combination thereof.

30 91. The composition of claim 90, wherein the antitumor agent is a cytotoxic agent, an agent that acts on tumor neovasculature, or a combination thereof.

92. The composition of claim 90, wherein the immunomodulator is α -interferon, γ -interferon, tumor necrosis factor- α or a combination thereof.
93. The composition of claim 90, wherein the immunostimulatory agent is interleukin-2, immunostimulatory oligonucleotides, or a combination thereof.
94. A composition comprising:
a combination of two or more antibodies or antigen-binding fragments thereof according to any one of claims 1-34 and a pharmaceutically acceptable carrier, excipient, or stabilizer.
95. The composition of claim 94, further comprising an antitumor agent, an immunostimulatory agent, an immunomodulator, or a combination thereof.
96. The composition of claim 95, wherein the antitumor agent is a cytotoxic agent, an agent that acts on tumor neovasculature, or a combination thereof.
97. The composition of claim 95, wherein the immunomodulator is α -interferon, γ -interferon, tumor necrosis factor- α or a combination thereof.
98. The composition of claim 95, wherein the immunostimulatory agent is interleukin-2, immunostimulatory oligonucleotides, or a combination thereof.
99. The isolated antibody or antigen-binding fragment thereof of claim 1, bound to a label.
100. The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 99, wherein the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.
101. A composition comprising:
an antibody or antigen-binding fragment thereof according to claim 99 and

a pharmaceutically acceptable carrier, excipient, or stabilizer.

102. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof specifically binds cell-surface PSMA and/or
5 rsPSMA with a binding affinity of about 1×10^{-9} M or less.

103. The isolated antibody or antigen-binding fragment thereof of claim 102, wherein the binding affinity is about 1×10^{-10} M or less.

10 104. The isolated antibody or antigen-binding fragment thereof of claim 103, wherein the binding affinity is about 1×10^{-11} M or less.

105. The isolated antibody or antigen-binding fragment thereof of claim 102, wherein the binding affinity is less than about 5×10^{-10} M.

15

106. The isolated antibody or antigen-binding fragment thereof of claim 1, bound to at least one therapeutic moiety .

107. The isolated antibody or antigen-binding fragment thereof of claim 106, wherein the antibody or antigen-binding fragment thereof mediates specific cell killing of PSMA-expressing cells with an IC_{50} of less than about 1×10^{-10} M.

108. The isolated antibody or antigen-binding fragment thereof of claim 107, wherein the IC_{50} is less than about 1×10^{-11} M.

25

109. The isolated antibody or antigen-binding fragment thereof of claim 108, wherein the IC_{50} is less than about 1×10^{-12} M.

110. The isolated antibody or antigen-binding fragment thereof of claim 107, wherein the IC_{50} is less than about 1.5×10^{-11} M.

111. The isolated antibody or antigen-binding fragment thereof of claim 106, wherein the therapeutic moiety is a drug.

112. The isolated antibody or antigen-binding fragment thereof of claim 106, wherein the therapeutic moiety is a replication selective virus.

5 113. The isolated antibody or antigen-binding fragment thereof of claim 111, wherein the drug is a cytotoxic drug.

114. The isolated antibody or antigen-binding fragment thereof of claim 113, wherein the cytotoxic drug is selected from the group consisting of: calicheamicin, esperamicin, 10 methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

115. The isolated antibody or antigen-binding fragment thereof of claim 106, wherein the therapeutic moiety is a toxin or a fragment thereof.

116. The isolated antibody or antigen-binding fragment thereof of claim 106, wherein the therapeutic moiety is an enzyme or a fragment thereof.

20 117. The isolated antibody or antigen-binding fragment thereof of claim 106, wherein the therapeutic moiety is an immunostimulatory or immunomodulating agent.

118. The isolated antibody or antigen-binding fragment thereof of claim 117, wherein the immunostimulatory or immunomodulating agent is selected from the group consisting of: a 25 cytokine, chemokine and adjuvant.

119. A composition comprising:
the antibody or antigen-binding fragment of claim 106 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

30 120. The isolated antibody or antigen-binding fragment thereof of 1, bound to a radioisotope.

121. The isolated antibody or antigen-binding fragment thereof according to claim 120, wherein the radioisotope emits α radiations.

122. The isolated antibody or antigen-binding fragment thereof according to claim 120, 5 wherein the radioisotope emits β radiations.

123. The isolated antibody or antigen-binding fragment thereof according to claim 120, wherein the radioisotope emits γ radiations.

10 124. The isolated antibody or antigen-binding fragment thereof according to claim 120, wherein the radioisotope is selected from the group consisting of ^{225}Ac , ^{211}At , ^{212}Bi , ^{213}Bi , ^{186}Rh , ^{188}Rh , ^{177}Lu , ^{90}Y , ^{131}I , ^{67}Cu , ^{125}I , ^{123}I , ^{77}Br , ^{153}Sm , ^{166}Ho , ^{64}Cu , ^{212}Pb , ^{224}Ra and ^{223}Ra .

15 125. A composition comprising the isolated antibody or antigen-binding fragment thereof of claim 120 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

126. A kit for detecting prostate cancer for diagnosis, prognosis or monitoring comprising: the isolated labeled antibody or antigen-binding fragment thereof of claim 99, and one or more compounds for detecting the label.

20 127. A kit according to claim 126, wherein the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

25 128. The isolated antibody or antigen-binding fragment thereof of any of claims 1, 99, 106 or 120 packaged in lyophilized form.

129. The isolated antibody or antigen-binding fragment thereof of any of claims 1, 99, 106 or 120 packaged in an aqueous medium.

30 139. An isolated antibody or an antigen-binding fragment thereof which specifically binds to an epitope on prostate specific membrane antigen (PSMA) defined by an antibody selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4,

PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA B3.1.3, PSMA B3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 5 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1, and antibodies comprising:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and

10 (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13.

131. The isolated antibody or antigen-binding fragment thereof according to claim 130, 15 wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA B3.1.3, PSMA B3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 20 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1 and antigen-binding fragments thereof.

132. The isolated antibody or antigen-binding fragment thereof according to claim 130, 25 wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of antibodies comprising:

(a) a heavy chain encoded by a nucleic acid molecule comprising the heavy chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and

30 (b) a light chain encoded by a nucleic acid molecule comprising the light chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13, and antigen-binding fragments thereof.

133. An isolated antibody which specifically binds to an epitope on prostate specific membrane antigen, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 90% identical to the nucleotide sequence encoding a 5 antibody of claim 132.

134. The isolated antibody of claim 133, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 95% identical.

10 135. The isolated antibody of claim 133, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 97% identical.

136. The isolated antibody of claim 133, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 98% identical.

15

137. The isolated antibody of claim 133, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 99% identical.

138. An antigen-binding fragment of the isolated antibody of claim 132, comprising:
20 (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding regions or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 14, 18, 22, 26 and 30, and
(b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or region of a nucleotide sequence selected from the group consisting of
25 nucleotide sequences set forth as: SEQ ID NOs: 16, 20, 24, 28 and 32.

139. The antigen-binding fragment of the isolated antibody of claim 132, comprising:
(a) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of amino acid sequences set forth as: SEQ ID NOs: 15, 19, 23, 27 and
30 31, and
(b) a light chain variable region comprising an amino acid sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 17, 21, 25, 29 and 33.

140. An isolated antigen-binding fragment which comprises a CDR of the antigen-binding fragment according to claim 138 or claim 139.

141. The isolated antigen-binding fragment of claim 140, wherein the CDR is CDR3.

5

142. An expression vector comprising an isolated nucleic acid molecule encoding the isolated antibody or antigen-binding fragment of any one of claims 130-138.

143. A host cell transformed or transfected by the expression vector of claim 142.

10

144. The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody or antigen-binding fragment thereof is selected for its ability to bind live cells.

15 145. The isolated antibody or antigen-binding fragment thereof of claim 144, wherein the cell is a tumor cell.

146. The isolated antibody or antigen-binding fragment thereof of claim 145, wherein the tumor cell is a prostate tumor cell.

20

147. The isolated antibody or antigen-binding fragment thereof of claim 146, wherein the tumor cell is a LNCaP cell.

148. The isolated antibody or antigen-binding fragment thereof according to claim 130, 25 wherein said antibody or antigen-binding fragment thereof mediates cytolysis of cells expressing PSMA.

149. The isolated antibody or antigen-binding fragment thereof of claim 148 wherein cytolysis of cells expressing PSMA is mediated by effector cells.

30

150. The isolated antibody or antigen-binding fragment thereof of claim 148 wherein cytolysis of cells expressing PSMA is complement mediated in the presence of effector cells.

151. The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody or antigen-binding fragment thereof inhibits the growth of cells expressing PSMA.

5 152. The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody or antigen-binding fragment thereof does not require cell lysis to bind to the epitope on PSMA.

10 153. The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, IgE or has immunoglobulin constant and/or variable domain of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgA or IgE.

15 154. The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody is a recombinant antibody.

155. The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody is a polyclonal antibody.

20 156. The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody is a monoclonal antibody.

25 157. The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody is a humanized antibody.

158. The isolated antibody or antigen-binding fragment thereof according to claim 157, wherein said antibody is a monoclonal antibody.

30 159. The isolated antibody or antigen-binding fragment thereof according to claim 157, wherein said antibody is a polyclonal antibody.

160. The isolated antibody or antigen-binding fragment thereof according to claim 157, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

161. The isolated antibody or antigen-binding fragment thereof according to claim 130, 5 wherein said antibody is a chimeric antibody.

162. The isolated antibody or antigen-binding fragment thereof according to claim 161, wherein said antibody is a monoclonal antibody.

10 163. The isolated antibody or antigen-binding fragment thereof according to claim 161, wherein said antibody is a polyclonal antibody.

164. The isolated antibody or antigen-binding fragment thereof according to claim 161, 15 wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

165. The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody is a human antibody.

166. The isolated antibody or antigen-binding fragment thereof according to claim 165, 20 wherein said antibody is a monoclonal antibody.

167. The isolated antibody or antigen-binding fragment thereof according to claim 165, wherein said antibody is a polyclonal antibody.

25 168. The isolated antibody or antigen-binding fragment thereof according to claim 165, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

169. The isolated antibody or antigen-binding fragment thereof according to claim 130, 30 wherein said antibody is a bispecific or multispecific antibody.

170. The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein the isolated antigen-binding fragment is selected from the group consisting of a Fab fragment, a F(ab')2 fragment, and a Fv fragment CDR3.

171. The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein the antibody is a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258),
5 PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293), PSMA 10.3 (PTA-3247), PSMA 1.8.3 (PTA-3906), PSMA B3.1.3 (PTA-3904),
PSMA B3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428),
Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557),
Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359),
10 Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362),
Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367),
Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388),
Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391),
Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

15

172. The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein the antibody or antigen-binding fragment thereof binds to a conformational epitope.

173. The isolated monoclonal antibody or antigen-binding fragment thereof according to
20 claim 130, wherein the antibody or antigen-binding fragment thereof is internalized into a cell with the prostate specific membrane antigen.

174. A hybridoma cell line that produces an antibody selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA
25 10.3, PSMA 1.8.3, PSMA B3.1.3, PSMA B3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1 and Abgenix 4.152.1.

30

175. The hybridoma cell line of claim 174, wherein the hybridoma cell line is selected from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-

3293), PSMA 10.3 (PTA-3247), PSMA 1.8.3 (PTA-3906), PSMA B3.1.3 (PTA-3904),
PSMA B3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428),
Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557),
Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359),
5 Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362),
Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367),
Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388),
Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391),
Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

10

176. A composition comprising:
an antibody or antigen-binding fragment thereof according to any one of claims 130-
141 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

15 177. The composition of claim 176, further comprising an antitumor agent, an
immunostimulatory agent, an immunomodulator, or a combination thereof.

178. The composition of claim 177, wherein the antitumor agent is a cytotoxic agent, an
agent that acts on tumor neovasculature, or a combination thereof.

20

179. The composition of claim 177, wherein the immunomodulator is α -interferon, γ -
interferon, tumor necrosis factor- α or a combination thereof.

180. The composition of claim 177, wherein the immunostimulatory agent is interleukin-2,
25 immunostimulatory oligonucleotides, or a combination thereof.

181. A composition comprising:
a combination of two or more antibodies or antigen-binding fragments thereof
according to any one of claims 130-141 and a pharmaceutically acceptable carrier, excipient,
30 or stabilizer.

182. The composition of claim 181, further comprising an antitumor agent, an
immunostimulatory agent, an immunomodulator, or a combination thereof.

183. The composition of claim 182, wherein the antitumor agent is a cytotoxic agent, an agent that acts on tumor neovasculature, or a combination thereof.

5 184. The composition of claim 182, wherein the immunomodulator is α -interferon, γ -interferon, tumor necrosis factor- α or a combination thereof.

185. The composition of claim 182, wherein the immunostimulatory agent is interleukin-2, immunostimulatory oligonucleotides, or a combination thereof.

10 186. The isolated antibody or antigen-binding fragment thereof of claim 130, bound to a label.

187. The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 186, wherein the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

188. A composition comprising:

20 an antibody or antigen-binding fragment thereof according to claim 186 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

189. The isolated antibody or antigen-binding fragment thereof of claim 130, wherein the antibody or antigen-binding fragment thereof specifically binds cell-surface PSMA and/or 25 rsPSMA with a binding affinity of about $1 \times 10^{-9} M$ or less.

190. The isolated antibody or antigen-binding fragment thereof of claim 189, wherein the binding affinity is about $1 \times 10^{-10} M$ or less.

30 191. The isolated antibody or antigen-binding fragment thereof of claim 189, wherein the binding affinity is about $1 \times 10^{-11} M$ or less.

192. The isolated antibody or antigen-binding fragment thereof of claim 189, wherein the binding affinity is less than about 5×10^{-10} M.

193. The isolated antibody or antigen-binding fragment thereof of claim 130, bound to at least one therapeutic moiety.

194 The isolated antibody or antigen-binding fragment thereof of claim 193, wherein the antibody or antigen-binding fragment thereof mediates specific cell killing of PSMA-expressing cells with an IC_{50} of less than about 1×10^{-10} M.

195. The isolated antibody or antigen-binding fragment thereof of claim 194, wherein the IC_{50} is less than about 1×10^{-11} M.

196. The isolated antibody or antigen-binding fragment thereof of claim 195, wherein the IC_{50} is less than about 1×10^{-12} M.

197. The isolated antibody or antigen-binding fragment thereof of claim 194, wherein the IC_{50} is less than about 1.5×10^{-11} M.

198. The isolated antibody or antigen-binding fragment thereof of claim 193, wherein the therapeutic moiety is a drug.

199. The isolated antibody or antigen-binding fragment thereof of claim 193, wherein the therapeutic moiety is a replication-selective virus.

200. The isolated antibody or antigen-binding fragment thereof of claim 198, wherein the drug is a cytotoxic drug.

201. The isolated antibody or antigen-binding fragment thereof of claim 200, wherein the cytotoxic drug is selected from the group consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

202. The isolated antibody or antigen-binding fragment thereof of claim 193, wherein the therapeutic moiety is a toxin or a fragment thereof.

5 203. The isolated antibody or antigen-binding fragment thereof of claim 193, wherein the therapeutic moiety is an enzyme or a fragment thereof.

204. The isolated antibody or antigen-binding fragment thereof of claim 193, wherein the therapeutic moiety is an immunostimulatory or immunomodulating agent.

10 205. The isolated antibody or antigen-binding fragment thereof of claim 204, wherein the immunostimulatory or immunomodulating agent is selected from the group consisting of: a cytokine, chemokine and adjuvant.

15 206. A composition comprising:
the antibody or antigen-binding fragment of claim 193 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

207. The isolated antibody or antigen-binding fragment thereof of 130, bound to a
20 radioisotope.

208. The isolated antibody or antigen-binding fragment thereof according to claim 207,
wherein the radioisotope emits α radiations.

25 209. The isolated antibody or antigen-binding fragment thereof according to claim 207,
wherein the radioisotope emits β radiations.

210. The isolated antibody or antigen-binding fragment thereof according to claim 207,
wherein the radioisotope emits γ radiations.

30 211. The isolated antibody or antigen-binding fragment thereof according to claim 207,
wherein the radioisotope is selected from the group consisting of ^{225}Ac , ^{211}At , ^{212}Bi , ^{213}Bi , ^{186}Rh , ^{188}Rh , ^{177}Lu , ^{90}Y , ^{131}I , ^{67}Cu , ^{125}I , ^{123}I , ^{77}Br , ^{153}Sm , ^{166}Ho , ^{64}Cu , ^{212}Pb , ^{224}Ra and ^{223}Ra .

212. A composition comprising the isolated antibody or antigen-binding fragment thereof of claim 207 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

5 213. A kit for detecting prostate cancer for diagnosis, prognosis or monitoring comprising: the isolated labeled antibody or antigen-binding fragment thereof of claim 186, and one or more compounds for detecting the label.

10 214. A kit according to claim 213, wherein the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

15 215. The isolated antibody or antigen-binding fragment thereof of any of claims 130, 186, 193 or 207 packaged in lyophilized form.

20 216. The isolated antibody or antigen-binding fragment thereof of any of claims 130, 186, 193 or 207 packaged in an aqueous medium.

217. A method for detecting the presence of PSMA, or a cell expressing PSMA, in a sample comprising:
contacting the sample with an antibody or antigen-binding fragment thereof according to claim 1 or 130 for a time sufficient to allow the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA, and
detecting the PSMA-antibody complex or PSMA-antigen-binding fragment complex,
25 wherein the presence of a complex in the sample is indicative of the presence in the sample of PSMA or a cell expressing PSMA.

218. A method for diagnosing a PSMA-mediated disease in a subject comprising:
administering to a subject suspected of having or previously diagnosed with PSMA-mediated disease an isolated amount of an antibody or antigen-binding fragment thereof according to claim 1 or 130,
allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA,

detecting the formation of the PSMA-antibody complex or PSMA-antigen-binding fragment complex to the target epitope,

wherein the presence of a complex in the subject suspected of having or previously diagnosed with PSMA-mediated disease is indicative of the presence of a PSMA-mediated disease.

219. The method of claim 218 wherein the PSMA-mediated disease is prostate cancer.

220. The method of claim 218 wherein the PSMA-mediated disease is a non-prostate cancer.

221. The method of claim 220 wherein the non-prostate cancer is selected from the group consisting of bladder cancer including transitional cell carcinoma; pancreatic cancer including pancreatic duct carcinoma; lung cancer including non-small cell lung carcinoma; kidney cancer including conventional renal cell carcinoma; sarcoma including soft tissue sarcoma; breast cancer including breast carcinoma; brain cancer including glioblastoma multiforme; neuroendocrine carcinoma; colon cancer including colonic carcinoma; testicular cancer including testicular embryonal carcinoma; and melanoma including malignant melanoma.

221. The method of claim 217 or claim 218 wherein the antibody or antigen-binding fragment thereof is labeled.

223. The method of claim 217 or claim 218 wherein a second antibody is administered to detect the first antibody or antigen-binding fragment thereof.

224. A method for assessing the prognosis of a subject with a PSMA-mediated disease: administering to a subject suspected of having or previously diagnosed with PSMA-mediated disease an effective amount of an antibody or antigen-binding fragment thereof according to claim 1 or 130, allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA, detecting the formation of the complex to the target epitope,

wherein the amount of the complex in the subject suspected of having or previously diagnosed with PSMA-mediated disease is indicative of the prognosis.

225. A method for assessing the effectiveness of a treatment of a subject with a PSMA-mediated disease:

5 administering to a subject suspected treated for a PSMA-mediated disease an effective amount of an antibody or antigen-binding fragment thereof according to claim 1 or 130, allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA,

10 detecting the formation of the complex to the target epitope, wherein the amount of the complex in the subject suspected of having or previously diagnosed with PSMA-mediated disease is indicative of the effectiveness of the treatment.

226. The method of claim 224 or claim 225 wherein the PSMA-mediated disease is prostate cancer.

227. The method of claim 224 or claim 225 wherein the PSMA-mediated disease is a non-prostate cancer.

20 228. The method of claim 227 wherein the non-prostate cancer is selected from the group consisting of bladder cancer including transitional cell carcinoma; pancreatic cancer including pancreatic duct carcinoma; lung cancer including non-small cell lung carcinoma; kidney cancer including conventional renal cell carcinoma; sarcoma including soft tissue sarcoma; breast cancer including breast carcinoma; brain cancer including glioblastoma multiforme; neuroendocrine carcinoma; colon cancer including colonic carcinoma; testicular cancer including testicular embryonal carcinoma; and melanoma including malignant melanoma.

229. The method of claim 224 or claim 225 wherein the antibody or antigen-binding fragment thereof is labeled.

230. The method of claim 224 or claim 225 wherein a second antibody is administered to detect the first antibody or antigen-binding fragment thereof.

231. A method for inhibiting the growth of a cell expressing PSMA comprising:
contacting a cell expressing PSMA with an amount of an antibody or antigen-binding fragment thereof according to claim 1 or 130 which specifically binds to an extracellular 5 domain of PSMA effective to inhibit the growth of the cell expressing PSMA.
232. A method for inducing cytolysis of a cell expressing PSMA comprising:
contacting a cell expressing PSMA with an amount of an antibody or antigen-binding fragment thereof according to claim 1 or 130 which specifically binds to an extracellular 10 domain of PSMA effective to induce cytolysis of the cell expressing PSMA.
233. The method of claim 232 wherein the cytolysis occurs in the presence of an effector cell.
- 15 234. The method of claim 232 wherein the cytolysis is complement mediated.
235. A method for treating or preventing a PSMA-mediated disease comprising:
administering to a subject having a PSMA-mediated disease or at risk of having a PSMA- 20 mediated disease an effective amount of an antibody or antigen-binding fragment thereof according to claim 1 or 130 to treat or prevent the PSMA-mediated disease.
236. The method of claim 235 wherein the PSMA-mediated disease is a cancer.
237. The method for claim 236 wherein the cancer is a prostate cancer.
- 25 238. The method for claim 236 wherein the cancer is a non-prostate cancer.
239. A method for treating or preventing a PSMA-mediated disease comprising:
administering to a subject having a PSMA-mediated disease or at risk of having a 30 PSMA-mediated disease an amount of an antibody or antigen-binding fragment thereof according to claim 1 or 130 effective to treat or prevent the PSMA-mediated disease.
240. The method of claim 239, wherein the PSMA-mediated disease is a cancer.

241. The method of claim 240, wherein the cancer is prostate cancer.

242. The method of claim 240, wherein the cancer is a non-prostate cancer.

5 243. The method of claim 242, wherein the non-prostate cancer is selected from the group consisting of: bladder cancer including transitional cell carcinoma; pancreatic cancer including pancreatic duct carcinoma; lung cancer including non-small cell lung carcinoma; kidney cancer including conventional renal cell carcinoma; sarcoma including soft tissue 10 sarcoma; breast cancer including breast carcinoma; brain cancer including glioblastoma multiforme; neuroendocrine carcinoma; colon cancer including colonic carcinoma; testicular cancer including testicular embryonal carcinoma; and melanoma including malignant melanoma.

15 244. The method of claim 239, further comprising administering another therapeutic agent to treat or prevent the PSMA-mediated disease at any time before, during or after the administration of the antibody or antigen-binding fragment thereof.

20 245. The method of claim 244, wherein the therapeutic agent is a vaccine.

246. The method of claim 245, wherein the vaccine immunizes the subject against PSMA.

247. The method of claim 244, wherein the antibody or antigen-binding fragment thereof is bound to at least one therapeutic moiety.

25 248. The method of claim 247, wherein the therapeutic moiety is a cytotoxic drug, a drug which acts on the tumor neovasculature and combinations thereof.

249. The method of claim 248, wherein the cytotoxic drug is selected from the group 30 consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

250. The method of claim 247, wherein the antibody or antigen-binding fragment thereof is bound to a radioisotope, wherein the radiations emitted by the radioisotope is selected from the group consisting of α , β and γ radiations.

5

251. The method of claim 250, wherein the radioisotope is selected from the group consisting of ^{225}Ac , ^{211}At , ^{212}Bi , ^{213}Bi , ^{186}Rh , ^{188}Rh , ^{177}Lu , ^{90}Y , ^{131}I , ^{67}Cu , ^{125}I , ^{123}I , ^{77}Br , ^{153}Sm , ^{166}Ho , ^{64}Cu , ^{212}Pb , ^{224}Ra and ^{223}Ra .

10 252. A method for inhibiting folate hydrolase activity comprising:
contacting a folate hydrolase polypeptide with an amount of isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 130 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits the folate hydrolase activity.

15

253. The method of claim 252 wherein the folate hydrolase polypeptide is isolated.

254. The method of claim 252 wherein the folate hydrolase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue
20 homogenate.

255. The method of claim 252 wherein the folate hydrolase polypeptide is contained in an organism.

25 256. The method of claim 255 wherein the organism is an animal.

257. The method of claim 256 wherein the animal is a mammal.

258. A method for enhancing folate hydrolase activity comprising:
30 contacting a folate hydrolase polypeptide with an amount of isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 130 under conditions wherein the isolated antibody or antigen-binding fragment thereof enhances the folate hydrolase activity.

259. The method of claim 258 wherein the folate hydrolase polypeptide is isolated.

260. The method of claim 258 wherein the folate hydrolase polypeptide is contained in a
5 sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

261. The method of claim 258 wherein the folate hydrolase polypeptide is contained in an organism.

10 262. The method of claim 261 wherein the organism is an animal.

263. The method of claim 262 wherein the animal is a mammal.

15 264. A method for inhibiting N-acetylated α -linked acidic dipeptidase (NAALADase) activity comprising:
contacting a NAALADase polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 130 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits NAALADase activity.

20 265. The method for claim 264 wherein the NAALADase polypeptide is isolated.

266. The method for claim 264 wherein the NAALADase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue
25 homogenate.

267. The method for claim 264 wherein the NAALADase polypeptide is contained in an organism.

30 268. The method for claim 267 wherein the organism is an animal.

269. The method for claim 268 wherein the animal is a mammal.

270. A method for enhancing N-acetylated α -linked acidic dipeptidase (NAALADase) activity comprising:

contacting a NAALADase polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 130 under conditions wherein
5 the isolated antibody or antigen-binding fragment thereof enhances NAALADase activity.

271. The method for claim 270 wherein the NAALADase polypeptide is isolated.

272. The method for claim 270 wherein the NAALADase polypeptide is contained in a
10 sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

273. The method for claim 270 wherein the NAALADase polypeptide is contained in an organism.

15

274. The method for claim 273 wherein the organism is an animal.

275. The method for claim 274 wherein the animal is a mammal.

20 276. A method for inhibiting dipeptidyl dipeptidase IV activity comprising:

contacting a dipeptidyl dipeptidase IV polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 130 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits dipeptidyl dipeptidase IV activity.

25

277. The method for claim 276 wherein the dipeptidyl dipeptidase IV polypeptide is isolated.

278. The method for claim 276 wherein the dipeptidyl dipeptidase IV polypeptide is
30 contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

279. The method for claim 276 wherein the dipeptidyl dipeptidase IV polypeptide is contained in an organism.

280. The method for claim 279 wherein the organism is an animal.

5

281. The method for claim 280 wherein the animal is a mammal.

282. A method for inhibiting dipeptidyl dipeptidase IV activity comprising:
contacting a dipeptidyl dipeptidase IV polypeptide with an amount of an isolated
10 antibody or antigen-binding fragment thereof according to claim 1 or claim 130 under
conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits
dipeptidyl dipeptidase IV activity.

283. The method for claim 282 wherein the dipeptidyl dipeptidase IV polypeptide is
15 isolated.

284. The method for claim 282 wherein the dipeptidyl dipeptidase IV polypeptide is
contained in a sample selected from the group consisting of a cell, a cell homogenate, a
tissue, or a tissue homogenate.

20

285. The method for claim 282 wherein the dipeptidyl dipeptidase IV polypeptide is
contained in an organism.

25

286. The method for claim 285 wherein the organism is an animal.

287. The method for claim 286 wherein the animal is a mammal.

288. A method for inhibiting γ -glutamyl hydrolase activity comprising:
contacting a γ -glutamyl hydrolase polypeptide with an amount of an isolated antibody
30 or antigen-binding fragment thereof according to claim 1 or claim 130 under conditions
wherein the isolated antibody or antigen-binding fragment thereof inhibits γ -glutamyl
hydrolase activity.

289. The method for claim 288 wherein the γ -glutamyl hydrolase polypeptide is isolated.

290. The method for claim 288 wherein the γ -glutamyl hydrolase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a
5 tissue homogenate.

291. The method for claim 288 wherein the γ -glutamyl hydrolase polypeptide is contained in an organism.

10 292. The method for claim 291 wherein the organism is an animal.

293. The method for claim 292 wherein the animal is a mammal.

294. A method for inhibiting γ -glutamyl hydrolase activity comprising:
15 contacting a γ -glutamyl hydrolase polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 130 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits γ -glutamyl hydrolase activity.

20 295. The method for claim 294 wherein the γ -glutamyl hydrolase polypeptide is isolated.

296. The method for claim 294 wherein the γ -glutamyl hydrolase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a
25 tissue homogenate.

297. The method for claim 294 wherein the γ -glutamyl hydrolase polypeptide is contained in an organism.

298. The method for claim 297 wherein the organism is an animal.
30

299. The method for claim 298 wherein the animal is a mammal.

300. A method of specific delivery of at least one therapeutic agent to PSMA-expressing cells, comprising:

administering an effective amount of an antibody or antigen-binding fragment thereof according to claim 1 or 130 conjugated to the at least one therapeutic agent.

5

301. The method of claim 300, wherein the therapeutic agent is a nucleic acid molecule.

302. The method of claim 300, wherein the therapeutic agent is an antitumor drug.

10 303. The method of claim 302, wherein the antitumor drug is selected from the group consisting of: a cytotoxic drug, a drug which acts on the tumor neovasculature and combinations thereof.

15 304. The method of claim 303, wherein the cytotoxic drug is selected from the group consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

20 305. The method of claim 300, wherein the therapeutic moiety is a toxin or a fragment thereof.

306. The method of claim 300, wherein the therapeutic moiety is an enzyme or a fragment thereof.

25

307. The method of claim 300, wherein the therapeutic moiety is a replication-selective virus.

308. The method of claim 300, wherein the therapeutic moiety is an immunostimulatory or 30 immunomodulating agent.

309. The method of claim 308, wherein the immunostimulatory or immunomodulating agent is selected from the group consisting of: a cytokine, chemokine and adjuvant.

310. An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer.

5 311. The isolated antibody or antigen-binding fragment thereof of claim 310, wherein the PSMA protein multimer is a dimer.

312. The isolated antibody or antigen-binding fragment thereof of claim 311, wherein at least one of the PSMA proteins forming the multimer is a recombinant, soluble PSMA

10 (rsPSMA) polypeptide.

313. The isolated antibody or antigen-binding fragment thereof of claim 312, wherein the rsPSMA polypeptide consists essentially of amino acids 44-750 of SEQ ID NO:1.

15 314. An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer, wherein the isolated antibody inhibits at least one enzymatic activity of the PSMA protein multimer.

315. The isolated antibody or antigen-binding fragment thereof of claim 314, wherein the

20 enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity, γ -glutamyl hydrolase activity and combinations thereof.

316. The isolated antibody or antigen-binding fragment thereof of claim 314, wherein the

25 enzymatic activity is in the extracellular domain of the PSMA molecule.

317. The isolated antibody or antigen-binding fragment thereof of claim 314, wherein the antibody or antigen-binding fragment thereof specifically binds to an extracellular domain of PSMA.

30 318. An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer, wherein the isolated antibody enhances at least one enzymatic activity of the PSMA protein multimer.

319. The isolated antibody or antigen-binding fragment thereof of claim 318, wherein the enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity, γ -glutamyl hydrolase activity and 5 combinations thereof.

320. The isolated antibody or antigen-binding fragment thereof of claim 318, wherein the enzymatic activity is in the extracellular domain of the PSMA molecule.

10 321. The isolated antibody or antigen-binding fragment thereof of claim 318, wherein the antibody or antigen-binding fragment thereof specifically binds to an extracellular domain of PSMA.

15 322. A composition comprising an isolated antibody or antigen-binding fragment thereof as in any of claims 310 – 321, and an immunostimulatory oligonucleotide.

323. A composition comprising an isolated antibody or antigen-binding fragment thereof as in any of claims 310 – 321, and a cytokine.

20 324. The composition of claim 323, wherein the cytokine is selected from the group consisting of IL-2, IL-12, IL-18 and GM-CSF.

325. The composition of any of claims 322 – 324, further comprising a pharmaceutically-acceptable carrier.

25 326. A method for inducing an immune response comprising administering to a subject in need of such treatment an effective amount of the isolated antibody or composition of any of claims 310-325.

30 327. An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer and inhibits at least one enzymatic activity of PSMA.

328. The isolated antibody or antigen-binding fragment thereof of claim 327, wherein the enzyme is selected from the group consisting of hydrolases and peptidases.

329. The isolated antibody or antigen-binding fragment thereof of claim 328, wherein the 5 hydrolase is selected from the group consisting of folate hydrolase and γ -glutamyl hydrolase.

330. The isolated antibody or antigen-binding fragment thereof of claim 329, wherein the hydrolase is folate hydrolase and the antibody is mAb 5.4 or mAb 3.9.

10 331. The isolated antibody or antigen-binding fragment thereof of claim 328, wherein the peptidase is selected from the group consisting of NAALADase and dipeptidyl dipeptidase IV.

15 332. The isolated antibody or antigen-binding fragment thereof of claim 327, wherein the enzyme is active in cancer cells and has lesser activity in normal cells than in cancer cells or no activity in normal cells.

20 333. The isolated antibody or antigen-binding fragment thereof of claim 332, wherein the cancer cells are prostate cancer cells.

334. An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer and enhances at least one enzymatic activity of PSMA.

25 335. The isolated antibody or antigen-binding fragment thereof of claim 334, wherein the enzyme is selected from the group consisting of hydrolases and peptidases.

336. The isolated antibody or antigen-binding fragment thereof of claim 335, wherein the hydrolase is selected from the group consisting of folate hydrolase and γ -glutamyl hydrolase.

30 337. The isolated antibody or antigen-binding fragment thereof of claim 335, wherein the peptidase is selected from the group consisting of NAALADase and dipeptidyl dipeptidase IV.

338. The isolated antibody or antigen-binding fragment thereof of claim 334, wherein the enzyme is active in normal cells and has lesser activity in cancer cells than in normal cells or no activity in cancer cells.

5 339. The isolated antibody or antigen-binding fragment thereof of claim 338, wherein the cancer cells are prostate cancer cells.

340. An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer, wherein the isolated antibody is raised by immunizing an animal
10 with a preparation comprising a PSMA protein multimer.

341. A composition comprising the isolated antibody or antigen-binding fragment thereof of claims 327 – 340, and a pharmaceutically acceptable carrier.

15 342. A composition comprising an isolated PSMA protein multimer.

343. The composition of claim 342, wherein the PSMA protein multimer is a dimer.

344. The composition of claim 342, wherein the composition comprises at least about 10%
20 PSMA protein multimer.

345. The composition of claim 344, wherein the composition comprises at least about 20% PSMA protein multimer.

25 346. The composition of claim 345, wherein the composition comprises at least about 30% PSMA protein multimer.

347. The composition of claim 346, wherein the composition comprises at least about 40% PSMA protein multimer.

30 348. The composition of claim 347, wherein the composition comprises at least about 50% PSMA protein multimer.

349. The composition of claim 348, wherein the composition comprises at least about 75% PSMA protein multimer.

350. The composition of claim 349, wherein the composition comprises at least about 90% 5 PSMA protein multimer.

351. The composition of claim 350, wherein the composition comprises at least about 95% PSMA protein multimer.

10 352. The composition of claim 342, wherein the PSMA protein multimer comprises noncovalently associated PSMA proteins.

353. The composition of claim 352, wherein the PSMA proteins are noncovalently associated under nondenaturing conditions.

15 354. The composition of any of claims 342-353, wherein at least one of the PSMA proteins forming the multimer is a recombinant, soluble PSMA (rsPSMA) polypeptide.

20 355. The composition of claim 342, wherein the PSMA protein multimer is reactive with a conformation-specific antibody that specifically recognizes PSMA.

356. The composition of claim 342, wherein the PSMA protein multimer comprises PSMA proteins in a native conformation.

25 357. The composition of claim 342, wherein the PSMA multimer is enzymatically active.

358. The composition of claim 357, wherein the enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity, γ -glutamyl hydrolase activity and combinations thereof.

30 359. The composition of any of claims 342-358, further comprising an adjuvant.

360. The composition of any of claims 342-358, further comprising a cytokine.

361. The composition of claim 360, wherein the cytokine is selected from the group consisting of IL-2, IL-12, IL-18 and GM-CSF.

5 362. The composition of any of claims 342-361, further comprising a pharmaceutically acceptable carrier.

363. A method for inducing an immune response comprising administering to a subject in need of such treatment an effective amount of the composition of any of claims 342-362.

10

364. An isolated recombinant soluble PSMA (rsPSMA) protein multimer.

365. An isolated rsPSMA protein dimer.

15

366. The isolated rsPSMA protein dimer of claim 365, wherein the dimer comprises noncovalently associated rsPSMA proteins.

367. The isolated rsPSMA protein dimer of claim 366, wherein the rsPSMA proteins are noncovalently associated under nondenaturing conditions.

20

368. The isolated rsPSMA protein dimer of claim 365, wherein the isolated rsPSMA dimer is reactive with a conformation-specific antibody that specifically recognizes PSMA.

25

369. The isolated rsPSMA protein dimer of claim 365, wherein the isolated rsPSMA dimer is enzymatically active.

370. The isolated rsPSMA protein dimer of claim 369, wherein the enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity, γ -glutamyl hydrolase activity and combinations thereof.

30

371. A method of screening for a candidate agent that inhibits at least one enzymatic activity of a PSMA enzyme comprising

- a) mixing the candidate agent with an isolated PSMA protein multimer to form a reaction mixture, followed by
 - b) adding a substrate for the PSMA enzyme to the reaction mixture, and
 - c) determining the amount of a product formed from the substrate by the PSMA
- 5 enzyme, wherein a decrease in the amount of product formed in comparison to a control is indicative of an agent capable of inhibiting at least one enzymatic activity of the PSMA enzyme.

372. The method of screening of claim 371, wherein the PSMA enzyme is selected from
10 the group consisting of NAALADase, folate hydrolase, dipeptidyl dipeptidase IV and
 γ -glutamyl hydrolase.

373. The method of screening of claim 371, wherein the PSMA multimer comprises recombinant soluble PSMA.

15 374. The method of screening of claim 371, wherein the candidate agent is selected from the group consisting of an antibody, a small organic compound, or a peptide.

20 375. A candidate agent that inhibits at least one enzymatic activity of PSMA identified according to the method of claim 371.

25 376. The candidate agent according to claim 375, wherein the agent is selected from a combinatorial antibody library, a combinatorial protein library, or a small organic molecule library.

377. A method of screening for a candidate agent that enhances at least one enzymatic activity of a PSMA enzyme comprising

- a) mixing the candidate agent with an isolated PSMA protein multimer to form a reaction mixture, followed by
 - b) adding a substrate for the PSMA enzyme to the reaction mixture, and
 - c) determining the amount of a product formed from the substrate by the PSMA
- 30 enzyme, wherein an increase in the amount of product formed in comparison to a control is

indicative of an agent capable of enhancing at least one enzymatic activity of the PSMA enzyme.

378. The method of screening of claim 377, wherein the PSMA enzyme is selected from 5 the group consisting of NAALADase, folate hydrolase, dipeptidyl dipeptidase IV and γ -glutamyl hydrolase.

379. The method of screening of claim 377, wherein the PSMA multimer comprises recombinant soluble PSMA.

10

380. The method of screening of claim 377, wherein the candidate agent is selected from the group consisting of an antibody, a small organic compound, or a peptide.

15

381. A candidate agent that enhances at least one enzymatic activity of PSMA identified according to the method of claim 377.

382. The candidate agent according to claim 381, wherein the agent is selected from a combinatorial antibody library, a combinatorial protein library, or a small organic molecule library.

20

383. A method for identifying a compound that promotes dissociation of PSMA dimers, comprising

contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound;

25

measuring the amount of PSMA monomer; and

comparing the amount of PSMA monomer measured in the presence of the compound with that observed in the absence of the compound;

30

wherein an increase in the amount of PSMA monomer measured in the presence of the compound indicates that the compound is capable of promoting dissociation of the PSMA dimer.

384. A method for identifying a compound that promotes dissociation of PSMA dimers, comprising

contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound;

measuring the amount of PSMA dimer; and

comparing the amount of PSMA dimer measured in the presence of the compound

5 with that observed in the absence of the compound;

wherein a decrease in the amount of PSMA dimer measured in the presence of the compound indicates that the compound is capable of promoting dissociation of the PSMA dimer.

10 385. A method for identifying a compound that promotes dissociation of PSMA dimers, comprising

contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound;

measuring the amounts of PSMA monomer and PSMA dimer;

15 calculating a ratio of PSMA monomer to PSMA dimer; and

comparing the ratio obtained in the presence of the compound with that obtained in the absence of the compound;

wherein an increase in the ratio measured in the presence of the compound indicates that the compound is capable of promoting dissociation of the PSMA dimer.